Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site.

# Cancer World Archive

## Sitemaps

- [XML Sitemap](https://archive.cancerworld.net/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [SPCC task force raises awareness of malnutrition and cachexia in cancer patients](https://archive.cancerworld.net/media-partnership/spcc-task-force-raises-awareness-of-malnutrition-and-cachexia-in-cancer-patients/) - Key points The presence of cachexia is being recognised to have a negative impact on surgery and immune therapy. In the absence of pharmacological therapies multimodal treatments, such as nutrition and exercise, should be used in cachexia patients. Surveys reveal majority of health care professionals are unaware of cachexia guidelines. Cross sectional CT scans and
- [Four steps to eliminating HPV infections across Europe: an ECCO call for EU action](https://archive.cancerworld.net/news/four-steps-to-eliminating-hpv-infections-across-europe-an-ecco-call-for-eu-action/) - A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating human papillomavirus (HPV) in Europe. The report was published by The European Cancer Organisation, Brussels on 7th October.1 The report, ‘Viral Protection: Achieving the Possible’ details a four step plan that calls for urgent action to eliminate the 87,000
- [Improving efficiency in cancer care: a multidisciplinary challenge ](https://archive.cancerworld.net/media-partnership/improving-efficiency-in-cancer-care-a-multidisciplinary-challenge/) - A joint ESO-SPCC task-force met to design a strategy to help different actors involved in cancer care to optimise patient journey, tackling challenges from different points of view. “I think the focus here is not about having something new, but how to use what we have in a better way”. With these words Matti Aapro,
- [Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide](https://archive.cancerworld.net/news/metastatic-prostate-cancer-cabazitaxel-shows-quality-of-life-benefits-over-both-abiraterone-and-enzalutamide/) - In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis of the CARD trial (Fizazi K et al. Lancet Oncol 2020). “This analysis can provide reassurance to physicians and patients
- [Combined therapies offer the key to drug-resistant cancer](https://archive.cancerworld.net/news/combined-therapies-offer-the-key-to-drug-resistant-cancer/) - For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in patients with treatment-refractory breast, ovarian and prostate cancers. The results were published in the journal Cancer Discovery (Yap TA et
- [Matteo Lambertini: keeping the family dream alive](https://archive.cancerworld.net/profile/matteo-lambertini-keeping-the-family-dream-alive/) - For many young women with breast cancer, the chance to have a child is a top priority. They want to know what different treatments could do to their fertility and the health of a future baby, whether getting pregnant could make a recurrence more likely, and how to access the services they need. Matteo Lambertini
- [Can advanced-stage ovarian cancer be cured?](https://archive.cancerworld.net/impact-factor/can-advanced-stage-ovarian-cancer-be-cured/) - Treatment of advanced-stage ovarian cancer should comprise optimal debulking surgery followed by adjuvant intraperitoneal chemotherapy. Steven Narod, from Women’s College Research Institute, Toronto, Canada, argues that widespread adoption of this model would increase cure rates for advanced ovarian cancers, from the current 20% to half of all patients. This is an abridged version of S
- [Extreme oncology in Romania](https://archive.cancerworld.net/voices/extreme-oncology-in-romania/) - Being an oncologist in Romania is an extreme job. Being a patient with cancer in Romania is an extreme experience. We have 250 oncologists to care for at least 500,000 people with cancer (the figures are uncertain because the National Cancer Registry is not up and running). Our hospitals are crowded, we lack medication, many
- [The ABC Global Alliance launch a Global campaign to raise awareness about advanced breast cancer](https://archive.cancerworld.net/highlight/the-abc-global-alliance-launch-a-global-campaign-to-raise-awareness-about-advanced-breast-cancer/) - There are over two million new cases of breast cancer a year in the world and 0.6 million deaths. About a third of all early breast cancer cases will become metastatic even with the best care, and the average overall survival for these patients is around three years. The ABC Global Alliance, a multi-stakeholder platform
- [Chiara Gasparotto – winning the case for better access to radiotherapy](https://archive.cancerworld.net/profile/chiara-gasparotto-winning-the-case-for-better-access-to-radiotherapy/) - A quarter of cancer patients who could benefit from radiotherapy do not receive it. As head of policy and partnerships, Chiara Gasparotto is positioning the European Society for Radiotherapy to make the case for better access and to alert policy makers and the public to the unmet need in their own countries. Peter McIntyre reports.
- [Biosimilars ‒ Policy failings that deny savings to countries that need it most](https://archive.cancerworld.net/spotlight-on/biosimilars-‒-policy-failings-that-deny-savings-to-countries-that-need-it-most/) - Competitor drugs entering the market are opening opportunities to make important savings on an increasing number of biological anticancer agents. But, as Rachel Brazil reports, many countries, including those with the most stretched health budgets, could do a lot more to reap the potential rewards. The promise of cheaper biological drugs is now coming to
- [Dr. Fraud's jungle, where science is the prey](https://archive.cancerworld.net/cover-story/dr-frauds-jungle-where-science-is-the-prey/) - With the advent of Open Access – a new publishing model that asks researchers to pay to make their research publicly accessible – unscrupulous predators were granted easy access to a house full of naïve and ingenuous scientists and doctors, and today thrive at their expense, and at the expense of science, including cancer research.
- [Published meta-analyses' long way to reproducibility](https://archive.cancerworld.net/news/published-meta-analyses-long-way-to-reproducibility/) - According to a recent study published in JAMA Oncology, the findings of published meta-analyses on cancer treatments can be recalculated only in 2 cases out of 3. This does not imply that the findings are not true, the authors say, but confirms that issues of reproducibility even in systematic reviews and meta-analyses are quite common.
- [Patient-reported outcomes have prognostic value in predicting survival](https://archive.cancerworld.net/news/patient-reported-outcomes-have-prognostic-value-in-predicting-survival/) - Quality of life assessment is becoming increasingly important in oncology: a paper published in The Lancet Oncology by Andrew Bottomley of the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, and colleagues from seven countries presents the findings of a meta-analysis of 44 clinical trials conducted between 2006 and 2018 on
- [Investment in childhood cancer research is lagging behind](https://archive.cancerworld.net/news/investment-in-childhood-cancer-research-is-lagging-behind/) - Relatively low levels of investments from major funders, no recent acceleration in funding observed, and a decline in new commitments to funding since 2011: this is the main – and somehow discouraging – picture of investments for childhood cancer research according to a systematic analysis published in The Lancet Oncology. Despite the efforts by the
- [Expectations in ovarian cancer: foreseeing the next year](https://archive.cancerworld.net/spotlight-on/expectations-in-ovarian-cancer-foreseeing-the-next-year/) - A special multidisciplinary session on ovarian cancer took place during the European Congress on Gynaecological Oncology, in Athens, with the aim of predicting what will happen in the field of ovarian cancer in the near future During ESGO 21st European Congress on Gynaecological Oncology that took place earlier this month in Athens, Greece, Cristiana Sessa
- [ABC5 reaches an agreement on advanced breast cancer](https://archive.cancerworld.net/spotlight-on/abc5-reaches-an-agreement-on-advanced-breast-cancer/) - Cancerworld witnessed the final consensus meeting that produced the new guidelines on advanced breast cancer. The consensus panel gathered in Lisbon during ABC5 to discuss, and sometimes to disagree. At the end, the experts voted more than 50 statements, some of them totally new for the topic Health professionals, patients and advocates have come to
- [Fear and lack of training may condemn cancer patients to live in pain](https://archive.cancerworld.net/spotlight-on/fear-and-lack-of-training-may-condemn-cancer-patients-to-live-in-pain/) - The US restrictions on the prescription of opioids had barely any effect in reducing opioid-related deaths, but are menacing the proper pain management care in cancer patients — and other chronic pain patients, Vera Novais reports from the ABC congress in Lisbon Teva Harrison had excruciating pain. “The ache was deep in my bones, like
- [Family history of cancer and starting age of screening: should guidelines be revised?](https://archive.cancerworld.net/news/family-history-of-cancer-and-starting-age-of-screening-should-guidelines-be-revised/) - When it comes to deciding the age for starting mammography, family history of cancer should count more, according to an analysis of Swedish registries just published in JAMA Oncology. To identify the risk-adapted starting age of breast cancer screening on the basis of a woman’s detailed family history, Trasias Mukama, from the National Center for
- [Breast cancer death rates keep declining, at a slower pace](https://archive.cancerworld.net/news/breast-cancer-death-rates-decline-at-a-slower-pace/) - While breast cancer incidence rates are still on the rise, mortality rates keep decreasing, although at slower pace than in past. This is one of the take-home messages from Breast Cancer Statistics 2019-2020, the biennial update of breast cancer statistics in the United States from the American Cancer Society (ACS), recently published in CA: A
- [It's hard to be a physician and a mother](https://archive.cancerworld.net/news/its-hard-to-be-a-physician-and-a-mother/) - The emotional support from colleagues is there, but many hurdles are present for physician mothers, making the maternity/family leave a big challenge for several women. “Physicians taking maternity leave experience unique challenges that require creative solutions, the seeds of which can be found in the lived experiences of women in medicine captured in the present
- [Lung cancer association takes a stand against e-cigarettes](https://archive.cancerworld.net/news/lung-cancer-association-takes-a-stand-against-e-cigarettes/) - On November 12, the International Association for the Study of Lung Cancer (IASLC) issued a policy statement that strongly discourages the use of electronic cigarettes (e-cigarettes, or e-cigs) by non-smokers. The timing of the release is not casual, since November is the Lung Cancer Awareness Month, and nothing could reduce the burden of lung cancer as
- [ABC Lisbon: good communication to improve patients' wellbeing ](https://archive.cancerworld.net/news/abc-lisbon-good-communication-to-improve-patients-wellbeing/) - “‘You look so well!’, has just got to be the worst thing you can say to someone with advanced breast cancer. Was it meant to be a compliment? Actually it makes me feel invisible,” says Clair Myerson, who lives with advanced breast cancer since 2015. “I haven’t lost my hair with this drug,” she explains, but
- [The higher price of new cancer drugs is rarely justified](https://archive.cancerworld.net/news/the-higher-price-of-new-cancer-drugs-is-rarely-justified/) - Most cancer drugs introduced since 2004 provide low added value compared to previously approved medications, but have much higher prices, according to a French study presented at the congress of the European Society for Medical Oncology (ESMO 2019) currently underway in Barcelona. «Most of the new cancer drugs had low added value, so doctors and patients
- [Stella Kyriakides named European Health Commissioner](https://archive.cancerworld.net/news/former-europa-donna-president-stella-kyriakides-named-european-health-commissioner/) - Stella Kyriakides, a medical psychologist with many years of experience in the field of social affairs, health and cancer prevention, will lead the health portfolio in the new European Commission, according to an announcement by President-elect of the European Commission, German Ursula von der Leyen, a former physician who taught at the Department of Epidemiology,
- [Artificial intelligence can help start dialogue on end of life options](https://archive.cancerworld.net/news/artificial-intelligence-can-help-start-dialogue-on-end-of-life-options/) - An algorithm might help to arrange a timely advance care planning conversation to agree with patients on their goals and wishes. The timing of such a discussion is crucial, and data have shown that the majority of cancer patients die without a documented conversation about their treatment and end-of-life preferences. A new study published in
- [Highlights of the 20th World Conference on Lung Cancer](https://archive.cancerworld.net/news/highlights-of-the-barcelona-20thworld-conference-on-lung-cancer/) - The latest developments in the field of lung cancer were discussed last week in Barcelona (Spain) during the 20th edition of the World Conference on Lung Cancer organized by the International Association for the Study of Lung Cancer (IASLC). The focus of clinical studies ranged from screening to treatment of advanced disease. “Administrations are reluctant to
- [20.03.2020 7th ESO Prostate Cancer Observatory: Innovation and care in the next 12 months](https://archive.cancerworld.net/agenda/20-03-2020-7th-eso-prostate-cancer-observatory-innovation-and-care-in-the-next-12-months/) - 20.03.2020 Amsterdam, The Netherlands The European School of Oncology is pleased to announce the 7th edition of "ESO Prostate Cancer Observatory: innovation and care in the next 12 months", which will be held during the EAU20 Congress on March 20 in Amsterdam. AIMS AND OBJECTIVES ESO Observatories are high level sessions organised during major international
- [31.01.2020  -  3.02.2020 2nd Masterclass in Endoscopy in Gastrointestinal Oncology](https://archive.cancerworld.net/agenda/31-01-2020-3-02-2020-2nd-masterclass-in-endoscopy-in-gastrointestinal-oncology/) - Nijmegen, The Netherlands 31.01.2020 - 03.02.2020 Chairs: M. Conio, IT - P.D. Siersema, NL - M. Wallace, US The aim of this Masterclass is to provide an update of the role of endoscopy in the diagnosis and treatment of gastrointestinal neoplasia. The Masterclass is specifically addressed to junior specialists and each topic will be analysed in a
- [26.08.2019 - 06.09.2019 - ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students](https://archive.cancerworld.net/past-events/26-08-2019-06-09-2019-eso-esso-estro-multidisciplinary-course-in-oncology-for-medical-students/) - 26.06.2019 - 06.09.2019Turin, Italy COURSE FORMAT• Ten working days • The programme covers all aspects of oncology • Theoretical plenary sessions of maximum 2 hours • Case presentations • Daily two-hour practical sessions in small groups (labs, ward visits, etc) • Preparation in small working groups of a presentation on a specific topic under the
- [15.06.2019  -  17.06.2019 - Lymphoma](https://archive.cancerworld.net/past-events/15-06-2019-17-06-2019-lymphoma/) - 15.06.2019 - 17.06.2019 Lugano, SwitzerlandOver the past twenty-five years or so, this course has become a renowned programme for physicians and scientists with an interest in the diagnosis and treatment of haematological cancers. It typically draws participants from most if not all continents and thus allows for a stimulating truly international gathering of colleagues interested in lymphoma
- [14.11.2019 - 16.11.2019 - ESO-ESMO Advanced Breast Cancer Fifth International Consensus Conference (ABC5)](https://archive.cancerworld.net/past-events/14-11-2019-16-11-2019-eso-esmo-advanced-breast-cancer-fifth-international-consensus-conference-abc5/) - Coordinating Chair - Fatima Cardoso Chairs - Eric P. Winer, Larry Norton, Alberto Costa Co-Chairs - Giuseppe Curigliano, Shirley A. Mertz The International Consensus Conference for Advanced Breast Cancer (ABC) will take place in Lisbon, Portugal, on 14-16 November 2019. Over the years it has established itself as the major international conference for advanced Breast Cancer.
- [29.11.2019  -  01.12.2019 - 4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers](https://archive.cancerworld.net/agenda/29-11-2019-01-12-2019-4th-eso-esmo-rce-clinical-update-on-rare-adult-solid-cancers/) - The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort, on an annual basis, conceived to strengthen the education of medical professionals willing to devote their career to rare cancers. Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus
- [A new form of psychotherapy overcomes the fear of cancer recurrence](https://archive.cancerworld.net/news/a-new-form-of-psychotherapy-overcomes-the-fear-of-cancer-recurrence/) - A pilot randomised clinical trial demonstrates that acceptance and commitment therapy (ACT) is a feasible and promising treatment for fear of cancer recurrence (FCR), a very disruptive condition affecting cancer survivors. Since the number of cancer survivors is expected to increase in the coming years, this treatment may be beneficial to a large number of
- [New cancer drugs may not work the way scientists thought](https://archive.cancerworld.net/news/new-cancer-drugs-may-not-work-the-way-scientists-thought/) - Many cancer drugs undergoing clinical trials kill malignant cells by acting on targets different from the one they were intended to hit. This surprising finding warns against poor preclinical characterization of targets and potential drugs that may result in the failure of clinical development. The study that revealed that off-target toxicity is the mechanism of
- [Older women rarely benefit from mammography](https://archive.cancerworld.net/news/older-women-rarely-benefit-from-mammography/) - Mammograms are unlikely to benefit older women with increased comorbidity, as they would probably die from something else before they could develop breast cancer. That is what results from a new study on more than 220,000 women, published in JNCI. "Our findings shed light on what age may be the best stopping point for mammography.
- [Highlights from ESMO 2019: bridging the gap between the research setting and the bedside](https://archive.cancerworld.net/news/highlights-from-esmo-2019-bridging-the-gap-between-the-research-setting-and-the-bedside/) - More than 28,500 participants from 138 countries worldwide pacifically invaded Barcelona, Spain, from September 27 to October 1, attending 299 sessions with 2,218 accepted abstracts and 93 late-breaking abstracts, during the event organized by ESMO in partnership with the European Association for Cancer Research (EACR). Basic, translational and clinical researchers met to discuss the latest
- [To close the quality gap, please listen more to local voices](https://archive.cancerworld.net/voices/to-close-the-quality-gap-please-listen-more-to-local-voices/) - As a medical oncologist, I feel it as a mission to try to improve patients’ outcomes by providing the best cancer patient care. One of ECCO’s missions is coherent with this, and their aim to contribute to improving access to high-quality screening, diagnostics and care across borders. This was a key reason for me to
- [Burden of cancer types is not reflected in research funding](https://archive.cancerworld.net/news/burden-of-cancer-types-is-not-reflected-in-research-funding/) - A new study on the allocation of research funding in the United States concluded that highly deadly cancer types are under-supported. This may be at least partially due to the impact of emotional choices on fundraising, since cancer types that appear most penalised are those that can be associated with stigmatized behaviours, such as drinking
- [Cancer data standards will make it easier to share information through the electronic health record](https://archive.cancerworld.net/news/cancer-data-standards-will-make-it-easier-to-share-information-through-the-electronic-health-record/) - The mCODE project will provide a common platform and language to collect all the data on cancer patients. The initial set of standards has been released at ASCO 2019 in Chiacgo Data collection, retrival and use both by patients and researchers are at the core of the debate at ASCO 2019, the largest cancer congress
- [Mind the label! Especially with low-risk neoplasms](https://archive.cancerworld.net/news/mind-the-label-especially-with-low-risk-neoplasms/) - According to a paper published in JAMA Oncology, the disease label has a profound influence on patient decision-making in the setting of low-risk malignant neoplasms and can also lead to overtreatment. In a discrete choice experiment, researchers from the University of Toronto asked 1.314 US residents to indicate their preferences between two hypothetical vignettes about
- [Kids born with assisted reproduction are not at higher risk of getting cancer](https://archive.cancerworld.net/news/kids-born-with-assisted-reproduction-are-not-at-higher-risk-of-getting-cancer/) - Do children born after assisted reproductive technology (ART) have an increased risk of developing cancer than other children? Many studies published in recent years have provided contradictory evidence, but the largest research just published on the topic in the journal Human Reproduction, ruled out such a causal effect. This study considered the long-term cancer risk in
- [Real world evidence: why we patients need it, and how we can get it](https://archive.cancerworld.net/featured/real-world-evidence-why-we-patients-need-it-and-how-we-can-get-it/) - Roger Wilson is a leading voice in cancer patient advocacy. He has been living with a recurrent sarcoma for 20 years, and is a co-founder of Sarcoma Patients Euronet. He is on the faculty of the EORTC/ESMO/ ECCO/AACR Methods in Clinical Cancer Research workshop, and has a particular interest in the use of patient reported
- [Cancerworld’s Albini in the list of top scientists](https://archive.cancerworld.net/in-the-media/cancerworlds-albini-in-the-list-of-top-scientists/) - Adriana Albini, the new editor in Chief of Cancerworld, is mentioned very high in the list of top 100,000 world scientists compiled by a group of experts of research methodology. The list of the top scientists from all disciplines was compiled based on citations and sophisticated metrics derived from them: “Citation metrics are widely used
- [Less frequent screening for lung cancer is equally lifesaving](https://archive.cancerworld.net/news/less-frequent-screening-for-lung-cancer-is-equally-lifesaving/) - When it comes to lung cancer screening less could be more, or at least could be as good as. The ten-year results of the Multicentric Italian Lung Detection (MILD) trial demonstrated that prolonged screening with biennial low-dose computed tomography (LDCT) is safe and effective compared to annual test, leading to a comparable reduction in lung
- [Major changes ahead](https://archive.cancerworld.net/editorial/major-changes-ahead/) - Last year we asked you to let us know how you would like to continue reading Cancer World articles. You told us that, while some of you still prefer holding a print copy in your hands, the great majority now read the magazine on your laptops, phones or tablets. Responding to this, beginning in January 2020
- [Maria Nazinkina Del Grande: bridging two worlds](https://archive.cancerworld.net/profile/maria-nazinkina-del-grande-bridging-two-worlds/) - A daughter and granddaughter of Russian heads of radiology, now living and working in southern Switzerland, medical oncologist Maria Nazinkina Del Grande is keen to play a part in bringing her two worlds closer together. She’s finding language offers a bridge not just to her native land but to the furthest frontiers of the Russian-speaking
- [How to become the best cancer doctor you can be](https://archive.cancerworld.net/cover-story/how-to-become-the-best-cancer-doctor-you-can-be/) - If your ambition is to excel at the oncology career you have chosen, you have to find your own pathway to success. Anna Wagstaff talked to three early-career oncologists who are trying to do just that, and asked them what worked, what didn’t, and what tips they have for others who are determined to be
- [Is precision medicine ignoring people dying of cancer?](https://archive.cancerworld.net/cutting-edge/is-precision-medicine-ignoring-people-dying-of-cancer/) - While we’re pouring resources into learning what keeps cancer cells alive, with the aim of blocking their supply lines, there is next to no interest in the molecular pathways that end up choking the life out of cancer patients, or in the biology behind the longer and better lives that palliative care can offer. Janet Fricker
- [The body after treatment: Do we do enough to protect our patients’ self-image?](https://archive.cancerworld.net/spotlight-on/the-body-after-treatment-do-we-do-enough-to-protect-our-patients-self-image/) - Studies indicate that a significant proportion of patients live to regret saying ‘yes’ to cancer treatments because of the impact on how they look, function or feel. Simon Crompton talks to patients and physicians about how oncologists and surgeons can minimise the number of their patients who end up feeling that way. It was only once
- [NETs – Why this master of disguise needs careful handling](https://archive.cancerworld.net/spotlight-on/nets-why-this-master-of-disguise-needs-careful-handling/) - Rare, hard to recognise, with primaries occurring at many different sites and associated with a wide variety of symptoms, tumours of the neuroendocrine system (NETs) are often detected too late to cure, and can be a cruel burden to live with. Sophie Fessl hears from patients and experts about why specialist NET services are so
- [The future is digital – but is it safe?](https://archive.cancerworld.net/featured/the-future-is-digital-but-is-it-safe/) - Joined-up patient-centred care requires sharing of data between patients, oncologists, hospitals, labs, GPs, nurses and even social care. But as apps designed to gather and share this data proliferate, so does the risk that the data ends up in the wrong hands, and possibly in identifiable form, as Peter McIntyre reports. Following treatment for prostate
- [Surviving in the workplace: Why it’s so hard and how we can make it easier](https://archive.cancerworld.net/spotlight-on/surviving-in-the-workplace-why-its-so-hard-and-how-we-can-make-it-easier/) - Working lives can be an important part of who we are, and many of us also need to work for financial reasons. Yet cancer survivors often have to struggle to get their working lives back on track. Rights, attitudes and policies could all make a big difference, but so can expectations, preparation and advice. Marc
- [Obesity and cancer](https://archive.cancerworld.net/e-grandround/obesity-and-cancer/) - Obesity is overtaking tobacco as the leading preventable cause of cancer. Oncologists have an important role to play in informing patients and directing them towards assistance in making lifestyle changes. Antonio Di Meglio reviews the links between obesity and cancer, the implications of weight gain after diagnosis and treatment, and strategies to help patients lower
- [Cancer is twice as deadly as heart disease in high-income countries](https://archive.cancerworld.net/news/cancer-is-twice-as-deadly-as-heart-disease-in-high-income-countries/) - Cardiovascular disease remains the leading cause of mortality among middle aged adults globally, accounting for 40% of all deaths, but in high-income countries cancer is now responsible for twice as many deaths as CVD (55% vs 23%), according to a new report from the Prospective Urban and Rural Epidemiologic (PURE) study published in The Lancet. The
- [Linking DNA methylation to Aspirin use and breast cancer survival](https://archive.cancerworld.net/news/linking-dna-methylation-to-aspirin-use-and-breast-cancer-survival/) - In women diagnosed with first primary breast cancer (BC), a closer look to epigenetic might be the “ace in the hole” to better understand the link between Aspirin use and prognosis and to refine patients stratification and risk-reducing strategies. Findings from a study recently published in Cancer suggest that the global and tissue-specific DNA methylation
- [How to nurse hope in recurrent ovarian cancer](https://archive.cancerworld.net/featured/how-to-nurse-hope-in-recurrent-ovarian-cancer/) - Results from studies on PARP inhibitors show that BRCA status and responsiveness to platinum analogues are much less binding that it was thought to achieve some improvements. But more clinical trials are needed to decide if PARP inhibitors should be used as part of first-line therapy or reserved for a later line Things are finally
- [Kid-friendly conferences might reduce gender inequalities](https://archive.cancerworld.net/news/kid-friendly-conferences-might-reduce-gender-inequalities/) - Among young oncologists, women encounter more difficulties than men in attending conferences and this may affect their professional satisfaction. This is the key message of a survey conducted by a group of researchers of the John Theurer Cancer Center (Hackensack, New Jersey, US) published on JAMA Oncology. The survey involved medical oncologists and radiation oncologists
- [Health warnings on alcohols are invisible for most young drinkers](https://archive.cancerworld.net/news/health-warnings-on-alcohols-are-invisible-for-most-young-drinkers/) - Labels containing warnings on the health risks associated with alcohol consumption are usually not noticed and remembered by teenagers, who should be in principle among the main targets. According to a study published in the Journal of Public Health by researchers of the University of Stirling and the Cancer Policy Research Centre at Cancer Research
- [Radio-immunotherapy, a work in progress](https://archive.cancerworld.net/featured/radio-immunotherapy-a-work-in-progress/) - The potential for combining radiotherapy with immunotherapy is enormous, yet experts say that radio-immunotherapy still has a long way to go before entering into routine clinical practice One of the hot topics discussed at ESTRO38, the annual congress of European Society for Radiotherapy and Oncology (ESTRO), was combining radiotherapy (RT) with immunotherapy. Just to get
- [The dismissed cancer tech assessment](https://archive.cancerworld.net/featured/the-dismissed-cancer-tech-assessment/) - Despite the prominent global debate on the ethics of technology and the increasing need for technology assessment before approval, anticipatory approaches, especially in oncology, are still in their infancy In the age of artificial intelligence (AI), big data and machine learning, technology assessment is becoming a necessity to ensure the approval of new technologies and
- [Tobacco control is improving (slowly) worldwide, WHO reports](https://archive.cancerworld.net/news/tobacco-control-is-improving-slowly-worldwide-who-reports/) - Launched in late June this year, the 2019 WHO Report "Offer help to quit tobacco use" claims that 5 billion people (65% of the world's population) are exposed to at least one measure to control the tobacco epidemic. They were 1 billion (15%) in 2007, four times fewer people than today. "More countries are making tobacco
- [The big challenge of treating adolescents and young adults with cancer](https://archive.cancerworld.net/spotlight-on/the-big-challenge-of-treating-adolescents-and-young-adults-with-cancer/) - No longer children and not yet adults, adolescents and young adults with cancer represent a specific patient population posing outstanding challenges to oncologists all over the world. Challenging but rewarding. This is how physicians described their experience of treating adolescents and young adults (AYAs) with cancer in a survey run during the 2019 Annual meeting
- [Nearly half of cancer patients don’t feel involved in treatment decisions, survey finds](https://archive.cancerworld.net/news/nearly-half-of-cancer-patients-dont-feel-involved-in-treatment-decisions-survey-finds/) - Almost half (47%) of patients with cancer do not think that they have been sufficiently involved in the treatment decision process. This is what the international All.Can cancer initiative reveals in its report Patient insights on cancer care: opportunities for improving efficiency, along with other patients’ outlooks concerning support and adequate information and care beyond
- [Cancer deaths translate to billions of lost earnings per year](https://archive.cancerworld.net/news/cancer-deaths-translate-to-billions-of-lost-earnings-per-year/) - Almost 95 billion dollars of lost earnings. That’s the estimated price USA paid in 2015 for cancer-related deaths in people aged 16 to 84 years, according to a paper recently published in JAMA Oncology by Farhad Islami, American Cancer Society, Atlanta (USA) and coauthors. “Cancer deaths impose a significant economic burden in the United States
- [Cancer patients advocates train up fellow activists across Europe](https://archive.cancerworld.net/news/cancer-patients-advocates-train-up-fellow-activists-across-europe/) - Cancer patient advocates from 26 European countries, active across a wide spectrum of cancer types, spent four days last week at the first training course to be developed and run by advocates themselves. The intensive training ‘Academy’ was organised by WECAN, an informal network of leaders of cancer patient umbrella organisations active in Europe (wecanadvocate.eu).
- [Cancer clinical trials recruit younger and younger patients](https://archive.cancerworld.net/news/clinical-trials-recruits-younger-and-younger-patients/) - Cancer clinical trial participants are significantly younger than the incident disease population. This age imbalance is particularly evident in industry-sponsored trials and raises concerns regarding the applicability of trial results. Seminal data from decades ago already demonstrated a marked underrepresentation of older patients in clinical trials: now a group of researchers from the University of
- [Why the Cancer World Journalism Award is more important than ever](https://archive.cancerworld.net/editorial/why-the-cancer-world-journalism-award-is-more-important-than-ever/) - What’s the real story? This month Cancer World launches its latest Journalism Award, and it’s more important than it’s ever been. A year ago, the overall winner of the last award explained why it meant so much to her. “I am glad that the voices of the poorest Indian cancer patients are heard across the
- [New evidence supports inverse association between cancer and Alzheimer ](https://archive.cancerworld.net/news/new-evidence-supports-inverse-association-between-cancer-and-alzheimer/) - Among patients with a history of cancer, risk of Alzheimer disease (AD) might be lower: a study published in JAMA Network Open showed that elderly cancer patients had modestly higher memory function and slower memory decline both before and after their diagnosis compared with similarly aged individuals who remained cancer free. This result suggests that
- [Social networks and digital oncology to reach young patients with cancer](https://archive.cancerworld.net/news/social-networks-and-digital-oncology-to-reach-young-patients-with-cancer/) - The scientific community should always be on the same page as the patients, and in order to really meet the needs of adolescents and young adults (AYA) a smart and flexible digital system is somehow mandatory in cancer care, according to an article published on The Lancet Oncology. Cancer patients in this unique age group
- [Novel hematological therapies were the main focus of the EHA congress](https://archive.cancerworld.net/news/novel-hematological-therapies-were-the-main-focus-of-the-eha-congress/) - Several new agents and combination therapies for the treatments of haematological malignant and non-malignant diseases were presented at the 24th congress of the European Haematology Association (EHA) that took place 13-16 June 2019 in Amsterdam (The Netherlands). “In these days, we heard very interesting news coming from study groups about novel drugs that can be
- [Access to quality cancer care: Is the cross border healthcare directive helping or hindering?](https://archive.cancerworld.net/spotlight-on/access-to-quality-cancer-care-is-the-cross-border-healthcare-directive-helping-or-hindering/) - The EU cross border healthcare directive – officially the ‘Directive on the application of patients’ rights in cross border healthcare’ – has been in force across member states for more than five years now. It enshrines the right of EU citizens to access healthcare in any EU country, to be reimbursed by their home country,
- [The real impact of checkpoint inhibitors is not as hoped](https://archive.cancerworld.net/news/the-real-impact-of-checkpoint-inhibitors-is-not-as-hoped/) - It seems that the big revolution linked to the introduction of checkpoint inhibitor drugs is still far to come. According to estimates recently published in JAMA Network Open, only a small percentage of patients eligible for these treatments respond to them, at odds with great – and probably unrealistic – expectations generated about this way
- [More than 50 percent rise in chemotherapy demand by 2040](https://archive.cancerworld.net/news/more-than-50-percent-rise-in-chemotherapy-demand-by-2040/) - Between 2018 and 2040, patients requiring first course chemotherapy will significantly increase annually, accordingly to a modelling study published in The Lancet Oncology. For the first time researchers estimated the scale of chemotherapy provision at regional, national and global level: Brooke Wilson and colleagues from the University of New South Wales and the Collaboration for Cancer
- [In memoriam, Evi Papadopoulou](https://archive.cancerworld.net/obituary/in-memoriam-evi-papadopoulou/) - The president of Europa Donna Cyprus, Evi Papadopoulou, died after a battle with breast cancer that lasted 34 years. “It is with deep regret and pain Europa Donna Cyprus announces the passing of its president, Evi Papadopoulou after a long battle with cancer. Farewell our Evi,” the organisation announced in a post on its Facebook
- [If it’s approved but not reimbursed, what do you say?](https://archive.cancerworld.net/spotlight-on/if-its-approved-but-not-reimbursed-what-do-you-say/) - “There are doctors who do not inform the patients about [non-reimbursed options] because it is less stressful”. “I explain to them that if they were treated in more developed countries, the treatment strategy would be different, and show them where they can find information about it”. “When you have learned from a clinical trial or
- [Better outcomes, better experiences: why cancer nursing is a job for specialists](https://archive.cancerworld.net/featured/better-outcomes-better-experiences-why-cancer-nursing-is-a-job-for-specialists/) - The European Oncology Nursing Society has compiled the evidence to show the value of the work cancer nurses do, and the specialist training and education they need to do it. Now they’re calling on policy makers to recognise cancer nursing skills, as outlined in the EONS Education Framework, as a speciality across Europe. Kate Griffin
- [‘Relentless and debilitating’: why is nausea still a problem, and how can we do better?](https://archive.cancerworld.net/spotlight-on/relentless-and-debilitating-why-is-nausea-still-a-problem-and-how-can-we-do-better/) - A whole armamentarium of antiemetic drugs has dramatically reduced the level of vomiting related to cancer treatment. But nausea, in particular, is still troubling patients. Sophie Fessl explores the causes, and asks: why is this still such a problem for patients, and how can it be sorted? There was a time when uncontrolled vomiting and being
- [Shortages of generic cancer medicines are harming patients. So why can’t we fix it?](https://archive.cancerworld.net/spotlight-on/shortages-of-generic-cancer-medicines-are-harming-patients-so-why-cant-we-fix-it/) - Despite more than a decade of efforts to address the problem, cancer patients across Europe and the US still cannot rely on essential drugs being available when they need them. Rachel Brazil looks at the size of the problem, its impact on patients and professionals, and the efforts to put in place policies and alternative
- [Better care or just more high-tech? Defining the value of new radiotherapy treatments](https://archive.cancerworld.net/cover-story/better-care-or-just-more-high-tech-defining-the-value-of-new-radiotherapy-treatments/) - Many patients are being treated with costly new radiotherapy treatments on the basis of hype rather than evidence that they stand to benefit. For others, lack of evidence is delaying access to new treatments that could make a real difference. Janet Fricker reports on efforts to develop a scale to measure the value of locoregional
- [The unreported results that are still undermining evidence-based medicine](https://archive.cancerworld.net/spotlight-on/the-unreported-results-that-are-still-undermining-evidence-based-medicine/) - The scandal of unreported trials has been known about for decades, prompting a variety of initiatives, legislative changes and campaigns. Sophie Fessl asks what impact these have had on reporting practices, and how far patients and clinicians can be confident that the evidence they can now access tells the full story. In 2010, Alessandro Liberati,
- [Management of toxicities related to immunotherapies](https://archive.cancerworld.net/e-grandround/management-of-toxicities-related-to-immunotherapies/) - Immunotherapy agents are being used to treat a growing range of cancers, but emerging evidence from randomised trials and clinical practice shows very different patterns of toxicity compared to chemotherapy. Jean-Marie Michot reviews what doctors should look out for when treating patients with immunotherapy, and the action to take. is assessed as grade 1 What
- [Stavroula Theophanous-Kitiri: a clinical pharmacy service that delivers for patients](https://archive.cancerworld.net/profile/stavroula-theophanous-kitiri-a-clinical-pharmacy-service-that-delivers-for-patients/) - It’s about getting the right drug, to the right patient, at the right time, in the right amount, with the right patient information on how, when and why to use it. Peter McIntyre talks to the woman who built up the clinical pharmacy service at Cyprus’s first dedicated cancer centre. When the Bank of Cyprus
- [Dina Tiniakos: President of the European Society of Pathology](https://archive.cancerworld.net/hot-seat/dina-tiniakos-president-of-the-european-society-of-pathology/) - Precision cancer medicine has put a spotlight on the role of pathologist, whose job it is to provide an accurate diagnosis as well as prognostic and predictive information on which to tailor the treatment plan. Cancer World asked Dina Tiniakos, President of the European Society of Pathology, how pathologists are rising to the challenge. Cancer
- [Winning where it matters](https://archive.cancerworld.net/editorial/winning-where-it-matters/) - We’re winning the war on cancer on a scientific level but losing it in the real world. That was the conclusion reached by 100 top researchers, clinicians and advocates at the first World Oncology Forum held in 2012. Developments in precision cancer medicine since then have proved them right. The new generations of high-tech designer
- [Incidence of colorectal cancer is on the rise among young adults](https://archive.cancerworld.net/news/incidence-of-colorectal-cancer-is-on-the-rise-among-young-adults/) - Data from 20 European countries show that in the past 15 years colorectal cancer (CRC) incidence increased among young adults. The awareness of the changing epidemiology of CRC could have a practical implication: to reconsider at which age to start screening. A team of researchers, guided by Manon Spaander, gastroenterologist at the Erasmus University Medical
- [Safety First, Safety Always](https://archive.cancerworld.net/voices/safety-first-safety-always/) - European Cancer Nursing Day (ECND2019) on 18 May sees the launch of the EONS Safety Manifesto. Here, EONS President Lena Sharp describes how this new initiative from the European Oncology Nursing Society will have a major impact on both patient and occupational safety in cancer care settings. Recent improved cancer treatments also carry with
- [A manifesto to make breast cancer a top priority in EU](https://archive.cancerworld.net/news/a-manifesto-to-make-breast-cancer-a-top-priority-in-eu/) - A group of members of the European Parliament is promoting a manifesto “to improve services for patients in an area of still high unmet need and reduce the societal impact of breast cancer by elevating it as a health policy priority to improve breast cancer prevention, diagnosis and care across Europe”, according to a press
- [Trials on anticancer drugs often have inadequate control arms](https://archive.cancerworld.net/news/trials-on-anticancer-drugs-often-have-inadequate-control-arms/) - Randomized controlled trials that have been used for the FDA approval of new anticancer drugs were sometimes based on a flawed design, with suboptimal control arms: “Using a suboptimal control arm may bias a trial in favour of the experimental arm and reduces a trial's external validity” explain the authors of a paper recently published in
- [The annual ESTRO congress outlines the future of radiotherapy](https://archive.cancerworld.net/news/the-annual-estro-congress-outlines-the-future-of-radiotherapy/) - The combination of immuno-oncology and radiotherapy, new technologies, new indications, the role of artificial intelligence: these are the main topics discussed at ESTRO38, the annual congress of European Society for Radiotherapy and Oncology (ESTRO) that took place 26-30 April 2019 in Milan, Italy. “The Tsunami of immuno-oncology is opening the doors to different kinds of disease
- [Cancer enters the campaign for European Commission President](https://archive.cancerworld.net/news/cancer-enters-the-campaign-for-european-commission-president/) - Manfred Weber, one of the leading candidates to become the next president of the European Commission, has promised to “make the fight against cancer an absolute priority” in the next five years. “While Europe is threatened both internally and externally, we must not forget our most insidious enemy that we are not able to defeat:
- [Bad for budgets, but also for patients - Challenging the in-patient culture of central and eastern Europe](https://archive.cancerworld.net/featured/bad-for-budgets-but-also-for-patients-challenging-the-in-patient-culture-of-central-and-eastern-europe/) - While many western countries are pioneering safe delivery of more cancer care in primary, community and home settings, across central and eastern Europe, beds in university hospitals and cancer centres are still filled unnecessarily with people requiring diagnostic procedures, routine care and check-ups. Marc Beishon looks at the implications and explores prospects for change. When
- [Comprehensive cancer care networks - Test driving the model in southern Czechia](https://archive.cancerworld.net/spotlight-on/comprehensive-cancer-care-networks-test-driving-the-model-in-southern-czechia/) - What does an ideal cancer service look like and how can countries/regions make that transformation? A European collaborative project spent two years trying to answer this question. The solution they came up with is now being piloted in the Czech Republic, as Sophie Fessl reports. “How do you reconcile providing cancer services near a patient’s
- [23.01.2020 - 27.01.2020 - 8th ESO Arab and Southern European Countries Masterclass in Clinical Oncology](https://archive.cancerworld.net/agenda/23-01-2020-27-01-2020-8th-eso-arab-and-southern-european-countries-masterclass-in-clinical-oncology/) - AIMS AND OBJECTIVESThis clinically oriented educational programme has been designed for medical and clinical oncologists who wish to improve their skills in the management of cancer patients.The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-orientated training. The programme focuses on breast, gynaecological, lung, urological and gastrointestinal cancers.
- [03.04.2019  -  07.04.2019 - 5th ESO-ESMO Latin-American Masterclass in Clinical Oncology](https://archive.cancerworld.net/past-events/03-04-2019-07-04-2019-5th-eso-esmo-latin-american-masterclass-in-clinical-oncology/) - 03.04.2019 - 07.04.2019 Lima, PeruIt It is with pleasure and gratefulness for the consideration of the local community, that ESO announces the fifth edition to be held in the region in 2019.The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based
- [12.04.2019  -  17.04.2019 - 6th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology](https://archive.cancerworld.net/past-events/12-04-2019-17-04-2019-6th-eso-esmo-eastern-europe-and-balkan-region-masterclass-in-medical-oncology/) - 12.04.2019 - 17.04.2019 Split, Croatia This residential programme has been designed for medical and clinical oncologists, who wish to improve their skills or those who are preparing for the national board or ESMO exam. The programme will expose participants to a full spectrum of issues in clinical and medical oncology from basic science to advanced knowledge of
- [Alternative therapies in cancer: don't ask don't tell?](https://archive.cancerworld.net/news/alternative-therapies-in-cancer-dont-ask-dont-tell/) - According to a nationwide survey, almost one out of three patients with cancer or cancer survivors in the US use complementary/alternative medicines (CAMs). And among them, three out of ten do not think that their physician should be informed. “CAMs, defined as therapies used in addition to or instead of conventional therapies, respectively, are frequently
- [On a Mumbai street, aspiring soldier endures India’s cancer-care crisis](https://archive.cancerworld.net/spotlight-on/on-a-mumbai-street-aspiring-soldier-endures-indias-cancer-care-crisis/) - Recent studies have begun to quantify the size of India’s cancer burden, and the barriers to accessing diagnosis and care. This article, first published in IndiaSpend, presents those data to a mass audience through the stories of patients waiting for treatment outside Mumbai’s Tata Memorial hospital. It won reporter Swagata Yadavar the overall Cancer World
- [Communicating with patients with advanced and metastatic cancer](https://archive.cancerworld.net/e-grandround/communicating-with-patients-with-advanced-and-metastatic-cancer/) - People with incurable cancer need doctors who offer them hope but also give them a clear idea of what is realistically possible. Doctors can find it hard to be both empathic and honest when the news is bad. Psycho-oncologist Lesley Fallowfield outlines the key issues that need to be addressed in consultations, and the pitfalls
- [FDA warns that we are trusting surgeon-robots too much](https://archive.cancerworld.net/news/fda-warns-that-we-are-trusting-surgeon-robots-too-much/) - The US Food and Drug Administration issued a safety communication about robotically-assisted surgical procedures for cancer prevention or treatment, pointing out that their safety and effectiveness has not been established yet. In the Unites States, the availability of robotically-assisted surgical devices has grown exponentially in the last few years. Surgeons are prone to offer the most
- [Home stool test might replace first-line colonoscopy](https://archive.cancerworld.net/news/home-stool-test-might-replace-first-line-colonoscopy/) - A new article published in Annals of Internal Medicine states that average-risk patients can safely choose for an annual home stool test instead of a screening colonoscopy. In many countries, such as United Kingdom, Canada, and Italy, colonoscopy is typically performed for average-risk individuals with no symptoms only if a fecal immunochemical test (FIT), which
- [An unexpected side-effect of radiotherapy](https://archive.cancerworld.net/news/an-unexpected-side-effect-of-radiotherapy/) - The staff of a crematorium in the United States was contaminated after dealing with the dead body of one or more persons who had died right after a radiotherapy course, raising concerns about the risk for human ashes to become potential source of radioactive contamination. Radiation protection is a safety concern that must be imperatively
- [ESMO delivers its recipe to prevent shortages of essential medicines in Europe](https://archive.cancerworld.net/news/esmo-delivers-its-recipe-to-prevent-shortages-of-essential-medicines-in-europe/) - Even essential medicines can at times become difficult to find in Europe, and this can in some cases represent a threat to the life of cancer patients who are otherwise being treated effectively: to prevent future shortages of essential drugs, the European Society for Medical Oncology (ESMO) collaborated with the European Parliament to organise a
- [One cycle of chemotherapy or radiotherapy does not affect sperm count](https://archive.cancerworld.net/news/one-cycle-of-chemotherapy-or-radiotherapy-does-not-affect-sperm-count/) - According to an article published in the journal Annals of Oncology, men with early stage testicular cancer (Testicular Cancer in Clinical Stage I, or TC CS I) can be treated with one course of chemotherapy or radiotherapy after surgery without long-term effects on their sperm count. Testicular cancer is the most common cancer among young
- [Brachytherapy: halting the spiral of decline](https://archive.cancerworld.net/cover-story/brachytherapy-halting-the-spiral-of-decline/) - Brachytherapy, a standard of care for some cancer indications, which involves delivering radiotherapy from a source within the tumour, is underfunded, increasingly marginalised and in decline across much of Europe. Janet Fricker talked to specialists from ten countries, and asked why is this happening, does it matter, and what can be done about it? In
- [New dawn in prostate cancer diagnosis](https://archive.cancerworld.net/cutting-edge/new-dawn-in-prostate-cancer-diagnosis/) - In expert hands, diagnostic multiparametric MRI is more effective than the dreaded prostate biopsy as the first step in identifying prostate cancers. It is certainly less unpleasant. Guidelines and practice are changing to reflect this, but concerns about capacity, access and risk stratification will need to be addressed, writes Simon Crompton. When Brian Kavanagh saw
- [Tit Albreht: Europe’s unofficial head of cancer policy](https://archive.cancerworld.net/featured/tit-albreht-europes-unofficial-head-of-cancer-policy/) - In 2006, ​Slovenia staged the ‘United Against Cancer’ summit, with a view to closing the gap ​in prevention and survival ​between ‘old’ and ‘new’ Europe. Tit Albreht, from the ​National ​Institute of Public Health, was a key player. He went on to pioneer a series of EU Joint Actions on cancer, where member states collaborated
- [Whatever happened to the minimum effective dose?](https://archive.cancerworld.net/cover-story/whatever-happened-to-the-minimum-effective-dose/) - Traditional assumptions about the benefits of higher doses are being challenged as patients demand more emphasis on quality of life and new knowledge emerges about the development of resistance. So why are drug developers still failing to explore dosing adequately, asks Simon Crompton. Five years ago, at a major ASCO event, the head of
- [Should breast surgeons use ultrasound?](https://archive.cancerworld.net/spotlight-on/should-breast-surgeons-use-ultrasound/) - Surgeons are increasingly using ultrasound for visual guidance, both in an interoperative setting, to help ensure a clean cut around the tumour, and also to guide breast biopsies. Radiologists however are warning that performing and interpreting ultrasound scans can be trickier than is often assumed and that, in untrained hands, ultrasound could harm patient care.
- [How to fill the gender gap in oncology](https://archive.cancerworld.net/cover-story/how-to-fill-the-gender-gap-in-oncology/) - The lack of women in apical positions is a weakness of oncology, and a loss for patients. Mentorship programs launched in recent years by scientific societies like ESMO and ASCO, together with practical support for career development, are starting to address the many factors that make the climb to success steeper for women The 2018
- [Big data and precision medicine in cancer: challenges to face](https://archive.cancerworld.net/cancerworld-plus/big-data-and-precision-medicine-in-cancer-challenges-to-face/) - While AI and big data are more and more used to tackle cancer, experts caution: there cannot be exceptionalism for AI in medicine. It requires rigorous studies, publication of the results in peer-reviewed journals, and clinical validation in a real-world environment, before implementation in patient care 2019 has begun with news regarding the use of
- [Cancer services: how much is enough?](https://archive.cancerworld.net/cancerworld-plus/cancer-services-how-much-is-enough/) - At a time when the search for the ideal recipe of the most effective multidisciplinary approach to cancer care is still on, the life of millions of cancer patients around the world could be saved with a better organization of healthcare, devoting the scarce resources available in each local context to the most effective mixture
- [I have cancer but I want to work](https://archive.cancerworld.net/cancerworld-plus/i-have-cancer-but-i-want-to-work/) - It is crucial to address disparities and harmonise standards for all European cancer patients. An event at the European Parliament in Brussels, organised by the ABC Global Alliance focused on working rights and policies to protect patient autonomy European politicians and policymakers were called on to implement consistent and flexible policies to enable cancer patients and
- [Nutrition and cancer: can we really trust experts’ recommendations?](https://archive.cancerworld.net/cancerworld-plus/nutrition-and-cancer-can-we-really-trust-experts-recommendations/) - No doubt that diet, as part of a healthy lifestyle, is a pillar of disease prevention and wellbeing, but judging the evidence and coming to strong recommendations in the field is a challenging issue, even for the experts In 2018 the Third Expert Report – Diet, Nutrition, Physical Activity and Cancer: a Global Perspective was published
- [That’s cancer, a long long time ago](https://archive.cancerworld.net/cancerworld-plus/thats-cancer-a-long-long-time-ago/) - Researchers are turning to mummies and human remains to study cancer, hoping it can inform screening and treatments in the future Modern lifestyle changes, such as smoking or a fast food diet, are often blamed for the rise in cancer cases around the world. While the links that researchers have found between these changes and
- [Team members learn from one another](https://archive.cancerworld.net/editorial/team-members-learn-from-one-another/) - “Multidisciplinary team meetings have become meaningless.” “It’s a rubber stamp.” “It’s a bureaucratic exercise.” These comments, made by oncologists from a number of countries at an ESO meeting to discuss training needs, paint quite a dispiriting picture. It seems we still need to win the argument with key clinicians about why care is better when
- [A Manifesto to put childhood cancers high in the European agenda](https://archive.cancerworld.net/news/a-manifesto-to-put-childhood-cancers-high-in-the-european-agenda/) - The European Parliament that will be elected in the coming months has to deal with more than 35.000 new cancer diagnoses in children and young people, more than 6.000 deaths among young patients, and nearly half a million childhood cancer survivors by 2020 – 2025: these are some of the figures contained in the “Manifesto
- [Early-phase trials are moving away from the “big killers”](https://archive.cancerworld.net/news/early-phase-trials-are-moving-away-from-the-big-killers/) - No more colorectal or lung cancer in phase 1 trials. Stretching the point, this could be the scenario in the near future following the trends described in an abstract presented at the International Congress on Targeted Anticancer Therapies held in Paris at the end of February 25-27, and published in a special Supplement of Annals
- [In Memoriam, Michel Richonnier](https://archive.cancerworld.net/obituary/in-memoriam-michel-richonnier/) - The Pioneer and first Head of the Europe against Cancer Programme has sadly left us on Monday 25 February 2019. He showed us that partnership at the European level can help defeat cancer. Michel Richonnier was an engineer and economist by training. He has dedicated most of his professional career to questions related to European
- [Half of pediatric cancers undiagnosed and untreated worldwide](https://archive.cancerworld.net/news/half-of-pediatric-cancers-undiagnosed-and-untreated-worldwide/) - Nearly one in two children with cancer are never diagnosed and may die untreated, according to a a new model proposed in a study published in The Lancet Oncology by Zachary Ward and colleagues from Harvard University T.H. Chan School of Public Health. In fact, the model estimates that there were 397.000 childhood cancer cases
- [Mammography screening and improved treatment saved half a million women](https://archive.cancerworld.net/news/mammography-screening-and-improved-treatment-saved-half-a-million-women/) - As many as Baltimore’s residents. This is the answer to the question: “How many breast cancer patients have been saved from death in the past 30 years thanks to mammography screening and improved treatment?”. Baltimore has over 600.000 residents. Being a pessimist, the answer could scale down to the population of a smaller city like
- [Gender gap in oncology and in scientific research is “actionable”](https://archive.cancerworld.net/editorial/gender-gap-in-oncology-and-in-scientific-research-is-actionable/) - It is well established that women are under-represented in positions of power and leadership, in scientific and health disciplines across the world. There is a lot of concern about it and it seems to be widely recognized, however very little is done, and only few, illuminated institutions are really trying to make a difference. Cancer World
- [Novel molecular insights in brain metastases will change diagnostics and therapy](https://archive.cancerworld.net/cancerworld-plus/novel-molecular-insights-in-brain-metastases-will-change-diagnostics-and-therapy/) - Brain metastases are an unmet need in current oncologic care. New hopes come from the characterization of their genomic evolution and from the study of circulating tumour cells Hearing the doctor say that the tests have discovered metastases, for a cancer patient, sounds as hearing a death sentence. Alongside the fear of dying, patients are
- [Case reports: when a consent could become a barrier to medical education](https://archive.cancerworld.net/news/case-reports-when-a-consent-could-become-a-barrier-to-medical-education/) - In a viewpoint published on JAMA Oncology, experts from University of Texas MD Anderson Cancer Center, Houston, have raised the question whether it is always convenient to ask patient consent before publishing case reports. The value of this kind of report is well recognised by clinicians and academics, given that it could help researchers generate
- [Regular NSAID use may improve survival in head and neck cancer](https://archive.cancerworld.net/news/regular-nsaid-use-may-improve-survival-in-head-and-neck-cancer/) - A subset of patients with head and neck cancer (HNC) who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 6 months showed longer disease-specific survival and overall survival than nonregular NSAID users. The authors of the study, just published by the Journal of Experimental Medicine, evaluated the impact of NSAID use
- [06.12.18 - ESO-EUSOBI-IBUS Workshop: Use of Ultrasound in Breast Cancer Surgery](https://archive.cancerworld.net/past-events/eso-eusobi-ibus-workshop-use-of-ultrasound-in-breast-cancer-surgery/) - 06.12.2018 Strasbourg, France The Convention Centre and Exhibition Park (Churchill Room) 14:00 - 16:00 Chairs: E. Aribal, TR - A. Costa, IT/CH14:00 Why does the breast surgeon need ultrasound F. Meani, CH 14:20 Role of ultrasound in a multidisciplinary setting R.M. Trimboli, IT 14:40 IBUS tips for better breast ultrasound A. Mundinger, DE 15:00 Who
- [Cancer and suicide risk: we know when, not who, how nor why](https://archive.cancerworld.net/news/cancer-and-suicide-risk-we-know-when-not-who-how-nor-why/) - In the six months after a diagnosis of cancer, suicide risk increases significantly, up to 20% relative to the general population, according to a paper recently published on JAMA Psychiatry. To evaluate the impact of a cancer diagnosis on suicide risk, a group of British researchers led by Katherine E. Henson from the National Cancer
- [The slow adoption of biomarkers affects cancer treatment in Greece](https://archive.cancerworld.net/news/the-slow-adoption-of-biomarkers-affects-cancer-treatment-in-greece/) - A huge gap in the Hellenic Organization for Health Care Services Provision reimbursement system (EOPPY) for cancer biomarkers is causing a lot of trouble for doctors and patients. At the moment the Ministry of health approved the use and reimbursement of 21 cancer biomarkers, but in a rapidly changing field many more are still not
- [World Oncology Forum articulates the case for investing in affordable cancer care](https://archive.cancerworld.net/news/world-oncology-forum-articulates-the-case-for-investing-in-affordable-cancer-care/) - Following the third UN high-level summit on non-communicable diseases last September, and with preparations for the 2019 high-level summit on Universal Health Coverage gathering speed, the World Oncology Forum (WOF) is making the case for investment in accessible cancer services to be an integral part of frameworks to improve global health. Work kicked off last
- [With ICIs, the effect of mutations changes with cancer types](https://archive.cancerworld.net/news/with-icis-the-effect-of-mutations-changes-with-cancer-types/) - “Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed”: starting from this premise, a group of researchers of the Memorial Sloan Kettering Cancer Center in New York led by Robert M. Samstein, Chung-Han Lee, Alexander N. Shoushtari and Matthew Hellmann, have examined in depth the association between the number
- [How should we assess the efficacy of new treatments in rare tumours?](https://archive.cancerworld.net/e-grandround/how-should-we-assess-the-efficacy-of-new-treatments-in-rare-tumours/) - Traditional approaches to generating clinical evidence rely on recruiting large numbers of patients into trials. Paolo Bruzzi reflects on the challenges of designing and analysing clinical trials in rare cancers, and reviews the potential for using alternative trial designs and Bayesian statistical approaches to build robust evidence where patient numbers are small. This grandround was
- [Lena Sharp: President of the European Oncology Nursing Society](https://archive.cancerworld.net/hot-seat/lena-sharp-president-of-the-european-oncology-nursing-society/) - The European Oncology Nursing Society is a pan-European organisation dedicated to the support and development of cancer nursing. It recently completed a landmark research project – RECaN – aimed at increasing recognition of the value and contribution of cancer nursing across Europe. Cancer World asked EONS president Lena Sharp what they learned and why it
- [Pushing the boundaries of curative treatment: more patients with oligometastatic disease could benefit from local therapies](https://archive.cancerworld.net/spotlight-on/pushing-the-boundaries-of-curative-treatment-more-patients-with-oligometastatic-disease-could-benefit-from-local-therapies/) - Is there an early stage in the metastatic process at which the possibility of a cure remains open? Marc Beishon looks at the science, the opportunities opened up by new and more accurate imaging and treatment modalities, and the clinical evidence. Can we cure any patients once their cancer has spread? It’s a question that
- [Csaba Dégi: Playing catch-up with the West](https://archive.cancerworld.net/profile/csaba-degi-playing-catch-up-with-the-west/) - Csaba Dégi is all set to study how patients in Romania transition back into primary care after their treatment is over, as part of current international efforts to focus on the needs of survivors. That’s something to be proud of, he tells Janet Fricker, given that as recently as ten years ago only a minority
- [The Car T cell revolution: what does it offer, and can we afford it?](https://archive.cancerworld.net/cutting-edge/the-car-t-cell-revolution-what-does-it-offer-and-can-we-afford-it/) - In August 2018 the first therapies aimed at re-engineering patients own T cells to attack cancer entered the European market. Rachel Brazil looks at how they work, what they achieve, and what the logistical and cost barriers will mean for patients hoping to get access. In 2012, Emily Whitehead, a six-year-old from Pennsylvania, USA, with
- [Breasts, cancer, and relationships: changing attitudes in central and eastern Europe](https://archive.cancerworld.net/spotlight-on/breasts-cancer-and-relationships-changing-attitudes-in-central-and-eastern-europe/) - Breast cancer impacts on the way a woman sees herself and on how she is seen by her partner and society in general. It’s getting easier to talk about, but are these conversations also happening in central and eastern Europe? Pawel Walewski reports. When Magda learned she had breast cancer, she felt it couldn’t have
- [The patient advocates will see you now: Cancer groups trial the AIDS model for interacting with industry](https://archive.cancerworld.net/patient-voice/the-patient-advocates-will-see-you-now-cancer-groups-trial-the-aids-model-for-interacting-with-industry/) - It’s easy to say you are patient centred – until you are asked to spell out what that means in terms of your processes and practice. Last summer 11 patient groups invited nine pharmaceutical companies to join in a frank discussion about how to make ‘patient centred’ a reality. Anna Wagstaff reports on how it
- [When more sleep won't do it: Tackling cancer-related fatigue](https://archive.cancerworld.net/spotlight-on/when-more-sleep-wont-do-it-tackling-cancer-related-fatigue/) - Cancer-related fatigue affects many people, before, during and after treatment. It can have a seriously debilitating impact on lives, but effective interventions have so far proved hard to find. Sophie Fessl explores what might be causing the condition, and asks healthcare providers and patients about how they manage it. “Before cancer, I did not know
- [Demystifying morphine and hospice in Africa](https://archive.cancerworld.net/voices/demystifying-morphine-and-hospice-in-africa/) - In Africa, palliative care equals death. Not because hospices are ill equipped, or governments have grossly neglected the patients, but because of cultural biases. Few households talk about end-of-life care even if a patient has incurable cancer. Few oncologists want to let go of patients and refer them to palliative specialists because of greed for
- [Milan (Italy), 22-26/1/2018 Clinical Oncology: Sarcomas](https://archive.cancerworld.net/past-events/milan-italy-22-2612018-clinical-oncology-sarcomas/) - University Post-graduate Course - Clinical Oncology: Sarcomas Scientific Coordinator: P.G. Casali, IT The University of Milan, Italy, in close collaboration with the European School of Oncology, will organise the first post-graduate course on clinical oncology of sarcomas. This programme is addressed to an international audience of clinical oncologists interested in advancing their knowledge and skills on
- [Lugano (Swi), 6-8/10/2018 - 4th ESO-ESMO Breast Cancer in Young Women International Conference (BCY4)](https://archive.cancerworld.net/past-events/lugano-svi-6-8102018-4th-eso-esmo-breast-cancer-in-young-women-international-conference-bcy4/) - Chair: O. Pagani, CH Breast cancer in young women is a complex disease, occurring when these women are at the peak of their reproductive years, family life and careers. Being a somewhat rare disease the optimal management of these patients is based on scientific data derived from clinical trials mostly conducted on older women. Many
- [The best decisions come from the best run MDTs](https://archive.cancerworld.net/editorial/the-best-decisions-come-from-the-best-run-mdts/) - Having just retired from active clinical practice as a breast surgeon, I can look back at how decision making has evolved over the course of my career, from when a single doctor took the decisions, to the multidisciplinary approach we advocate today. It was in breast cancer, with the discovery of the importance of hormonal
- [Adjuvant therapy in stage III colon cancer: is less (really) better?](https://archive.cancerworld.net/news/adjuvant-therapy-in-stage-iii-colon-cancer-is-less-really-better/) - Are 6 months of adjuvant chemotherapy really necessary for a patient with a stage III colorectal cancer? The answer should be “yes”, at least according to a paper recently published on the New England Journal of Medicine by Axel Grothey from the Division of Medical Oncology, Mayo Clinic Cancer Center, Rochester, USA, and colleagues. Strictly
- [It’s urgent to learn more on Immune Checkpoint Inhibitor Toxicity](https://archive.cancerworld.net/news/its-urgent-to-learn-more-on-immune-checkpoint-inhibitor-toxicity/) - Recently, Allison and Honjo have been awarded with the Nobel prize for their findings leading to the new cancer treatment approaches known as immune checkpoint inhibitors (ICIs). Thanks to these discoveries in fact, the management of the disease has profoundly changed, producing remarkable results on several tumors, even if checkpoint inhibitors have significant side effects, that
- [For cervical cancer, open surgery is better than minimally invasive surgery](https://archive.cancerworld.net/news/for-cervical-cancer-open-surgery-is-better-than-minimally-invasive-surgery/) - In patients with early cervical cancer, minimally invasive surgery is likely not the best option, according to two studies with “alarming data” appearing in the latest issue of the New England Journal of Medicine. “Minimally invasive radical hysterectomy in patients with cervical cancer was associated with a higher rate of recurrence and a lower rate
- [EuropaColon expands into Digestive Cancers Europe
](https://archive.cancerworld.net/news/europacolon-expands-into-digestive-cancers-europe
/) - With the goal of “saving additional 250,000 Europeans every year”, EuropaColon decided to expand its activities to all digestive cancers: oesophageal, stomach, colon, rectum, pancreas and rare digestive cancers. Digestive Cancers Europe, as the new patient organisation is named, is based in Brussels. It is formally founded as a Belgian non-profit organisation by Jola Gore-Booth,
- [World Thrombosis Day: what's the role of thrombosis in cancer?](https://archive.cancerworld.net/news/world-thrombosis-day/) - There is too little awareness about cancer associated thrombosis: this is the main result of the first survey on awareness of cancer related thrombosis presented by ECPC (the European Cancer Patient Coalition) for the World Thrombosis Day. A preventable disease Thrombosis is the second most common preventable cause of death in patients with cancer, and therefore
- [Lung cancer mortality expected to decrease over the next half century](https://archive.cancerworld.net/news/lung-cancer-mortality-expected-to-decrease-over-the-next-half-century/) - “Tobacco control efforts implemented since the 1960s will continue to reduce lung cancer rates well into the next half-century. Additional prevention and cessation efforts will be required to sustain and expand these gains to further reduce the lung cancer burden in the United States”: this is the conclusion of a study just published in the
- [Hopes for faster access to beneficial new drugs hang in the balance](https://archive.cancerworld.net/spotlight-on/hopes-for-faster-access-to-beneficial-new-drugs-hang-in-the-balance/) - After more than ten years developing and piloting a collaborative approach to evaluating new medical technologies, EUnetHTA will come to an end in 2020. The Commission is proposing a replacement with mandatory powers, but are Europe’s governments prepared to sign up to it? Peter McIntyre reports on the battle lines and the debate. The European
- [Mind your head (and neck), say famous paintings](https://archive.cancerworld.net/news/mind-your-head-and-neck-say-famous-paintings/) - Over 20 specialised centres that will be open to the public, and events in ten cities will be part of the Italian effort to raise public awareness on early diagnosis in head and neck cancers, within the European “Make Sense Campaign”. The campaign, promoted by the European Head and Neck Society (EHNS) during the head
- [Fatal reactions to immunotherapies are rare, but have diverse causes](https://archive.cancerworld.net/news/fatal-reactions-to-immunotherapies-are-rare-but-have-diverse-causes/) - The most commonly prescribed class of immunotherapies (called ICIs, immune checkpoint inhibitors) are not free from fulminant and fatal toxic side effects; the researchers of the Vanderbilt-Ingram Cancer Center recently evaluated their toxicities, publishing the results in JAMA Oncology.The investigation about fatal immune checkpoint inhibitors concluded that, although such events do happen, the risks are
- [Low-adherence to hormonal therapy among premenopausal early breast cancer patients](https://archive.cancerworld.net/news/low-adherence-to-hormonal-therapy-among-premenopausal-early-breast-cancer-patients/) - “At one year from initiation of TAM, plasma measurements show that a substantial proportion of premenopausal patients are not adequately adherent to this treatment. Poorly-adherent patients could benefit from metabolic and pharmacogenetic investigations. Identification of patients at risk of non-adherence allows early targeted interventions to promote adherence in this unique population”: this is the conclusion
- [Reimbursement of newly approved cancer drugs may take more than one year](https://archive.cancerworld.net/news/reimbursement-of-newly-approved-cancer-drugs-may-take-more-than-one-year/) - After the European Medicines Agency (EMA) approves a new cancer drug, reimbursement decisions by each country’s health authorities can take up to one year, with wide variations between countries. according to a study just presented at ESMO 2018 Congress in Munich (Germany). Kerstin Vokinger from University Hospital of Zurich, Switzerland, and Harvard Medical School, Boston,
- [When patients ask you to help them die](https://archive.cancerworld.net/spotlight-on/when-patients-ask-you-to-help-them-die/) - The public, politicians, and legislators debate the morals, ethics, and unintended consequences of assisted dying. But it is clinicians, in the privacy of their consulting room, who face requests to be the person giving that assistance. How do cancer professionals feel about being asked to help someone die, and what do they do? Cancer World
- [Helen Boyle: putting personalised care into practice](https://archive.cancerworld.net/profile/helen-boyle-putting-personalised-care-into-practice/) - Whether the patient in front of her is old and frail, young and trying to keep their life on track, or simply struggling to come to terms with a terminal diagnosis, Helen Boyle goes the extra mile to ensure each one gets the care that is right for them. Doing all this at a time
- [The personalisation lottery – Lack of accessible regulated testing services is putting patients and health budgets at risk](https://archive.cancerworld.net/featured/the-personalisation-lottery-lack-of-accessible-regulated-testing-services-is-putting-patients-and-health-budgets-at-risk/) - Health systems and insurances take decisions on reimbursing targeted medicines, doctors focus increasingly on tailoring treatments to individual patients and the molecular biology of their disease. But the need for funded quality-controlled services to do the testing required for the tailoring has been largely overlooked, as Janet Fricker reports. Biomarker testing is key to personalising
- [Primary therapy of early oesophageal and gastric cancers](https://archive.cancerworld.net/e-grandround/__trashed/) - What does our growing understanding of the molecular subtypes of gastric and oesophageal cancers, and the results of recent trials testing multimodal therapies, mean for the way we classify, diagnose and treat these tumours? Jonas Feilchenfeldt presents key points from the 2018 St Gallen GI Cancer Conference. This grandround was first presented by Jonas Feilchenfeldt,
- [Need a doctor? Send in your digital twin!](https://archive.cancerworld.net/spotlight-on/need-a-doctor-send-in-your-digital-twin/) - Max Rauner, Science editor at ZEIT Wissen, the popular science magazine of Germany’s largest weekly newspaper Die ZEIT, won the Cancer World Journalism Award for best article on research, with this piece on the use of modelling ‘virtual patients’. The award recognises the value of journalism that explains cancer research and its potential application in
- [Thierry Philip – President, Organisation of European Cancer Institutes](https://archive.cancerworld.net/hot-seat/thierry-philip-president-organisation-of-european-cancer-institutes/) - Whether you are a designated cancer centre leading international translational research projects, or a cancer service working to deliver high-quality treatment at a university hospital, the Organisation of European Cancer Institutes (OECI) is where you belong. So says OECI’s new President, Thierry Philip, who spoke to Cancer World about his plans to drive forward OECI’s
- [Tumour microenvironment the new battlespace in the war against cancer](https://archive.cancerworld.net/cover-story/tumour-microenvironment-the-new-battlespace-in-the-war-against-cancer/) - No cancer cell can survive, thrive, proliferate, infiltrate or metastasise without concerted help from the tumour microenvironment (TME). So shouldn’t treatment strategies aim to modify what’s happening around the cancer as much as directly targeting the cancer itself? Janet Fricker looks at some key TME battlefronts, and hears from people leading efforts to move treatment
- [Algorithmic surveillance to prevent serious failures in oncology](https://archive.cancerworld.net/featured/algorithmic-surveillance-to-prevent-serious-failures-in-oncology/) - Lorena Jaume-Palasí is co-founder of the NGO AlgorithmWatch, a non-profit devoted to reveal problematic Automated Decision Making (ADM) processes, algorithm biases and software failures that might have “enormous” consequences in cancer diagnosis, forecast and treatment. One year ago, ProPublica uncovered the case of New York City’s crime lab technique to analyse especially difficult DNA samples under
- [Beating cancer at its own game](https://archive.cancerworld.net/cutting-edge/beating-cancer-at-its-own-game/) - Game theory has been used to understand economics, ecology and evolution. It is now being used to try to help us outwit cancer. Sophie Fessl asks: will evolutionary game theory guide the way to a more strategic use of available cancer drugs? Cancer isn’t a game – but if we treat it that way for
- [From numbers to new drugs, the crisis of paradigms in medicine](https://archive.cancerworld.net/editorial/from-numbers-to-new-drugs-the-crisis-of-paradigms-in-medicine/) - The recent controversy that has shaken the International Cochrane Network to its roots is very troubling. It is not yet clear if the disagreements on the quality of a recent systematic review on the efficacy and safety of the HPV vaccine had any role in the dispute, but for sure this quarrel risks to compromise
- ['Me doctor, you patient’ – can’t we do better than that?](https://archive.cancerworld.net/editorial/me-doctor-you-patient-cant-we-do-better-than-that/) - While holidaying on the Greek island of Ithaca, where the Odyssey ended, I met a man of my age and my country who had just finished his treatment for colorectal cancer. He now lives on Ithaca most of the year, returning home only in winter, and enjoys a simple life in a place where there
- [Immunologists Allison and Honjo won the Nobel prize for their work on checkpoints](https://archive.cancerworld.net/news/immunologists-allison-and-honjo-won-the-nobel-prize-for-their-work-on-checkpoints/) - American James Allison and Japanese Tasuku Honjo have been awarded the 2018 Nobel Prize for Physiology or Medicine thanks to their findings leading to recent new approaches in cancer treatment. James Allison, born in Texas 70 years ago, has already won numerous awards for his studies as a cancer immunologist, as well as Tasuku Honjo,
- [How much is too much? Will someone please take charge of finding answers?](https://archive.cancerworld.net/spotlight-on/risks-benefits-how-much-is-too-much-will-someone-please-take-charge-of-finding-answers/) - Precision medicine was meant to see the end of ‘maximum tolerated dose’ as the standard for introducing new drugs. It hasn’t happened, and many patients continue to suffer unnecessary toxicity from overtreatment, with health services picking up the bill. Peter McIntyre asks: who should be responsible for optimising our use of cancer drugs? Developing innovative
- [The toxic effects of hidden costs](https://archive.cancerworld.net/spotlight-on/the-toxic-effects-of-hidden-costs/) - A growing body of literature has described the so called “financial toxicity” of cancer, a common consequence of treatments, that sometimes leads patients to bankruptcy, and affects quality of life and clinical outcomes. “We don't travel; we don't do anything now because it's a $100,000 illness… What are you going to do? Caught between a
- [The fight against cancer benefits from a stronger European union of registries](https://archive.cancerworld.net/featured/the-fight-against-cancer-benefits-from-a-stronger-european-union-of-registries/) - In February this year there was a significant announcement from the European Commission – the Joint Research Centre (JRC) launched the European Cancer Information System (ECIS), the result of several years’ work to integrate data from European cancer registries. The ECIS has data from about 150 European population-based cancer registries from 25 EU member states and 7 non-EU
- [Catalan independence yellow ribbons clashing with a cancer symbol in Spain](https://archive.cancerworld.net/news/catalan-independence-yellow-ribbons-clashing-with-a-cancer-symbol-in-spain/) - On Tuesday 11th of September Catalonia (Spain) celebrated its 'National Day'. Hundreds of thousands Catalans in favor of independence filled the streets, wearing yellow ribbons: the symbol they are using for claiming freedom for the jailed Catalan politicians. Independentists have been using those ribbons for the last few months, clashing with the golden ribbons used
- [Terminally ill patients are given preventative medicines until they die](https://archive.cancerworld.net/news/terminally-ill-patients-are-given-preventative-medicines-until-they-die/) - Among patients hospitalised for advanced lung cancer, the prescription of preventative medicines for diabetes, hypertension, hyperlipidemia, antiplatelet agents, and vitamins/minerals is very common not only at the moment of admission, but also at discharge, according to a study that has collected data from two tertiary care centers, in the US and in the UK: MD
- [Don't play with numbers](https://archive.cancerworld.net/editorial/dont-play-with-numbers/) - This editorial looks at how to present statistical information in a way that is easy for readers to interpret and apply, and calls on everyone involved writing educational material and press releases to make a conscious effort to use the most effective statistical formats. Seven simple lifestyle ‘steps’ can cut your risk of getting cancer
- [Navigating uncertainty in the era of MMM](https://archive.cancerworld.net/featured/navigating-uncertainty-in-the-era-of-mmm/) - Some scholars recently coined the expression “Medical Misinformation Mess” to describe current clinical medicine as a realm in which it is very difficult to evaluate both reliability and practical meaning of research studies. A realm in which most actors – patients, families, and also medical professionals – don’t even realize how hard is the challenge
- [The trouble with health statistics](https://archive.cancerworld.net/cover-story/the-trouble-with-health-statistics/) - Some commonly used statistical concepts are hard to master not only for most patients, but for many professionals as well. Especially when it comes to cancer screening A common assumption, when addressing informed decision making in medicine, is that many patients find it hard to grasp statistical concepts, and the meaning of evidence, due to
- [Second opinions offend oncologists in two ways](https://archive.cancerworld.net/news/second-opinions-offend-oncologists-in-two-ways/) - Physicians seem to accommodate to patients’ requests of second opinions trying not to harm neither the relationship with patients themselves nor with colleagues. Oncologists usually cooperate among each other, even though they do not often perceive an added value in such second opinions, according to a small study from The Netherlands recently published in JAMA
- [Countering the rise of cancer in sub-Saharian Africa](https://archive.cancerworld.net/featured/countering-the-rise-of-cancer-in-sub-saharian-africa/) - Clinicians around the world use NCCN Clinical Practice Guidelines in Oncology as a standard for clinical decision-making. The NCCN Harmonized Guidelines are targeted regional resources created as part of a collaborative effort to combat the skyrocketing cancer rates and unique care circumstances.25 new guidelines will be available by the end of the year 2018 to
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround/) - Higher quality colonoscopies reduce cancer deaths without higher costs => JAMA Higher rates of detection of precancerous adenoma were associated with lower lifetime risks of colorectal cancer and colorectal cancer mortality and did not result in greater overall healthcare costs, a Dutch microsimulation model study has found. Colonoscopy reduces colorectal cancer mortality through detection and
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-3/) - Most oncology patient requests are appropriate =>JAMA Oncology Patient demands or requests for tests or treatments occur in less than 10% of outpatient oncology encounters, with just 0.14% of encounters resulting in clinicians complying with inappropriate demands or requests, a recent study has found. When surveyed, physicians often place responsibility for high medical costs on
- [Blind women lend a hand for early detection of breast cancer](https://archive.cancerworld.net/news/blind-women-lend-a-hand-for-early-detection-of-breast-cancer/) - The enhanced tactile sensitivity of blind and visually impaired women might make them especially suitable for breast examination, according to a visionary German gynaecologist. If it’s true that mammography is an effective breast cancer screening method until now, it’s costly and often not available for free, especially in low income level countries with a low
- [Doctors should care more of financial toxicity, US survey warns](https://archive.cancerworld.net/news/doctors-should-care-more-of-financial-toxicity-us-survey-warns/) - For many patients newly diagnosed with cancer, financial toxicity should be on top of the list of their doctors concerns: according to a US survey described on the peer-reviewed journal Cancer, published by the American Cancer Society, up to 45% of them (depending on ethnicity) would need to discuss more with healthcare providers about the financial impact
- [Users of alternative remedies tend to refuse cancer treatments, with increased mortality](https://archive.cancerworld.net/news/users-of-alternative-remedies-tend-to-refuse-cancer-treatments-with-increased-mortality/) - Cancer patients who use complementary medicine tend to refuse effective treatments more often than non users, and this reflects on increased mortality: this is the conclusion of an observational study just published on Jama Oncology, that involved patients with four common cancers (breast, prostate, lung or colorectal). Skyler Johnson and colleagues from the Yale School of Medicine
- [New markers could pave the way to early diagnosis of AML in the healthy population](https://archive.cancerworld.net/news/new-markers-could-pave-the-way-to-early-diagnosis-of-aml-in-the-healthy-population/) - A research letter just published in the journal Nature by an International group of researchers directed by Grace Collord of the Wellcome Sanger Institute and University of Cambridge, in England, "provides proof-of-principle that it may be possible to develop tests to identify people at a high risk of developing acute myeloid leukemia (AML)". The group included researchers at the
- [Cycling around the world to spread the message of prevention](https://archive.cancerworld.net/voices/cycling-around-the-world-to-spread-the-message-of-prevention/) - In June of this year I finally completed more than a year of gruelling treatment for breast cancer, which started with a double mastectomy and continued with various types of chemotherapy. I will be taking tamoxifen for the next 10 years. In July I set off with my partner Chris on a seven-year cycling tour
- [A new test for castration-resistant prostate cancer welcomed warmly](https://archive.cancerworld.net/news/a-new-test-for-castration-resistant-prostate-cancer-welcomed-warmly/) - A blood test that can predict how men with advanced prostate cancer will respond to specific treatments has been validated in a multi-institution cohort study, recently published on Jama Oncology by an International group coordinated by Howard Scher, of the Memorial Sloan Kettering Cancer Center in New York, accompanied by a commentary that invites to
- [Simon Crompton: we need inquisitive minds to write on cancer](https://archive.cancerworld.net/voices/simon-crompton-we-need-inquisitive-minds-to-write-on-cancer/) - If the 181 entries to this year’s Cancer World Journalism Award proved anything, it was that journalists are putting cancer on the agenda in every corner of the world. Articles and programmes were submitted from 39 countries, and most were not produced by specialist writers, or aimed at health-educated audiences. They were produced by general
- [Ask cancer for its name, not only for its address](https://archive.cancerworld.net/featured/ask-cancer-for-its-name-not-only-for-its-address/) - Is the paradigm of cancer treatment bound to change? At a time when new drugs are registered for use on a specific molecular target instead of a specific tumor, experts raise some warnings: this new model might be hard to sustain financially, and might spark too much optimism, if one doesn't take into account tumor
- [Meanings and Measures of Quality of Life in Head and Neck Cancer](https://archive.cancerworld.net/featured/meanings-and-measures-of-quality-of-life-in-head-and-neck-cancer/) - It’s not just a matter of clinical outcomes: quality of life goes far beyond the final result of a cancer treatment and involves several aspects of daily life, both for patients and their caregivers. And accurate assessment is not always easy “Survivorship requires as much attention from patient and health care professionals as the treatment
- [Governments urged to do more against cancer and other non-communicable diseases](https://archive.cancerworld.net/news/governments-urged-to-do-more-against-cancer-and-other-non-communicable-diseases/) - The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are worried by the "tsunami of future cancer cases that will drain our health systems and our economies", and call on heads of state and health ministers to attend the meeting of the General Assembly of the United Nations on the
- [Chasing teenage clouds away, with music](https://archive.cancerworld.net/news/chasing-clouds-away-with-music/) - The song is captivating, with professional music and arrangements. The voices are those of the teenage patients of the pediatric unit of Milan’s Istituto Nazionale dei Tumori who worked for several months to record a video just released on YouTube. The song it’s titled “You are the summer. The reverse rain dance”, and is part
- [Outstanding journalism recognised in the Cancer World Award](https://archive.cancerworld.net/news/outstanding-journalism-recognised-in-the-cancer-world-award/) - Journalists from India, Germany, France, Pakistan and Syria have been recognised for their outstanding achievement in the 2018 Cancer Journalism Award, organised by Cancer World magazine. A remarkable 181 entries produced in 2017 and 2018 – print, online, radio, video and television – were submitted by journalists working in 39 countries. There were winners
- [The National Guideline Clearinghouse will be shut down soon](https://archive.cancerworld.net/news/the-national-guideline-clearinghouse-will-be-shut-down-soon/) - The website of the US National Guideline Clearinghouse, that currently makes available 359 guidelines related to oncology, will be closed in mid-July, for lack of federal funding: “The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to
- [Surviving cancer: but why am I not happy?](https://archive.cancerworld.net/voices/surviving-cancer-but-why-am-i-not-happy/) - At the just concluded Uppsala Health Summit in Sweden, the Member of the Swedish Parliament Maria Weimer talked about breast cancer from the perspective of a young woman survivor, and I listened to her with utmost keenness. At some point, I felt like she was sharing my story. I come from Kenya, a low-income country
- [A man who dedicated his life to his patients - Agim Sallaku passed away](https://archive.cancerworld.net/obituary/a-man-who-dedicated-his-life-to-improving-the-life-of-oncologic-patients-professor-dr-agim-sallaku-passed-away/) - Prof. Dr. Agim Sallaku was born in Tirana, Albania in 1956. He received his medical degree from the Faculty of Medicine at the University of Tirana in 1981 and in the same year he started working as a radiotherapist at the Oncological Service. In 1998 he was a full time Professor at the Faculty of
- [Why patients are central to reversing the decline in value: a response to Richard Sullivan](https://archive.cancerworld.net/voices/why-patients-are-central-to-reversing-the-decline-in-value-a-response-to-richard-sullivan/) - My good friend Professor Richard Sullivan wrote an excellent piece for Cancer World on how to reverse the decline in the benefit per cost of cancer interventions. It gave me food for thought. Sullivan gave an excellent description of the process of defining value through the cost-per-QALY process. Using data from clinical trials and Patient
- [SEEKing cancer with liquid biopsy](https://archive.cancerworld.net/news/seeking-cancer-with-liquid-biopsy/) - It’s called CancerSEEK the first experimental noninvasive blood test that could screen eight different cancers and localize their source. It was developed by an international research team based at Johns Hopkins University in Baltimore, USA. The team focused on breast, colorectal, esophagus, liver, lung, ovary, pancreas, and stomach cancers, which are common in Western populations
- [Acupuncture and behavioral therapy can improve sleep in cancer survivors](https://archive.cancerworld.net/news/acupuncture-and-behavioral-therapy-can-improve-sleep-in-cancer-survivors/) - Acupuncture and cognitive behavioral therapy for insomnia (CBT-I) can improve insomnia severity beyond traditional medicine, and have lasting effects, according to a study – funded by the Patient-Centered Outcomes Research Institute (PCORI) - that will be presented in June at the upcoming 2018 American Society of Clinical Oncology Annual Meeting in Chicago. The researchers analyzed
- [Be a champion for change](https://archive.cancerworld.net/editorial/be-a-champion-for-change/) - A n estimated 50,000 people who die from cancer every year could still be alive if the quality of diagnosis and care in European countries with the poorest survival rates were as good as the median across Europe. That number rises to 100,000 lives per year if countries with the poorest outcomes could improve to the
- [Improving outcomes – a practical guide](https://archive.cancerworld.net/cover-story/improving-outcomes-a-practical-guide/) - After 25 years of trying to improve the way we organise and deliver cancer care we now have a fairly clear idea about what changes are needed to get the best patient outcomes. Finding ways to make those changes happen at every level and in every country remains a challenge. Anna Wagstaff asked key figures
- [Reciprocity in informed consent: a fairer framework for first-in-human trials](https://archive.cancerworld.net/featured/reciprocity-in-informed-consent-a-fairer-framework-for-first-in-human-trials/) - Patients play an integral part in the clinical trial process that enables new treatments to be approved and adopted into clinical practice. Without patients, no trials can be undertaken, and thus no drugs can be approved or new standards of care established. Yet, the informed consent process in relation to trial participation indicates that patients
- [Gut response: Does benefit from immunotherapy depend on the bacteria in our intestines?](https://archive.cancerworld.net/cutting-edge/gut-response-do-the-bacteria-in-our-colons-determine-who-benefits-from-immunotherapy/) - A spate of recent studies suggest that differences in population of bacteria and other micro-organisms that inhabit our intestines may be a key factor differentiating between people who respond to immune checkpoint inhibitors and those who do not. Sophie Fessl looks at the evidence and asks what it could mean for patients. Accepting a course
- [Bahadir Güllüoğlu: driving up standards in Turkey towards the best in breast](https://archive.cancerworld.net/profile/bahadir-gulluoglu-driving-up-standards-in-turkey-towards-the-best-in-breast/) - As a young surgeon, Bahadir Güllüoğlu was drawn to specialising in breast cancer because of the opportunities that were opening up to work closely with other types of specialists, as well as with patients and their families. Marc Beishon talked to him about how his passion for quality, collaboration and networking is raising the standard
- [Mind the gap! Who cares for patients after treatment is over?](https://archive.cancerworld.net/featured/mind-the-gap-who-should-help-patients-with-long-term-effects-and-how/) - Specialists feel responsible for their patients, but lack time to offer long-term care. Patients feel abandoned as their treatment ends, but lack resources to seek the care they need. GPs lack confidence to deal with cancer-related issues, and feel it is not their job. Simon Crompton asks how health systems can overcome these barriers to
- [Hereditary mutations in cancer: the use of panels and genetic counselling](https://archive.cancerworld.net/e-grandround/hereditary-mutations-in-cancer-the-use-of-panels-and-genetic-counselling/) - Testing for hereditary mutations that increase the risk of cancer is important for risk reduction, early detection and choice of treatment. Ephrat Levy-Lahad offers an overview of what we know ‒ and what remains uncertain ‒ about the rationale for testing, the risk implications, and how to discuss these with patients and families to enable
- [Personalised cancer medicine: What’s the evidence it works?](https://archive.cancerworld.net/spotlight-on/personalised-cancer-medicine-whats-the-evidence-that-it-works/) - If we can only find out what is driving a given cancer and/or what mechanism is creating resistance to treatment, it should be possible to at least halt the progress of the tumour by blocking the driver or the cause of the resistance. Cancers – particularly advanced solid tumours – are much too complex to
- [Negotiating a global cancer plan: the first two acts of a three-part drama](https://archive.cancerworld.net/our-world/negotiating-a-global-cancer-plan-the-first-two-acts-of-a-three-part-drama/) - In recent years, a series of World Oncology Forums have brought cancer specialists together with global health organisations and national health policy makers from many countries to try to develop a global response that could do for cancer what the Global Fund does for AIDS, tuberculosis and malaria. Anna Wagstaff and Richard Sullivan sketch out
- [Advanced Breast Cancer: what’s new in treatment and care?](https://archive.cancerworld.net/spotlight-on/advanced-breast-cancer-whats-new-in-treatment-and-care/) - Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in recent times, although there are signs that better care at earlier stages is reducing the numbers of advanced cases. As
- [Annette Berendsen – Researcher, Oncology in Primary Care](https://archive.cancerworld.net/featured/annette-berendsen/) - Transferring more responsibility for the care of cancer patients and survivors from specialists to general practitioners (GPs) is seen as key to coping with rising patient numbers. GPs, specialists and patients question how this can work with such a complex disease. Cancer World asked Annette Berendsen, a GP by profession, who is leading efforts to
- [Art and oncology: one life](https://archive.cancerworld.net/featured/art-and-oncology-one-life/) - Scientist or artist? Michael Peckham, who is best known for his contribution to the treatment of testicular cancer and Hodgkin lymphoma, and was involved in founding the European School of Oncology, refuses to choose and has always been both. Painting and medicine have complemented one another throughout his career, as he explains. When I decided
- [Challenging the sceptics with stories of hope](https://archive.cancerworld.net/spotlight-on/challenging-the-sceptics-with-stories-of-hope/) - It was stumbling across a poster for a meeting about cancer in the developing world that turned journalist Joanne Silberner from a sceptic into a believer, and prompted her to do her bit to change fatalistic attitudes about tackling the disease in poorer countries. Outside a cancer outpatient centre in Kampala, Uganda, the sound of
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-6/) - Selected reports edited by Hannah Brown Download full article
- [Cancer nurses want to make a difference in people's lives](https://archive.cancerworld.net/voices/lena-sharp-cancer-nurses-want-to-make-a-difference-in-peoples-lives/) - As cancer nurses, we truly make a difference to people’s lives. Nursing is the most trusted profession in many countries and I can understand why. We interact in so many ways with patients, their families and friends and support them through all the difficulties they experience related to cancer. As a young nursing student in
- [Cannabis can be an option in palliative care](https://archive.cancerworld.net/news/marijuana-is-a-desirable-option-in-palliative-care/) - Cannabis is an effective and safe option to help patients cope with malignancy related symptoms, such as nausea, vomiting, sleep disorders, pain, anxiety, and depression. In a scenario where a physician often prescribes one medication for each symptom, cannabis becomes a desirable therapeutic option, as a comprehensive treatment. These are the conclusions of a study,
- [Math models for medical decision-making: a double-edged sword](https://archive.cancerworld.net/spotlight-on/math-models-for-medical-decision-making-a-double-edged-sword/) - In the golden age of computing, both the present and future of medical decision-making seem to depend on new mathematical models and systems built around artificial intelligence (AI). But how will doctors and patients feel about using (and trusting) them? Artificial intelligence is everywhere, even in our mobile phone. And so are apps that allow
- [Liquid biopsies are not fit for clinical practice, yet](https://archive.cancerworld.net/news/liquid-biopsies-are-not-fit-for-clinical-practice-yet/) - More convenient and less risky for patients than proper, traditional ones, liquid biopsies are being rapidly adopted; they can be performed on a serial basis and, in theory, give more complete information. However, doubts were raised on their impact and utility in clinical practice: now a review article published by scholars from the American Society
- [Californian coffee will soon carry a label on cancer risk](https://archive.cancerworld.net/news/californian-coffee-will-soon-carry-a-label-on-cancer-risk/) - In California, coffee will soon have to carry a label stating that the beverage can cause cancer: a court decided to impose the warning because of the presence of acrylamide in the drink. The compound is used in certain industrial processes, but it can also be the result of high-temperature cooking, and when coffee beans
- [New rules limit the professional exposure to cancer-causing substances in Europe](https://archive.cancerworld.net/news/new-rules-limit-the-professional-exposure-to-cancer-causing-substances-in-europe/) - The European Commission has recently annonced its proposal to limit workers' exposure to five cancer-causing chemicals, in addition to the 21 substances that have already been limited or proposed to be limited, estimating that these new restrictions would benefit over one million of workers in the European Union with a net balance of some 22.000 cases
- [Cancer in childhood leaves a burden on mental health](https://archive.cancerworld.net/news/cancer-in-childhood-leaves-a-burden-on-mental-health/) - Being diagnosed with cancer in childhood is associated with an increased risk of mental health events as an adult: according to an article recently published in Cancer, childhood cancer survivors have more chances to experience psychotic disorders compared to peers. Dr. Paul C. Nathan from The Hospital for Sick Children in Toronto and colleagues compared
- [To stay afloat, cancer patients in the US need a “financial navigator”](https://archive.cancerworld.net/news/to-stay-afloat-cancer-patients-in-the-us-need-a-financial-navigator/) - A cancer diagnosis in the United Stated is so costly, on so many different aspects, that a new professional figure of “financial navigator” is emerging, to manage all the issues that so far have been partially followed by medical or administrative staff, often without realising how crucial it is for patients to receive the right
- [A new tool for mastering cancer genetics: the Pan Cancer Atlas](https://archive.cancerworld.net/news/the-pan-cancer-atlas-the-new-human-genome-project/) - The Pan Cancer Atlas – the largest survey conducted so far on the genetics of tumours, that has catalogued over 11 thousand tumours from 33 of the most prevalent forms of cancer – was made available online. The immense work has just been published in 27 different studies, in four scientific journals: Cell, Cancer Cell, Cell Reports
- [Clinical trials: too much of a good thing?](https://archive.cancerworld.net/voices/clinical-trials-too-much-of-a-good-thing/) - As a journalist, I often wonder about the exact location of the fine line that separates justified enthusiasm from self-serving hype, especially when it comes to clinical trials. Last week, I asked the question of an excellent physician and researcher I was interviewing, specifically showing him a story just published by STATnews that announced a
- [A single PSA test in asymptomatic men has no mortality benefit](https://archive.cancerworld.net/news/a-single-psa-test-in-asymptomatic-men-has-no-mortality-benefit/) - The efficacy of a single prostate specific antigen (PSA) screening intervention as a prevention strategy is a controversial topic and the data on this subject are much debated: now a huge British trial recently published on JAMA concluded that it is not effective in reducing prostate cancer mortality. To assess the effect of a low intensity
- [Don’t shoot the driver! It’s about taxonomy more than targets](https://archive.cancerworld.net/cutting-edge/dont-shoot-the-driver-its-about-taxonomy-more-than-targets/) - Could tailoring treatments to broad taxonomies work where targeting individual – or even multiple – genetic mutations has not? A growing number of researchers working on specific tumour types and/or across tumours believe this integrative approach, involving ‘precision classification’, could be the way to go. Janet Fricker talked to some of the key players. In
- [Bringing you extra in 2018](https://archive.cancerworld.net/editorial/bringing-you-extra-in-2018/) - The Cancer World team hopes that all our readers have had a good start to 2018. We look forward to bringing you critical, independent and rounded coverage of the big stories affecting quality cancer care that are set to develop during the course of the year. After two years in which we more than tripled
- [Dr. Roberto Pradier, Director of the National Cancer Institute of Argentina, passed away](https://archive.cancerworld.net/obituary/obituary-dr-roberto-pradier-director-of-the-national-cancer-institute-of-argentina/) - The National Cancer Institute of Argentina announced that its President Roberto Pradier passed away. Dr. Roberto Pradier obtained a Medical degree from the School of Medicine, University of Buenos Aires (UBA) in 1955. He received his Ph.D. with honors in 1962. Intern and resident in surgery at Hospital de Clínicas of the University of Buenos Aires
- [Agnes Buzyn](https://archive.cancerworld.net/featured/minister-agnes-buzyn/) - A professor of haematology, specialising in bone marrow transplants and leukaemia, with a career that has spanned clinical practice, research, policy making and now political office – Agnès Buzyn has an unrivalled breadth of experience in tackling cancer. In 2017, after five years at the head of the French National Cancer Institute, INCa, she was
- [Gathering long-term data on what happens next](https://archive.cancerworld.net/spotlight-on/gathering-long-term-data-on-what-happens-next/) - ‘Survivorship’ is a rapidly growing field of research, as more cancer patients live longer, and require different types of support to get their lives back on track. Typically such research has been disconnected from clinical trials, but this may be starting to change, as Anna Wagstaff reports. Survival is a necessity after a cancer diagnosis,
- [PROMs put patients at the heart of research and care](https://archive.cancerworld.net/featured/proms-put-patients-at-the-heart-of-research-and-care/) - The need to give greater weight to patients’ own assessments of treatment impacts is increasingly accepted in principle. Putting it into practice will require a lot of hard work, developing tools that work for specific conditions and treatments, are easy to use, and command an international consensus. Simon Crompton talks to some of the people
- [Four cities, three continents, 12 million people: Can the City Cancer Challenge succeed where others have failed?](https://archive.cancerworld.net/our-world/four-cities-three-continents-12-million-people-can-the-city-cancer-challenge-succeed-where-others-have-failed/) - When it comes to developing capacity for tackling cancer, all too often the best intentions founder because key players are not engaged, costings are not done, sustainable funding is not secured, visiting experts dispense their wisdom and fly off home. Peter McIntyre reports on a new initiative designed with those pitfalls in mind. Four cities
- [Cancer surgery: the key factors that influence outcomes](https://archive.cancerworld.net/e-grandround/cancer-surgery-the-key-factors-that-influence-outcomes/) - Cancer patients are put at risk unless the surgeons who operate on them understand the principles of the disease, work closely with other oncology disciplines, and know which patients need to be referred to high-volume specialist centres. This grandround looks at the key surgical factors that influence cancer outcomes, and how to optimise them. This
- [Anastassia Negrouk: fixing the system](https://archive.cancerworld.net/profile/anastassia-negrouk-fixing-the-system/) - Legislators and policy makers could do a lot more to promote cancer research if they understood that improving treatment strategies is not all about new drugs, and that patients and health budgets pay a high price for failures to coordinate across Europe. Anastassia Negrouk tells Sophie Fessl about her efforts to get those messages across.
- [How does treating the primary affect risk of a secondary?](https://archive.cancerworld.net/spotlight-on/how-does-treating-the-primary-affect-risk-of-a-secondary/) - Most solid tumours will prove fatal if they are not treated with surgery and/or radiotherapy and medical therapies. But evidence is building to show that treating the primary may raise the risk of metastatic spread. Sophie Fessl looks at the evidence and the implications. Even after treatment, patients with seemingly locoregionally defined solid tumours frequently
- [Too high or too low? ESMO’s clinical benefit scale fuels debate over approval thresholds](https://archive.cancerworld.net/cover-story/too-high-or-too-low-esmos-clinical-benefit-scale-fuels-debate-over-approval-thresholds/) - Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports on how ESMO’s new scale for scoring clinical benefit has added a new dimension to this long-running debate. About 10
- [Value and cancer – this is how we reverse the decline](https://archive.cancerworld.net/comment/value-and-cancer-this-is-how-we-reverse-the-decline/) - ‘Value’ is the latest buzzword in cancer: value-based pricing, delivering value for cancer care, enhancing the value offering for cancer technologies... It makes sense, as focusing on the value of interventions we invest in is the only way to stop wasting precious health resources on poor value healthcare interventions and missing out on interventions that
- [Hats off to the patient advocates](https://archive.cancerworld.net/editorial/hats-off-to-the-patient-advocates/) - “A room full of healers.” This is how Larry Norton, Medical Director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering, described the feel of the auditorium during the 4th Advanced Breast Cancer conference, which took place in Lisbon last November. The ABC conference is about healing, in that it addresses the full
- [Dangerous Healers](https://archive.cancerworld.net/focus/dangerous-healers/) - It’s not uncommon for people diagnosed with cancer to explore how alternative practitioners might help. Some can, or at least do no harm. But the chances of running into a charlatan whose advice could be fatal are shockingly high, as this undercover investigation, first published in the German magazine Stern, demonstrates. The spirit healer had
- [Can global barriers to meeting the cancer challenge be overcome?](https://archive.cancerworld.net/voices/can-global-barriers-to-meeting-the-cancer-challenge-be-overcome/) - According to an article by Rifat Atun and Franco Cavalli in the Lancet (03 Feb 2018) the global fight against cancer is hampered by multiple barriers that include a lack of robust leadership, lack of a cohesive global social movement, a fragmented narrative, poor alignment to other important global health goals, weak health systems, low
- [Breast cancer patients say excessive fears surround radiation therapy](https://archive.cancerworld.net/news/breast-cancer-patients-say-excessive-fears-surround-radiation-therapy/) - The perspective of undergoing radiation therapy usually scares most breast cancer patients, but according to a new study most women treated with modern breast radiation therapy describe their experience as much better than they expected. “The word radiation itself sounds frightening and is associated with many negative news stories, but the implications of this study
- [Precision medicine is making progress in NSCLC](https://archive.cancerworld.net/cutting-edge/precision-medicine-is-making-progress-in-nsclc/) - Clinical oncologists face many challenges to identify the best use of the anti-EGFR drugs in patients with non-small-cell-lung cancer. Thanks to genetic analysis, they are now able to identify responders from non-responders and to counteract the development of resistance. How to cover the cost of the treatment for all the patients who could benefit remains
- [The silent cancer refugees crisis](https://archive.cancerworld.net/featured/the-silent-cancer-refugees-crisis/) - Relief efforts aim at primary care, leaving refugees and displaced people with cancer without treatments or psychological support. In a worsening scenario, doctors are daily confronted with the hard choice between using the scarce resources to offer basic care to many or saving a single life When one-year-old Farah and her parents fled from Syria
- [The do-nothing dilemma](https://archive.cancerworld.net/featured/the-do-nothing-dilemma/) - To treat or not to treat? Different people respond in different ways to learning they have lesions that may or may not develop into threatening cancers. Charlotte Huff talks to ‘patients’, doctors and psychologists about reaching a decision on what to do next. Imagine for a moment that you have a tiny but worrisome lung
- [A world without cancer: how a pseudoscientific congress opened a fierce debate in Spain](https://archive.cancerworld.net/news/a-world-without-cancer-how-a-pseudoscientific-congress-opened-a-fierce-debate-in-spain/) - “Breast cancer can be cured just being aware of the disease and doing nothing". It’s just one of the many senseless things attendees heard at the congress A World Without Cancer: what your doctor is not telling you, held last month in Barcelona (Spain). Other absurdities include: "There are spots that are called ‘cancer spots’
- [The European Commission wants more reliable tools for health technology assessment](https://archive.cancerworld.net/news/the-european-commission-wants-more-reliable-tools-for-health-technology-assessment/) - «Better quality, innovative healthcare for the benefit of patients, especially those with unmet medical needs» this is the main goal of the proposal for strenghtening cooperation within the European Union on the assessment of health technology, in the words of EU Commissioner for Health and Food Safety, Vytenis Andriukaitis. The new regulation on health technology
- [Europa Donna Italy provides guidelines for voluntary associations working in breast centres](https://archive.cancerworld.net/news/europa-donna-provides-guidelines-for-voluntary-associations-working-in-breast-centres/) - «A common platform for a proper understanding of the interaction system and knowledge between voluntary associations operating in breast centres, specialists of breast centre, political and territorial authorities involved in the healthcare system and women»: this is the main goal of the new guidelines (“The Voluntary Associations within the Multidisciplinary Breast Care Centers”) promoted by
- [ESMO publishes the Patient Guide on Survivorship](https://archive.cancerworld.net/news/esmo-publishes-the-patient-guide-on-survivorship/) - The new "Patient Guide on Survivorship" produced jointly by the European Society for Medical Oncology (ESMO) the European Cancer Patient coalition (ECPC) and the International Psycho-Oncology Society (IPOS) is now available on the web in PDF. «A section on support in coping with the new reality elaborates cancer rehabilitation, patient support groups, psychological support of
- [A call to action to defeat advanced and metastatic breast cancer](https://archive.cancerworld.net/news/a-call-to-action-to-defeat-advanced-and-mestastatic-breast-cancer/) - A call to action to intervene on the many gaps in the care of patients with advanced or metastatic breast cancer (ABC/mBC), the European School of Oncology announced at the 15th St. Gallen International Breast Cancer Conference in Vienna, Austria. Although much progress has been made in the diagnosis, management and outcomes of early breast cancer,
- [US doctors continue to recommend mammography more often than most International guidelines](https://archive.cancerworld.net/news/us-doctors-continue-to-recommend-mammography-more-often-than-most-international-guidelines/) - When it comes to breast cancer screening with mammography, are women receiving a coherent message about the best age to start and to stop, and about frequency? A survey examined the situation in the United States, and concluded that at least three different guidelines inform the medical practice, with somehow conflicting messages, and a different
- [Biosimilars in oncology: challenges and opportunities](https://archive.cancerworld.net/news/biosimilars-in-oncology-challenges-and-opportunities/) - An ESO task force met to discuss the potential for “biosimilar” medical products in oncology, analyzing facts and debunking some myths. Some of the most used biologic drugs in oncology are going off patent in the near future, and this will give pharmaceutical companies the opportunity to create “biosimilar” drugs. These copies of the originator
- [For the first time, the FDA approves a cancer drug for use based on biomarker and not origin](https://archive.cancerworld.net/news/for-the-first-time-the-fda-approves-a-cancer-drug-for-use-based-on-biomarker-and-not-origin/) - Pembrolizumab is the first drug approved by the U.S. Food and Drug Administration for use based on a biomarker (a specific genetic feature) rather than the location in the body where the tumor originated. The drug is indicated for unresectable or metastatic solid tumors that have been identified as having a biomarker referred to as «microsatellite instability-high» (MSI-H) or
- [PSA for prostate cancer screening: still a balancing act](https://archive.cancerworld.net/news/psa-for-prostate-cancer-screening-still-a-balancing-act/) - The conclusions of the 2012 Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) could be wrong: the authors of the trial – published on the Journal of the National Cancer Institute – had found no reduction in prostate cancer mortality, but a reanalysis of the original data just published on the Annals of Internal Medicine
- [BRCA1 could not wait: Mary-Claire King tells the story of her "special" week of 36 years ago](https://archive.cancerworld.net/news/brca1-could-not-wait-mary-claire-king-tells-the-story-of-her-special-week-of-36-years-ago/) - What happens to a strong and motivated scientist when she is left by her husband? When it happened to Mary-Claire King, many unusual things happened: she learned that she had just been awarded tenure at the Berkeley University, and immediately after that she found her house robbed (all in one day). Still, she managed to
- [Is a global movement to tackle cancer possible?](https://archive.cancerworld.net/news/is-a-global-movement-to-tackle-cancer-possible/) - At some point in this century cancer will become the leading cause of global deaths. It is already the leading cause of premature death under the age of 70 in 48 higher income countries and second or third in another 100 countries. It is the single most significant barrier to increasing the human life span.
- [Cancer risk factors are in eye of the beholder?](https://archive.cancerworld.net/news/cancer-risk-factors-are-in-eye-of-the-beholder/) - An undesired effect of preventive screening for cancer is often overlooked: it's not only the tendency to diagnose more and more cancers that would be likely to grow slowly – and to increase overdiagnosis – but also the risk of misrepresenting the influence of specific risk factors that might instead have no real role, argue two
- [Cancer vaccines - hope or hype?](https://archive.cancerworld.net/drug-watch/cancer-vaccines-hope-or-hype/) - There have been many false dawns in the field of cancer vaccines, but some of the new products look distinctly promising.
- [Welcome to our World](https://archive.cancerworld.net/editorial/welcome-to-our-world/)
- [Betting on e-collaboration](https://archive.cancerworld.net/senza-categoria/betting-on-e-collaboration/) - Interview with Dr Alex Jadad
- [Cancer in the   year 2025](https://archive.cancerworld.net/e-grandround/cancer-in-the-year-2025/) - How will cancer look in the year 2025? More than fifty UK cancer care specialists – physicians, scientists, health managers, economists, health service watchers – together with cancer charities and patients spent two days together in late 2003 asking themselves this question. Here is what they came up with.
- [Advanced  head and neck cancers](https://archive.cancerworld.net/impact-factor/advanced-head-and-neck-cancers/) - Transatlantic collaboration shows results
- [Secrets of success](https://archive.cancerworld.net/senza-categoria/secrets-of-success/) - In the world of oncology drugs, Roche is one of the giants. Here, Chief Executive Franz Humer talks about the research and business strategies behind his company’s success, and about novel therapies in the pipeline that could help alleviate patients’ experience of cancer. He also speake of his mission to save Europe from relegation in
- [Bob Pinedo:  Bringing two worlds together](https://archive.cancerworld.net/senza-categoria/bob-pinedo-bringing-two-worlds-together/) - At the tender age of 29, Dr Pinedo found himself in charge of a group of cancer patients who were being left to die, and he set out to find a way to treat them. What followed was a remark- able story of one man and his lab, whose pioneering work brought new hope to
- [Nothing about us without us](https://archive.cancerworld.net/patient-voice/nothing-about-us-without-us/) - Europe’s patient advocates gather for the first time
- [New law boosts EMEA role](https://archive.cancerworld.net/senza-categoria/new-law-boosts-emea-role/)
- [EBCC: Driving up  standards  in breast care](https://archive.cancerworld.net/spotlight-on/ebcc-driving-up-standards-in-breast-care/) - The European Breast Cancer Conference set up by researchers, clinicians and advocates who wanted to co-ordinate their work and widen the fight against cancer to include the public and politicians. This year it took place under the shadow of the Clinical Trials Directive.
- [Our partnership with patients](https://archive.cancerworld.net/editorial/our-partnership-with-patients/)
- [It’s not a war... and we are not losing](https://archive.cancerworld.net/e-grandround/its-not-a-war-and-we-are-not-losing/) - Dispatches from the European front
- [Tailor-made vaccine hailed  as milestone in renal-cell cancer](https://archive.cancerworld.net/impact-factor/tailor-made-vaccine-hailed-as-milestone-in-renal-cell-cancer/) - A new vaccine obtained from the patient’s own tumour tissue may offer the first effective adjuvant treatment for renal-cell carcinoma following surgery. The findings of the phase III clinical trial are being hailed as a breakthrough in immunology therapy.
- [Interfacing with Mogalakwena](https://archive.cancerworld.net/senza-categoria/interfacing-with-mogalakwena/) - Hewlett Packard does its bit to bridge the digital divide
- [Louis Denis: Urology’s foremost  free thinker](https://archive.cancerworld.net/senza-categoria/louis-denis-urologys-foremost-free-thinker/) - The son of a Belgian docker, Louis Denis, now Director of the Antwerp Oncology Centre, joined the army to get through medical school. Though often at odds with the medical establishment, he rose to the top of his field, and helped shape European oncology through his commitment to prevention, research, professional education and innovation
- [Talk to me not to your feet](https://archive.cancerworld.net/patient-voice/talk-to-me-not-to-your-feet/) - What do patients have a right to expect from their oncologists? Cancer World asked glioma patient Ivan Noble for his views, after he issued a public Plea to the Medics in his widely read Tumour Diary column for BBC News Online, which is printed overleaf.
- [EIO: A truly European Centre  to rival the best](https://archive.cancerworld.net/spotlight-on/eio-a-truly-european-centre-to-rival-the-best/) - It seemed like a gamble when the European Institute of Oncology opened in Milan ten years ago. But this centre of excellence reversed the brain drain and set some of the highest standards for patient-centred treatment and research anywhere in the world
- [Britain’s Cancer Czar](https://archive.cancerworld.net/systems-services/britains-cancer-czar/)
- [Tito Fojo: Cancer drugs not delivering on their potential](https://archive.cancerworld.net/news/6446tito-fojo-cancer-drugs-not-delivering-on-their-potential/) - New drugs being approved for treatment of patients with cancer are providing an average of only 2.5 months of extra life, a leading researcher has told the World Oncology Forum (WOF). Tito Fojo, Professor of Medicine at Columbia University, New York, and a former principal investigator for the National Cancer Institute, said that the clinical
- [Richard Sullivan: «How about a 5% levy on research to boost global cancer aid?»](https://archive.cancerworld.net/voices/richard-sullivan-how-about-a-5-levy-on-research-to-boost-global-cancer-aid/) - High-income countries need to target cancer when allocating health care funds to emerging and low income countries, says Richard Sullivan, Professor of Cancer and Global Health at Kings College London. He proposes that those funding research programmes in richer countries should pay a 5% donations levy to support cancer services in the developing world. •
- [Sharon Kapambwe: Meet the team, not just the Minister to support cancer strategies](https://archive.cancerworld.net/voices/sharon-kapambwe-meet-the-team-not-just-the-minister-to-support-cancer-strategies/) - Global cancer programmes and projects must pay greater attention to national priorities and structures when they offer support to developing countries, says the doctor responsible for efforts to reduce women’s cancer in Zambia. Sharon Kapambwe who helped to start the cervical cancer prevention programme in Zambia and now has overall responsibility for cancer prevention, said
- [Sharing with an unwelcome partner](https://archive.cancerworld.net/voices/sharing-with-an-unwelcome-partner/) - The other day someone asked me what it feels like living, day in day out, with a cancer. I’ve been thinking about the answer to that question since. I don’t really think I have a clear answer, because I don’t really have a clear understanding of the different feelings. It usually feels like i’m sharing
- [Europe set to act   over paediatric drugs](https://archive.cancerworld.net/drug-watch/europe-set-to-act-over-paediatric-drugs/)
- [Too valuable to put a price on](https://archive.cancerworld.net/editorial/too-valuable-to-put-a-price-on/)
- [Access all areas](https://archive.cancerworld.net/senza-categoria/access-all-areas/)
- [A good prognosis for progress in breast cancer](https://archive.cancerworld.net/e-grandround/a-good-prognosis-for-progress-in-breast-cancer/)
- [Treatment of metastatic CRC  takes two steps forward](https://archive.cancerworld.net/impact-factor/treatment-of-metastatic-crc-takes-two-steps-forward/)
- [Richard Doll:  Science will always  win in the end](https://archive.cancerworld.net/senza-categoria/richard-doll-science-will-always-win-in-the-end/)
- [Just the job?](https://archive.cancerworld.net/patient-voice/just-the-job/)
- [Flims:   Building  the next generation  of clinical researchers](https://archive.cancerworld.net/spotlight-on/flims-building-the-next-generation-of-clinical-researchers/)
- [Ireland’s bumpy road to a  world-class cancer service](https://archive.cancerworld.net/systems-services/irelands-bumpy-road-to-a-world-class-cancer-service/)
- [Princess Dina Mired: «Support developing countries to make cancer control plans»](https://archive.cancerworld.net/voices/princess-dina-mired-support-developing-countries-to-make-cancer-control-plans/) - Princess Dina Mired, President-elect of the Union for International Cancer Control (UICC) is calling on the international cancer community to change the way it supports developing countries. Princess Dina who was Director of the King Hussein Cancer Foundation in Jordan for 15 years, says that despite good intentions, most international aid for cancer does not
- [Rifat Atun: Seven point strategy to tackle global cancer](https://archive.cancerworld.net/news/rifat-atun-seven-point-strategy-to-tackle-global-cancer/) - Rifat Atun, Director of Global Health Systems at Harvard, warns the cancer community they must heal fragmented delivery and financing systems to tackle cancer worldwide. He summarises a seven point strategy from the World Oncology Forum to boost innovation and service delivery and to achieve impact at scale. WATCH THE OTHER SHORT VIDEOS FROM WOF
- [Mary Gospodarowicz: «We need a ‘can-do’ attitude to global cancer control»](https://archive.cancerworld.net/voices/mary-gospodarowicz-we-need-a-can-do-attitude-to-global-cancer-control/) - “I absolutely hate the assumption that cancer is too complicated for us to act. In fact probably cancer care and control is much less complicated than running the infrastructure in Mumbai, or London or Manhattan.” Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, and Medical Director of the Princess Margaret Cancer
- [Austerity measures in Greece leave cancer patients without treatment](https://archive.cancerworld.net/news/austerity-measures-in-greece-leave-cancer-patients-without-treatment/) - Swiss drugmaker Roche confirmed on Monday October 30th the withdrawal from the «positive list» of drugs reimbursed in Greece of cobimetinib, used to treat melanoma in adults in combination with vemurafenib, after the government imposed a mandatory 25% discount on the reimbursement price of innovative drugs. Greece imposed the 25% rebate on branded drugs as
- [Chatham House calls on oncology community to join global drive for universal health coverage](https://archive.cancerworld.net/news/chatham-house-calls-on-oncology-community-to-join-global-drive-for-universal-health-coverage/) - Robert Yates from the Chatham House policy institute has called on the oncology community to join the global campaign for universal health coverage as the best way of ensuring that governments allocate sufficient resources to prevention, treatment and care. Interviewed during the World Oncology Forum, Robert Yates, who is director of the Chatham House Universal
- [ABC4, Lisbon 2017: day two report](https://archive.cancerworld.net/news/abc4-lisbon-2017-day-two-report/) - Day two of ABC-Lisbon featured a pioneer in metastatic breast cancer advocacy, Musa Mayer, who gave the ABC Award lecture. Mayer told the history of how the “silent voices” of women with advanced disease came eventually to be heard, greatly helped by the uniting force of online communities. Despite the fears of healthcare professionals, these
- [At the ABC in Lisbon, crossing the lines between being a doctor and patient](https://archive.cancerworld.net/news/at-the-abc-in-lisbon-crossing-the-lines-between-being-a-doctor-and-patient/) - One talk dominated the opening day of the fourth Advanced Breast Cancer conference in Lisbon (ABC-Lisbon) – a powerful, personal testimony from Bella Kaufman, an Israeli breast cancer oncologist and ABC-Lisbon faculty member who in 2013 was diagnosed with metastatic breast cancer. Her talk crossed and joined the lines between being a doctor and patient,
- [Tehran (Iran) 18/10/2017 – ESO Breast Cancer Observatory: innovation and care](https://archive.cancerworld.net/past-events/tehran-iran-18102017-eso-breast-cancer-observatory-innovation-and-care/) - The European School of Oncology is pleased to announce the "ESO Breast Cancer Observatory: innovation and care in the next 12 months", which will be held in conjunction with the International Tehran Breast Cancer Congress (TBCC9) -Multidisciplinary Approach to Breast Cancer, on October 18 in Tehran (Iran) and chaired by Dr. A. Costa. Chair: A. Costa, IT - S.
- [Franco Cavalli: «Policy makers must be more engaged in the fight against cancer»](https://archive.cancerworld.net/voices/franco-cavalli-policy-makers-must-be-more-engaged-in-the-fight-against-cancer/) - The World Oncology Forum in Lugano, Switzerland, in October set a global challenge to address the growing threat from cancer in middle and low income countries. In the first of a series of short videos, WOF chair Franco Cavalli explains what the Forum is seeking to do. WATCH THE OTHER SHORT VIDEOS FROM WOF 2017.
- [Freddie Bray: «Four in five countries cannot accurately report cancer deaths»](https://archive.cancerworld.net/voices/freddie-bray-four-in-five-countries-cannot-accurately-report-cancer-deaths/) - Countries across the world need to prepare for a 60% rise in cancer incidence over the next two decades. Freddie Bray Head of Cancer Surveillance at the International Agency for Research on Cancer (IARC) told the World Oncology Forum in Lugano that countries must gather better data to plan more effective action. WATCH THE OTHER
- [Chuck Bogosta, President, UPMC International](https://archive.cancerworld.net/featured/chuck-bogosta/) - UPMC is a 14-billion-dollar integrated global health enterprise, closely linked to the University of Pittsburgh. Twenty years ago it opened a transplant hospital in Sicily. Since then, its International arm has expanded to build hospitals and offer consultancy and other services worldwide, with a special focus on cancer care. Fabio Turone asked UPMC International President
- [Radiotherapy and immunotherapy: a beneficial liaison?](https://archive.cancerworld.net/impact-factor/radiotherapy-and-immunotherapy-a-beneficial-liaison/) - Ralph Weichselbaum and colleagues explore how enhancing innate and adaptive immunity by combining radiotherapy and immune therapy could tip the balance of the host immune response to promote cure. This is a summary, by Janet Fricker, of a longer article that was first published in Nature Reviews Clinical Oncology: Ralph R. Weichselbaum, Hua Liang, Liufu Deng
- [Immunotherapy in relapsed refractory Hodgkin lymphoma](https://archive.cancerworld.net/e-grandround/immunotherapy-in-relapsed-refractory-hodgkin-lymphoma/) - A chromosomal alteration present in almost all patients with Hodgkin lymphoma makes the disease uniquely vulnerable to PD-1/PD-L1 immune checkpoint blockers. Astrid Pavlovsky reviews the trial evidence and clinical experience, and looks to the future possible use of this class of therapy. This grandround was first presented by Astrid Pavlovsky, from the Department of Haematology,
- [Advanced breast cancer advocacy goes global](https://archive.cancerworld.net/patient-voice/advanced-breast-cancer-advocacy-goes-global/) - The advanced breast cancer community has spent many years defining the treatment, care and support patients need to help them live longer and feel and function better. They’ve now formed an alliance to advocate for those needs to be met across the globe. Marc Beishon reports. A generation ago, stigma surrounding breast cancer – whether
- [Omar Youssef: aesthetic surgery is not just a Western luxury](https://archive.cancerworld.net/profile/omar-youssef-aesthetic-surgery-is-not-just-a-western-luxury/) - Training Egypt’s breast surgeons in techniques of plastic surgery is giving survivors a better quality of life and transforming women’s attitudes towards the disease. Having proved it is possible in his own country, Omar Youssef is now helping other developing countries do the same, as Anna Rouillard reports. Breast cancers in Egypt are more deadly
- [Let's be honest: our research efforts centre on drugs not patients](https://archive.cancerworld.net/featured/lets-be-honest-our-research-efforts-centre-on-drugs-not-patients/) - Precision oncology is about understanding what is driving an individual’s cancer growth, resistance and metastasis, and then targeting those pathways accordingly. Our current research models are good at developing drugs to hit targets. They are bad at learning about which targets need hitting in which patients and how best to do that. A truly patient-centred
- [Building the clinical evidence on metformin and cancer](https://archive.cancerworld.net/cutting-edge/can-metformin-deliver-for-cancer-patients/) - Population studies, mouse models, and mechanistic studies all show that metformin, a cheap well-tolerated diabetes drug, impacts in some way on how some cancers develop and progress. Anna Wagstaff talks to clinicians and researchers building the evidence on what it can deliver in the clinic. In the early 2000s diabetologists began reporting an unusually low
- [Ending the isolation: a guide to developing national rare cancers networks](https://archive.cancerworld.net/cover-story/ending-the-isolation-a-guide-to-developing-national-rare-cancers-networks/) - European Reference Networks can only work if member states designate and develop their own accredited specialist centres that can network across borders. Simon Crompton talks to some of the policy makers, clinicians and patient advocates who are making it happen. “Don’t speak about things you know nothing about.” Medical oncologist Lisa Licitra remembers the message
- [We're researching the history of oncology: What's in it for you?](https://archive.cancerworld.net/editorial/were-researching-the-history-of-oncology-whats-in-it-for-you/) - The history of medicine has often been reduced to hagiography – a celebration of past events lacking critical scrutiny. The contemporary history of oncology, with its ‘breakthroughs’ and ‘disruptive’ innovations, has likewise been exposed to such ‘Whiggish’ approaches, which assume that history follows a path of inevitable progression and improvement. Historians have long rejected this
- [Who's Who and programmes 2017 - Thirty-five Years of Education in Cancer Medicine](https://archive.cancerworld.net/past-events/whos-who-and-programmes-2017-thirty-five-years-of-education-in-cancer-medicine/) - ESO's brochure "Who's Who and Programmes 2017" is now available (click on the image to download the pdf).
- [A is for apple (but not always in Africa)](https://archive.cancerworld.net/news/a-is-for-apple-but-not-always-in-africa/) - In many books used for teaching the alphabet to children, the letter A is associated to an apple: the association may seem obvious, but usually it is not so for an African child: in Africa A is not for apple, but more likely for ant or avocado… The same is true in the “cancer world”
- [The (overrated) power of the hazard ratio](https://archive.cancerworld.net/news/the-overrated-power-of-the-hazard-ratio/) - «Maybe in our fight against cancer we are just looking at the wrong endpoints, focusing our attention on techinicalities like the hazard ratio of a trial instead of thinking at the best way to help the patients improve their quality of life and possibly their survival»: this thought was expressed several times, with some variants,
- [Are cancer patients right in looking for robotic surgery?](https://archive.cancerworld.net/news/are-cancer-patients-right-in-looking-for-robotic-surgery/) - Does robotic surgery offer superior outcomes? Yes and no – or better: yes and maybe ­– answers a study published earlier this month in The Lancet Oncology: their clinical benefit is still uncertain, but robots appear to offer superior outcomes in terms of marketing, attracting patients and helping surgical centers stay open. «Several countries have
- [Belgrade (Republic of Serbia) 30/6/2017-5/7/2017 – 4th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology](https://archive.cancerworld.net/past-events/belgrade-republic-of-serbia-3062017-572017-4th-eso-esmo-eastern-europe-and-balkan-region-masterclass-in-medical-oncology/) - This residential programme has been designed for medical and clinical oncologists, who wish to improve their skills or those who are preparing for the national board or ESMO exam. The programme will expose participants to a full spectrum of issues in clinical and medical oncology from basic science to advanced knowledge of systemic therapy
- [Ascona (Switzerland) 10-13/06/2017 - Leukaemia and Lymphoma](https://archive.cancerworld.net/past-events/ascona-switzerland-10-13062017-leukaemia-and-lymphoma/) - The programme is designed for postgraduate medical doctors at any stage of clinical career who are interested in haematological oncology. A mix of experienced clinicians or pathologists etc., and oncology/haematology trainees is welcome. Scientists (PhD) are very welcome too, but they should be advised that the course will emphasise clinical aspects rather than basic
- [Boston (USA) 15-7-2017 - Breast Cancer in Young Women: Joint DFCI-ESO Symposium](https://archive.cancerworld.net/past-events/boston-usa-15-7-2017-breast-cancer-in-young-women-joint-dfci-eso-symposium/) - The first edition of the Joint "ESO-DFCI Breast Cancer in Young Women Symposium" will be held during the Breast Cancer: New Horizons, Current Controversies Course, on July 15 in Boston, United States. Breast cancer in young women is a complex disease, occurring when these women are at the peak of their reproductive years, family life
- [Scanners, zappers and nanobots: are patient groups missing a trick?](https://archive.cancerworld.net/voices/scanners-zappers-and-nanobots-are-patient-groups-missing-a-trick/) - When we talk about advances in cancer care patient advocacy groups tend to focus on the development of new drugs, immunotherapy being the latest flavour. This is encouraged by the pharma industry, keen to gain traction for new treatments wherever it can. It means that we find it easy to overlook the arrival of new
- [End this secrecy over clinical trials](https://archive.cancerworld.net/editorial/end-this-secrecy-over-clinical-trials/) - Ninety-six of every 100 adult cancer patients do not enrol in a clinical trial. One reason is that many trials are shrouded in a veil of secrecy, and patients find it hard to locate one that addresses their specific condition. Existing registries list only a small percentage of trials in progress, the information they contain
- [Stella Kyriakides: the torch bearer](https://archive.cancerworld.net/cover-story/stella-kyriakides-the-torch-bearer/) - When Dolly Triantafyllides, a prominent member of Cypriot society, contracted breast cancer in the late 1960s, she broke with traditional taboos and went public, becoming one of the island's first advocates. Many years after her death, her daughter Stella faced the same diagnosis. She took up the torch of advocacy and has been running with
- [Cancer in pregnancy: the cruellest dilemma](https://archive.cancerworld.net/e-grandround/cancer-in-pregnancy-the-cruellest-dilemma/) - When a pregnant woman discovers she has cancer, her doctor faces a challenge with few guidelines, and little evidence of optimal treatment. The woman faces a cruel dilemma – does she lose the baby to save her life, or risk her life to try to save the baby? Download full article
- [Let's talk Chinese milk vetch](https://archive.cancerworld.net/drug-watch/lets-talk-chinese-milk-vetch/) - Quack remedies' have long been a thorn in the side of the medical establishment, but fear of ridicule means many patients don't tell their doctors about any additional medicines they may be using. This problem may now be compromising research results. Downaload full article
- [Sophie Fosså: The survival expert](https://archive.cancerworld.net/senza-categoria/sophie-fossa-the-survival-expert/) - Choosing a career as a urologist in Norway was always going to be a tough option for a German woman in the 1960s, and she often felt isolated and unwelcome. But Sophie Fosså's outstanding work as a researcher gained her recognition, and eventually gave her the confidence to look beyond the purely medical needs of
- [Show me the evidence](https://archive.cancerworld.net/senza-categoria/show-me-the-evidence/) - Haematologist Else Borst Eilers was handed a poisoned chalice as the Minister asked to make cuts in healthcare costs in the Netherlands. She found her salvation in the patient viewpoint, and evidence-based care. Download full article
- [Doctors who shun guidelines get worse results](https://archive.cancerworld.net/impact-factor/doctors-who-shun-guidelines-get-worse-results/) - An unhelpful straightjacket or an essential tool for optimal treatment? Some physicians still trust their own skill and judgement above all else, but new evidence shows that patients do best when their doctors follow consensus guidelines. Downoload full article
- [Nurses to get frontline training in haematological toxicities](https://archive.cancerworld.net/spotlight-on/nurses-to-get-frontline-training-in-haematological-toxicities/) - Nurses need to know about haematological toxicities so that they understand how to manage problems and are able to identify who is at risk and teach patients the danger signs. A new course will soon be available to further develop their expertise. Download full article
- [Inspiring the oncologists of tomorrow](https://archive.cancerworld.net/spotlight-on/inspiring-the-oncologists-of-tomorrow/) - Given that cancer is the number two killer in the world, oncology is surprisingly poorly taught at medical schools. So last September, the European School of Oncology piloted its first course aimed specifically at undergraduates. Download full article
- [e-Lessons of yesterday point the way ahead](https://archive.cancerworld.net/senza-categoria/e-lessons-of-yesterday-point-the-way-ahead/) - From Harlem to Helsinki, from Stirling to Sarajevo, the Internet is being put to novel uses in the cause of cancer prevention and care. The lessons learned have now been used to map out an action plan for Cancer on the Internet. Download full article
- [The sounds of silence](https://archive.cancerworld.net/focus/the-sounds-of-silence/) - Negative clinical-trial results are underreported. But this may soon change. Download full article
- [The power of words](https://archive.cancerworld.net/editorial/the-power-of-words/) - Blogging – a novel form of Internet communication – is starting to enter the cancer world. A ‘blogger' is someone who posts their thoughts and opinions to an online journal (called a ‘web log' or ‘blog'). The best bloggers are insiders – people who can candidly describe a particular reality, warts and all. Download full
- [Bruce Ponder: plugging the research gaps](https://archive.cancerworld.net/cover-story/bruce-ponder-plugging-the-research-gaps/) - “Just do it” is a lesson Bruce Ponder learnt early in his research career, and it has stood him in good stead. He is now director designate of one of Europe's largest cancer research centres, where he intends to plug many of the research gaps that the cancer community has been complaining about for so
- [Treating anaemia: damned if you do, damned if you don't](https://archive.cancerworld.net/e-grandround/treating-anaemia-damned-if-you-do-damned-if-you-dont/) - Many cancer patients suffer unnecessary levels of fatigue due to a failure to treat their anaemia. But just as the cost of erythropoiesis-stimulating proteins looks set to fall, surprise research results are prompting questions over whether these drugs might actually be stimulating tumour growth. Download full article
- [Brainwaves in drug delivery](https://archive.cancerworld.net/drug-watch/brainwaves-in-drug-delivery/) - Delivering drugs through the blood-brain barrier has always confounded scientists, but new developments in both non-invasive targeted brain delivery and brain-implanted drug formulations may provide a way forward. Download full article
- [Jean-Claude Horiot: the innocent inquisitor](https://archive.cancerworld.net/senza-categoria/jean-claude-horiot-the-innocent-inquisitor/) - In 1972 Jean-Claude Horiot left a wonderful research job in the US to join a cancer centre in Dijon that was too small to conduct clinical trials on its own. He teamed up with similar centres, and in so doing laid the basis for cooperative research and helped end a culture in which medics and
- [Women doctors offer alternative to costly mammography](https://archive.cancerworld.net/spotlight-on/women-doctors-offer-alternative-to-costly-mammography/) - Breast examination by specially trained young women doctors is proving effective at picking up tumours in the general population in a number of developing countries. If it can be shown to affect mortality rates, this low-tech screening method could provide a solution for poorer nations, and may even force a rethink in richer ones. Download
- [Poorer countries take their place at the World Cancer Conference](https://archive.cancerworld.net/spotlight-on/poorer-countries-take-their-place-at-the-world-cancer-conference/) - Last November 800 people working to control cancer in 82 countries across the world gathered in Dublin to share their experiences of what works and what doesn't. This was the fourth World Conference of Cancer Organisations, but for a number of developing nations it was a first. Download full article
- [Has tamoxifen had its day?](https://archive.cancerworld.net/impact-factor/has-tamoxifen-had-its-day/) - Anastrozole is being hailed by some as the new tamoxifen. But many researchers feel there is a great deal more we need to know before we consider casting aside the hormonal treatment that has served so many women so well. Download full article
- [Look – no strings!](https://archive.cancerworld.net/patient-voice/look-–-no-strings/) - As patient groups begin to gain access to the corridors of power, the spotlight is falling on their relations with the powerful pharmaceutical industry. In an effort to protect their credibility from a murky sea of rumour and speculation, many patient groups are now trying to negotiate a more transparent and arm's length relationship with
- [Cancer nurses partners in care](https://archive.cancerworld.net/systems-services/cancer-nurses-partners-in-care/) - Cancer nursing is changing across Europe. Nurses are studying to higher levels, taking greater responsibility and making more autonomous clinical decisions. One important result is that they are better able to help cancer patients make sense of what is happening and learn to become partners in their own care. Download full article
- [Portrait of palliative medicine as a young art](https://archive.cancerworld.net/senza-categoria/portrait-of-palliative-medicine-as-a-young-art/) - This is an excellent reference book for anyone involved in palliative care. It covers every aspect of the specialty, and is accessible to medical professionals and lay readers alike. Download full article
- [IBM Watson's skills in oncology? Elementary, according to an investigation](https://archive.cancerworld.net/news/ibm-watsons-skill-for-oncology-elementary-according-to-an-investigation/) - The «intelligent» supercomputer that IBM started selling around three years ago as "Watson for Oncology" claiming that it was capable of recommending the best cancer treatments to doctors was the object of an in-depth investigation by STAT, the science-oriented online magazine recently launched by the Boston Globe. The conclusions are striking: the supercomputer «is still struggling with the
- [Balancing safety against need](https://archive.cancerworld.net/editorial/balancing-safety-against-need/) - When Pfizer followed Merck & co in withdrawing one of their COX-2 inhibitors from the market owing to increased risks of cardiovascular complications, it provided a timely reminder that medicines are not without their risks. We have known about the potential harm associated with medicines for centuries. Almost 500 years ago Paracelsus wrote: Dosis facit
- [José Baselga: playing to Europe's strengths](https://archive.cancerworld.net/cover-story/jose-baselga-playing-to-europes-strengths/) - It took José Baselga just a few years to build the oncology department at Barcelona's Vall d'Hebron hospital from a few shabby consulting rooms to a leading centre for research into targeted therapies. Europe has the edge in this type of research because we are better at working together, says Baselga. But we still have
- [They could be alive today](https://archive.cancerworld.net/e-grandround/they-could-be-alive-today/) - Every year thousands of people die unnecessarily from cancer because their care is sub-optimal or arrives too late. Europe has known where the problems are for more than a decade and has the knowledge to improve matters. It is the political will that is lacking. Download full article
- [What do animal experiments really tell us?](https://archive.cancerworld.net/drug-watch/what-do-animal-experiments-really-tell-us/) - Do animal models reliably predict toxic effects in humans, or are they actually blocking development of vital new drugs? Two recent major health scares have reignited the old debate. Download full article
- [EPO rules on contested gene patent](https://archive.cancerworld.net/senza-categoria/epo-rules-on-contested-gene-patent/) - The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form. Download full article
- [Tackling cancer: the view from Brussels](https://archive.cancerworld.net/senza-categoria/tackling-cancer-the-view-from-brussels/) - Things seem to have gone quiet at the EC since 2000, when Europe Against Cancer – a concerted programme aimed at reducing cancer deaths by 15% – came to an end. Where is Europe concentrating its cancer effort now? Cancer World asked Markos Kyprianou, who took over as Commissioner for Health and Consumer Protection last
- [Vince DeVita: the view from the top](https://archive.cancerworld.net/senza-categoria/vince-devita-the-view-from-the-top/) - As director of the NCI between 1980 and 1988, Vince DeVita was a Commander in Chief of America's War on Cancer. He has little time for those who now criticise the plan of attack – or the outcome. But he warns that if we are to win the battles in the molecular arena, we will
- [Rising to the challenge in the developing world](https://archive.cancerworld.net/spotlight-on/rising-to-the-challenge-in-the-developing-world/) - Most cancer deaths are in the developing world and the problem is set to escalate, yet cancer has never received the attention given diseases such as AIDS and malaria. Equipping less-developed health systems with the resources and expertise needed for effective cancer control has been posed as the great challenge of this century. Download full
- [Does your hospital pass the palliative care test?](https://archive.cancerworld.net/spotlight-on/does-your-hospital-pass-the-palliative-care-test/) - In a bid to raise standards in palliative care, ESMO has drawn up a list of criteria that hospitals must fulfill to qualify as centres of excellence. Would your hospital pass the test? Download full article
- [Neoadjuvant studies offer mixed messages](https://archive.cancerworld.net/impact-factor/neoadjuvant-studies-offer-mixed-messages/) - Three recent papers have failed to confirm any clear benefit of neoadjuvant treatment on overall survival. But its value in minimising the extent of surgery and its potential for greater survival effect using newer drugs may yet repay the faith many oncologists have in this approach to treatment. Download full article
- [Cancer vaccine for CML shows promise](https://archive.cancerworld.net/impact-factor/cancer-vaccine-for-cml-shows-promise/) - Vaccines have long been seen as a potentially attractive option for treating cancer. Now a group targeting a peptide that plays a key role in CML think they may be onto a winner. Download full article
- [Symptom management at the touch of a button](https://archive.cancerworld.net/senza-categoria/symptom-management-at-the-touch-of-a-button/) - Side-effects of chemotherapy are nasty and can be dangerous. But soon patients may be able to log symptoms and receive prompt advice or, if necessary, medical attention, using nothing but a mobile phone... and a rather sophisticated computer programme. Download full article
- [Oncology under the microscope](https://archive.cancerworld.net/senza-categoria/oncology-under-the-microscope/) - This latest edition of Cancer: Principles and Practice of Oncology is a one-stop shop for everything you ever wanted to know about oncology. Download full article
- [Who pays the piper...](https://archive.cancerworld.net/focus/who-pays-the-piper/) - The world's largest sponsor of medical research has brought open access one step closer by setting time limits for research it funds to be published online. Download full article
- [A quiet revolution](https://archive.cancerworld.net/editorial/a-quiet-revolution/) - Every two years, doctors specialising in breast cancer gather in St Gallen to discuss developments and update guidelines on adjuvant therapies. It is always an important conference, but its conclusions tend to be measured rather than headline grabbing. Download full article
- [Peter Boyle: the man behind the statistics](https://archive.cancerworld.net/cover-story/peter-boyle-the-man-behind-the-statistics/) - As a young epidemiologist, Peter Boyle once had to give a talk on trends in smoking-related cancer, having lost his father to the disease that same morning. Now head of the IARC, his great strength is an ability to inject a sense of the reality behind the statistics his staff work on every day, and
- [European research crisis: the cancer community must make its voice heard](https://archive.cancerworld.net/e-grandround/european-research-crisis-the-cancer-community-must-make-its-voice-heard/) - The European Union aims to become “the most competitive and dynamic knowledge-based economy in the world”. Why then does it put so many obstacles in the way of research? And why is a world-beating breast cancer trial left short of funding and support? Download full article
- [Mutation explains relapse on EGFR products](https://archive.cancerworld.net/drug-watch/mutation-explains-relapse-on-egfr-products/) - A discovery made simultaneously by two groups of US researchers may help lung cancer patients who relapse after an initial response to novel targeted therapies. Download full article
- [Putting breast cancer on the political agenda](https://archive.cancerworld.net/senza-categoria/putting-breast-cancer-on-the-political-agenda/) - Two years ago, the European Parliament passed a landmark resolution which set goals and standards for breast cancer services. It all started when a surgeon saved Karin Jöns MEP from an unnecessary mastectomy, and introduced her to the concept of specialist breast units. “This is what women need. You are a politician. Do something,” he
- [Finding the viral link: the story of Harald zur Hausen](https://archive.cancerworld.net/senza-categoria/finding-the-viral-link-the-story-of-harald-zur-hausen/) - German virologist Harald zur Hausen was convinced by the early 1970s that the skin wart virus, human papilloma, was implicated in cervical cancer. Thirty years later we stand on the threshold of a vaccine to prevent this major killer of women. Looking back, it could have happened earlier Download full article
- [Sentinel node biopsy gets an excellent report](https://archive.cancerworld.net/impact-factor/sentinel-node-biopsy-gets-an-excellent-report/) - The latest study on use of the sentinel node biopsy has prompted calls for the procedure to be universally adopted. But can inexperienced teams be trusted to get it right? Download full article
- [Glioblastoma: two studies herald a new start](https://archive.cancerworld.net/impact-factor/glioblastoma-two-studies-herald-a-new-start/) - Surprise results of a temozolomide trial, and a new marker predicting who will benefit, offer hope for progress in the treatment of a highly aggressive brain tumour. Download full article
- [Follicular lymphoma: side-lined drug excites new interest](https://archive.cancerworld.net/impact-factor/follicular-lymphoma-side-lined-drug-excites-new-interest/) - A study showing that follicular lymphoma patients benefit from adding interferon to standard chemotherapy has opened up new avenues for research. Download full article
- [Fertility: it's up to doctors to think ahead](https://archive.cancerworld.net/patient-voice/fertility-its-up-to-doctors-to-think-ahead/) - Young cancer patients should feel lucky to survive, and stop fussing about their prospects of having children. This attitude, though still widespread, is now being challenged by many patients and doctors, who argue that it is inexcusable to prescribe treatments that could render a patient infertile, without a thorough discussion of all the options. Download
- [A healthy diet is simply a matter of good taste](https://archive.cancerworld.net/systems-services/a-healthy-diet-is-simply-a-matter-of-good-taste/) - When cancer patients lose their appetite, serving food they like eating, at the time they want to eat it, is more effective than prescribing healthy meals that end up left on the plate. Download full article
- [Science or humanism?](https://archive.cancerworld.net/senza-categoria/science-or-humanism/) - Two new oncological publications offer equal value in terms of their scientific and medical content. Where they differ is in their approach to patients and in their human vision. Download full article
- [A stronger voice within Europe](https://archive.cancerworld.net/editorial/a-stronger-voice-within-europe/) - An opportunity is opening up for Europe's cancer community to increase its influence over health and research policies, by overcoming its fragmentation to speak with a single voice. Download full article
- [John Smyth: unity is strength](https://archive.cancerworld.net/cover-story/john-smyth-unity-is-strength/) - John Smyth likes to get things done. Head of a major research centre and member of EMEA's scientific advisory committee, he argues for closer cooperation between academia and industry. He also wants a stronger voice for oncology in Europe, and hopes to convince his FECS colleagues to opt for greater unity when he takes on
- [On the road to a single European cancer society](https://archive.cancerworld.net/e-grandround/on-the-road-to-a-single-european-cancer-society/) - Members of the Federation of European Cancer Societies are debating how to present a united front to win a better deal for research and treatment. But how can disciplines with different priorities and agendas speak with one voice? Download full article
- [Cancer vaccines edge towards success](https://archive.cancerworld.net/drug-watch/cancer-vaccines-edge-towards-success/) - A number of cancer vaccines are now entering the final stage of clinical development. Are vaccines finally on their way to enjoying mainstream success in the oncology arena? Download full article
- [Let's be honest…](https://archive.cancerworld.net/senza-categoria/lets-be-honest…/) - Playwright, dissident, and first President of post-communist Czechoslovakia, Vaclav Havel lost his first wife to cancer in 1996, and was himself diagnosed with lung cancer later that same year. He'd survived years of suppression and imprisonment and had begun to lead his country into a new era. How did Havel now cope with this new
- [All in the blood](https://archive.cancerworld.net/senza-categoria/all-in-the-blood/) - Despite being home to three generations of Pavlovskys – Alfredo, the founder, Santiago, now medical director, and Astrid a fellow – Fundaleu is no family firm. On the contrary, it was the Pavlovskys' commitment to looking outward to international networks that made it possible to develop this world-class leukaemia centre in Buenos Aires. Download full
- [ESMO Minimum Clinical Recommendations](https://archive.cancerworld.net/spotlight-on/esmo-minimum-clinical-recommendations/) - Inadequate diagnostics, inappropriate treatment and poor follow-up deny cancer patients their best chance of survival. Whether you work in a hospital in rural Hungary or at the Jules Bordet in Brussels, ESMO's updated recommendations spell out what you need to do to ensure your patients receive an acceptable standard of care. Download full article
- [MEPs join forces against cancer](https://archive.cancerworld.net/spotlight-on/meps-join-forces-against-cancer/) - Europe could do so much more to boost cancer research and ensure all its citizens get good quality treatment. Now a group of politicians has got together to make sure it does. Download full article
- [Award for journalist who exposed failings in Hungary's cancer services](https://archive.cancerworld.net/senza-categoria/award-for-journalist-who-exposed-failings-in-hungarys-cancer-services/) - Viktória Kun, Health Correspondent on the leading Hungarian national daily newspaper Népszabadság, is one of two winners* of this year's ACE (Awarding Cancer Enlightenment) Reporters' Award. Here we reprint an article in which she highlights flaws in the country's oncology services that are responsible for some of the worst outcome statistics in Europe. Download full
- [Minimising radiotherapy in children with rhabdomyosarcoma](https://archive.cancerworld.net/impact-factor/minimising-radiotherapy-in-children-with-rhabdomyosarcoma/) - US and European paediatric oncologists are finally finding common ground over which patients need potentially damaging aggressive local treatment, and which can be spared. Download full article
- [Could COX-2s stage a comeback in cancer?](https://archive.cancerworld.net/impact-factor/could-cox-2s-stage-a-comeback-in-cancer/) - Hopes for a drug that could inhibit colorectal cancer took a knock last year due to revelations of serious side-effects. But a combination therapy may now offer a way forward. Download full article
- [When alternative becomes mainstream](https://archive.cancerworld.net/patient-voice/when-alternative-becomes-mainstream/) - Evidence base or no evidence base, complementary and alternative medicine use in Europe is edging closer to the rates reported in the US. Can Europe's doctors learn anything from their American colleagues about how to respond? Download full article
- [The no-computer virus](https://archive.cancerworld.net/senza-categoria/the-no-computer-virus/) - Costs, compatibility and patient privacy have all been cited as reasons why patient records cannot be computerised. But the inability, and reluctance, of doctors and hospitals to use information technology more widely is killing thousands of people. Download full article
- [The grief that cannot speak its name](https://archive.cancerworld.net/senza-categoria/the-grief-that-cannot-speak-its-name/) - The loss of a sibling can lead to endless suffering when the loss is not given the attention it requires and when grief work is incomplete. A courageous victim of sibling loss tells how she healed her wound and re-appropriated her personal story. Download full article
- [A European report card](https://archive.cancerworld.net/editorial/a-european-report-card/) - Disparities in the speed at which patients in different European countries get access to the latest cancer drugs were highlighted last month in a report published by Stockholm's Karolinska Institute. The Roche-sponsored study, launched at a press conference at the European Parliament, shows that patients in Austria, Spain and Switzerland tend to get quickest access,
- [Fatima Cardoso: the next generation](https://archive.cancerworld.net/cover-story/fatima-cardoso-the-next-generation/) - Fatima Cardoso's determination to put her considerable abilities to best use landed her the scientific directorship of a groundbreaking translational research trial at the tender age of 37. A founder of the Flims Alumni Club, she's now calling on other budding young researchers not to wait until they become the big shots, but to make
- [We will help you live until you die'](https://archive.cancerworld.net/e-grandround/we-will-help-you-live-until-you-die/) - Cicely Saunders touched the lives of millions of terminally ill patients through her promotion of hospices and palliative care. Though she died this summer at the London hospice she founded in 1967, her fight for all patients to have the right to live well and die pain free and in dignity goes on. Download full
- [Switzerland's cancer president](https://archive.cancerworld.net/senza-categoria/switzerlands-cancer-president/) - When it comes to fighting cancer, coordination is key. And in the fiercely autonomous cantons of Switzerland, that coordination is provided by a network of institutes, leagues and foundations that covers everything from prevention and fundraising to clinical research. They all have one man in common – Giorgio Noseda. Download full article
- [Radiotherapy report sets new targets for Europe](https://archive.cancerworld.net/spotlight-on/radiotherapy-report-sets-new-targets-for-europe/) - Radiotherapy is the most cost-effective treatment for many cancers. Now radiation oncologists have adopted an evidence-based approach to assessing need throughout Europe. And the league table for meeting that need reveals some surprising results Download full article
- [How the hostage-taking of Twist hit the mass media](https://archive.cancerworld.net/senza-categoria/how-the-hostage-taking-of-twist-hit-the-mass-media/) - Ioanna Soufleri writes for the Greek daily newspaper To Vima. In a series of articles that jointly won her the 2005 ACE (Awarding Excellence in Cancer) Reporter's Award, she has shown that progress in cancer can make fascinating reading without resorting to misleading talk of ‘wonder drugs' and ‘breakthroughs'. Below we reprint a sample of
- [Lung cancer: spotting the symptoms](https://archive.cancerworld.net/impact-factor/lung-cancer-spotting-the-symptoms/) - New research reveals that lung cancers could be picked up much earlier if only the public and health professionals learnt how to recognise the critical symptoms. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-44/) - Selected Press Reports compiled by the Cancer Media Centre Download full article
- [The news is bad... the message may be worse](https://archive.cancerworld.net/patient-voice/the-news-is-bad-the-message-may-be-worse/) - Despite recognised regional differences in how doctors and patients deal with bad news, recent research shows every country has patients who seek information and others who avoid information, and doctors need training to cater for them all. Download full article
- [Specialist centres: can surgeons heal the wounds?](https://archive.cancerworld.net/systems-services/specialist-centres-can-surgeons-heal-the-wounds/) - The policy of specialist centres for certain cancers is backed by research on outcomes. But surgeons in hospitals denied the right to treat cancer patients can find themselves cut adrift. Much of the UK has recently gone through the upheaval of regional specialisation. Are there lessons to be learnt from that experience? Download full article
- [Cure should also mean care](https://archive.cancerworld.net/senza-categoria/cure-should-also-mean-care/) - Enabling cancer patients to talk about their illness, lives and suffering, as unique individuals, is as essential to a patient's recovery as is medical treatment. Download full article
- [Hope or hype?](https://archive.cancerworld.net/editorial/hope-or-hype/) - Decades of experience have taught us to guard against the temptation to trumpet early impressive results as breakthroughs. Yet some of the comments over the promising results from trials testing Herceptin (trastuzumab) in early-stage breast cancer raise questions Download full article
- [Michael Baumann: the dynamo of Dresden](https://archive.cancerworld.net/cover-story/michael-baumann-the-dynamo-of-dresden/) - Michael Baumann went into radiation oncology because it has all the biological interest of medical oncology with added technical excitement. He claims the new targeted therapies will only come into their own when combined with radiotherapy, and last year he cofounded OncoRay, a state-of-the-art research facility, to help find out how this can best be
- [Lost in translation](https://archive.cancerworld.net/e-grandround/lost-in-translation/) - Cancer drugs often deliver less than they promise. The BDA believes the problem may lie not in the drugs themselves, but in the way they are targeted, tested and used. It organises regular get-togethers where the main players can share information and discuss strategies for the future. Download full article
- [What's coming up in colorectal cancer?](https://archive.cancerworld.net/e-grandround/whats-coming-up-in-colorectal-cancer/) - A panel of experts is predicting that colorectal cancer patients will soon feel the benefits of the sort of individualised therapies that are beginning to be used in breast cancer. More effort is needed to promote a multidisciplinary approach, improve staging and raise awareness of the benefits of screening. Download full article
- [Gynaecological oncology: Hungary has a word for it](https://archive.cancerworld.net/senza-categoria/gynaecological-oncology-hungary-has-a-word-for-it/) - Péter Bösze, professor, gynaecologist, geneticist, chemotherapist, radiotherapist and teacher, helped found the Budapest school of radical surgery. Today he is still encouraging young gynae-oncologists to think radically and practise holistically – and he is helping ensure that they can do both in their own mother tongue. Download full article
- [Can science win back public trust?](https://archive.cancerworld.net/spotlight-on/can-science-win-back-public-trust/) - Confidence in science is becoming dangerously eroded in the face of a rise in religious fundamentalism and a general scepticism that scientific advances will be used for the good of humanity as a whole. Will a global alliance for science win back some respect? Download full article
- [The rocky road to unity](https://archive.cancerworld.net/spotlight-on/the-rocky-road-to-unity/) - As FECS prepares to welcome organ-based societies through the front door, the medical oncologists threaten to leave by the back. Download full article
- [Coming out for breast cancer country by country](https://archive.cancerworld.net/spotlight-on/coming-out-for-breast-cancer-country-by-country/) - Walks to raise awareness of breast cancer are established traditions in many countries. But in many more, breast cancer remains hidden from public and political agendas. Avon's Walk Around the World helped connect everyone fighting to raise the profile of breast cancer across the globe. Download full article
- [Radiofrequency ablation in hepatocellular carcinoma](https://archive.cancerworld.net/impact-factor/radiofrequency-ablation-in-hepatocellular-carcinoma/) - A new study supports the use of image-guided radiofrequency ablation as a first-line treatment for well-selected cirrhotic patients with early-stage hepatocellular carcinoma. Download full article
- [Relapsed Hodgkin's lymphoma: new twist to the standard regimen](https://archive.cancerworld.net/impact-factor/relapsed-hodgkins-lymphoma-new-twist-to-the-standard-regimen/) - Results of a multicentre study show that a sequential high-dose chemotherapy variant of the standard treatment is safe and effective in relapsed Hodgkin's patients. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-43/) - Selected press reports compiled by the ESO Cancer Media Centre Download full article
- [Two sides to every study](https://archive.cancerworld.net/focus/two-sides-to-every-study/) - If research is worth funding at all, isn't it worth paying a little extra to make the results – positive or negative – available as freely and speedily as possible? Download full article
- [The drowned and the saved](https://archive.cancerworld.net/senza-categoria/the-drowned-and-the-saved/) - In recounting their personal stories, cancer patients are not only sharing their experiences and feelings – they are providing practical support to others and are gradually influencing the way cancer is perceived and treated. Download full article
- [We don't have to be a year behind](https://archive.cancerworld.net/editorial/we-dont-have-to-be-a-year-behind/) - Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) – the first new drug approved for this disease in the last 10 years. Manufacturer Bayer had filed an application for approval with the European Medicines Agency (EMEA) around the same time as its application to
- [Lesley Fallowfield: getting the message across](https://archive.cancerworld.net/cover-story/lesley-fallowfield-getting-the-message-across/) - It was while studying the benefits of offering patients a choice between radical and breast conserving therapy that Lesley Fallowfield first demonstrated the importance of doctor patient communication. Her findings haven't always been welcome, but cancer doctors who are now getting trained in talking to patients, and to each other, should know whom to thank.
- [Beyond the Herceptin hype…](https://archive.cancerworld.net/drug-watch/beyond-the-herceptin-hype…/) - Herceptin may turn out to be the biggest advance in treating breast cancer since tamoxifen. But if we are to prevent soaring drugs bills eating up our health budgets or barring Europe's poorer patients from the latest therapies, cancer professionals will have to wrest back the debate from the unfettered hype of the mass media.
- [Phase III trials in oncology](https://archive.cancerworld.net/senza-categoria/phase-iii-trials-in-oncology/) - Survival data from phase III trials can be very misleading because patients are not offered the best follow-up therapy argue Siegfried Seeber and Ada Braun in CancerWorld's new Forum section. Emma Mason canvassed clinical trial leaders, and presents their responses in the Debate section that follows. Download full article
- [Mr Hodgkin's disease](https://archive.cancerworld.net/senza-categoria/mr-hodgkins-disease/) - Volker Diehl cultured the cells that characterise Hodgkin's disease when everyone else had failed. He has high hopes that molecular medicine will throw light on many questions that remain unanswered. But he stresses that it is the disciplined clinical work on the wards that saves lives in this disease, where the line between cure and
- [Is radical prostatectomy of benefit in men with localised prostate cancer?](https://archive.cancerworld.net/impact-factor/is-radical-prostatectomy-of-benefit-in-men-with-localised-prostate-cancer/) - In men with intermediate- to high-risk prostate cancer, radical prostatectomy has been shown to lower the risk of local or systemic progression, and cancer-specific and overall mortality, compared with watchful waiting. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-42/) - Selected press reports complied by the ESO Cancer Media Centre Download full article
- [When clinical trials are compromised](https://archive.cancerworld.net/patient-voice/when-clinical-trials-are-compromised/) - Advocates for early access to unproven treatments may believe they are helping patients, but their actions can put current patients at risk and deny future patients the knowledge they need to make evidence-based treatment decisions, argues Musa Mayer. Download full article
- [A trial of strength](https://archive.cancerworld.net/senza-categoria/a-trial-of-strength/) - Patients, doctors, academic researchers and the World Health Organization all want industry to be a lot more open about the drugs they are trialling. The industry is pleading commercial confidentiality. The two sides are locked in an argument over the requirements of a proposed WHO clinical trials registry. The question is: who will blink first?
- [Getting serious about e-qual @ccess](https://archive.cancerworld.net/editorial/getting-serious-about-e-qual-ccess/) - More and more cancer patients are using the Internet to find out about their disease and treatment, to seek support from online patient communities and to communicate with their professional carers and loved ones. However, not everyone is benefiting from this digital revolution. Download full article
- [Laura van 't Veer: the person behind personalised treatments](https://archive.cancerworld.net/cover-story/laura-van-t-veer-the-person-behind-personalised-treatments/) - Our new-found ability to profile the gene expression of a tumour is transforming the way we characterise cancers and decide on treatment. Laura van 't Veer was there from the start, and she's now splitting her time between the academic and biotech sector, driving the translation of the new technique into diagnostic tools not just
- [The dream team: when will we make it a reality?](https://archive.cancerworld.net/e-grandround/the-dream-team-when-will-we-make-it-a-reality/) - Multidisciplinary teams provide the best quality cancer care, as specialists come together to discuss diagnoses and plan treatments. They raise standards, improve patient experiences and save lives. Sadly, most of Europe's cancer patients never have the chance to feel their benefits. Download full article
- [PHARE: shining a light for academic research in Europe](https://archive.cancerworld.net/drug-watch/phare-shining-a-light-for-academic-research-in-europe/) - Clinical research activity may be plummeting in the rest of Europe, but in France they're determined to substantially increase the numbers of hospitals and patients involved in clinical trials – starting with a strategic trial on Herceptin. Download full article
- [If the cardiologists can do it, so can we](https://archive.cancerworld.net/senza-categoria/if-the-cardiologists-can-do-it-so-can-we/) - Michael Sporn believes the best bet for controlling cancer is to pick up the warning signs and nip it in the bud. A pot of gold awaits any drugs company that can come up with a Lipitor for cancer, says Sporn, and easy-to-use biomarkers would already be on the market had one-tenth of the research
- [Chernobyl 20 years on](https://archive.cancerworld.net/spotlight-on/chernobyl-20-years-on/) - Estimates of the death toll from the nuclear reactor disaster at Chernobyl vary widely depending on who you listen to. But with leukaemia rates still rising, and a recent marked increase in solid tumours among the 600,000 workers who were sent in to clean up the mess, the real question is whether the worst may
- [Putting cancer on the global agenda](https://archive.cancerworld.net/spotlight-on/putting-cancer-on-the-global-agenda/) - The International Union Against Cancer has launched a childhood cancer campaign to show that better awareness, early detection and appropriate treatment can make a difference in the developing world. Download full article
- [When should radiotherapy for low-grade glioma be given: straight after surgery or at progression?](https://archive.cancerworld.net/impact-factor/when-should-radiotherapy-for-low-grade-glioma-be-given-straight-after-surgery-or-at-progression/) - Upfront radiation improves progression-free survival and should be offered as an option to patients presenting with low-grade gliomas. Download full article
- [Is intraoperative lymphatic mapping and sentinel node biopsy effective and safe in early-stage melanoma?](https://archive.cancerworld.net/impact-factor/is-intraoperative-lymphatic-mapping-and-sentinel-node-biopsy-effective-and-safe-in-early-stage-melanoma/) - Lymphatic mapping and sentinel lymph node biopsy is a safe, accurate, and low-morbidity method for the pathologic staging of the regional nodal basin in primary cutaneous melanoma. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-41/) - Selected press reports compiled by the ESO Cancer Media Centre Download full article
- [Solange Peters will be ESMO President for 2020-2021](https://archive.cancerworld.net/news/solange-peters-will-be-esmo-president-for-2020-2021/) - Solange Peters, MD, PhD, head of the Medical Oncology Service, chair of Thoracic Oncology, Oncology Department, of the University Hospital in Lausanne, Switzerland (Centre Hospitalier Universitaire Vaudois, CHUV), will be the President of the European Society of Medical Oncology (ESMO) for 2020-2021. «Over the past decade, Solange Peters has made exceptional contributions to the field
- [Haemato-oncology – Where precision medicine is finding its target](https://archive.cancerworld.net/cover-story/haemato-oncology-where-precision-medicine-is-finding-its-target/) - With the prospect of a chemo-free cure for some blood cancers, and with new targets and new drugs emerging at an unprecedented pace, Simon Crompton asks: Is haematology where the promise of precision medicine will finally be realised? We have come a long way since pioneering French microscopist Alfred Donné provided the first cellular description
- [UICC - taking on mission impossible](https://archive.cancerworld.net/editorial/uicc-taking-on-mission-impossible/) - For almost 75 years the International Union Against Cancer (UICC) has been the only international non-governmental organisation dedicated exclusively to the global control of cancer. But with many societies currently ‘going global', including ASCO and the American Association for Cancer Research, questions could be raised about whether the UICC is really needed anymore. I'm convinced
- [David Khayat: driving the French cancer plan](https://archive.cancerworld.net/cover-story/david-khayat-driving-the-french-cancer-plan/) - A committed medical oncologist, David Khayat reluctantly dragged himself away from his patients in 2003 to oversee the implementation of the French cancer plan. This grand and sweeping venture exercises huge control over cancer services, education and research. But its real value, says Khayat, is that it treats cancer patients as normal human beings. Download
- [Are you feeling lucky?](https://archive.cancerworld.net/e-grandround/are-you-feeling-lucky/) - Doctors use trial-based evidence and years of experience to assess risks of treatment and relapse. But patients make choices based on their own experiences and priorities. How can doctors best explore treatment options with patients? CancerWorld asked the experts and offers Ten Tips for Effective Communication About Risk. Download full article
- [RNA-bound: the future of antisense drugs](https://archive.cancerworld.net/drug-watch/rna-bound-the-future-of-antisense-drugs/) - The use of nucleic acid therapies to block RNA function was first described in 1978. The latest generation of these compounds, LNA antagonists, is now overcoming the main obstacle to the success of its predecessors, through a greater ability to bind to RNA. Download full article
- [Has TNM been overtaken by science?](https://archive.cancerworld.net/senza-categoria/has-tnm-been-overtaken-by-science/) - The biology of a cancer is a key factor determining prognosis and prediction of response. So should we still be characterising it by the size of the tumour and spread of the disease? In a debate at the European Breast Cancer Conference in Nice, a packed hall of delegates was, reportedly, evenly split on the
- [The Moscow smokebuster](https://archive.cancerworld.net/senza-categoria/the-moscow-smokebuster/) - There are smokers in Russia alive today thanks to David Zaridze and the lead he took in halving tar levels 20 years ago. He has a long history in cancer prevention, but believes the biggest gains may lie in early detection. Will the country that discovered the first liver cancer marker give the world the
- [Does regular use of aspirin reduce the risk of colorectal cancer?](https://archive.cancerworld.net/impact-factor/does-regular-use-of-aspirin-reduce-the-risk-of-colorectal-cancer/) - Use of at least two standard aspirin weekly, for 10 years or more, reduces colon cancer risk in women. Subject to certain caveats, aspirin should be considered for colon cancer prophylaxis. Download full article
- [Factors predictive for response of follicular and mantle cell lymphoma to rituximab](https://archive.cancerworld.net/impact-factor/factors-predictive-for-response-of-follicular-and-mantle-cell-lymphoma-to-rituximab/) - A recent analysis of prognostic factors may help identify which follicular and mantle cell lymphoma patients should be excluded from trials of single-agent rituximab therapy. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-40/) - Selected press reports compiled by the ESO Cancer Media Centre Download full article
- [Does being a patient have to be a full-time job?](https://archive.cancerworld.net/patient-voice/does-being-a-patient-have-to-be-a-full-time-job/) - Most doctors believe in holistic care, yet the clinical guidelines they use, and the way they discuss and deliver care, rarely take into account the demands that a given treatment option will make on the patient and their daily life. Anna Wagstaff reports on calls for this to change. Additional reporting by Peter McIntyre. A
- [Improving early diagnosis of symptomatic cancer](https://archive.cancerworld.net/impact-factor/improving-early-diagnosis-of-symptomatic-cancer/) - Focusing on the UK situation, Willie Hamilton and colleagues investigate why speeding up diagnosis of symptomatic cancers may be important, how to achieve it, who to focus on and where, and finally how much such strategies could cost/save in economic terms. This is an abridged version of Willie Hamilton et al. (2016) Improving early diagnosis
- [Do I refer this patient on? European family doctors swap notes on how they decide who should be tested for cancer](https://archive.cancerworld.net/systems-services/do-i-refer-this-patient-on-european-family-doctors-swap-notes-on-how-they-decide-who-should-be-tested-for-cancer/) - Symptomatic cancers are diagnosed quicker in some countries than others. A group of European primary care physicians recently set out to discover why this is, by gathering information about the different factors that influence decision-making. Janet Fricker talked to one of them, to find out what they learned. For the great majority of cancers, diagnosing
- [Virtual trials in virtual patients. Is this how we will accelerate progress in personalised treatments?](https://archive.cancerworld.net/cutting-edge/virtual-trials-in-virtual-patients-is-this-how-we-will-accelerate-progress-in-personalised-treatments/) - If mind-boggling complexity is the barrier to developing personalised cancer care strategies, could mathematical modelling – long used by economists, meteorologists and others – be the answer? Marc Beishon talks to leading figures who are exploring this approach. We’re making progress of sorts in personalised medicine, as headline results at ASCO revealed, for example on
- [Use of PARP inhibitors in ovarian cancer](https://archive.cancerworld.net/e-grandround/use-of-parp-inhibitors-in-ovarian-cancer/) - PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future possible use in subsets of ovarian cancers without the BRCA germline mutation. This grandround was first presented by Alexandra Leary,
- [Lisa Hutchinson: teasing out the signal from the noise](https://archive.cancerworld.net/profile/lisa-hutchinson-teasing-out-the-signal-from-the-noise/) - The explosion of new information in the era of personalised medicine has created a headache for busy clinicians. Lisa Hutchinson has spent the past 13 years helping them keep abreast of developments by sifting, sorting and summarising the clinical research findings that matter most. She talked to Anna Wagstaff about the joys of her job
- [Josep Tabernero  ESMO President Elect](https://archive.cancerworld.net/hot-seat/josep-tabernero-esmo-president-elect/) - Josep Tabernero is active at many levels. He does hands-on translational research in the lab and clinic, he directs one of Europe’s top cancer institutes, and he will shortly be taking over the leadership of the European Society for Medical Oncology. Alberto Costa asked him about his strategy for delivering progress for patients. Alberto Costa:
- [Prevention and early detection – If we don’t prioritise them, why  should anyone else?](https://archive.cancerworld.net/comment/prevention-and-early-detection-if-we-dont-prioritise-them-why-should-anyone-else/) - Oncology is understandably fascinated by ideas around precision treatment. As a medical oncologist who was there when the germs of this approach first appeared 50 years ago, I do of course share the excitement over the news that continues to stream out of molecular tumour biology – but I am also aware of its likely
- [A visionary who made a lasting contribution – Patrick Johnston, medical oncologist 1958–2017](https://archive.cancerworld.net/obituary/a-visionary-who-made-a-lasting-contribution-patrick-johnston-medical-oncologist-1958-2017/) - The European School of Oncology has lost a supporter, colleague and friend, writes Mike Clarke, who co-chaired ESO’s Systematic Reviews Masterclass alongside Patrick Johnston. With the sudden and unexpected death of Patrick Johnston on 4 June 2017, the world of cancer has lost an internationally renowned researcher and practitioner, and Queen’s University Belfast in Northern
- [Learning from haematology](https://archive.cancerworld.net/editorial/learning-from-haematology/) - Many of our most profound insights into the nature of cancer and its treatment have originated in the field of haematology. It was the high levels of bone marrow toxicity among soldiers who had been exposed to mustard gas in in World War II that first alerted researchers to the potential of chemotherapy. The unexpected
- [Making rights a reality](https://archive.cancerworld.net/editorial/making-rights-a-reality/) - That all cancer patients should have the right to quality care is something we can all agree on. But there have been few attempts to define exactly what this means. After a lengthy consultation exercise, two influential oncology organisations, the American Society of Clinical Oncology and the European Society for Medical Oncology, have now issued
- [Jacques Bernier: keeping the faith](https://archive.cancerworld.net/cover-story/jacques-bernier-keeping-the-faith/) - As a young medical school graduate in the '70s, Jacques Bernier ignored warnings that drugs were about to replace radiotherapy. He believed that new technology would make it safer and more effective. Today, he has faith that synergies between radiotherapy and targeted drugs can bring further benefits – and he is determined to see Europe
- [Targeted drug development by trial or error?](https://archive.cancerworld.net/e-grandround/targeted-drug-development-by-trial-or-error/) - Bringing the new wave of targeted cancer drugs to the market poses new challenges for researchers and clinicians. It is not enough to design a smart drug to hit a molecular target. Researchers need to know how to test and develop the drug. The potential prizes are enormous – so is the price of failure.
- [New drugs and survival: does the Karolinska report make sense?](https://archive.cancerworld.net/senza-categoria/new-drugs-and-survival-does-the-karolinska-report-make-sense/) - Is it possible to demonstrate that access to new drugs impacts on a country's survival rates? Last September, the Karolinska report claimed to have done just that. Here, Michel Coleman argues that its conclusions were misleading and unsupported by the data and analysis. In the Debate that follows, the authors respond and health economists and
- [How to help a friend with metastatic breast cancer](https://archive.cancerworld.net/voices/how-to-help-a-friend-with-metastatic-breast-cancer/) - So, your friend endured any number of treatments: chemotherapy, lumpectomy or mastectomy, possibly reconstruction, radiation therapy... and then when scans were done, instead of hearing the magical words “remission” or “cured,” your friend heard, “your cancer has metastasized to the…” (usually the bones, liver, brain, spine, or lungs). Now your friend, instead of “beating cancer,”
- [The man behind the margins](https://archive.cancerworld.net/senza-categoria/the-man-behind-the-margins/) - Roland Holland started investigating mammograms and their relation to pathological findings as part of the first European pilot of breast screening. His findings were later used by Umberto Veronesi as key evidence in support of breast-conserving surgery. More than 20 years on, his data are again being called into service, this time by America's brachytherapists.
- [Quality cancer care](https://archive.cancerworld.net/spotlight-on/quality-cancer-care/) - If equal access to quality cancer care is to be more than an aspiration, we need to define minimum standards. ASCO and ESMO have now taken a lead with a consensus statement. Download full article
- [Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?](https://archive.cancerworld.net/impact-factor/does-trastuzumab-increase-the-risk-of-isolated-cns-metastases-in-patients-with-breast-cancer/) - Research shows that brain metastasis of breast cancer may occur more often in women with HER2 overexpression. These patients require more aggressive surveillance to identify disease earlier, and new therapies are needed that can overcome barriers to effective CNS drug delivery. Download full article
- [Radiation dose for prostate cancer: is more better?](https://archive.cancerworld.net/impact-factor/radiation-dose-for-prostate-cancer-is-more-better/) - In prostate cancer, a trial comparing conventional- versus high-dose conformal radiotherapy has shown that increasing the dose can improve outcome, with only slight increases in toxicity. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-11/) - Selected press reports compiled by the ESO Cancer Media Centre Download full article
- [Guardian journalist named Best Cancer Reporter](https://archive.cancerworld.net/senza-categoria/guardian-journalist-named-best-cancer-reporter/) - The Best Cancer Reporter Award 2006, sponsored by the European School of Oncology, has gone to Sarah Boseley, health reporter for the UK's Guardian newspaper. She was commended for her ‘thorough, balanced, informed and articulate' approach to covering cancer from a wide variety of angles. Below we reprint one of her articles, entitled: Can you
- [Take one at bedtime and you'll soon feel worse](https://archive.cancerworld.net/patient-voice/take-one-at-bedtime-and-youll-soon-feel-worse/) - Many cancer patients, intentionally or by mistake, fail to take their medication as prescribed. Understanding why can help doctors encourage their patients to stick with the treatment. Download full article
- [Reefer madness](https://archive.cancerworld.net/focus/reefer-madness/) - Marijuana is medically useful, whether politicians like it or not. Download full article
- [The write stuff](https://archive.cancerworld.net/editorial/the-write-stuff/) - Cancer has a pretty poor public image. Myths and misconceptions fuel negative attitudes and ignorance about the disease. The media, in turn, can either fuel these misconceptions, or it can challenge them. Download full article
- [Lynn Faulds Wood: tell it like it is](https://archive.cancerworld.net/cover-story/lynn-faulds-wood-tell-it-like-it-is/) - Doctors don't know best if they haven't been trained. Embarrassment isn't the reason why colon cancer is picked up late. People will watch TV programmes that talk sense about cancer. Journalist and cancer survivor Lynn Faulds Wood knows how to get to the bottom of a problem and tell the world what she has found.
- [Turn up the volume](https://archive.cancerworld.net/e-grandround/turn-up-the-volume/) - If you had cancer, you'd want to be treated by experienced specialists working within a specialised multidisciplinary team. So why are so many of Europe's cancer patients still being treated in hospitals whose case-loads are clearly too low to provide this level of care? Download full article
- [Spread the word](https://archive.cancerworld.net/senza-categoria/spread-the-word-2/) - Specialising in a cancer with very poor prognosis, Heine Hansen is as keen as anyone to find new therapies that can improve survival. But he also believes that significantly better results could be achieved using currently available treatments, if only everyone knew about and followed best-practice guidelines – and he has done more than most
- [Record-breaking stamp raises sticky questions](https://archive.cancerworld.net/spotlight-on/record-breaking-stamp-raises-sticky-questions/) - Concern that vital research is being side-lined for lack of funds prompted US breast cancer surgeon Ernie Bodai to campaign for a special fundraising stamp. Despite the 6-cent mark-up, it has outsold all previous commemorative stamps including one of Elvis Presley. Yet Bodai has met with harsh criticism from some surprising quarters. Download full article
- [Helping the media to get the message](https://archive.cancerworld.net/spotlight-on/helping-the-media-to-get-the-message/) - How do you report on an issue that is publicly taboo and personally sensitive, and where the data are scant and the professionals can be unhelpful? Seven journalists who gathered at the UICC conference in July found they could learn a lot from one another. Download full article
- [Reporting cancer from the inside](https://archive.cancerworld.net/senza-categoria/reporting-cancer-from-the-inside/) - Catherine Kalamis of the Guernsey Press won a Best Reporter Award 2006 for a series of articles based on personal experiences of living with cancer. Below we reprint A life-changing moment, where she explains why good information is so vital to patients and she sends out a message about turning a threatening change into something
- [The subject is complex, the story is clear](https://archive.cancerworld.net/senza-categoria/the-subject-is-complex-the-story-is-clear/) - Overblown claims and contradictory messages on cancer can lead to confusion and scepticism. Health journalist Simon Crompton was recognised in the 2006 Best Reporter Awards for the clear and informative articles he has written for the Body&Soul section of The Times (UK). Below we reprint an example, which throws light on the link between exercise
- [Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?](https://archive.cancerworld.net/impact-factor/does-chemotherapy-given-directly-to-the-liver-improve-survival-in-patients-with-hepatic-metastasis/) - A study using hepatic arterial infusion to deliver treatment to colorectal cancer patients with liver metastases is unlikely to lead to wholesale changes in clinical practice, but may spur new studies into the role of local delivery of triple combination chemotherapy in these patients. Download full article
- [Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?](https://archive.cancerworld.net/impact-factor/should-patients-with-ovarian-cancer-receive-intraperitoneal-chemotherapy-following-initial-cytoreductive-surgery/) - A novel intraperitoneal chemotherapy regimen, trialled in the GOG 172 study, represents a new standard of care for patients with optimally resected stage III ovarian cancer, but should be offered on an individualised basis. Download full article
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-39/) - Selected press reports complied by the ESO Cancer Media Centre Download full article
- [What's brave about having cancer?](https://archive.cancerworld.net/focus/whats-brave-about-having-cancer/) - On September 1st, exactly six years after being told she had only six months to live, Jane Tomlinson completed a gruelling 6,780-km bike trek across America. Before setting out, she talked about why she refuses to sit at home waiting to die. Download full article
- [A question of public trust](https://archive.cancerworld.net/editorial/a-question-of-public-trust/) - Recent headlines in the UK press have again put the issue of pharmaceutical company sponsorship of cancer initiatives under the spotlight, rekindling the debate about its dangers and its merits. Whenever a non-profit advocacy, patient or professional group opens itself up to accusations that it is acting as a front for a commercial company, all
- [Jan Foubert: champion of cancer nursing](https://archive.cancerworld.net/cover-story/jan-foubert-champion-of-cancer-nursing/) - Jan Foubert knows the value of a good cancer nurse – someone who understands the patient's needs, knows how to help them cope with the disease, symptoms and side-effects and has skills to apply that knowledge. He believes it's up to Europe's nurses to redefine their role in cancer care – but he'd also welcome
- [A second opinion, because there's no second chance](https://archive.cancerworld.net/e-grandround/a-second-opinion-because-theres-no-second-chance/) - Patients want the option of consulting a second doctor, and the evidence shows that, for a minority of them, treatment decisions have altered significantly as a result. But could granting every patient the legal right to a second opinion tie up precious resources as each one ‘shops around' in search of the opinion they want
- [Fast and effective?](https://archive.cancerworld.net/drug-watch/fast-and-effective/) - EMEA's new system for fast-tracking drugs aims to offer quicker access to promising new therapies without jeopardising essential research. Draft Guidance on the use of the new conditional marketing approval procedure will shortly be published, and patients, professionals and the public are being invited to have their say. Download full article
- [From plan to practice](https://archive.cancerworld.net/senza-categoria/from-plan-to-practice/) - The French Cancer plan of 2003 raised expectations among the public and patients.This article, which looks at how a key measure is being implemented in practice, was one of several stories that earned Paul Benkimoun recognition in the 2006 ESO Best Reporter Awards. Download full article
- [Tackling cancer the Tunisian way](https://archive.cancerworld.net/senza-categoria/tackling-cancer-the-tunisian-way/) - Farhat Ben Ayed played a key role in building Tunisia's cancer services, armed with little more than a solid education, a sense of duty and a remarkable talent for motivating others. Fighting cancer, he believes, is a question of citizenship and solidarity, and limited resources cannot be allowed to stand in the way. Download full
- [Not ( just) another declaration](https://archive.cancerworld.net/spotlight-on/not-just-another-declaration/) - The World Cancer Declaration, issued in July, aims to mobilise efforts behind a limited number of aims that will make a big difference and can be quickly achieved. Download full article
- [Closing the survival gap](https://archive.cancerworld.net/spotlight-on/closing-the-survival-gap/) - EU countries from Central and Eastern Europe are trying to close the gap with Western Europe in cancer prevalence and survival rates. In Ljubljana, politicians, experts and patients came together to debate cancer plans, political will, funding and ways to stop skilled staff leaving home. Download full article
- [Gene expression profiling for individualised breast cancer chemotherapy: success or not?](https://archive.cancerworld.net/impact-factor/gene-expression-profiling-for-individualised-breast-cancer-chemotherapy-success-or-not/) - Results of a recent study indicate that gene expression profiling seems to improve prediction of chemotherapy effect in breast cancer, but methodological caveats remain worrisome. Download full article
- [Poor correlation between physician and patient assessment of quality of life in palliative care](https://archive.cancerworld.net/impact-factor/poor-correlation-between-physician-and-patient-assessment-of-quality-of-life-in-palliative-care/) - Wide variations found between quality of life assessments made by patients and by physicians indicate that patient symptom expression is a complex multidimensional construct. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-10/) - Selected press reports compiled by the ESO Download full article
- [Immune no longer](https://archive.cancerworld.net/focus/immune-no-longer/) - Two patients out of 17 may not seem very impressive. But their recovery has boosted hopes that we can find ways to teach our immune systems to kill cancer cells. Download full article
- [The challenge for St Gallen](https://archive.cancerworld.net/editorial/the-challenge-for-st-gallen/) - In mid-March 2007, the breast cancer world will again converge on the beautiful Swiss town of St Gallen, for what will be the 10th Anniversary Conference on the Primary Therapy of Early Breast Cancer. Download full article
- [Aron Goldhirsch: dogmatically anti-dogma](https://archive.cancerworld.net/cover-story/aron-goldhirsch-dogmatically-anti-dogma/) - To find out what makes cancers tick and work out how best to treat them, oncology must continually reinvent itself, applying rigorous methodology to interpret the results of welldesigned and accurately reported studies. So says Aron Goldhirsch, who has revelled in a career doing just that in breast cancer – possibly the most biologically complex
- [Don't sideline the guidelines](https://archive.cancerworld.net/e-grandround/dont-sideline-the-guidelines/) - Many patients are still being let down by a failure to follow clinical guidelines. It's all very well to blame know-it-all doctors, but if the guidelines are hard to access and tricky to use, and if treatment centres don't take steps to ensure new guidelines are implemented and continue to be observed, then what should
- [No-name heroes can save Europe billions](https://archive.cancerworld.net/drug-watch/no-name-heroes-can-save-europe-billions/) - European countries struggle to fund new cancer drugs which bring benefits at a high price. Meanwhile billions of euros are wasted, say researchers, because doctors prescribe branded drugs when a generic equivalent is just as good, and because the cost of generics is far too high. Download full article
- [You need to divorce to become good friends](https://archive.cancerworld.net/senza-categoria/you-need-to-divorce-to-become-good-friends/) - Hernán Cortés-Funes scored a victory for medical oncology when he helped convince Spain to become the first European country to grant the discipline specialist status. A bitter split with radiotherapy dating from that time has now given way to mutual respect, and the big challenge today is how to get specialists and hospitals working together
- [What they never taught you at medical school](https://archive.cancerworld.net/spotlight-on/what-they-never-taught-you-at-medical-school/) - Interest in addressing cancer patients' emotional and psychological needs is far outstripping access to training all over the world. Now the International Psycho-Oncology Society and the European School of Oncology have clubbed together to fill the gap. Download full article
- [Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?](https://archive.cancerworld.net/impact-factor/does-a-new-model-improve-decisions-about-mismatch-repair-genetic-testing-and-lynch-syndrome-identification/) - A new predictive model developed by clinical geneticists in Edinburgh offers a useful tool for physicians making decisions relating to genetic testing, although its clinical application in patients with colorectal cancer for the identification of Lynch syndrome requires caution. Download full article
- [Is breast conservation a reasonable option for women with BRCA-associated breast cancer?](https://archive.cancerworld.net/impact-factor/is-breast-conservation-a-reasonable-option-for-women-with-brca-associated-breast-cancer/) - A recent study has shown that women with BRCA mutations are as likely to achieve local control with breast-conserving treatment as women without mutations, but have increased long-term risk of ipsilateral and contralateral breast cancer. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-9/) - Selected press reports compiled by the ESO Download full article
- [No one told me I had a choice](https://archive.cancerworld.net/patient-voice/no-one-told-me-i-had-a-choice/) - The right of every patient to play a full role in decisions relating to their treatment remains more of an aspiration than a reality, according to a recent survey of breast cancer patients. For the situation to improve, doctors will need to take more time and learn better ways to communicate, particularly with their more
- [Savings lives through changing systems and practices](https://archive.cancerworld.net/systems-services/savings-lives-through-changing-systems-and-practices/) - There is no secret about the steps needed to improve cancer survival and revolutionise the patient experience. But change is a challenge for professionals and managers alike. The first ever CancerWorld conference focused on this challenge – how can you change systems and practices to improve quality of care across the board? Download full article
- [Elderly patients deserve better](https://archive.cancerworld.net/editorial/elderly-patients-deserve-better/) - Two sets of statistics have recently been published which together have major implications for Europe's cancer patients of the future. In February the International Agency for Research on Cancer revealed that the number of new cases in Europe rose by 10% between 2004 and 2006, from 2.9 million to 3.2 million. In March, a report
- [Tanja Cufer: all the confidence of new Europe](https://archive.cancerworld.net/cover-story/tanja-cufer-all-the-confidence-of-new-europe/) - Tanja Cufer, based in Slovenia's main cancer centre, is fighting on every front, championing academic research, arguing over the structure of her country's cancer services, agitating for holistic patient care. Far from playing catch-up with the West, she believes countries like hers can help Europe shed the baggage of the ‘old fashioned' disease-oriented approach. Download
- [When treatment gets under your skin…](https://archive.cancerworld.net/e-grandround/when-treatment-gets-under-your-skin…/) - EGFR inhibitors represent a bright hope for modern cancer therapies. But treatment comes at a price – an acne-like rash and other skin problems that can blight people's lives. As these drugs become used more widely and at earlier stages of treatment, it becomes increasingly urgent to learn how to treat the side-effects and help
- [Bringing personalised cancer treatments to the people](https://archive.cancerworld.net/drug-watch/bringing-personalised-cancer-treatments-to-the-people/) - Personal genetic signatures may help assess a person's risk of getting cancer, predict risk of recurrence, or identify the best treatment for them. At a Meet the Experts session, nine ASCO luminaries explained to press and public why it is crucial to invest in this area of research. Download full article
- [Where East meets West](https://archive.cancerworld.net/senza-categoria/where-east-meets-west/) - The fall of the Iron Curtain offered European oncology the chance to swell its ranks with new cadres, keen to learn and bursting with ideas and confidence. Christoph Zielinski, born of Polish emigrés and raised in post-war Austria, grasped the opportunity. He set about building Central Europe into a centre of academic gravitation, and is
- [MRI directive threatens the care of Europe's cancer patients](https://archive.cancerworld.net/spotlight-on/mri-directive-threatens-the-care-of-europes-cancer-patients/) - If EU Physical Agents (EMF) Directive 2004/40/EC goes through in its current form, hospitals may have to stop using MRI or open themselves to the risk of being sued by employees. Campaigners are now hopeful of a last-minute reprieve. Download full article
- [What radiation dose is safe in patients with non-small-cell lung cancer?](https://archive.cancerworld.net/impact-factor/what-radiation-dose-is-safe-in-patients-with-non-small-cell-lung-cancer/) - A recent study has found that high-dose radiation can be safely delivered for non-small-cell lung cancer provided careful consideration is given to the dose–volume relationship. Download full article
- [Should patients with anaplastic oligodendroglial tumours receive adjuvant chemotherapy?](https://archive.cancerworld.net/impact-factor/should-patients-with-anaplastic-oligodendroglial-tumours-receive-adjuvant-chemotherapy/) - Anaplastic oligodendrogliomas are sensitive to chemotherapy, but the role and timing of chemotherapy remain controversial, according to the findings of a recent study. Download full article
- [N e w s r o u n d](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-8/) - Selected reports edited by Hannah Brown Download full article
- [Neither child nor adult](https://archive.cancerworld.net/patient-voice/neither-child-nor-adult/) - Should teenager cancer patients be treated as children or as adults? The answer is surely that they should be treated as teenagers – but that's not an option available to many of them. Download full article
- [Why so much medical research is rot](https://archive.cancerworld.net/focus/why-so-much-medical-research-is-rot/) - If you trawl around looking for statistical relationships the chances are you will find some. Yet many researchers still assume such findings to be meaningful, and many readers are still all too ready to take their word for it. Download full article
- [Our responsibility to survivors](https://archive.cancerworld.net/editorial/our-responsibility-to-survivors/) - According to the media version, an individual who develops cancer embarks on a ‘battle' – those who win are cured, while those who lose die. This simplistic story overlooks the many whose cancer is brought under control rather than cured, as cancer becomes more like a chronic disease. You do not, after all, fight a
- [Nicholas Pavlidis: on the path of Hippocrates](https://archive.cancerworld.net/cover-story/nicholas-pavlidis-on-the-path-of-hippocrates/) - When he's not writing ESMO guidelines or caring for patients, Nicholas Pavlidis spends time boosting the meagre training received by many of Europe's young medical oncologists. In a field of medicine where treatments can easily do more harm than good, he calls on the wisdom of a fellow Greek – arguably the first oncologist –
- [Bridging the communications gap](https://archive.cancerworld.net/e-grandround/bridging-the-communications-gap/) - To give top-quality care an oncologist must understand the slightest changes in tumour characteristics. But when it comes to understanding human reactions and emotions, some scarcely know where to start. Doctors who want to explain treatment options or break bad news must first learn to make human contact with the patient. Download full article
- [HPV vaccine promises much but screening remains vital](https://archive.cancerworld.net/drug-watch/hpv-vaccine-promises-much-but-screening-remains-vital/) - The new HPV vaccines have shown impressive results in their target population, but if immunisation programmes come at the expense of existing or planned cytological screening, deaths from cervical cancer may increase. Download full article
- [The minimalist of St Mark's](https://archive.cancerworld.net/senza-categoria/the-minimalist-of-st-marks/) - “It takes a surgeon to stop a surgeon,” says John Northover, consultant surgeon at London's world-renowned colorectal hospital. And between his heavy clinical and teaching commitments, he concentrates on helping minimise patient interventions, through promoting screening and prevention, and discouraging treatment and follow-up of dubious clinical benefit. Download full article
- [AACR marks 100 years of researching cancer](https://archive.cancerworld.net/spotlight-on/aacr-marks-100-years-of-researching-cancer/) - In its centennial year the AACR maps the landmarks of progress in our understanding of cancer, and calls for renewed commitment to the search for prevention and cure. Download full article
- [Cardiac side-effects of trastuzumab: lessons learned from targeting cancer pathways](https://archive.cancerworld.net/impact-factor/cardiac-side-effects-of-trastuzumab-lessons-learned-from-targeting-cancer-pathways/) - A recent study has found that symptomatic cardiac toxicity may be a little higher in actual practice than in reports from the clinical trial of trastuzumab, and this finding needs to be incorporated into decision making, especially for lower-risk cases. Download full article
- [Magnetic resonance imaging for rectal cancer](https://archive.cancerworld.net/impact-factor/magnetic-resonance-imaging-for-rectal-cancer/) - A prospective observational study has concluded that MRI is the gold-standard method for preoperative pelvic assessment for rectal cancer. Download full article
- [Ne w s r o u n d](https://archive.cancerworld.net/senza-categoria/ne-w-s-r-o-u-n-d/) - Download full article
- [Living with the consequences](https://archive.cancerworld.net/patient-voice/living-with-the-consequences/) - Oncologists know well the fear and desperation of patients faced with a cancer diagnosis. They are far less familiar with the daily struggle to cope with functional impairments, pain or psychological damage that a significant minority of those same patients face once their treatment has ended. Here some survivors damaged by radiotherapy tell their stories.
- [Hair loss caused by chemo: an online registry will help to learn more](https://archive.cancerworld.net/news/hair-loss-caused-by-chemo-an-online-registry-will-help-to-learn-more/) - Hair loss can be a big concern for many cancer patients undergoing chemotherapy, and according to a recent review of the literature published on the Clinical Journal of Oncology Nursing, «scalp cooling efficacy is dependent on many factors but demonstrates better hair preservation than no cooling». Now the manufacturers of the two scalp cooling products approved
- [Passing on the baton](https://archive.cancerworld.net/editorial/passing-on-the-baton/) - Twenty-five years ago, a wealthy Italian industrialist who had been undergoing treatment for arthritis for a year found out that he was in fact suffering from prostate cancer, which had metastasised to the bone. He sought out Umberto Veronesi, Italy's leading cancer doctor, and told him that he wished to prevent the same delay in
- [Michael Stevens: curing the whole child](https://archive.cancerworld.net/cover-story/michael-stevens-curing-the-whole-child/) - When paediatric oncologist Michael Stevens talks ‘grades' with parents, he is as likely to be discussing their child's schooling as their cancer. If young patients are to have a future, you must look at their life as a whole, he says. He wants greater support for survivors and more research to predict which patients can
- [It's creative chaos in the colorectal cancer clinic](https://archive.cancerworld.net/e-grandround/its-creative-chaos-in-the-colorectal-cancer-clinic/) - After years of relying on 5FU, colorectal cancer clinicians now have a wealth of targeted therapies and combination protocols to choose from. The question is, what to use in which patients and when? Download full article
- [Healthcare rationing: the moral dilemma](https://archive.cancerworld.net/senza-categoria/healthcare-rationing-the-moral-dilemma/) - If Europe is to ensure that the latest therapies can be made available to all cancer patients who might benefit, getting maximum value from every euro spent on health will be essential. But who is to adjudicate that one patient can't have something they need, because another with different needs could derive greater benefit for
- [The birth of the breast unit: a Florentine tale](https://archive.cancerworld.net/senza-categoria/the-birth-of-the-breast-unit-a-florentine-tale/) - The story of how breast care in Europe moved from one-size-fits-all mutilating mastectomy towards a model of care tailored to the individual, stressing breast conservation and delivered by multidisciplinary breast teams is one that workers in other areas of cancer would love to emulate. Florence's Luigi Cataliotti saw it all, and played a key role
- [Polish reporter wins ESO award for coverage of colonoscopy screening](https://archive.cancerworld.net/senza-categoria/polish-reporter-wins-eso-award-for-coverage-of-colonoscopy-screening/) - Colonoscopy screening has the potential to save thousands of lives, but only if the public is prepared to go along with it. Polish journalist Pawel Walewski won the ESO Best Reporter Award 2007 for his article on the subject ‘It's a shame to be ashamed'. It was first published in Polityka, Poland's largest-circulation weekly, and
- [ESO marks 25 years of championing excellence in cancer education](https://archive.cancerworld.net/spotlight-on/eso-marks-25-years-of-championing-excellence-in-cancer-education/) - The European School of Oncology was set up in 1982 to help prevent needless death and suffering by educating Europe's young cancer doctors. ESO looks to a future where all patients are treated by specialist teams who keep abreast of developments and keep an eye on their own level of performance. But we're not there
- [Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?](https://archive.cancerworld.net/impact-factor/is-stereotactic-radiosurgery-the-best-treatment-option-for-patients-with-spinal-metastases/) - Results of new research show that high-precision radiotherapy, such as radiosurgery, represents an alternative to conventional irradiation for painful spinal metastases in selected patients with a favourable survival prognosis. Download full article
- [Could a pelvic and abdominal symptom index assist in early detection of ovarian cancer?](https://archive.cancerworld.net/impact-factor/could-a-pelvic-and-abdominal-symptom-index-assist-in-early-detection-of-ovarian-cancer/) - Findings from a recent study indicate that the novel Goff symptom index is a first step in identifying women at high risk of having ovarian cancer. Further evaluation is required, however, before it is widely promoted. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-7/) - Selected reports edited by Hannah Brown Download full article
- [Don't look away](https://archive.cancerworld.net/patient-voice/dont-look-away/) - In the second part of our series on Living with the consequences, survivors of head and neck cancer talk about the social isolation and despair of living with mutilated faces and struggling to talk, chew and swallow. Head and neck teams will fail their patients unless they go beyond check-ups for recurrence, and address their
- [How cancer hit the Romanian political agenda](https://archive.cancerworld.net/systems-services/how-cancer-hit-the-romanian-political-agenda/) - Romania's forgotten cancer patients erupted onto the public scene when they staged a demonstration outside the Ministry of Health in May. Things will never be the same again... Download full article
- [Tackling the adherence crisis](https://archive.cancerworld.net/editorial/tackling-the-adherence-crisis/) - Two recent reports are flagging up a problem of near crisis proportions that is leading to unnecessary disease progression, reduced quality of life or even death, and costs an estimated $150– $300 billion annually in the US alone. The US National Council on Patient Information and Education is talking in terms of “America's other drug
- [Hein Van Poppel: Urological cancer is what we do](https://archive.cancerworld.net/cover-story/hein-van-poppel-urological-cancer-is-what-we-do/) - Hein Van Poppel, director of the European School of Urology, is driving forward the training and accreditation of Europe's urological oncologists. He wants to see an end to untrained urologists dishing out cancer medicines – but he is no more keen on medical oncologists who treat kidneys, prostates and bladders without any specialist training in
- [Breast screening: a question of pros and cons not right or wrong](https://archive.cancerworld.net/e-grandround/breast-screening-a-question-of-pros-and-cons-not-right-or-wrong/) - Decades after breast screening programmes first started, their value remains hotly disputed. Some lives are saved, but it's hard to tell how many. False-positives are a problem, but it's a risk some are happy to take. Women need to weigh up for themselves the pros and cons of attending screening – but they can only
- [Dying for a lack of compassion?](https://archive.cancerworld.net/senza-categoria/dying-for-a-lack-of-compassion/) - For dying cancer patients who have run out of therapeutic options, getting hold of drugs that are still in trials can offer them a last throw of the dice. Yet many find the system for getting early access to drugs, for so-called ‘compassionate use', is beset by obstacles and delays. They want a greater sense
- [The passion behind big cancer projects](https://archive.cancerworld.net/senza-categoria/the-passion-behind-big-cancer-projects/) - Kris Vantongelen, now managing director of the Breast International Group, has played a pivotal role in two arenas that have been essential to the progress of oncology in recent decades: the development of systems for data collection and analysis, and the organisation of international interdisciplinary collaboration. She describes herself as ‘a believer'. Download full article
- [Do-it-yourself Chemotherapy Access](https://archive.cancerworld.net/senza-categoria/do-it-yourself-chemotherapy-access/) - Internet chatrooms offer patients a forum to discuss new therapies and exchange tips on how to get access to experimental drugs – sometimes from sources that have neither responsibility for nor interest in their welfare. Linda Geddes received an ESO Best Cancer Reporter Award for looking at the case of DCA, in her article When
- [New breast care network seeks to push up standards across the globe](https://archive.cancerworld.net/spotlight-on/new-breast-care-network-seeks-to-push-up-standards-across-the-globe/) - Cancer clinicians have a long history of collaborating across national boundaries to try to find out which therapies and protocols are most effective. Now a group of leading breast clinics have scored a first by setting up an international network focused primarily on improving the quality of their own clinical practice. Download full article
- [Is surgery necessary following chemoradiation for patients with locally advanced cancer of the oesophagus?](https://archive.cancerworld.net/impact-factor/is-surgery-necessary-following-chemoradiation-for-patients-with-locally-advanced-cancer-of-the-oesophagus/) - A landmark study has shown that patients with locally advanced epidermoid cancer of the oesophagus who respond well to induction chemoradiotherapy do not benefit from subsequent surgery and, therefore, seemto be well treated with definitive chemoradiotherapy. Download full article
- [Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?](https://archive.cancerworld.net/impact-factor/is-rituximab-maintenance-therapy-useful-following-rituximab-salvage-in-refractory-or-relapsed-follicular-lymphoma/) - A study by the German Low Grade Lymphoma Study Group has shown that rituximab maintenance following salvage with rituximab-containing chemotherapy is the standard of care for advanced-stage refractory or relapsed follicular lymphoma. Download full article
- [The X factor](https://archive.cancerworld.net/systems-services/the-x-factor/) - How can cancer services deliver top-quality, affordable care to aging populations in an era of fast-changing treatments and escalating costs? Five countries with something to offer and something to learn met to compare notes. Download full article
- [Men's health matters too](https://archive.cancerworld.net/editorial/mens-health-matters-too/) - Europe's women are much more likely to survive a cancer diagnosis than their male counterparts. According to EUROCARE-4, after adjusting for age and casemix, 54.6% of the women diagnosed between 1995 and 1999 survived for at least five years, but only 44.8% of men. The gap is the more worrying because, while differences in survival
- [Clifton Leaf: asking the difficult questions](https://archive.cancerworld.net/cover-story/clifton-leaf-asking-the-difficult-questions/) - Clifton Leaf sparked a lively public debatewith a hard-hitting cover story for Fortune magazine, which asserted that America's ‘war on cancer' is being lost. He calls on the cancer research community to show stronger leadership, increased cooperation, better focus and, above all, greater honesty about its successes and its shortcomings. Download full article
- [Our responsibility, our choices](https://archive.cancerworld.net/e-grandround/our-responsibility-our-choices/) - The European School of Oncology marked the end of its 25th anniversary year by inviting a top-level line up of experts to debate, in front of the media, how effectively we are tackling cancer and whether a change of direction is needed. Download full article
- [My wife has breast cancer](https://archive.cancerworld.net/senza-categoria/my-wife-has-breast-cancer/) - The psychological impact of breast cancer on women is now widely recognised. But what about the men struggling to find ways to support their partners and adapt to a new reality? María Valerio Sáinz, health reporter for the web edition of the Spanish daily El Mundo, asked some of them to share their stories. The
- [A very useful doctor](https://archive.cancerworld.net/senza-categoria/a-very-useful-doctor/) - Ferdy Lejeune went into medicine to be ‘useful', and he did well. Thousands of amputations have been avoided thanks to a technique he pioneered. His focus on tumour blood vessels and immunology helped pave the way for some of the most exciting areas of cancer research today. For Lejeune, however, ‘useful' is as much a
- [ECCO seeks healing touch for oncology's lost voice](https://archive.cancerworld.net/spotlight-on/ecco-seeks-healing-touch-for-oncologys-lost-voice/) - It's been a frustrating couple of years for those anxious to see a single strong voice for oncology at a European level. But with the launch of the European CanCer Organisation at ECCO14, things may be looking up. Download full article
- [Does a prompt list help patients and caregivers to ask questions about cancer prognosis and care?](https://archive.cancerworld.net/impact-factor/does-a-prompt-list-help-patients-and-caregivers-to-ask-questions-about-cancer-prognosis-and-care/) - Results of a randomised controlled trial show that question prompt lists may benefit communication. However, there are still areas to investigate before prompt lists can be described as evidence-based medicine. Download full article
- [Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin?](https://archive.cancerworld.net/impact-factor/does-adjuvant-radiotherapy-increase-survival-in-patients-with-merkel-cell-carcinoma-of-the-skin/) - The findings of a large retrospective study show that postoperative radiotherapy is associated with a significant improvement in survival, and is indicated in all patients with local or locoregional Merkel cell carcinoma. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-5/) - Selected reports edited by Hannah Brown Download full article
- [Surviving childhood cancer](https://archive.cancerworld.net/patient-voice/surviving-childhood-cancer/) - Childhood cancer is increasingly about being cured. But developing bodies can suffer life-long damage from toxic treatments, and developing personalities become moulded by the experience of battling cancer and living with uncertainty. In the third part of our series on Living with the consequences, survivors and doctors talk about managing a journey that never ends.
- [Diet and exercise: it's time to act on the evidence](https://archive.cancerworld.net/editorial/diet-and-exercise-its-time-to-act-on-the-evidence/) - What if you could prescribe your patients a therapy that had proven powers to lift quality of life, boost psychological well-being, improve cardiorespiratory and physical fitness, and reduce fatigue? Download full article
- [Giovanni Paganelli: nuclear medicine's enthusiastic ambassador](https://archive.cancerworld.net/cover-story/giovanni-paganelli-nuclear-medicines-enthusiastic-ambassador/) - Radioisotopes can be used to locate tumours and to deliver targeted therapeutic radiation internally. Sounds ideal for cancer, yet nuclear medicine remains an underdeveloped field, held back by irrational fears of all things nuclear, false perceptions of its potential, and bureaucratic and cost barriers to accessing agents. Giovanni Paganelli is a believer, and he is
- [Personalised cancer therapies: why we may never reach the promised land](https://archive.cancerworld.net/e-grandround/personalised-cancer-therapies-why-we-may-never-reach-the-promised-land/) - New technologies offer wonderful possibilities for cancer patients. But the development of personalised therapies is being squeezed between the priorities of industry and a regulatory system that offers poor value for money. Is there a champion to clear a route to this revolution in treatment? Download full article
- [Scientific integrity must always come first](https://archive.cancerworld.net/senza-categoria/scientific-integrity-must-always-come-first/) - Challenging medical orthodoxies is essential in the interests of good science and improving patient care. All top-class doctors do it, but few enjoy the battle as much as breast cancer specialist Michael Baum. He has been called ‘provocative' and ‘perverse', but a career championing evidence-based patient-centred medicine has left him with huge respect among his
- [Are patients with multiple hepatic metastases from colorectal cancer candidates for surgery?](https://archive.cancerworld.net/impact-factor/are-patients-with-multiple-hepatic-metastases-from-colorectal-cancer-candidates-for-surgery/) - Results froma retrospective reviewof data from patients who under went resection for colorectal liver metastases indicate that partial hepatectomy for four or more hepatic colorectal cancer metastases is no longer contraindicated and is associated with a five-year survival rate of 28–51%. Download full article
- [Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukaemia?](https://archive.cancerworld.net/impact-factor/is-drug-treatment-superior-to-allografting-as-first-line-therapy-in-chronic-myeloid-leukaemia/) - A study comparing the survival times of patients who received allogeneic transplantation for early stage CML with those of patients who received drug treatment showed that, with very few exceptions, drug treatment is the therapy of choice for this group of patients. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-4/) - Selected reports edited by Hannah Brown Download full article
- [It's not just about surviving, it's about getting your life back](https://archive.cancerworld.net/patient-voice/its-not-just-about-surviving-its-about-getting-your-life-back/) - Recent issues of CancerWorld have looked at the physical and psychosocial damage than can be inflicted by radiotherapy, chemotherapy and surgical cancer treatments. The final part of our series on Living with the consequences looks at the transition from patient to survivor and the sort of tailored support survivors need to help them live their
- [To avoid the Big C, stay small](https://archive.cancerworld.net/focus/to-avoid-the-big-c-stay-small/) - Every day there are new stories in the tabloids about the latest link, sometimes tenuous, sometimes contradictory, between cancer and some aspect of lifestyle. If this is a recipe for confusion, then the antidote is probably a weighty new tome from the World Cancer Research Fund (WCRF). Download full article
- [Shameful statistics of pain](https://archive.cancerworld.net/editorial/shameful-statistics-of-pain/) - In early March the International Narcotics Control Board (INCB), a UN agency, issued its annual report highlighting – yet again – the plight of millions of people around the world who continue to suffer acute and chronic pain because of insufficient use of analgesics. Download full article
- [Ulrik Ringborg: tackling the fragmentation of Europe's cancer efforts](https://archive.cancerworld.net/cover-story/ulrik-ringborg-tackling-the-fragmentation-of-europes-cancer-efforts/) - Ulrik Ringborg remembers a time before pressure on cancer services led Sweden to abandon a model that combined clinical and research responsibilities. He believes comprehensive cancer centres, similar to those in the US, are key to restoring that link, and could provide the backbone to unify efforts to improve cancer care in Europe. Download full
- [Translating good science into new treatments](https://archive.cancerworld.net/e-grandround/translating-good-science-into-new-treatments/) - Europe has money, human resources and a basic-science base that produces world-leading cancer research. Why, then, aren't these assets being translated into clinical advances? Download full article
- [How Europe is taking on the big biobank challenge](https://archive.cancerworld.net/senza-categoria/how-europe-is-taking-on-the-big-biobank-challenge/) - Cancer research is being held back by a shortage of high-quality, well-documented biological specimens. However, convincing hospitals to pool their specimens in a regional, national or international biobank is not always easy, adding to the logistical, technical, ethical, legal and IT obstacles of such a venture. Little by little, it seems, Europe is getting there.
- [The people's pharmacologist](https://archive.cancerworld.net/senza-categoria/the-peoples-pharmacologist/) - Silvio Garattini gave up a glittering academic career to found his own set-up where research could be carried out free from commercial or political agendas. Today, the Mario Negri Institute and its founder play a vital role on the European scene, championing a ‘rational approach' to drugs, and a research culture based on collaboration and
- [A man with a vision with the drive to achieve it – Patrick Johnston, medical oncologist 1958–2017](https://archive.cancerworld.net/obituary/a-man-with-a-vision-with-the-drive-to-achieve-it-patrick-johnston-medical-oncologist-1958-2017/) - The European School of Oncology has lost a supporter, colleague and friend, writes Mike Clarke, who co-chaired ESO’s Systematic Reviews Masterclass alongside Patrick Johnston. With the sudden and unexpected death of Patrick Johnston on 4 June 2017, the world of cancer has lost an internationally-renowned researcher and practitioner, and Queen’s University Belfast in Northern Ireland
- [Europe should act to curb alcohol consumption, cancer experts say](https://archive.cancerworld.net/news/europe-should-act-to-curb-alcohol-consumption-cancer-experts-say/) - Rates of alcohol-related digestive cancers are expected to increase very rapidly in Europe, according to an alarming new report issued by United European Gastroenterology (UEG) that calls for a new strategic, political and clinical effort: «It is time for Europe to change its approach and attitude towards alcohol consumption» declared Paul Fockens, professor of gastrointestinal endoscopy
- [There's a shadow in your head”](https://archive.cancerworld.net/senza-categoria/theres-a-shadow-in-your-head”/) - Eric Baumann, a healthy 34-year-old, in love with life and his new girlfriend, had just started as the new London correspondent for the Swiss daily Tages-Anzeiger when he was diagnosed with brain cancer. His description, republished here, of the seven tumultuous days that changed everything, and how he still manages to retain his love of
- [European Leukemia Network: making fragmentation a thing of the past](https://archive.cancerworld.net/spotlight-on/european-leukemia-network-making-fragmentation-a-thing-of-the-past/) - Efforts to improve the care of Europe's leukaemia patients have been boosted by a highly motivated, well-focused network that is integrating thework of trial groups and partner groups, involving diagnostics, treatment, registries and guidelines. Download full article
- [Outcomes after cisplatin alone or in combination regimens versus hydroxyurea during pelvic irradiation for cervical cancer](https://archive.cancerworld.net/impact-factor/outcomes-after-cisplatin-alone-or-in-combination-regimens-versus-hydroxyurea-during-pelvic-irradiation-for-cervical-cancer/) - Cisplatin-based chemoradiation has been shown to be superior to radiotherapy plus hydroxyurea for stage IB to III cervical cancer, conferring better survival rates withmodest long-term toxicity. Download full article
- [Are metastatic testicular tumours curable with high-dose chemotherapy and stem-cell rescue?](https://archive.cancerworld.net/impact-factor/are-metastatic-testicular-tumours-curable-with-high-dose-chemotherapy-and-stem-cell-rescue/) - A retrospective study has shown that haematopoietic stem cell rescue in tandem with high-dose chemotherapy should be considered a major treatment option in patients with testicular cancer following first-salvage chemotherapy and/or in cisplatin-refractory disease. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-3/) - Selected reports edited by Janet Fricker Download full article
- [Protection of employment rights: still work in progress](https://archive.cancerworld.net/patient-voice/protection-of-employment-rights-still-work-in-progress/) - Despite an EU directive out lawing job discrimination, cancer patients are still routinely forced out of work by employers who don't want themor refuse to accommodate their need for lighter work or a shorter working day. Changing attitudes and improving the information and support available to patients will be key to turning the letter of
- [A question of human dignity](https://archive.cancerworld.net/editorial/a-question-of-human-dignity/) - Social and economic progress over the course of the last century has helped people in many countries enjoy longer, healthier lives. Public health, by and large, has improved and health interventions are now available to prevent or treat most conditions, including cancer. Download full article
- [Mike Richards: the man with the plan](https://archive.cancerworld.net/cover-story/mike-richards-the-man-with-the-plan/) - Congratulations, you are now in charge of sorting out England's failing cancer services, what are your plans and can you start on Monday?” The job offer took Mike Richards by surprise but, mindful of the fickle nature of political support, he accepted the post, got straight down to work, and within six months he not
- [The hopes and frustrations of a career in cancer](https://archive.cancerworld.net/e-grandround/the-hopes-and-frustrations-of-a-career-in-cancer/) - Young oncologists want the chance to develop their skills, reach their full potential and give of their best. But a Cancer World survey shows many are frustrated by too heavy clinical workloads, too few chances to lead research and get published, and too little recognition for their clinical skills. Are potential leaders of oncology in
- [Personalised medicine: the dream and the reality](https://archive.cancerworld.net/senza-categoria/personalised-medicine-the-dream-and-the-reality/) - Recent years have seen a scramble to identify the genetic variance that predisposes or protects against certain cancers and the tumour gene signatures that could indicate which therapies will work and which won't. A picture is now emerging of an infinitely complex field that is unlikely ever to live up to the high hopes of
- [A scientist without borders](https://archive.cancerworld.net/senza-categoria/a-scientist-without-borders/) - A biostatistician with medical training, Hélène Sancho-Garnier helped drive the shift towards evidence-based clinical practice in the '60s and '70s. Stepping nimbly over traditional boundaries, she went on to apply this approach to cancer registries, screening, and now prevention and the ultimate challenge of how to communicate health messages to stroppy teenagers. Download full article
- [Tackling cancer in the Middle East](https://archive.cancerworld.net/spotlight-on/tackling-cancer-in-the-middle-east/) - Cancer is now the fastest growing killer in the Arab world. There is an urgent need to train health professionals on strategies for prevention, screening and appropriate care, and convince governments to act. ESO hopes to contribute to this effort through its Euro-Arab partnership. Download full article
- [Does prophylactic cranial irradiation reduce the incidence of brain metastases in extensive small-cell lung cancer?](https://archive.cancerworld.net/impact-factor/does-prophylactic-cranial-irradiation-reduce-the-incidence-of-brain-metastases-in-extensive-small-cell-lung-cancer/) - A phase III study has shown that prophylactic cranial irradiation decreases the risk of symptomatic brain metastases and may improve overall survival for patients with extensive small-cell lung cancer and response to systemic chemotherapy. Download full article
- [Comparison of gemcitabine plus platinum analogue with gemcitabine alone in advanced pancreatic cancer](https://archive.cancerworld.net/impact-factor/comparison-of-gemcitabine-plus-platinum-analogue-with-gemcitabine-alone-in-advanced-pancreatic-cancer/) - A pooled analysis of two randomised trials has shown that gemcitabine in combination with a platinumanalogue (cisplatin or oxaliplatin) is a potential front-line treatment option in advanced pancreatic adenocarcinoma. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d-2/) - Selected reports edited by Janet Fricker Download full article
- [We're back!](https://archive.cancerworld.net/systems-services/were-back/) - When Europe Against Cancer ended, the need for a Europe-wide strategy to tackle Europe's growing cancer problem fell off the political agenda. Now, thanks to an impressive two-year campaign by patients and their parliamentary allies, key EU bodies are starting to give this issue the attention it deserves. Download full article
- [Europe must tackle health illiteracy to avoid a health ‘underclass'](https://archive.cancerworld.net/patient-voice/europe-must-tackle-health-illiteracy-to-avoid-a-health-‘underclass/) - A quarter of Europe's citizens may miss out on better health, unless policy makers address functional illiteracy and improvements in the way information is presented. Download full article
- [ECCO–ESMO: a powerful partnership](https://archive.cancerworld.net/editorial/ecco–esmo-a-powerful-partnership/) - Bridging the bench-to-bedside gap and promoting multidisciplinarity are pivotal to advancing research and improving patient treatment and care. The implementation and measurable outcomes of both ideals in everyday practice generally translate into increased dialogue and debate between professional specialties and communities. In the battle to eliminate cancer much more can – and will – be
- [Nadia Harbeck: breaking with convention](https://archive.cancerworld.net/cover-story/nadia-harbeck-breaking-with-convention/) - Gynaecologists don't win top awards at ASCO. German oncologists don't make it on the international stage. Women who want large families can't expect to be leaders in their field. Nadia Harbeck's high-flying career and relaxed leadership style demonstrate the great possibilities that open up if you refuse to let conventional wisdom and prejudices stand in
- [The modern approach to managing locally advanced rectal cancer](https://archive.cancerworld.net/e-grandround/the-modern-approach-to-managing-locally-advanced-rectal-cancer/) - The traditional approach to managing locally advanced rectal cancer has shifted to the concept of total mesorectal excision and the use of MRI for local staging and selecting patients for multimodal therapy. This case report highlights the key role of the pathologist, the benefits of preoperative concurrent chemoradiation and the importance of multidisciplinary discussion. Download
- [Stopping trials prematurely: sorting the right decisions from the wrong](https://archive.cancerworld.net/senza-categoria/stopping-trials-prematurely-sorting-the-right-decisions-from-the-wrong/) - Allegations that commercial pressures may be leading to cancer drug trials being halted prematurely hit the news on both sides of the Atlantic last April. Industry leaders are pleading ‘not guilty'. But how can we judge when calling an early halt to a trial is the right thing to do? Download full article
- [Balancing cure and care](https://archive.cancerworld.net/senza-categoria/balancing-cure-and-care/) - Cornelis van de Velde went into cancer because he loved the complexity. Throughout his career he has grasped each new development across the disciplines to see how it could help resolve the difficult balance between curing a patient and preserving their quality of life. Spreading excellence in surgery, he says, is the single most important
- [The neglected magic bullet](https://archive.cancerworld.net/senza-categoria/the-neglected-magic-bullet/) - Surgery still offers by far the best hope of a cure in solid tumours. Yet patients are being let down by too great a focus on drugs at the expense of investment in surgical equipment and training, argues Simon Crompton, in an article for the The Times that won him a Best Cancer Reporter Award,
- [Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer](https://archive.cancerworld.net/impact-factor/adjuvant-ebrt-improves-survival-in-patients-with-lymph-node-negative-pancreatic-cancer/) - Though the role of radiation therapy in the adjuvant treatment of pancreatic cancer remains controversial, a recent large retrospective study indicates that radiation is associated with improved survival. Download full article
- [Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma](https://archive.cancerworld.net/impact-factor/lenalidomide-plus-dexamethasone-is-efficacious-in-patients-with-relapsed-or-refractory-multiple-myeloma/) - Two recent studies have shown that lenalidomide in combination with high-dose dexamethasone is significantly more effective than high-dose dexamethasone alone in patients with relapsed multiple myeloma. Download full article
- [Why is cancer killing more men than women?](https://archive.cancerworld.net/systems-services/why-is-cancer-killing-more-men-than-women/) - A rising focus on men's health issues, more sophisticated registry data and new techniques for investigating the biology of cancers are fuelling interest in unravelling what lies behind gender differences in cancer incidence and mortality. Getting answers could boost prevention and early detection and could even lead to better targeted therapies. Download full article
- [Why ‘plenty of bed rest' could be bad advice](https://archive.cancerworld.net/patient-voice/why-‘plenty-of-bed-rest-could-be-bad-advice/) - Evidence from a growing number of robust studies points incontrovertibly towards the benefits of regular, moderate activity not just in preventing cancer, but in rehabilitation for survivors and protection against recurrence. The question, as ever, is how to help those who need it most to get the message and act on it. Downlaod full article
- [A window of opportunity](https://archive.cancerworld.net/editorial/a-window-of-opportunity/) - Millions of people will die unnecessarily unless a massive effort is made to tackle the worsening global cancer epidemic. But the investment in cancer control that is so desperately needed, particularly in low - and middle-income countries, will not happen until cancer control becomes a development priority. The momentum generated by the launch of the
- [Paolo Casali: the man with the method](https://archive.cancerworld.net/cover-story/paolo-casali-the-man-with-the-method/) - Paolo Casali specialises in sarcoma, a ‘rare' cancer with at least 50 subgroups.Good practice, he believes, starts with a deep knowledge of the disease in front of you. This, in turn, requires a rigorous approach to clinical methodology – something he feels the cancer community should pay more attention to, for the benefit of both
- [Controversial issues in managing locally advanced head and neck cancers](https://archive.cancerworld.net/e-grandround/controversial-issues-in-managing-locally-advanced-head-and-neck-cancers/) - Great strides have beenmade inmanaging patients with locally advanced squamous cell cancer of the head and neck over the past 20 years. Novel approaches using chemoradiation (CRT) have improved disease control and quality of life. But controversies remain about how to optimise the use of CRT, including the role for targeted therapies, and how best
- [When is it OK to randomise cancer patients to placebo?](https://archive.cancerworld.net/senza-categoria/when-is-it-ok-to-randomise-cancer-patients-to-placebo/) - No-one wants to see progress in cancer research more than the patients themselves. But how do we deal with potential conflicts of interest when testing new drugs involves giving placebos to people dying of cancer? Download full article
- [A reverence for life in turbulent times](https://archive.cancerworld.net/senza-categoria/a-reverence-for-life-in-turbulent-times/) - A young child in war time Germany, Stephan Tanneberger grew up to take a lead in oncology in the communist East, which achieved some of the lowest cancer mortality rates in Europe. His career was cut short after reunification, but Germany's loss proved a gain to the developing world, and to Italy, where he still
- [If nothing is done...](https://archive.cancerworld.net/senza-categoria/if-nothing-is-done/) - The more we know about cancer, the harder it becomes to present a coherent and accurate picture of the nature of the threat and what can–and what cannot –be achieved through changing lifestyles, screening and investing in the search for a cure. Ulrich Bahnsen won a Best Cancer Reporter Award for his comprehensive article in
- [Bringing truths about cancer to new audiences](https://archive.cancerworld.net/spotlight-on/bringing-truths-about-cancer-to-new-audiences/) - When it comes to challenging taboos and giving a voice to ordinary people with extraordinary stories, film can be immensely powerful, as was shown at the first ever Reel Lives: Cancer Chronicles Film Festival, held in Geneva at the end of August. Download full article
- [Concomitant difluoromethylornithine/ sulindac chemoprevention of colorectal adenomas: a major clinical advance](https://archive.cancerworld.net/impact-factor/concomitant-difluoromethylornithine-sulindac-chemoprevention-of-colorectal-adenomas-a-major-clinical-advance/) - Combining two drugs, i.e. difluoromethylornithine and sulindac, at low doses has been shown, for the first time, to provide both great efficacy and great safety for clinical colon cancer prevention. Download full article
- [The ROC ‘n' role of the multiplex assay for early detection of ovarian cancer](https://archive.cancerworld.net/impact-factor/the-roc-‘n-role-of-the-multiplex-assay-for-early-detection-of-ovarian-cancer/) - The sensitivity and specificity of CA125 for early detection of ovarian cancer is improved when analysed in combination with novel biomarkers, although further validation studies are required to confirm the clinical utility of the multiplex assay. Download full article
- [N E W S R O U N D](https://archive.cancerworld.net/senza-categoria/n-e-w-s-r-o-u-n-d/) - Selected reports edited by Janet Fricker Download full article
- [A diet of hopes and half-truths](https://archive.cancerworld.net/systems-services/a-diet-of-hopes-and-half-truths/) - The media often hype the benefits of ‘superfoods' to protect against or even cure cancer. But keeping weight down and taking exercise are known to offer far greater protection than any individual food or nutrient – however full of antioxidants it may be. How can health professionals support their patients to sort fact from fiction
- [Senior, elderly, geriatric: we are all getting older](https://archive.cancerworld.net/editorial/senior-elderly-geriatric-we-are-all-getting-older/) - Politically correct wording seems to be a must, and in many areas this leads to variously differing solutions, which can all be criticised. But a fact is a fact, and hiding it behind ‘nicer' words is not going to help. Download full article
- [Jean-Pierre Droz: We can do better for our older patients](https://archive.cancerworld.net/cover-story/jean-pierre-droz-we-can-do-better-for-our-older-patients/) - Cancer is classically a disease of the elderly, yet all too often the special needs of older patients seem to be ignored. Routine use of screening to distinguish patients healthy enough to receive standard therapy from those who need adaptations, a greater input from geriatricians and geriatric oncologists and better all-round clinical training are needed,
- [Combining hormonal therapy with local treatment in prostate cancer](https://archive.cancerworld.net/e-grandround/combining-hormonal-therapy-with-local-treatment-in-prostate-cancer/) - Hormonal treatment remains a main stay of systemic therapy for prostate cancer despite recent developments in chemotherapy and intensive research with targeted drugs and immunotherapy. Its efficacy in palliative management of advanced disease has prompted its use as an adjunct to local treatments in earlier disease stages, but results of trials in some settings remain
- [Oncology's successes must not fail the heart](https://archive.cancerworld.net/senza-categoria/oncologys-successes-must-not-fail-the-heart/) - Targeted therapies seek to close down signalling pathways that allow tumours to prosper. But these pathways may also be vital to other clinical functions. With rising concern about collateral cardiac damage from cancer treatment comes a call for a new partnership between oncology and cardiology, to avoid problems and to treat them quickly and expertly
- [Siding with the vulnerable](https://archive.cancerworld.net/senza-categoria/siding-with-the-vulnerable/) - Silvio Monfardini's great contribution to oncology has been raising the standard of care for older patients. His story is a shining example of what can be achieved when scientific rigour is combined with a deep-rooted commitment to equality and a willingness to take a lead. Download full article
- [Everyone deserves the best chance to survive](https://archive.cancerworld.net/senza-categoria/everyone-deserves-the-best-chance-to-survive/) - When it comes to cancer, newspapers tend to home in on tragic stories of young mothers or children. The big story of the explosion of cancer cases among the elderly and the urgent need for better training in geriatric oncology remains largely untold. Päivi Repo won a Best Cancer Reporter Award for her piece, which
- [Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma](https://archive.cancerworld.net/impact-factor/adoptive-transfer-of-antigen-specific-cd4-t-cells-in-the-treatment-of-metastatic-melanoma/) - The adoptive transfer of antigen-specific CD4+ cells is a feasible treatment for cancer and provides critical insight into immune mechanisms involved in durable clinical responses. Download full article
- [Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer](https://archive.cancerworld.net/impact-factor/determining-the-survival-benefit-of-adjuvant-radiotherapy-in-patients-with-node-positive-head-and-neck-cancer/) - Postoperative radiotherapy with or without chemotherapy remains part of the standard treatment regimen to improve locoregional control for patients with head and neck cancer who have adverse pathologic factors after surgery. Whether an overall survival benefit can be expected remains unclear. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-38/) - Selected reports edited by Janet Fricker Download full article
- [The root of all evil?](https://archive.cancerworld.net/focus/the-root-of-all-evil/) - Cancer may be caused by stem cells gone bad. If that proves to be correct, it should revolutionise treatment. Download full article
- [Europe's nurses: an untapped resource](https://archive.cancerworld.net/editorial/europes-nurses-an-untapped-resource/) - Ambulatory care services are coming under huge pressure from the steady rise in the number of cancer patients who require long-term follow-up. Facilities are overcrowded, staff overstretched, and extended clinic waiting times are becoming the norm. Patients' physical, emotional and social welfare are often overlooked because there is not enough time to explore their needs
- [Emiel Rutgers: a surgeon for the genomic era](https://archive.cancerworld.net/cover-story/emiel-rutgers-a-surgeon-for-the-genomic-era/) - Emiel Rutgers was 'tailoring' his therapies long before the term was popularised. He pioneered breast conservation and neo-adjuvant chemotherapy in the Netherlands against opposition, but was also an advocate, just as controversially, of complete mastectomy of healthy breasts as an option for women at high risk. To be effective in this genomic era, cancer surgeons
- [New oncoplastic techniques can avoid mastectomy](https://archive.cancerworld.net/e-grandround/new-oncoplastic-techniques-can-avoid-mastectomy/) - New oncoplastic techniques are revolutionising the surgical management of breast cancer in much the same way that breast conserving surgery did in the 1970s. These technically demanding procedures are used as alternatives to mastectomy in an increasing number of women. Emerging data on outcomes are confirming the clinical utility of this approach. Download full article
- [New drug combinations are not the solution: Sweden's screening guru argues early detection is what works in breast cancer](https://archive.cancerworld.net/senza-categoria/new-drug-combinations-are-not-the-solution-swedens-screening-guru-argues-early-detection-is-what-works-in-breast-cancer/) - If caught early, only the most aggressive breast cancers require any treatment beyond surgery, says László Tabár. He wants governments to provide effective population screening from the age of 40, and he would like medical oncologists to stop overtreating ‘baby cancers' and concentrate on finding solutions to the small minority of hard-to-treat tumours. Download full
- [Helping women make the right choices: Europa Donna launches Breast Health Day](https://archive.cancerworld.net/spotlight-on/helping-women-make-the-right-choices-europa-donna-launches-breast-health-day/) - A variety of factors are now known to contribute to raising women's risk of developing breast cancer. Ensuring key messages on breast health become as familiar as themessage ‘ Smoking is bad for your health'may help prevent needless suffering and death. Download full article
- [Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?](https://archive.cancerworld.net/impact-factor/which-questions-remain-unanswered-following-the-successful-development-of-sorafenib-in-hepatocellular-carcinoma/) - In patients with advanced hepatocellular carcinoma who have a good performance status and Child—Turcotte—Pugh class A liver function, sorafenib represents a new standard of care. Download full article
- [How does extended lymphadenectomy influence practical care for patients with gastric cancer?](https://archive.cancerworld.net/impact-factor/how-does-extended-lymphadenectomy-influence-practical-care-for-patients-with-gastric-cancer/) - A recent study showed no benefit from extending lymphadenectomy beyond D1+ in gastric cancer. Adequate lymphadenectomy at high-volume institutions is essential for locoregional control and survival in this group of patients. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-37/) - Selected reports edited by Janet Fricker Download full article
- [Emaciated but not unloved Patients and carers need support to cope with the distressing effects of cachexia](https://archive.cancerworld.net/patient-voice/emaciated-but-not-unloved-patients-and-carers-need-support-to-cope-with-the-distressing-effects-of-cachexia/) - Images of gaunt, wasted bodies are shocking and often linked to feelings of shame, blame or guilt. When patients with advanced cancer begin to look this way, the problem lies with the cancer more than any lack of appetite. But if this is not well understood, friends and family can feel at fault, and cajoling
- [Europe's rare cancer community calls for a more radical approach](https://archive.cancerworld.net/systems-services/europes-rare-cancer-community-calls-for-a-more-radical-approach/) - The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict close working between researchers, companies, patients and regulators. Download full article
- [Yes we can treat cancer – even in the poorest countries](https://archive.cancerworld.net/senza-categoria/yes-we-can-treat-cancer-–-even-in-the-poorest-countries/) - So says Ian Magrath and his INCTR partners, and they have the evidence to prove it that will be crucial to the success of current efforts to stem the rise of cancer in the developing world. Download full article
- [It's about living not just surviving](https://archive.cancerworld.net/editorial/its-about-living-not-just-surviving/) - Patients are living with advanced cancer for ever more prolonged periods of time. But information and support services have been slow to catch up with clinical progress, and the needs of this rapidly growing group of patients are not being met. Download full article
- [Pat Price: asking the right questions](https://archive.cancerworld.net/cover-story/pat-price-asking-the-right-questions/) - Pat Price pioneered the use of PET imaging to investigate how cancer drugs move in the body and the effect they have. She worries that oncology has lost its way: ‘translational research' has become a byword for sample collection and biology, masking the lack of experimental oncologists able to identify key questions in patient care
- [Decision making for systemic treatment of non-small-cell lung cancer](https://archive.cancerworld.net/e-grandround/decision-making-for-systemic-treatment-of-non-small-cell-lung-cancer/) - Non-small-cell lung cancers (NSCLC) covers a heterogeneous group of diseases, accounting for around 80% of all lung cancers, which were previously lumped together because there was no apparent reason to use different therapeutic approaches for the various histologies. This has now changed, and choosing the best treatment option for NSCLC patients is increasingly complex. Download
- [Health rationing in Europe: can cancer get a fair hearing?](https://archive.cancerworld.net/senza-categoria/health-rationing-in-europe-can-cancer-get-a-fair-hearing/) - Faced with escalating drug prices and rising patient expectations, Europe's governments are anxious to ensure value for money from their overstretched health budgets. But how can one measure the value of a few extra precious months of life, and could requirements to show strong evidence of value for money in the short term hinder the
- [Closing the gap with the West](https://archive.cancerworld.net/senza-categoria/closing-the-gap-with-the-west/) - Polish surgeon Marek Nowacki has always had a very dynamic approach to cancer care, travelling extensively to pick up new tricks and techniques, and publishing his own innovations to spread the benefit. Today, thanks to his vision and drive, the rest of Europe could learn some important lessons from Poland, not least on implementing effective
- [Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck](https://archive.cancerworld.net/impact-factor/cetuximab-therapy-for-patients-with-advanced-squamous-cell-carcinomas-of-the-head-and-neck/) - Cetuximab increases overall survival in patients with recurrent or metastatic squamous cell carcinomas of the head and neck. Reasonable treatment strategies include the use of first-line platinum, 5-fluorouracil and cetuximab combination, or cetuximab used following progression after a platinum-based regimen. Download full article
- [Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer](https://archive.cancerworld.net/impact-factor/optimal-timing-of-surgery-after-preoperative-chemoradiotherapy-for-rectal-cancer/) - The optimal timing for rectal cancer surgery after neoadjuvant chemoradiotherapy, in terms of risk of complications or tumour response, remains uncertain. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-36/) - Selected repor ts edited by Janet Fricker Download full article
- [Why are cancer patients still suffering unnecessary pain?](https://archive.cancerworld.net/systems-services/why-are-cancer-patients-still-suffering-unnecessary-pain/) - More than 20 years since the WHO published its three-step guideline for controlling cancer pain, European patients are still complaining of pain that is long lasting, interferes with their daily activities and can even be ‘intolerable'. Better basic medical training in how to assess and control cancer pain is urgently required, say the experts. Download
- [Chemobrain: delving into possible mechanisms](https://archive.cancerworld.net/focus/chemobrain-delving-into-possible-mechanisms/) - ‘Chemobrain' is an informal term coined by patients who are – or were – on chemotherapy, to express the feeling of being not quite switched on or able to think clearly and focus on the tasks in hand. Recent studies have begun to identify the mechanisms by which it works, who is most at risk
- [Prostate cancer screening: a question of common sense](https://archive.cancerworld.net/editorial/prostate-cancer-screening-a-question-of-common-sense/) - First results of randomised clinical screening trials are traditionally met with a barrage of comments by opinionated observers, and the back-to-back publication in the March 26 issue of the New England Journal of Medicine on the mortality results of two major PSA screening trials – one European, one American – was no exception. Not only
- [Michael Gnant: pushing the boundaries](https://archive.cancerworld.net/cover-story/michael-gnant-pushing-the-boundaries/) - Suppressing metastases by changing microenvironments doesn't sound like heartland research for a surgeon. But that hasn't deterred Michael Gnant, who presented a paper on this subject at last year's ASCO. He argues that cancer surgery risks reverting to a ‘manual profession'unless others follow his lead and engage farmore deeply with other disciplines, both in the
- [Advanced epithelial ovarian cancer: improvements in first- and second-line treatment](https://archive.cancerworld.net/e-grandround/advanced-epithelial-ovarian-cancer-improvements-in-first-and-second-line-treatment/) - The treatment of ovarian cancer and management of advanced ovarian cancer have progressed over the past few decades through several key milestones, including improvements in surgery, the evolution of chemotherapy and the establishment of an organisation of international co-operative groups for clinical trials in gynaecologic cancer. Download full article
- [Beyond trench warfare American and European researchers in search of a winning strategy](https://archive.cancerworld.net/senza-categoria/beyond-trench-warfare-american-and-european-researchers-in-search-of-a-winning-strategy/) - Too slow, too expensive, too ineffective. Researchers are crying out for a new battle plan that will aim high and deliver on the great promise of personalised therapies. We all want to see target patient populations identified early, and marketing access denied to drugs that aren't ever going to be much use. The question is,
- [Surfing the wave](https://archive.cancerworld.net/senza-categoria/surfing-the-wave/) - Mario Dicato is one of a dwindling band of academic haemato-medical oncologists, who has relished a career jumping from one topic to the next as opportunities arise. Whether treating patients with confiscated marijuana, developing the world's leading congress on gastroinstestinal cancers or doing a speaking tour of Colombia and Peru, Dicato is sure to make
- [Bortezomib in newly diagnosed multiple myeloma](https://archive.cancerworld.net/impact-factor/bortezomib-in-newly-diagnosed-multiple-myeloma/) - Preclinical studies have shown that, in addition to showing anti-multiple-myeloma activity as single agents, new agents such as bortezomib also enhance the efficacy of chemotherapy and steroids. A randomised trial has now established that bortezomib prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy. Download full article
- [Vaccine trials in melanoma - time for reflection](https://archive.cancerworld.net/impact-factor/vaccine-trials-in-melanoma-time-for-reflection/) - The disappointing results of the large, randomised controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-35/) - Selected reports edited by Janet Fricker Download full article
- [EUROCARE 4 delivers its verdict](https://archive.cancerworld.net/systems-services/eurocare-4-delivers-its-verdict/) - The EUROCARE 4 report has delivered an implicit merit mark to eastern European countries, whose relatively poor survival figures are now improving faster than those in the rest of Europe. But older patients are still far less likely to survive a cancer diagnosis than younger patients, and the gap is getting wider. The verdict? Must
- [Angiogenesis inhibition: do tumours have a plan B?](https://archive.cancerworld.net/focus/angiogenesis-inhibition-do-tumours-have-a-plan-b/) - Hopes that angiogenesis inhibition could improve outcomes when used adjuvantly in colorectal cancer received a setback at the end of April, with the announcement that the NSABP C-08 trial had failed to meet its primary endpoint. Recent research into how tumours respond to these drugs may help explain the disappointing results. Download full article
- [Talking the same language](https://archive.cancerworld.net/editorial/talking-the-same-language/) - Download full article
- [Eric Van Cutsem: closing in on GI tumours](https://archive.cancerworld.net/cover-story/eric-van-cutsem-closing-in-on-gi-tumours/) - Eric Van Cutsem has been at the forefront of developing new molecular therapies for gastrointestinal cancers, but he's not relying on finding that magic bullet. He advocates a many-fronted attack, combining genetic counselling with screening and specialist multidisciplinary care, and he believes that specialist GI oncology units, like his centre in Leuven, are the way
- [State-of-the-art and controversies in germ-cell cancer](https://archive.cancerworld.net/e-grandround/state-of-the-art-and-controversies-in-germ-cell-cancer/) - Many different, intersecting strategies are available for managing germ-cell cancers, particularly in early-stage disease. Which is ‘right' remains a matter of debate, and requires balancing efficacy against late effects, bearing in mind the complexity of treatment strategies and the available expertise. Download full article
- [Gotta get that rhythm - Circadian timing systems and cancer](https://archive.cancerworld.net/spotlight-on/gotta-get-that-rhythm-circadian-timing-systems-and-cancer/) - The role of circadian rhythms in cancer hit the headlines this year because of growing evidence that night shift work may increase the risk of breast cancer. But could a better understanding of the role of disruption to the daily rhythms that regulate the behaviour of cells open up new possibilities for treatment? One group
- [Are we educating women to be afraid? UK health reporter questions the value of simplistic screening messages](https://archive.cancerworld.net/spotlight-on/are-we-educating-women-to-be-afraid-uk-health-reporter-questions-the-value-of-simplistic-screening-messages/) - Breast screening programmes won't work if women don't attend. But can this justify campaigns that exaggerate both the risk of getting breast cancer and the benefits of screening? Margaret McCartney believes not. She won a Best Cancer Reporter Award for her article, Reality Check, which was first published in the Financial Times weekend supplement, and
- [Vested interests are undermining our efforts to beat cancer - The worries of a battle-hardened German oncologist](https://archive.cancerworld.net/spotlight-on/vested-interests-are-undermining-our-efforts-to-beat-cancer-the-worries-of-a-battle-hardened-german-oncologist/) - Cancer treatment is at a critical juncture, says Dieter K Hossfeld, veteran campaigner for the recognition of medical oncology in Germany. Future progress, he believes, depends on reasserting the interests of society at large over those of the pharmaceutical industry, the medical establishment and even individual patients. Download full article
- [Effect of treatment interruptions in prostate cancer](https://archive.cancerworld.net/impact-factor/effect-of-treatment-interruptions-in-prostate-cancer/) - A recent study has shown that treatment interruptions during a fractionated external-beam radiotherapy course for localised prostate cancers may have a negative effect on patient outcome. Limiting or modifying the overall elapsed time between treatments is necessary. Download full article
- [Endocrine-therapy-related symptoms and breast cancer](https://archive.cancerworld.net/impact-factor/endocrine-therapy-related-symptoms-and-breast-cancer/) - The association of a treatment-related adverse effect with treatment success has been reported in various clinical situations. The development of vasomotor or joint symptoms is an indication of therapeutic benefit in women receiving endocrine treatment for hormonereceptor-positive breast cancer. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-34/) - Selected reports edited by Janet Fricker Download full article
- [A man with a woman's cancer How can we do better for male breast cancer patients?](https://archive.cancerworld.net/patient-voice/a-man-with-a-womans-cancer-how-can-we-do-better-for-male-breast-cancer-patients/) - Being diagnosed with a “woman's” cancer can pose all sorts of problems for a man. Should breast cancer advocacy groups be more welcoming? Do men need their own groups, or don't they do that sort of thing? And can greater public and professional awareness combat the awkwardness and marginalisation felt by many men being treated
- [Rare cancers in Europe - tackling a common problem](https://archive.cancerworld.net/editorial/rare-cancers-in-europe-tackling-a-common-problem/) - A campaign to tackle the particular problems posed by rare cancers was launched this summer. European Action Against Rare Cancers (www.rarecancers.eu) is determined to put this neglected set of diseases firmly on the European health agenda and to bring some much-needed attention to the challenges faced not only by patients living with rare cancers, but
- [Vesna Kesic: exporting excellence in women's cancers](https://archive.cancerworld.net/cover-story/vesna-kesic-exporting-excellence-in-womens-cancers/) - Working at a massive hospital in a country with high rates of advanced women's cancers gave Vesna Kesic the ideal opportunity to hone her skills as a gynaecological oncology surgeon. Thanks to her commitment to plugging the widespread gap in specialist training, the benefits of her expertise are being felt by patients well beyond the
- [Addressing fertility issues in patients with breast cancer](https://archive.cancerworld.net/e-grandround/addressing-fertility-issues-in-patients-with-breast-cancer/) - Many breast cancer therapies affect a woman's chances of having a child in the future. A growing body of literature is beginning to throw some light on the impact of different treatment options. How can doctors help their patients to make the right choices? Download full article
- [The ‘no miracle cure' story](https://archive.cancerworld.net/spotlight-on/the-‘no-miracle-cure-story/) - The story of step-by-step progress, with occasional leaps forward and frequent setbacks, is not one the media enjoys telling. But it does need to be told if patients and society are to learn to live with cancer as a chronic disease. Linda Geddes received a Best Cancer Reporter Award for her article Living with the
- [The power behind the World Cancer Declaration](https://archive.cancerworld.net/spotlight-on/the-power-behind-the-world-cancer-declaration/) - There was a time when the International Union Against Cancer (UICC) was not so international – being focused primarily on Western countries – and not so much of a union – lacking the ability to fight coordinated campaigns. But the escalation of cancer rates in developing countries cried out for a powerful global voice for
- [Should we expect better from the media?](https://archive.cancerworld.net/senza-categoria/should-we-expect-better-from-the-media/) - A conversation with health journalists Download full article
- [Addicted to wonder drugs](https://archive.cancerworld.net/spotlight-on/addicted-to-wonder-drugs/) - When stories exaggerate the implications of the latest research, is this the fault of the media? Asession on reporting cancer breakthroughs found pressure also comes from researchers and pharmaceutical companies. Maybe the greatest pressure comes froma public desperate for hope. Download full article
- [Mass media's hit or myth approach to cancer](https://archive.cancerworld.net/spotlight-on/mass-medias-hit-or-myth-approach-to-cancer/) - When it comes to prevention, screening, treatment and coping with the experience of cancer, the media can play an important role in equipping people to make the best possible choices. At an ESO workshop at the World Conference of Science Journalists, health reporters explored how they can get across vital information while acknowledging uncertainty and
- [GIST adjuvant therapy - some answers and more questions](https://archive.cancerworld.net/impact-factor/gist-adjuvant-therapy-some-answers-and-more-questions/) - Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumours. A randomised, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy after surgical resection of a primary gastrointestinal stromal tumour. Download full article
- [Role of lymphadenectomy in the staging of endometrial cancer](https://archive.cancerworld.net/impact-factor/role-of-lymphadenectomy-in-the-staging-of-endometrial-cancer/) - Pelvic lymphadenectomy offers no therapeutic benefit to women diagnosed with early-stage endometrial cancer according to a new study. Lymphadenectomy can only be recommended as part of a clinical trial in this disease setting; however, it can offer valuable staging information in patients with advanced disease. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-33/) - Selected reports edited by Janet Fricker Download full article
- [A Partnership with potential](https://archive.cancerworld.net/editorial/a-partnership-with-potential/) - How do you help close the gap between the worst and the best cancer outcomes in Europe, when you have no legal basis for intervening in Member States' health policies and have precious little money set aside? Download full article
- [The BMJ decries the gap in cancer mortality between rich and poor countries](https://archive.cancerworld.net/news/the-bmj-decries-the-gap-in-cancer-mortality-between-rich-and-poor-countries/) - Cancer control measures that have contributed to increase life expectancy in rich populations have yet to be seen in poorer populations, according to a study just published on The BMJ by a group led by Dr. Bochen Cao of the International Agency for Research on Cancer (IARC), that calls for urgent global action. In most
- [Cyclists raise funds for the Cancer Association of Botswana](https://archive.cancerworld.net/news/cyclists-raise-funds-for-the-cancer-association-of-botswana/) - Gaborone - Botswana’s cancer conscious cyclists – Team Chainring have embarked on a 1000 kilometres ‘Ride for Pink’ to create awareness and raise funds for the Cancer Association of Botswana (CAB). The cyclists’ 1000 kilometres voyage from the resort town of Kasane through several towns and villages to the capital Gaborone is one of the
- [Jan Geißler: We, the patients](https://archive.cancerworld.net/cover-story/jan-geisler-we-the-patients/) - Keeping your life together when you have cancer is hard. To achieve this and still find the energy to work with other patients to influence decisions that shape the services and treatments you rely on is asking a lot from anyone. Download full article
- [Indolent prostate cancer and active surveillance](https://archive.cancerworld.net/e-grandround/indolent-prostate-cancer-and-active-surveillance/) - Early aggressive treatment in patients whose cancer is likely to progress slowly, if at all, causes side-effects and reduces their quality of life for no benefit. Can active surveillance avoid this? Download full article
- [Keyhole surgery](https://archive.cancerworld.net/cutting-edge/keyhole-surgery/) - Advances in cancer surgery over the past couple of decades have led to significant increases in cure rates in many cancers. How can we ensure these new techniques don't put at risk the gains of the past decades? Download full article
- [Ten years reporting from the front line](https://archive.cancerworld.net/senza-categoria/ten-years-reporting-from-the-front-line/) - Rabiya Tuma won a Best Cancer Reporter Award for her contributions to The Economist. Here her article highlights some of the growing evidence about the role of stem cells in cancer. Download full article
- [Specialism: political oncology](https://archive.cancerworld.net/senza-categoria/specialism-political-oncology/) - In five brief years on the political stage in Brussels, Adamos Adamou successfully built alliances, mongered resolutions and agitated for action aimed at ensuring all of Europe's citizens have access to quality screening and treatment. Download full article
- [Adjuvant chemotherapy in older patients with breast cancer](https://archive.cancerworld.net/impact-factor/adjuvant-chemotherapy-in-older-patients-with-breast-cancer/) - A prospective, randomised trial has shown that standard adjuvant chemotherapy is superior to capecitabine in the treatment of women with breast cancer aged 65 years or older; on the basis of the results of this study, capecitabine cannot be recommended in this setting. Download full article
- [PET–CT imaging in non-small-cell lung cancer](https://archive.cancerworld.net/impact-factor/pet–ct-imaging-in-non-small-cell-lung-cancer/) - Imaging is performed in patients with early-stage non-small-cell lung cancer (NSCLC) for disease staging and to identify the patients most likely to benefit from surgery. Two recent randomised trials compared conventional staging plus PET with conventional staging alone in patients with NSCLC. Patients who underwent PET were more likely to avoid futile thoracic surgery. Download
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-32/) - Selected reports edited by Janet Fricker Download full article
- [Shall we try for a baby?](https://archive.cancerworld.net/patient-voice/shall-we-try-for-a-baby/) - Deciding to start a family is the most momentous decision many people will ever take. For someone living with a cancer diagnosis, new life can seem particularly important, but it also carries particular risks. Download full article
- [Stop excluding male patients](https://archive.cancerworld.net/editorial/stop-excluding-male-patients/) - Male breast cancer is a rare disease, accounting for less than 1% of all breast cancers worldwide but how does their disease differ from breast cancers in women? Fatima Cardoso explains why men should be included in breast cancer trials. Download full article
- [Alain Fourquet: taking multidisciplinarity one step further](https://archive.cancerworld.net/cover-story/alain-fourquet-taking-multidisciplinarity-one-step-further/) - Fourquet will become the first radio-oncologist to chair Europe's major breast cancer conference, EBCC 7, in March. Here he argues that radio-oncologists need to be involved in the design stage of trials. Download full article
- [Neutropenia in cancer patients: risk factors and management](https://archive.cancerworld.net/e-grandround/neutropenia-in-cancer-patients-risk-factors-and-management/) - Neutropenia poses a serious threat to patients on chemotherapy - exposes them to infection, leads to delays in treatment and reductions in dose intensity. Awareness of the risks and prompt action are essential. Download full article
- [MRI for breast cancer: who benefits, who is harmed?](https://archive.cancerworld.net/cutting-edge/mri-for-breast-cancer-who-benefits-who-is-harmed/) - When a woman is diagnosed with breast cancer, and a technique exists that could identify additional lesions in the same or the opposite breast, what possible reason could there be for not using it? Download full article
- [From unwanted interference to indispensable partner](https://archive.cancerworld.net/senza-categoria/from-unwanted-interference-to-indispensable-partner/) - As founding president of Europa Donna, Gloria Freilich helped transform attitudes towards patient advocacy. She would like to see further progress and advises that her softly softly approach is the way to go. Download full article
- [Future directions in multimodality therapy for NSCLC](https://archive.cancerworld.net/impact-factor/future-directions-in-multimodality-therapy-for-nsclc/) - Patients with stage III non-small-cell lung cancer comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III NSCLC. Download full article
- [Sunitinib versus interferon-á in metastatic RCC](https://archive.cancerworld.net/impact-factor/sunitinib-versus-interferon-a-in-metastatic-rcc/) - Motzer and colleagues presented updated results from a multicentre, phase III trial of sunitinib versus interferon-á as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal
- [Spreading the word](https://archive.cancerworld.net/patient-voice/spreading-the-word/) - Patient groups are uniquely placed to challenge fears and misperceptions that hamper prevention and contribute to late diagnoses, poor treatment and the social isolation of patients. Acting locally but using the Internet they are now campaigning globally. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-31/) - Selected reports edited by Janet Fricker Download full article
- [When the trial you need is just over the border](https://archive.cancerworld.net/editorial/when-the-trial-you-need-is-just-over-the-border/) - The bureaucratic obstacles that often prevent European cancer patients from joining clinical trials in other Member States came under the spotlight recently in the case of a young woman with melanoma. Download full article
- [Jaap Verweij: an intelligent approach to drug](https://archive.cancerworld.net/cover-story/jaap-verweij-an-intelligent-approach-to-drug/) - Jaap Verweij, head of medical oncology and an early-phase trials expert at the Erasmus University Medical Centre in Rotterdam invites you to reappraise the way we are going about improving cancer therapies. Download full article
- [The treatment of gastrointestinal stromal tumours (GIST)](https://archive.cancerworld.net/e-grandround/the-treatment-of-gastrointestinal-stromal-tumours-gist/) - Better understanding of the different mutations that drive GIST is leading to new paradigms of tailored treatment that break many norms of chemotherapy, especially in management of progression. Download full article
- [Who's who in the world of personalised cancer treatments?](https://archive.cancerworld.net/cutting-edge/whos-who-in-the-world-of-personalised-cancer-treatments/) - The number of drugs being developed to target specific mutations is rising steadily. But finding which targeted therapies work best for which sets of mutations is proving an elusive goal. Download full article
- [Blazing a trail in a new type of research](https://archive.cancerworld.net/spotlight-on/blazing-a-trail-in-a-new-type-of-research/) - When confronted with the novel gene technology of the early '70s, molecular biologist Axel Ullrich posed the question: what use can this be to medicine? Opening the door to translational research Download full article
- [Trials and tribulations in primary CNS lymphoma](https://archive.cancerworld.net/impact-factor/trials-and-tribulations-in-primary-cns-lymphoma/) - A minority of patients with primary central nervous system lymphoma achieve a complete response to therapy andmost patients have a poor prognosis.A recent randomised phase II trial demonstrated that the addition of high-dose cytarabine to high-dosemethotrexate increases the complete response rate and improves patient outcome. Download full article
- [Androgen deprivation therapy for prostate cancer: true love or heartbreak?](https://archive.cancerworld.net/impact-factor/androgen-deprivation-therapy-for-prostate-cancer-true-love-or-heartbreak/) - The addition of hormonal therapy to radiation therapy improves survival inmenwith unfavourable risk prostate cancer.Yet,menwith prostate cancer have higher rates of non-cancer death than the general population andmost will die fromcauses other than their indexmalignancy. Comorbid cardiovascular disease is strongly associatedwith cause of death and this raises the possibility that prostate cancer or its treatment
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-30/) - Selected reports edited by Janet Fricker Download full article
- [Should you respect a dying wish?](https://archive.cancerworld.net/systems-services/should-you-respect-a-dying-wish/) - Some terminally ill cancer patients, seeing only suffering and indignity ahead, want to die at a time and in a manner of their own choosing. But how does legal backing for assisted dying impact on efforts to strengthen palliative care? Download full article
- [Turning the World Cancer Declaration into action](https://archive.cancerworld.net/editorial/turning-the-world-cancer-declaration-into-action/) - Cancer kills more people than AIDS, tuberculosis and malaria combined. Going by recent global health trends, this year will see cancer emerge as the world's single leading cause of death. Download full article
- [Serigne Magueye Gueye: an agent for change](https://archive.cancerworld.net/cover-story/serigne-magueye-gueye-an-agent-for-change/) - After decades of international declarations and pilot projects, Africa is taking control of its efforts to tackle cancer. At the helm is Serigne Gueye, professor of Urology and president of AORTIC. Download full article
- [Pitfalls and uncommon problems in thyroid cancer management](https://archive.cancerworld.net/e-grandround/pitfalls-and-uncommon-problems-in-thyroid-cancer-management/) - Thyroid cancers are fairly common, but medical oncology departments generally come across only a small minority of patients with advanced or recurrent disease who respond poorly to standard treatments. Download full article
- [Grapefruit juice and St John's Wort are just the tip of the iceberg](https://archive.cancerworld.net/cutting-edge/grapefruit-juice-and-st-johns-wort-are-just-the-tip-of-the-iceberg/) - Certain foods, prescription drugs and complementary remedies interact with cancer therapies, altering the effective dose and putting patients at risk. How can damaging interactions be prevented? Download full article
- [Chemoradiation in head-and-neck cancer — are we any closer?](https://archive.cancerworld.net/impact-factor/chemoradiation-in-head-and-neck-cancer-—-are-we-any-closer/) - A recent study analysed the timing of non-platinum chemotherapy in combination with radiotherapy in patients with head-and-neck cancer and showed that only those who had not undergone surgery benefited from the chemoradiation therapy. However, inconsistencies between some results of this study and those of previous studies, along with the advent of novel, less toxic combinations
- [Preoperative biliary drainage – better stents in specialised centres are needed](https://archive.cancerworld.net/impact-factor/preoperative-biliary-drainage-–-better-stents-in-specialised-centres-are-needed/) - A recent trial concluded that preoperative biliary drainage (PBD) in patients with pancreatic head cancer increases complications but is unlikely to change clinical practice. The difference in the outcomes reported was because of excessive complications in the PBDgroup using plastic stents. We argue that these patients need treatment in regional pancreatic cancer centres using low
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-29/) - Selected reports edited by Janet Fricker Download full article
- [When sex lives suffer](https://archive.cancerworld.net/patient-voice/when-sex-lives-suffer/) - Addressing issues of pain, fatigue and functional impairment such as incontinence is widely accepted as essential to helping cancer patients rebuild their lives. For many people, however, restoring a fulfilling sex life can be at least as important. Download full article
- [Is it safe, is it tolerable? Why not ask the patients?](https://archive.cancerworld.net/editorial/is-it-safe-is-it-tolerable-why-not-ask-the-patients/) - Many cancer medications are being prescribed by the month, year, or even indefinitely, tolerability is increasingly more important, yet patients have no direct input into evaluating a new drug. Download full article
- [Angelo Di Leo: mapping the geography of breast cancer](https://archive.cancerworld.net/cover-story/angelo-di-leo-mapping-the-geography-of-breast-cancer/) - Angelo Di Leo cut his research teeth on the first studies that looked for biological markers that could predict which patients respond to what, and he's never looked back. Download full article
- [Neurological side-effects caused by recently approved chemotherapy drugs](https://archive.cancerworld.net/e-grandround/neurological-side-effects-caused-by-recently-approved-chemotherapy-drugs/) - How can you get the greatest efficacy from neurotoxic drugs without putting patients at risk of acute or chronic damage to their nervous system? Download full article
- [Charged particle therapy](https://archive.cancerworld.net/cutting-edge/charged-particle-therapy/) - Charged particle therapy has been known for 60 years as an alternative radiotherapy, more precise and potentially more safe and/or effective for some patients. But there are calls for caution until more robust clinical evidence has been generated. Download full article
- [Prize for journalist who tackled taboo subject of rationing cancer therapies](https://archive.cancerworld.net/spotlight-on/prize-for-journalist-who-tackled-taboo-subject-of-rationing-cancer-therapies/) - We republish here a article that earned health journalist Nicola Kuhrt a Best Cancer Reporter Award. Download full article
- [Putting the person back into personalised therapies: The concerns of a head and neck cancer specialist](https://archive.cancerworld.net/senza-categoria/putting-the-person-back-into-personalised-therapies-the-concerns-of-a-head-and-neck-cancer-specialist/) - Listening and learning remains the key to personalising therapy, says Jan Vermorken, who spent a career specialising in the cruellest of cancers. Download full article
- [Neoadjuvant trial design: time for a brave new world?](https://archive.cancerworld.net/impact-factor/neoadjuvant-trial-design-time-for-a-brave-new-world/) - In the NOAH clinical trial, trastuzumab treatment for locally advanced breast cancer, given prior to surgery, was associated with increased complete and overall response rate and improved event free survival.The ability to identify this advantage suggests that the neoadjuvant setting might serve to inform the design of adjuvant trials and indicate appropriate off-study adjuvant therapy.
- [Are macrophages the bad guys in Hodgkin lymphoma?](https://archive.cancerworld.net/impact-factor/are-macrophages-the-bad-guys-in-hodgkin-lymphoma/) - Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualised therapy. A recent gene-expression profiling study, translated into a routine immunohistological test, identified genes of tumour-associated macrophages as being responsible for treatment outcome in patients with Hodgkin lymphoma. If this finding is confirmed by other investigators, it could be
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-28/) - Selected reports edited by Janet Fricker Download full article
- [Adopting a child after cancer](https://archive.cancerworld.net/patient-voice/adopting-a-child-after-cancer/) - For would-be parents rendered infertile by cancer or its treatment, adoption can offer a happy future for them and their child. This article looks at varying attitudes and practices in different countries, and offers tips to cancer survivors looking to adopt. Download full article
- [Fake drugs pose a threat to Europe's cancer patients](https://archive.cancerworld.net/editorial/fake-drugs-pose-a-threat-to-europes-cancer-patients/) - The counterfeit drugs trade, once largely confined to the developing world, is now firmly established in western countries. Greater vigilance from the cancer community is need. Download full article
- [Sara Faithfull: unleashing the potential of cancer nursing](https://archive.cancerworld.net/cover-story/sara-faithfull-unleashing-the-potential-of-cancer-nursing/) - Many cancer nurses are still undervalued and underused, with few opportunities for specialist training and little guidance on best practice. Sara Faithfull is working to change all that. Download full article
- [Cancer of unknown primary: a diagnostic and therapeutic dilemma](https://archive.cancerworld.net/e-grandround/cancer-of-unknown-primary-a-diagnostic-and-therapeutic-dilemma/) - Cancer of unknown primary origin is difficult to manage because, even when the primary can be detected, it behaves differently to cancers of the same type and location that are discovered as primaries. Download full article
- [Therapeutic cancer vaccines – there's a new kid on the block](https://archive.cancerworld.net/cutting-edge/therapeutic-cancer-vaccines-–-theres-a-new-kid-on-the-block/) - Efforts to treat cancers using vaccines have seen many false dawns. Now the first therapeutic cancer vaccine has won approval for treating prostate cancer, with more waiting in the wings. Could compounds that teach the immune system to fight tumours be about to achieve their promise? Download full article
- [Shining a light on nanoparticle therapy](https://archive.cancerworld.net/spotlight-on/shining-a-light-on-nanoparticle-therapy/) - Steering the right course between simplistic talk of ‘wonder drugs' and baffling readers with unnecessary scientific detail can be tricky. Mark Henderson, of the UK national daily The Times, won a Best Cancer Reporter Award for his story about a novel nanoparticle therapy. Download full article
- [Steadfast in Sarajevo](https://archive.cancerworld.net/spotlight-on/steadfast-in-sarajevo/) - Half the staff at the Clinical Centre left and 50 were killed during the siege of Sarajevo. But Hiba Basic stuck to her post and took over the oncology department. Download full article
- [The Clinical Trials Directive: can we get it right second time around?](https://archive.cancerworld.net/spotlight-on/the-clinical-trials-directive-can-we-get-it-right-second-time-around/) - Though well-intended, the European Clinical Trials Directive severely impeded clinical research. The Commission is now trying to revise the Directive, and is inviting researchers, patient groups and others to submit concrete suggestions. Download full article
- [200 mg-m2 melphalan – the gold standard for multiple myeloma](https://archive.cancerworld.net/impact-factor/200-mg-m2-melphalan-–-the-gold-standard-for-multiple-myeloma/) - Palumbo and co-authors report on the results of a randomised trial comparing two doses of melphalan in patients with symptomatic multiple myeloma. Overall complete response rates, median progression-free survival and projected five-year overall survival were significantly higher among patients receiving the higher melphalan dose. These results confirm that for this patient population melphalan 200 mg/m2
- [The National Health Insurance Fund now helps Kenyans with cancer](https://archive.cancerworld.net/news/the-national-health-insurance-fund-now-helps-kenyans-with-cancer/) - Thousands of cancer patients in Kenya die prematurely due to lack of treatment. In a country where health insurance is a preserve of the wealthy, most patients are forced to sell their cows or land to pay for surgery, radiotherapy and chemotherapy or forego treatment and wait to die. However, a government-backed insurer has eased
- [Supporting others, while dealing with my own fears](https://archive.cancerworld.net/voices/supporting-others-while-dealing-with-my-own-fears/) - My first cancer experience came in September 2014. Then the second cancer followed, to finish what the first has left ... There were long surgeries, chemotherapies, double mastectomy, dark thoughts, pain, despair. And I always needed psychological support ... When I was diagnosed with cancer, I was lost. I looked for active support from a
- [John Crown: Move aside bureaucrats and let us take a lead](https://archive.cancerworld.net/cover-story/john-crown-move-aside-bureaucrats-and-let-us-take-a-lead/) - Decisions on how best to deliver high-quality care should be left to the clinicians who run the services. John Crown, who has long played a leading role in both the clinic and research is one of the few oncologists to seek elected office in order to pursue the point more effectively. Outspoken oncologists, willing to
- [Join the battle for biomedical research](https://archive.cancerworld.net/editorial/join-the-battle-for-biomedical-research/) - Once every seven years an opportunity arises to influence the shape of the European science research effort. This editorial takes a look at what is at stake in the current discussions around the European Research Framework programme for 2014-2020. by Kathy Redmond The battle is onto shape the agenda for European research up until 2020.The
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-27/) - Complications from robotic prostatectomy no better than conventional surgery ‹ Journal of Clinical Oncology Problems with continence and sexual function are common following both robot-assisted laparoscopic radical prostatectomy (RALRP) and open retropubic radical prostatec-tomy (ORRP), a US study has found. Conventional wisdom holds that men undergoing the robotic procedure experience less post-surgical urinary incontinence and
- [First-line bevacizumab for ovarian cancer - new standard of care?](https://archive.cancerworld.net/impact-factor/first-line-bevacizumab-for-ovarian-cancer-new-standard-of-care/) - Demonstration of the clinically significant activity of bevacizumab in advanced-stage ovarian cancer has attracted a great deal of interest. Here, we summarize the two positive phase III trials that led to EMA approval of bevacizumab as first-line therapy and discuss the optimum use of the drug in this disease. by Susana Banerjee and Stan Kaye
- [Localised non-bulky Hodgkin lymphoma - future questions](https://archive.cancerworld.net/impact-factor/localised-non-bulky-hodgkin-lymphoma-future-questions/) - Late toxicities from radiation therapy are frequent in patients with Hodgkin lymphoma and can hamper survival. These late toxicities should decrease with modern radiation therapy, but results are not mature and so the importance of this decrease is still unknown. Hence, all studies in Hodgkin lymphoma must report longer-term outcome. by Bertand Coiffier and Olivier
- [Prostate cancer units: it's about options and quality](https://archive.cancerworld.net/systems-services/prostate-cancer-units-its-about-options-and-quality/) - Men diagnosed with prostate cancer have a wealth of options on how to proceed, but they can pay a high price if the quality of treatment is substandard. Could delivering all prostate care through specialist multiprofessional units be the answer to safeguarding both standards and choice? The most common cancer in men has seen a
- [Fixing the holes in the opioid supply lines](https://archive.cancerworld.net/spotlight-on/fixing-the-holes-in-the-opioid-supply-lines/) - Patients are still dying in agony despite concerned efforts over many years to change attitudes towards the use and control of opiates. Could a new initiative, which works with NGOs, governments and policy makers to address practical problems, finally hit the spot? When his cancer pain grew so great he could see no other means
- [Can the Reverend Bayes help deliver proven therapies for patients with rare cancers?](https://archive.cancerworld.net/cutting-edge/can-the-reverend-bayes-help-deliver-proven-therapies-for-patients-with-rare-cancers/) - Conducting clinical trials in people with rare cancers is not easy when the number in a small trial do not add up to convincing evidence. Now some researchers are pressing for a new approach--using Bayesian trial designs to make the most of available knowledge. When you are diagnosed with cancer, the last thing you want
- [Recent trials in osteosarcoma and their implications for future studies](https://archive.cancerworld.net/e-grandround/recent-trials-in-osteosarcoma-and-their-implications-for-future-studies/) - In this overview a sarcoma specialist present current evidence on the best way to manage osteosarcoma patients and looks at what has to be done to improve prognosis in this disease, where survival rates have not changed since the early 1980's. Osteosarcoma is a malignant mesenchymal tumour producing osteoid. It is a rare type of
- [Mahasti Saghatchian: pioneering a quality mark for Europe's cancer centres](https://archive.cancerworld.net/cover-story/mahasti-saghatchian-pioneering-a-quality-mark-for-europes-cancer-centres/) - She's an internationalist, she believes in quality control and she's not afraid of a bit of friction. Who better, then, to lead the project to define standards for Europe's cancer centres and sort the centres that meet them from those that need to do better? In Europe, if a hospital chooses to call itself a
- [Framing the argument over futile care](https://archive.cancerworld.net/editorial/framing-the-argument-over-futile-care/) - This editorial argues that handling the transition from active to palliative care is indeed a weak point in oncology, and if the cancer community fails to address it, we will leave it open to the accountants to set the agenda on futile care. We “overdiagnose, overtreat and overpromise”. This was the claim made by numerous
- [International guidelines offer hope of speeding up progress in advanced breast cancer](https://archive.cancerworld.net/cutting-edge/international-guidelines-offer-hope-of-speeding-up-progress-in-advanced-breast-cancer/) - Patient advocates and professionals alike believe these groundbreaking guidelines will raise standards of care, give much-needed structure to clinical research and improve awareness about a group of patients whose needs have been neglected for too long. At about 1pm on 5 November 2011 – just after the scheduled end of the ABC1 (Advanced Breast Cancer)
- [Endotherapy for Barrett's oesophagus with early neoplasia](https://archive.cancerworld.net/e-grandround/endotherapy-for-barretts-oesophagus-with-early-neoplasia/) - Massimo Conio looks at the evidence for two alternatives to oesophagectomies--endoscopic mucosal resection and radiofrequency ablation--and discusses which patients should be eligible and where the treatments should be carried out. We can safely and effectively use an endotherapy approach in patients who have Barrett’s oesophagus lesions infiltrating to the muscularis mucosae, which means a T1a
- [Living with the timebomb of a childhood cancer](https://archive.cancerworld.net/spotlight-on/living-with-the-timebomb-of-a-childhood-cancer/) - Being alert to early signs of cancer gives the best chance of survival. Silja Paavle, reporter on the Estonian daily Öhtuleht, helped to pass on this message with this article which won her a Best Cancer Reporter merit award. One shouldn’t walk through life with one’s eyes closed and, when you hear about terrible things,
- [A world-class centre arises from the French ground-zero](https://archive.cancerworld.net/spotlight-on/a-world-class-centre-arises-from-the-french-ground-zero/) - From a disastrous chemical explosion in Toulouse arises an innovative hospital with unique links to research and industry. Jean-Pierre Armand has seen his dream cancer centre at the Toulouse 'oncopole' through to completion. "If only we could start from scratch.” This thought has no doubt crossed the minds of many senior figures in cancer as
- [How are we doing?](https://archive.cancerworld.net/systems-services/how-are-we-doing/) - Information on how the performance of individual clinicians, teams and hospitals compares with the best is key to driving up standards in cancer care. ECCO is designing and implementing an audit framework named EURECCA to do so. Improving the quality of cancer care through performance feedback to hospitals and healthcare professionals is a topic of
- [The importance of local control in pancreatic cancer](https://archive.cancerworld.net/impact-factor/the-importance-of-local-control-in-pancreatic-cancer/) - THE ECOG E4201 study adds another piece of information to a growing body of evidence pointing strongly to the importance of local control and the role of radiotherapy in unresectable pancreatic cancer. Based on this evidence, we believe radiotherapy should be used routinely in this setting. The role of radiotherapy in unresectable adenocarcinoma of the
- [Time for another rethink on prostate cancer screening](https://archive.cancerworld.net/impact-factor/time-for-another-rethink-on-prostate-cancer-screening/) - Screening for prostate cancer using PSA is a careful balance of benefits and harms. But current US practice involves testing older men who have little to gain and aggressively treating low-risk cancers. Debates about whether to test need to be replaced by debates on how to test better. The US Preventive Services Task Force (USPSTF)
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-26/) - Everolimus plus octreotide improves progression-free survival in advanced NET => The Lancet The addition of everolimus to octreotide improved progression-free survival in patients with advanced neuroendocrine tumours (NETs) associated with carcinoid syndrome, the phase III RADIANT-2 study has concluded. Advanced NET remains a clinical challenge due to the lack of effective treatment options. Generally, chemotherapeutic
- [Aspirin for cancer prevention: why wait?](https://archive.cancerworld.net/editorial/aspirin-for-cancer-prevention-why-wait/) - The prospect is too exciting to dismiss: a single, inexpensive pill that, taken regularly, can reduce the risk of developing or dying from several types of cancer. The prospect is too exciting to dismiss: a single pill – a cheap one too – that, taken regularly, can reduce the risk of not only heart attack,
- [Stein Kaasa: Let me show you what integrated palliative care can do](https://archive.cancerworld.net/cover-story/stein-kaasa-let-me-show-you-what-integrated-palliative-care-can-do/) - According to Kaasa, head of the Cancer Clinic at Trondheim University Hospital, patients are falling through gaps in care provision because palliative care is seen as an add-on rather than integral to care plans. The World Health Organization has a definition of palliative care, but it is by no means a short one. Yes, it
- [Optimising dose-dense regimens for early breast cancer](https://archive.cancerworld.net/e-grandround/optimising-dose-dense-regimens-for-early-breast-cancer/) - Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added. Dose-dense regimens are intended to increase efficacy, not by increasing the patient’s total exposure to a drug, but by decreasing the time
- [Picture this: The new imaging techniques that can help doctors select the right treatment at the right time](https://archive.cancerworld.net/cutting-edge/picture-this-the-new-imaging-techniques-that-can-help-doctors-select-the-right-treatment-at-the-right-time/) - The more we learn about biological variations and changes within a tumour the more daunting becomes the challenge of personalising therapies. On the road towards personalised cancer therapies, the tasks of identifying new targets and devising ways to hit them seem to be coming along quite nicely. Right now, the big challenge is all about
- [Is hope worth any price?](https://archive.cancerworld.net/spotlight-on/is-hope-worth-any-price/) - When every additional day of life matters on the one hand, and the interests of a multibillion dollar industry are at stake on the other, promoting an informed debate about reimbursement policies can be quite a challenge. Hope – its colour is white for Wolfgang Behling and it has come into his life through a
- [Still waiting for the world to catch up](https://archive.cancerworld.net/spotlight-on/still-waiting-for-the-world-to-catch-up/) - When Ignace Vergote opted to specialise in gynaecological oncology, his country wasn't ready, and he's been waiting for the world to catch up with him ever since. Professor Ignace Vergote is a busy man. Arranging even an hour of his time is a difficult business, and when I meet him in his office at the
- [After the treatment's over...](https://archive.cancerworld.net/systems-services/after-the-treatments-over/) - As more cancer patients survive longer, the need for rehabilitation services is rising up the political agenda, driven by patients who want their lives back, and by policy makers who want people to get back to work, or at least become as independent as possible. By 2030 an estimated 75 million people will be living
- [The silent minority - unpublished data on cancer care](https://archive.cancerworld.net/impact-factor/the-silent-minority-unpublished-data-on-cancer-care/) - From 1989 to 2003, 709 phase III trials evaluating systemic cancer treatment were presented at ASCO meetings. Tam and collaborators have now reported that 9% of these trials were never published, and 13% were published after a five-year delay. More than half of these studies would have had clinical impact if published promptly. Two key
- [Hodgkin lymphoma - absence of evidence not evidence of absence!](https://archive.cancerworld.net/impact-factor/hodgkin-lymphoma-absence-of-evidence-not-evidence-of-absence/) - The optimal treatment for patients with advanced-stage Hodgkin lymphoma is an ongoing controversy. A recent trial seemed to answer some of the important open questions in the field; however, closer examination of the data indicates that the answers are not as clear as they might initially seem. The majority of patients (85–95%) with advanced-stage Hodgkin
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-25/) - Study helps define melanoma tumour margins => The Lancet For cutaneous melanomas thicker than 2 mm resection margins of 2 cm are sufficient and safe, a collaborative study between the Swedish Melanoma Study group and the Danish Melanoma Group has found. The study, say investigators led by Peter Gillgren from the Karolinska Institute (Stockholm, Sweden),
- [Our role in moulding the image of cancer](https://archive.cancerworld.net/editorial/our-role-in-moulding-the-image-of-cancer/) - The mass media and high-profile cancer campaigns have a major influence in shaping public perceptions of cancer. But who can influence the media? Download full article
- [Klaus Meier: together we can offer the best of both worlds](https://archive.cancerworld.net/cover-story/klaus-meier-together-we-can-offer-the-best-of-both-worlds/) - As more cancers are treated as chronic diseases, and cancer regimens become more complex, difficulties with adherence and the potential for damaging interactions are steadily rising. Download full article
- [Management of metastatic pancreatic cancer: current strategies and future directions](https://archive.cancerworld.net/e-grandround/management-of-metastatic-pancreatic-cancer-current-strategies-and-future-directions/) - Despite recent progress, pancreatic cancer remains one of the worst cancer diagnoses. Malcolm Moore reviews current management and considers future progress. Download full article
- [Promoting genetic literacy: cancer control in the BRCA era](https://archive.cancerworld.net/cutting-edge/promoting-genetic-literacy-cancer-control-in-the-brca-era/) - As more is learned about inherited genetic mutations that make cancers more likely, there is an acute need to give those who live with the mutated genes clear information and accurate advice. Download full article
- [Desperately seeking a bone marrow match](https://archive.cancerworld.net/spotlight-on/desperately-seeking-a-bone-marrow-match/) - A powerful media campaign that wiil transform the prospects of Romanian patients in need of transplant treatments won TV journalist Paula Herlo an ESO BCRA. Download full article
- [Real compassion is about moving things forward](https://archive.cancerworld.net/spotlight-on/real-compassion-is-about-moving-things-forward/) - The decision to focus on infections associated with cancer treatments, back in the early '70s, put Jean Klastersky on a path that would lead to him pioneering the field of supportive care in cancer. Download full article
- [Gemcitabine alone or plus cisplatin for biliary tract cancer?](https://archive.cancerworld.net/impact-factor/gemcitabine-alone-or-plus-cisplatin-for-biliary-tract-cancer/) - A randomised phase III trial comparing cisplatin plus gemcitabine with gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (overall survival, disease-free survival and disease control rate) was significantly better in the combination arm, with no increase in toxic effects
- [Molecular selection for ‘smart' study design in lung cancer](https://archive.cancerworld.net/impact-factor/molecular-selection-for-‘smart-study-design-in-lung-cancer/) - The ZODIAC trial reported that the addition of vandetanib to docetaxel in second-line treatment of unselected patients with metastatic non-small-cell lung cancer resulted in a statistically significant improvement in progression-free survival compared with docetaxel alone. Identification of biomarkers to assist in molecular selection of patients for targeted therapy is a tool for ‘smart' clinical trial
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-24/) - Selected Reports by Janet Fricker Download full article
- [“The Big Four of the Millennium” in Women’s Health](https://archive.cancerworld.net/news/the-big-four-of-the-millennium-in-womens-health/) - “The Big Four of the Millennium” was recently announced at the 61st Congress of the German Society of Gynaecology and Obstetrics. This honor identifies four individuals, whose life’s work created the standards of women’s health that we enjoy today. The four recipients of this honor are: Umberto Veronesi, MD, Knight Grand Cross, OMRI: Trained as
- [A million voices against cancer](https://archive.cancerworld.net/editorial/a-million-voices-against-cancer/) - The UN General Assembly Special Session on Non-Communicable Diseases this September offers an all-too-rare window of opportunity to push cancer well up the global health agenda. Read more to see how you can help! Download full article
- [Ruth Ladenstein: raising standards of care for our young patients](https://archive.cancerworld.net/cover-story/ruth-ladenstein-raising-standards-of-care-for-our-young-patients/) - Paediatric oncologists have a well-deserved reputation for collaborating and treating patients within trial protocols, but there are limits to what they can achieve alone. Download full article
- [Treatment of triple negative breast cancer](https://archive.cancerworld.net/e-grandround/treatment-of-triple-negative-breast-cancer/) - Triple negative breast cancers, as a subgroup, are associated with a poor prognosis. But different subtypes within triple negative disease are associated with different outcomes... Download full article
- [Reading the signs](https://archive.cancerworld.net/cutting-edge/reading-the-signs/) - The concept of a genomic signature that can define any tumour according to its unique biology has been central to the emerging paradigm of personalised therapy. But how helpful are multi-gene assays in guiding treatment decisions in clinical practice? Download full article
- [Think before you ruin your patient's chance of parenthood](https://archive.cancerworld.net/spotlight-on/think-before-you-ruin-your-patients-chance-of-parenthood/) - The plight of cancer patients for whom treatment means risking losing the opportunity to have children was taken up in a piece that earned Sławomir Zagórski a BCRA. Download full article
- [A simple doctor's quest to improve on today's treatments](https://archive.cancerworld.net/spotlight-on/a-simple-doctors-quest-to-improve-on-todays-treatments/) - Stan Kaye, head of drug development at the Royal Marsden treasures the moments when a new drug turns up that shows real value. The big challenge is to understand who benefits from what. Download full article
- [Where are the consensus guidelines for women with metastatic disease?](https://archive.cancerworld.net/spotlight-on/where-are-the-consensus-guidelines-for-women-with-metastatic-disease/) - Women with advanced breast cancer can live a full and active life. But median survival is still hovering around three years and progress is frustratingly slow. A new conference now seeks to change this. Download full article
- [An advanced oncology degree for busy specialists across the globe](https://archive.cancerworld.net/systems-services/an-advanced-oncology-degree-for-busy-specialists-across-the-globe/) - Oncologists wanting to develop and work can find it hard to balance the competing priorities of clinical practice and study. This new online MSc in Advanced Oncology run by the University of Ulm may be the answer. Download full article
- [Failure of bevacizumab in early-stage colon cancer](https://archive.cancerworld.net/impact-factor/failure-of-bevacizumab-in-early-stage-colon-cancer/) - A randomised phase III trial of patients with stage II and III colon cancer showed no benefit of adding bevacizumab to standard adjuvant oxaliplatin plus fluorouracil and leucovorin. Despite suggestive evidence of a short-term benefit, these data and other similar findings dictate that adjuvant bevacizumab should not be used in colon cancer. Download full article
- [Ultra-targeted accelerated partial breast irradiation using TARGIT – a cautionary note](https://archive.cancerworld.net/impact-factor/ultra-targeted-accelerated-partial-breast-irradiation-using-targit-–-a-cautionary-note/) - One of the seven ongoing trials of accelerated partial breast irradiation (APBI) has concluded that single-dose intraoperative radiotherapy should be considered as an alternative to protracted whole-breast irradiation. With a median follow up of two years, such conclusions seem premature. Until the risk and pattern of recurrence is reported at longer follow up, APBI should
- [NEWSROUND](https://archive.cancerworld.net/senza-categoria/newsround-23/) - Selected reports edited by Janet Fricker Download full article
- [Tattoo works of art on the breast after mastectomy gives back the self-confidence](https://archive.cancerworld.net/news/tattoo-works-of-art-on-the-breast-after-mastectomy-gives-back-the-self-confidence/) - "The first time I felt a little awkward because I had never seen a breast with mastectomy and it was not an easy case. This woman had undergone many surgeries in her effort to make her breast look normal. We draw branches of flowers on it. One of them covered the missing nipple. The trust
- [Adapting services to the age of oral therapies](https://archive.cancerworld.net/editorial/adapting-services-to-the-age-of-oral-therapies/) - The increasing use of oral cancer drugs is contributing to a change in the way cancer services are organised, leading to many more patients receiving care in an ambulatory setting. Download full article
- [Jean-Yves Blay: integrating translational and clinical research](https://archive.cancerworld.net/cover-story/jean-yves-blay-integrating-translational-and-clinical-research/) - Jean-Yves Blay is leading efforts to reshape cancer research so that every trial has a translational element that can build knowledge about the mechanisms driving the disease. Download full article
- [New approaches to treating gastro-oesophageal cancer](https://archive.cancerworld.net/e-grandround/new-approaches-to-treating-gastro-oesophageal-cancer/) - Robust evidence on the value of neoadjuvant chemotherapy, together with more effective imaging modalities, are opening up new options for gastro-oesophageal cancer. Download full article
- [International biobanking regulations: the promise and the pitfalls](https://archive.cancerworld.net/cutting-edge/international-biobanking-regulations-the-promise-and-the-pitfalls/) - A single infrastructure for Europe's rapidly evolving biobanks is urgently needed. But finding agreement on the ethics, language and operating standards is proving quite a challenge. Download full article
- [The secret behind a successful clinical trial](https://archive.cancerworld.net/spotlight-on/the-secret-behind-a-successful-clinical-trial/) - Good clinical trials are proposed by clinicians, have the potential for real patient benefit and increase knowledge about the disease, says Pinuccia Valagussa, who is dedicated to helping more centres join trials. Download full article
- [Cutting unnecessary deaths from cervical cancer](https://archive.cancerworld.net/systems-services/cutting-unnecessary-deaths-from-cervical-cancer/) - Given how preventable cervical cancer is, setting up screening programmes must be a key element in Europe's cancer strategy. But as this six country initiative is finding out, it takes a lot. Download full article
- [Hypoxia modification with radiotherapy for bladder cancer](https://archive.cancerworld.net/impact-factor/hypoxia-modification-with-radiotherapy-for-bladder-cancer/) - The outcomes in bladder cancer treated with radiotherapy are suboptimal. Recently, Hoskin et al. reported improved survival in patients with bladder cancer treated with radiation therapy with concurrent hypoxia-modification therapy. These results are promising but must be viewed in the context of previous studies and alternative treatment approaches. Download full article
- [An 18-gene signature (ColoPrint) for colon cancer prognosis](https://archive.cancerworld.net/impact-factor/an-18-gene-signature-coloprint-for-colon-cancer-prognosis/) - ColoPrint is an 18-gene expression signature designed to predict disease relapse in patients with early-stage colorectal cancer (CRC). We discuss the potential impact of ColoPrint on clinical practice, and its contribution to our knowledge of CRC molecular heterogeneity. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-22/) - Selected reports edited by Janet Fricker Download full article
- [Patients need information. Is that clear?](https://archive.cancerworld.net/editorial/patients-need-information-is-that-clear/) - The urgent quest for novel cancer treatments engages much of our attention, but could we be overlooking other opportunities for increasing patients' survival and quality of life? Download full article
- [Peter Naredi: a ‘can do' leader for Europe's cancer surgeons](https://archive.cancerworld.net/cover-story/peter-naredi-a-‘can-do-leader-for-europes-cancer-surgeons/) - There are so many ways cancer surgeons can help improve outcomes, and Peter Naredi embraces them all. As ESSO president, he now hopes to enthuse Europe's cancer surgeons to follow his lead. Download full article
- [Decision making in the treatment of gliomas](https://archive.cancerworld.net/e-grandround/decision-making-in-the-treatment-of-gliomas/) - This overview looks at the role of age, tumour size, performance status and various predictive and prognostic biomarkers in guiding treatment in newly diagnosed and recurrent disease. Download full article
- [Beyond Survival--what should new cancer drugs have to prove and how?](https://archive.cancerworld.net/cutting-edge/beyond-survival-what-should-new-cancer-drugs-have-to-prove-and-how/) - As our understanding of cancer increases are randomised controlled trials still the way to get the best drugs into use most quickly? Download full article
- [For the love of the job](https://archive.cancerworld.net/spotlight-on/for-the-love-of-the-job/) - Elisabeth de Vries enjoys investigating whether we can push the potential of imaging techniques to the point where a patient's response to a drug can routinely be measured in an outpatient clinic. Download full article
- [Unshackling progress in the care of childhood cancers](https://archive.cancerworld.net/spotlight-on/unshackling-progress-in-the-care-of-childhood-cancers/) - A meeting held in the run up to International Childhood Cancer Day reviewed how well we are doing to help young cancer patients. Download full article
- [Think yourself better](https://archive.cancerworld.net/focus/think-yourself-better/) - In oncology, the contribution of the human touch which alternative medical treatments offer, and the placebo effect they induce, can be easy to overlook. Download full article
- [Rituximab for follicular lymphoma: maintaining an open mind](https://archive.cancerworld.net/impact-factor/rituximab-for-follicular-lymphoma-maintaining-an-open-mind/) - New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations of cost, inconvenience, toxic effects, efficacy of retreatment and lack of survival benefit should focus future clinical research on more-effective induction strategies. Download full article
- [ASTER--another flow in the diagnostic field of lung cancer?](https://archive.cancerworld.net/impact-factor/aster-another-flow-in-the-diagnostic-field-of-lung-cancer/) - Mediastinal staging of patients with lung cancer is used to avoid futile thoracotomies. Endoscopic, oesophageal and bronchial ultrasound procedures are methods to identify involved lymph nodes. The ASTER study indicates that the sensitivity of these new techniques is high, reducing the number of futile thoracotomies and improving outcomes when combined with mediastinoscopy. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-21/) - Selected reports by Janet Fricker Download full article
- [Securing quality cancer care: Governments must step up to the plat](https://archive.cancerworld.net/editorial/securing-quality-cancer-care-governments-must-step-up-to-the-plat/) - The OECD recently made a cross-country analysis of how cancer care systems work in an attempt to explain variations in cancer survival in Europe.
- [Julio Celis: bridging science and politics](https://archive.cancerworld.net/cover-story/julio-celis-bridging-science-and-politics/) - Julio Celis, a scientist to his core, has arguably had the greatest impact in helping shape the structures of Europe's cancer research effort. Download full article
- [State-of-the-art treatment for advanced melanoma](https://archive.cancerworld.net/e-grandround/state-of-the-art-treatment-for-advanced-melanoma/) - Progress in treating melanoma has lagged behind many other cancers for decades. But a number of novel approaches are now offering a glimmer of hope. Download full article
- [The future of cancer, as told through the story of Renee](https://archive.cancerworld.net/spotlight-on/the-future-of-cancer-as-told-through-the-story-of-renee/) - Explaining the science which offers new hope to cancer patients. Download full article
- [The ESO Masterclass: where those most eager to learn meet those most willing to teach](https://archive.cancerworld.net/spotlight-on/the-eso-masterclass-where-those-most-eager-to-learn-meet-those-most-willing-to-teach/) - The annual week-long course lies at the very heart of ESO's mission and shapes the oncology leaders of tomorrow. Download full article
- [A minimum acceptable standard of care for every patient](https://archive.cancerworld.net/systems-services/a-minimum-acceptable-standard-of-care-for-every-patient/) - How can we transmit knowledge about cancer patients' needs to the people who have the power to act, in a way they can quickly and easily understand? Download full article
- [Denosumab - a new option for solid tumours metastatic to bone](https://archive.cancerworld.net/impact-factor/denosumab-a-new-option-for-solid-tumours-metastatic-to-bone/) - Zoledronic acid is a potent bisphosphonate used as the standard therapy for the prevention of skeletal-related events in patients with solid tumours metastatic to bone. Three phase III studies have reported head-to-head comparisons of zoledronic acid with denosumab, an inhibitor of the RANK signaling pathway. Download full article
- [Perioperative therapy improves gastro-oesophageal cancer survival](https://archive.cancerworld.net/impact-factor/perioperative-therapy-improves-gastro-oesophageal-cancer-survival/) - A randomised phase III study has reported significant improvements in RO resection rate and overall survival associated with perioperative cisplatin and 5-fluorouracil treatment compared with surgery alone in patients with gastro-oesophageal adenocarcinoma. These data support the results of the randomised phase III MAGIC study that reported a 13% five-year survival benefit from perioperative chemotherapy. Download
- [Newsround](https://archive.cancerworld.net/spotlight-on/newsround-20/) - Cancer family histories found to be inaccurate Download full article
- [To cut or not to cut? Why surgeons don't have all the answers](https://archive.cancerworld.net/editorial/to-cut-or-not-to-cut-why-surgeons-dont-have-all-the-answers/) - Years ago, surgery was the principal way of treating most cancers. Nowadays, surgery has become more conservative as the concept of operability is changing. Download full article
- [Luzia Travado: improving outcomes for patients by attending to their distress](https://archive.cancerworld.net/cover-story/luzia-travado-improving-outcomes-for-patients-by-attending-to-their-distress/) - Luzia Travado's determination to improve the psychosocial care for cancer patients has made her a familiar face across Europe and beyond. Download full article
- [Prognostic and predictive markers in colorectal cancer: implications for clinical management](https://archive.cancerworld.net/e-grandround/prognostic-and-predictive-markers-in-colorectal-cancer-implications-for-clinical-management/) - Efforts to find genetic patterns may offer the basis for identifying subgroups of colorectal cancer similar to those now used in breast cancer. Download full article
- [Hope for me, and for others who come after: Victoria Lambert's award-winning article explores the impact of a new network of early trial centres](https://archive.cancerworld.net/spotlight-on/hope-for-me-and-for-others-who-come-after-victoria-lamberts-award-winning-article-explores-the-impact-of-a-new-network-of-early-trial-centres/) - Delays in getting promising new treatments into trials are slowing progress in cancer care and failing patients who have run out of options and are running out of time. Download full article
- [Redefining the role of pathology: how Giuseppe Viale embraced the new responsibilities of the molecular era](https://archive.cancerworld.net/spotlight-on/redefining-the-role-of-pathology-how-giuseppe-viale-embraced-the-new-responsibilities-of-the-molecular-era/) - In the era of personalised therapies, complete and accurate pathology reports are vital. Giuseppe Viale is helping pathologists rise to their new responsibilities and ensuring they are given the opportunity to play a full role. Download full article
- [Taking the first step on the road to cancer control](https://archive.cancerworld.net/systems-services/taking-the-first-step-on-the-road-to-cancer-control/) - The UN Summit on Non-Communicable Diseases opened a window of opportunity for decisive action to set poorer countries on the road towards sustainable cancer control. Download full article
- [An important piece of the localised prostate cancer puzzle?](https://archive.cancerworld.net/systems-services/an-important-piece-of-the-localised-prostate-cancer-puzzle/) - Download full article
- [Front-line therapy in lung cancer with mutations in EGFR](https://archive.cancerworld.net/impact-factor/front-line-therapy-in-lung-cancer-with-mutations-in-egfr/) - Large randomised phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harbouring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy. Download full article
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-19/) - Selected reports by Janet Fricker Download full article
- [Systematic reviews – your key to evidence-based medicine](https://archive.cancerworld.net/spotlight-on/systematic-reviews-your-key-to-evidence-based-medicine/) - Evidence-based medicine is the cornerstone of medical practice, and yet clinicians are rarely offered training in the tricky business of finding, evaluating and making sense of the evidence they need. Anna Rouillard reports on an ESO-Cochrane Masterclass which seeks to fill that gap. With the abundance of scientific literature on cancer treatments available, choosing the
- [A breakthrough business model for drug development](https://archive.cancerworld.net/featured/a-breakthrough-business-model-for-drug-development/) - Anna Wagstaff looks at changes in the business, regulatory and science arenas that could open the way to delivering better cancer treatments, faster and cheaper. Of 91 new therapies approved for solid tumours between 2002 and 2016, the median reported gain in overall survival was 2.2 months. Cancer drugs costs are rising five times faster
- [The role of Internet resources in clinical oncology: promises and challenges](https://archive.cancerworld.net/impact-factor/the-role-of-internet-resources-in-clinical-oncology-promises-and-challenges/) - Bradford Hesse and colleagues explore insights gained from over a decade of data gathered by the US National Cancer Institute to monitor changes in the communication environment regarding cancer-related information. This is an abridged version of Bradford Hesse, Alexandra Greenberg and Lila Finney-Rutten (2016) The role of Internet resources in clinical oncology: promises and challenges.
- [Developing new drugs for children and adolescents with cancer](https://archive.cancerworld.net/e-grandround/developing-new-drugs-for-children-and-adolescents-with-cancer/) - Stimulating development of more and better paediatric cancer drugs will be key to making progress, particularly in some of the hardest-to-treat childhood cancers. Gilles Vassal, past-President of the European Society for Paediatric Oncology, outlines emerging strategies to make this happen. This grandround was first presented by Gilles Vassal, Director of Clinical Research at the Gustave
- [Improving pharmacovigilance through direct patient reporting](https://archive.cancerworld.net/patient-voice/improving-pharmacovigilance-through-direct-patient-reporting/) - With increasing numbers of cancer drugs being approved on shorter trials that involve fewer patients, getting accurate reports of adverse events and side effects after approval is increasingly important. Maria Delaney reports on efforts to encourage us all to be alert for – and report – possible side effects from the medications we take. Have
- [Elżbieta Senkus: Facing down the fear](https://archive.cancerworld.net/profile/elzbieta-senkus-facing-down-the-fear/) - How is it possible to help patients decide on the best treatment option for them, when they are scared, and when there is such uncertainty? Elżbieta Senkus, a specialist in breast and prostate cancers, talks to Anna Rouillard about her own approach and the urgent need to learn more about how the recommended treatments should
- [Using Darwin’s notebook to outsmart resistance](https://archive.cancerworld.net/cutting-edge/using-darwins-notebook-to-outsmart-resistance/) - Clonal evolution and the ‘survival of the nastiest’ remain the chief obstacles to curing cancer. But what if we could find a way to use the principles of evolution to beat evolving cancers cells at their own game? Simon Crompton explores cutting edge efforts to do just that. As notebook scrawls go, this one was
- [Reality check in Mumbai – Experts debate the evidence on leaving cancer care to the market](https://archive.cancerworld.net/our-world/reality-check-in-mumbai-experts-debate-the-evidence-on-leaving-cancer-care-to-the-market/) - How far can private and philanthropic providers meet the rapidly rising need for cancer detection, treatment and care in low- and middle-income countries? Sandhya Srinivasan reports on a high-profile debate involving economists, policy makers, clinicians and a range of healthcare providers. India is a technically sophisticated country and an important player in science and medicine.
- [What can ’omics add to personalised risk assessment?](https://archive.cancerworld.net/cutting-edge/what-can-omics-add-to-personalised-risk-assessment/) - For a disease that has led the field of molecular biology, it is surprising perhaps that so few biomarkers have been identified that can predict a person’s risk of developing cancer. Researchers are now looking at what genetics and epigenetics can add to traditional risk factors such as age, weight and family history, and at
- [Male breast cancer is not congruent with the female disease](https://archive.cancerworld.net/impact-factor/male-breast-cancer-is-not-congruent-with-the-female-disease/) - Male breast cancer is almost always oestrogen receptor positive, and is traditionally treated in line with guidelines for treating hormone-sensitive breast cancers in postmenopausal women. Ian Fentiman questions the rationale for this approach, pointing to key biological differences between male and female breast cancers. This is an abridged version of Ian Fentiman (2016) Male breast
- [Non-invasive metabolic imaging of brain tumours in the era of precision medicine](https://archive.cancerworld.net/impact-factor/non-invasive-metabolic-imaging-of-brain-tumours-in-the-era-of-precision-medicine/) - Sriram Venneti and colleagues examine non-invasive metabolic imaging strategies that can be used to interrogate some of the genomic alterations in brain tumours, with the ultimate goal of informing patient management. This is an abridged version of Michelle M. Kim et al. (2016) Non-invasive metabolic imaging of brain tumours in the era of precision medicine.
- [Complementary and integrative medicine for cancer patients – A purely ideological debate?](https://archive.cancerworld.net/spotlight-on/complementary-and-integrative-medicine-for-cancer-patients-a-purely-ideological-debate/) - With studies showing that around half of all cancer patients use therapies that are not part of mainstream medicine, Cancer World Editor Alberto Costa explores some aspects of the discussion on what complementary and integrative medicine can offer cancer patients, and the supporting evidence behind a range of options. Cancer patients have been turning to
- [Communication – the core skill that can make or break multiprofessional care](https://archive.cancerworld.net/featured/communication-the-core-skill-that-can-make-or-break-multiprofessional-care/) - Complex healthcare cannot succeed without effective communication between everyone involved in the patient’s care, with each understanding and respecting the contribution of others. Peter McIntyre looks at where things can go wrong, and how to help ensure they go right. The patient was watching the chemotherapy passing down the tube into her arm when she
- [Prostate cancer: hope in the blood](https://archive.cancerworld.net/voices/prostate-cancer-hope-in-the-blood/) - May was awash with news stories about blood tests for prostate cancer. Reports that a new serum test called IsoPSA could predict prostate cancer more precisely than conventional PSA testing brought obvious interest. The new test, studied at five centres in the US, measures structural changes in PSA rather than concentration. There are early indications
- [Too affordable: how can we overcome the drug repurposing paradox?](https://archive.cancerworld.net/featured/too-affordable-how-can-we-overcome-the-drug-repurposing-paradox/) - Looking for anticancer activity among off-patent drugs that are already approved to treat other conditions might seem a sensible way to speed up access to affordable new therapy options. Linda Geddes asks how such a strategy can work in practice, when the drugs are so cheap but the cost of approval is so high. When
- [Silke Gillessen: tackling uncertainties and access in advanced prostate cancer](https://archive.cancerworld.net/profile/silke-gillessen-tackling-uncertainties-and-access-in-advanced-prostate-cancer/) - Prioritising collaboration over self-interest is the way to learn about who gets the best from which treatments in the complex world of advanced prostate cancer. Silke Gillessen talked to Simon Crompton about how she is trying to bring people together to make it happen. Prostate cancer is lethal. With medics increasingly aware of the prevalence
- [Ending substandard treatment in lung cancer](https://archive.cancerworld.net/spotlight-on/ending-substandard-treatment-in-lung-cancer/) - Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast and prostate. Marc Beishon talked to some of the specialists who are determined to turn this around. “A fatalistic professional
- [Pain! The denial needs to end](https://archive.cancerworld.net/cover-story/pain-the-denial-needs-to-end/) - Uncontrolled pain can blight the lives of cancer patients and survivors. But all too often, health professionals don’t ask, and patients don’t tell. Simon Crompton looks at why this is still the case, and what can be done about it. It isn’t as if cancer pain isn’t talked about. The need to manage cancer pain
- [Rare cancers account for one fifth of new diagnoses in the US](https://archive.cancerworld.net/news/rare-cancers-account-for-one-fifth-of-new-diagnoses-in-the-us/) - According to an analysis just published on American Cancer Society's CA: A Cancer Journal for Clinicians, rare cancers account for almost a fifth of all new diagnoses, and up to over two thirds of all new diagnoses when it comes to pediatric cancers hitting children and adolescents. «Rare cancers present unique challenges for clinicians and their patients. For
- [Recognising the value of cancer nurses – today and every day!](https://archive.cancerworld.net/voices/recognising-the-value-of-cancer-nurses-today-and-every-day/) - On May 18th The European Oncology Nursing Society (EONS for short) will be celebrating the first European Cancer Nursing Day. We are doing this because we feel it is important for everyone to understand what cancer nurses do, how the role varies across Europe and how cancer nurses could contribute further to excellent cancer care.
- [The elephant in the room](https://archive.cancerworld.net/editorial/the-elephant-in-the-room/) - Ne umquam pars pro toto (Plinius). Can anyone remember a bit of Latin? This quotation was used in a slide presentation given a few weeks ago by Louis Denis, urologist and prostate cancer patient, at the congress of the European Association of Urology (EAU), where he was representing the patient coalition Europa Uomo. It means
- [Ivana Božović-Spasojević: A Bordet for Belgrade](https://archive.cancerworld.net/profile/ivana-bozovic-spasojevic-a-bordet-for-belgrade/) - A chance to work at the heart of the trailblazing MINDACT trial gave Ivana Božović-Spasojević a memorable lesson in the value of international academic trials, and the logistics of how to run them. She spoke to Anna Rouillard about her efforts to use what she learnt to ramp up academic research efforts in her own
- [Cancer drugs: don’t give in to political pressure, warns report](https://archive.cancerworld.net/news/cancer-drugs-dont-give-in-to-political-pressure-warns-report/) - Countries struggling to broaden access to expensive new cancer drugs are being strongly warned to put cost-effectiveness first and not give in to political pressure. A team of researchers studied the impact of the NHS Cancer Drugs Fund (CDF) that was introduced in the UK in 2010 following media criticism that cancer patients were being
- [Winning or losing? ESO asks the experts](https://archive.cancerworld.net/editorial/winning-or-losing-eso-asks-the-experts/) - To mark 30 years of helping to improve the quality of care provided to cancer patients, ESO is convening a jury of 100 experts at the World Oncology Forum in Lugano this October to examine the progress in the war against cancer. Guest editor Franco Cavalli asks: what will the verdict be? by Franco Cavalli
- [Patients pay a price for spending cuts](https://archive.cancerworld.net/systems-services/patients-pay-a-price-for-spending-cuts/) - Austerity measures brought in to tackle the debt crisis are affecting frontline healthcare services in many countries, particularly in the complex, expensive field of oncology. Cancer World asked readers to share their first-hand experiences. Doctors are sounding the alarm about the price cancer patients are paying for dramatic cuts in public spending. In the countries
- [Mary Gospodarowicz: Just do it](https://archive.cancerworld.net/cover-story/mary-gospodarowicz-just-do-it/) - Implement guidelines, adopt what works and reject what doesn't, focus on cost-effectiveness--there are so many ways cancer care could be improved. Mary Gospodarowicz, believer, pragmatist and 'raving optimist', is determined to make it happen. Implement guidelines, adopt what works and reject what doesn’t, focus on cost-effectiveness – there are so many ways cancer care could
- [New accomplishments in breast cancer chemoprevention](https://archive.cancerworld.net/e-grandround/new-accomplishments-in-breast-cancer-chemoprevention/) - Too toxic, too untargeted, too difficult to prove. These assumptions about chemoprevention are being challenged by important developments in the search for preventive options tailored to specific risk factors in breast cancer. Recent years have seen some important developments in chemoprevention of breast cancer. These include the use of aromatase inhibitors (AIs) for prevention, including
- [Breaking Boundaries](https://archive.cancerworld.net/spotlight-on/breaking-boundaries/) - Often mistaken for a radiotherapist or medical oncologist, this expert in voice-box sparing strategies has reached out to a wide variety of professionals-- most recently actors-- in his quest to improve the chances of patients with head and neck cancers. It’s fitting that one of the world’s most influential specialists on cancers that threaten speech
- [If you could see it through my eyes...](https://archive.cancerworld.net/patient-voice/if-you-could-see-it-through-my-eyes/) - Cancer patients who do not share their doctors' belief in the drug they are prescribed, or find living with the side-effects hard to bear, may fail to take their pills according to the prescription-- and may prefer to keep this failing to themselves. Just before Easter, a group of women who had been treated for
- [Salvage chemotherapy in gastric cancer – more than a straw?](https://archive.cancerworld.net/impact-factor/salvage-chemotherapy-in-gastric-cancer-–-more-than-a-straw/) - The benefit of salvage chemotherapy in gastric cancer refractory to first-line platinum and fluoropyrimidine therapy was previously unknown. A randomised multicentre study has shown that irinotecan or docetaxel administered as single agents improved survival compared with best supportive care alone. Hence, salvage chemotherapy is now a proven option in pretreated gastric cancer. Gastric cancer is
- [Manufacturer sponsorship bias in economic analyses matters](https://archive.cancerworld.net/impact-factor/manufacturer-sponsorship-bias-in-economic-analyses-matters/) - A qualitative study indicates that there is a positive selection bias towards favourable economic analysis of targeted therapies when these are funded by the manufacturer. At a time of increasing budgetary constraints and public scrutiny of the relationship between industry and the professions, we need a more mixed economy of funding for this field. In
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-18/) - Selected reports edited by Janet Fricker Stereotactic body radiation therapy for spinal metastases => Lancet Oncology Stereotactic body radiation therapy (SBRT) delivers significant reductions in patient-reported pain and other symptoms six months post treatment, a phase I/II US trial has found. Around 40% of cancer patients develop spinal metastases during the course of their disease,
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-17/) - Selected reports edited by Janet Fricker Preoperative chemoradio-therapy improves survival in oesophageal cancer => New England Journal of Medicine Preoperative chemoradiotherapy improves survival among patients with potentially curable oesophageal or oesophagogastric-junction cancers, a phase III Dutch study has found. Oesophageal cancer, which is the eighth most common cancer worldwide, is responsible for more than 400,000
- [Personalised medicine: a note of caution](https://archive.cancerworld.net/editorial/personalised-medicine-a-note-of-caution/) - Tailoring a patient's treatment to the particular biology of their cancer holds out the enticing prospect of avoiding over-treatment and reducing unnecessary toxicity. But delivering the right option for the right patient at the right time takes more than having the right biomarkers. Tailoring a patient’s treatment to the particular biology of their cancer holds
- [Siddhartha Mukherjee: explaining cancer](https://archive.cancerworld.net/cover-story/siddhartha-mukherjee-explaining-cancer/) - With our new-found understanding of cancer biology comes the opportunity to explain a disease that for centuries has confounded doctors and engendered stigma and superstition. Siddhartha Mukherjee took that opportunity and turned it into a best seller. Just who is Siddhartha Mukherjee? This is the question many veterans of the cancer community asked as a
- [We told you so: How the persistence of](https://archive.cancerworld.net/cutting-edge/we-told-you-so-how-the-persistence-of/) - With two novel immunotherapies approved and many more in the pipeline, is it time to announce that a new treatment modality has emerged? A class of therapy that has long held promise for treating cancer patients may finally have come of age. Immunotherapy, or biological therapy to give the broadest term, can use the body’s
- [Futile care: Why does it happen, how can we avoid it?](https://archive.cancerworld.net/systems-services/futile-care-why-does-it-happen-how-can-we-avoid-it/) - Why are cancer patients being given medically futile treatment in the last weeks of their life? We hear this question raised time and again at international meetings and in journal articles, provoking polarised views and occasional acrimony. Why are cancer patients being given medically futile treatment in the last weeks of their life? We hear
- [In the jungle of the miracle healers](https://archive.cancerworld.net/spotlight-on/in-the-jungle-of-the-miracle-healers/) - It was her own fault that she lost her chance to be cured. Or was it? This article, which was first published in the German weekly news magazine Der Spiegel, and won its author a Best Cancer Reporter Award, explores what makes people choose alternative over conventional treatments. It was on a Monday three and
- [How exposure to a mother's cancer treatment during pregnancy impacts on the child](https://archive.cancerworld.net/e-grandround/how-exposure-to-a-mothers-cancer-treatment-during-pregnancy-impacts-on-the-child/) - When your patient is pregnant, uncertainty about the impact different therapies may have on the child makes it hard to discuss treatment options. A study of children exposed to cancer treatments before birth is now starting to provide some welcome evidence. ESO presents weekly e-grandrounds which offer participants the opportunity to discuss a range of
- [How bad news can be good news for cancer services](https://archive.cancerworld.net/spotlight-on/how-bad-news-can-be-good-news-for-cancer-services/) - Knowing what needs to be done is one thing. Making it happen is quite another. Well-informed media stories that highlight shortcomings and failings can help focus minds on the need for urgent action. The media plays a critical role in creating political momentum for change to improve health services, according to the UK’s National Cancer
- [For localised prostate cancer, does technology equal progress?](https://archive.cancerworld.net/impact-factor/for-localised-prostate-cancer-does-technology-equal-progress/) - Recent evolution of prostate cancer treatment reflects technological arms races driven by economic incentives rather than high-quality evidence – as exemplified by proton-beam radiation, recently found markedly inferior to far less expensive alternatives. Another study found promise for focal treatment, but much research is required before this could become a standard option. This article was
- [Gemtuzumab ozogamicin in acute myeloid leukaemia](https://archive.cancerworld.net/impact-factor/gemtuzumab-ozogamicin-in-acute-myeloid-leukaemia/) - Gemtuzumab ozogamicin was withdrawn from the market after being evaluated in combination with chemotherapy in the frontline treatment of patients aged 18 to 60 years with acute myeloid leukaemia (AML). More-recent randomised trials demonstrate that low doses of gemtuzumab added to cytarabine and anthracycline-based chemotherapy benefit patients with better-risk AML. This article was first published
- [My World](https://archive.cancerworld.net/systems-services/my-world-3/) - Ruth Conroy is a specialist registrar in clinical oncology at the Christie Hospital in Manchester, UK. She came first out of a class of 62 young oncologists from 28 countries in the learning assessment test at the end of this year's ESO Masterclass in Clinical Oncology. Why I chose to work in oncology… I didn’t
- [Penalised for having cancer](https://archive.cancerworld.net/editorial/penalised-for-having-cancer/) - Many cancer patients are being tipped into poverty as a direct result of their illness, which adds stress and misery to an already very difficult situation. In this editorial, Cancer World looks at the many ways that a having cancer can hit people's living standards. Much attention is given to the spiralling cost of treating
- [Andreas Engert: Learning from Hodgkin's](https://archive.cancerworld.net/cover-story/andreas-engert-learning-from-hodgkins/) - Hodgkin's patients survive for longer – but with more serious and lasting damage – than almost any other group of cancer patients. Finding ways to address the problems of both current and future survivors can provide valuable lessons for other cancers. Why should we bother with Hodgkin lymphoma? It accounts for only 1% of cancers,
- [Testing the testers](https://archive.cancerworld.net/cutting-edge/testing-the-testers/) - Treating the right patient with the right therapy at the right time depends on having the right picture of every patient's key biological markers. A number of initiatives are now springing up across Europe to ensure that the testers are indeed getting it right. As the era of personalised medicine has developed, it has brought
- [Late diagnosis: Why does it happen? How can we do better?](https://archive.cancerworld.net/spotlight-on/late-diagnosis-why-does-it-happen-how-can-we-do-better/) - When GPs fail to identify symptomatic cancers on time it can be fatal for patients and frustrating for the specialists who treat them. In this article, GP Tina Eriksson and gastrointestinal cancer specialist Eric Van Cutsem exchange views on why this is such a problem and what can be done about it. Patients whose cancers
- [The origin of a special success](https://archive.cancerworld.net/spotlight-on/the-origin-of-a-special-success/) - Cancer genetics is intriguing, exciting and offers hope for real progress in treatment, but try telling that to non-scientists. Clive Cookson, science editor at the Financial Times, did just that. His article, explaining the evolutionary process that drives cancer, won him a Best Cancer Reporter Award Cancer scientists have a new patron saint: Charles Darwin.
- [OECI accreditation: is yours a top-class cancer centre?](https://archive.cancerworld.net/e-grandround/oeci-accreditation-is-yours-a-top-class-cancer-centre/) - Whether you work at a cancer unit, a cancer centre or a comprehensive cancer centre, applying for OECI accreditation is a good way to find out how your institute compares with the best, and get advice on how to address any shortcomings. The European School of Oncology presents weekly e-grandrounds which offer participants the chance
- [Lungscape: a living lung laboratory](https://archive.cancerworld.net/spotlight-on/lungscape-a-living-lung-laboratory/) - The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer centres is planning to transform the way that the findings of molecular research into non-small-cell lung cancer (NSCLC) are brought
- [Gastro-oesophageal cancer –is CROSSing over so hard to do?](https://archive.cancerworld.net/impact-factor/gastro-oesophageal-cancer-–is-crossing-over-so-hard-to-do/) - Suboptimal studies had established preoperative chemoradiation as the preferred strategy in the management of localised oesophageal cancer (LEC) and gastro-oesophageal cancer. The recent CROSS trial has now demonstrated considerable benefit from preoperative chemoradiation over surgery alone in patients with LEC. But are these results only reinforcing advocates of the preoperative chemoradiation strategy? This article was
- [Cetuximab dosing by rash ­– is the scaling of EVEREST meaningful?](https://archive.cancerworld.net/senza-categoria/cetuximab-dosing-by-rash-­–-is-the-scaling-of-everest-meaningful/) - The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab efficacy could be observed, data from the ongoing EVEREST II trial must be awaited before dose escalation can be considered for clinical use. This
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-16/) - Selected reports edited by Janet Fricker Glioblastoma: temozolomide offers alternative to radio-therapy in elderly patients => The Lancet Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options for elderly patients with glioblastoma, a phase III study from the Nordic Clinical Brain Tumour Study Group (NCBTSG) has found. In 2004 chemoradiotherapy with temozolomide
- [My World](https://archive.cancerworld.net/spotlight-on/my-world-2/) - Maria João Cardoso is head breast surgeon at the Champalimaud Cancer Centre in Lisbon. She founded the patient support centre Mama Help, and leads a research group at the Institute for Systems and Computer Engineering, in Porto, on improving outcomes in breast reconstruction. Why I chose to work in cancer Because it was and still
- [Time to act on trials](https://archive.cancerworld.net/editorial/time-to-act-on-trials/) - Many of the worst economic and bureaucratic burdens that have proved such a deterrent to multi-country clinical trials look set to be addressed with the overhaul of the EU Clinical Trials Directive, but should we sit back and wait for this to be done? Many of the worst economic and bureaucratic burdens that have proved
- [Vincenzo Valentini: putting knowledge to work](https://archive.cancerworld.net/cover-story/vincenzo-valentini-putting-knowledge-to-work/) - Patients are being let down by a failure to integrate the knowledge we have to get the best possible results for each individual patient and for cancer patients as a whole. Vincenzo Valentini, the ESTRO president with a talent for maths, believes we must do better. The paradigm of personalised medicine has ushered in a
- [The reoperation lottery](https://archive.cancerworld.net/cutting-edge/the-reoperation-lottery/) - The odds that a woman will be told she needs a reoperation after conservative breast surgery vary between treatment centres, prompting calls for international guidelines – and greater oversight of surgeons. For many women with early breast cancer, hearing that they can safely be treated with breast-conserving therapy comes as a big relief. What they
- [Stop Cancer Now!](https://archive.cancerworld.net/systems-services/stop-cancer-now/) - Cancer poses a rising threat to global health as well as the world economy. International experts have agreed on a strategy that can meet the challenge. They are now calling on world leaders to wake up to their responsibilities and act. It’s official. Non-communicable diseases now account for two out of every three deaths worldwide
- [Me and my cancer](https://archive.cancerworld.net/spotlight-on/me-and-my-cancer/) - Journalists who write about their own cancer journeys are able to convey important insights in a language that people understand – and are eager to read It is not surprising that a lot of journalists have written about their personal experiences of cancer: cancer is common; writers like writing about themselves; and they also know
- [Survivor services: supporting patients living with and beyond cancer](https://archive.cancerworld.net/e-grandround/survivor-services-supporting-patients-living-with-and-beyond-cancer/) - Helping patients make the best of their lives after treatment starts with thinking ahead before treatment and tailoring support for as long as it is needed. A leader in the field talks about key issues and a new European collaborative group. Who is a cancer survivor? The US National Cancer Institute suggests that an individual
- [Taking the isolation out of isolation](https://archive.cancerworld.net/spotlight-on/taking-the-isolation-out-of-isolation/) - The isolation that is essential to the physical health of people undergoing stem cell transplantation can be terrible for their mental health at a time of great stress. Patients are giving the thumbs up to a novel way of staying connected. Leukaemia patients who undergo stem cell transplants spend four to six weeks in an
- [Diabetes risk after radiation – not out of the woods](https://archive.cancerworld.net/impact-factor/diabetes-risk-after-radiation-–-not-out-of-the-woods/) - A retrospective cohort study has shown that pancreatic radiation is a risk factor for diabetes in survivors of paediatric cancer. This validates and refines prior epidemiological observations of diabetes after radiation to the abdomen and total-body irradiation, and will result inmodification of surveillance recommendations in national survivor guidelines. Survival of paediatric cancer has improved significantly
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-15/) - Selected reports edited by Janet Fricker Aprepitant for managing pruritus =>  Lancet Oncology Use of anaprepitant decreased the severity of pruritus induced by biological cancer treatments, an Italian pilot study reports. Pruritus (itch) is a common symptom amoung patients taking targeted drugs, especially those targeting the EGFR pathway. Treatment of pruritus is considered important
- [My World](https://archive.cancerworld.net/spotlight-on/my-world/) - Ramon Salazar is head of translational research at the Institut Català d'Oncologia near Barcelona. He leads the Early Clinical Research Unit and is in charge of the colorectal and neuroendocrine tumour clinics. He is a leading figure in national and European groups on GI cancers and NETs. Why I chose to work in cancer I
- [Struck by cancer, killed by ageism](https://archive.cancerworld.net/editorial/struck-by-cancer-killed-by-ageism/) - Care of elderly cancer patients has improved over recent years; however, younger patients in Europe still survive longer than more elderly patients, and the difference cannot be accounted for by the higher likelihood of dying from all causes as you get older. Care of elderly cancer patients has improved over recent years; however, younger patients
- [Richard Sullivan: Why are we doing this?](https://archive.cancerworld.net/cover-story/richard-sullivan-why-are-we-doing-this/) - Cancer policy is determined by opinions not evidence, with the loudest voice setting the agenda. This is the worry of Richard Sullivan, who is on a mission to open the discussion to voices beyond the “comfortable little world of oncology”, and allow new evidence and intelligence in. Richard Sullivan would like you to ask yourself
- [We hit the spot](https://archive.cancerworld.net/cutting-edge/we-hit-the-spot/) - Less invasive than surgery and less toxic than systemic therapy, will the fast-growing specialty of interventional radiology join the ‘big three' as the fourth pillar of cancer care? Looking at the specialists in the front-line of oncology, the ‘big three’ of surgeon, medical oncologist and radiotherapist are the dominant forces, and rightly so, as the
- [Centralising cancer services: is this the best way to improve results?](https://archive.cancerworld.net/spotlight-on/centralising-cancer-services-is-this-the-best-way-to-improve-results/) - Is the centralisation of cancer services justified? Could many cancers be treated more locally without compromising safety? Cancer World's Anna Wagstaff posed this question to two experts: Susan O'Reilly and Renée Otter. In an effort to improve outcomes, some countries are concentrating the care of cancer patients in a few designated centres, where they can
- [Tobacco tactics in the headlines](https://archive.cancerworld.net/spotlight-on/tobacco-tactics-in-the-headlines/) - At a time when the British media has been under the spotlight for its for poor ethical standards, The Independent's Big Tobacco Exposed series shows why good investigative journalism remains so important in opening powerful bodies up to public scrutiny. The day I spoke to Gerard Hastings, director of the Institute for Social Marketing, at
- [Skin toxicities caused by targeted therapies](https://archive.cancerworld.net/e-grandround/skin-toxicities-caused-by-targeted-therapies/) - Targeted drugs can result in a variety of skin toxicities that are unpleasant for patients and, if unattended to, can lead them to stop taking their drug as prescribed. Effective teamwork is required to ensure symptoms are identified and managed. The European School of Oncology presents weekly e-grandrounds which offer participants the chance to discuss
- [Is there an app for that?](https://archive.cancerworld.net/focus/is-there-an-app-for-that/) - Smartphones give patients the technology not only to record a consultation but also to share it privately, post it on a social network or even upload it to a public website. What does this mean for doctors and their relationship with patients? Smartphones are everywhere – the subway, coffee shop, and even my clinic. As
- [Aprepitant and control of emesis induced by five-day chemotherapy](https://archive.cancerworld.net/impact-factor/aprepitant-and-control-of-emesis-induced-by-five-day-chemotherapy/) - Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving five-day cisplatin-containing chemotherapy, a new trial shows. Some needs in antiemetic therapy remain unmet, including control of emesis with multiple-day chemotherapy and control of nausea. The past few decades have seen remarkable progress
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-4/) - Selected reports edited by Janet Fricker Leisure time physical activity is inversely associated with CRC mortality => Journal of Clinical Oncology For patients with colorectal cancer (CRC) leisure time physical activity (LTPA) both before and after diagnosis is inversely associated with all-cause mortality, an analysis of the National Institutes of Health (NIH) American Association of
- [My World - Jacob Scott](https://archive.cancerworld.net/spotlight-on/my-world-jacob-scott/) - My World Jacob Scott uses approaches from his previous life as a physicist and engineer to build models of cancer biology and evolution from first principles, in the hope of generating novel, translatable hypotheses. On leave from his post as a radiotherapist, he is a researcher at the H Lee Moffitt Cancer Center’s department of
- [Agnes Buzyn:protecting France's AAA rating for cancer care](https://archive.cancerworld.net/cover-story/agnes-buzynprotecting-frances-aaa-rating-for-cancer-care/) - France's relatively low profile on the European cancer stage belies a creative and innovative approach to research and care that other countries could learn from. Agnès Buzyn lifts the lid on how French cancer services continue to earn their ranking among the best in the world. On the first day of her job as president
- [Finding breakthrough treatments: how do we fix the broken model?](https://archive.cancerworld.net/spotlight-on/finding-breakthrough-treatments-how-do-we-fix-the-broken-model/) - Are dysfunctional relations between academia and industry hindering the process of turning progress in our understanding of cancer into truly effective treatments? The business model for developing new cancer drugs is broken and needs replacing with more efficient forms of public–private collaboration. This was a key message from the Stop Cancer Now! appeal made to
- [What counts as a ‘successful' outcome?](https://archive.cancerworld.net/patient-voice/what-counts-as-a-‘successful-outcome/) - Every patient wants to be cured. But a culture that defines success as ‘cure' condemns many patients and doctors to failure. What does treatment ‘success’ mean in cancer? Does it only mean curing the cancer? Or controlling it? Extending life? Or providing a good quality of life, even for a short time? How we define
- [When in doubt, ask an expert](https://archive.cancerworld.net/systems-services/when-in-doubt-ask-an-expert/) - No pathologist can be an expert in every type of cancer. But there is a lot that can be done to greatly improve the accuracy of diagnoses, particularly in rare cancers, as a recent European survey has shown. The best quality treatment based on clinical guidelines carefully adapted to the individual patient can be worthless
- [Chronic and late effects: how physical activity can help](https://archive.cancerworld.net/e-grandround/chronic-and-late-effects-how-physical-activity-can-help/) - An exercise programme can improve patients' physical ability to function, lift their mood and may even lower their chance of recurrence. Four million people will be living with a diagnosis of cancer in the UK alone by 2030 (www.macmillan.org.uk). This is equivalent to more than 7 out of every 100 members of the adult population
- [Once upon a loss](https://archive.cancerworld.net/focus/once-upon-a-loss/) - Do you ever let the death of a patient get to you? In this Focus piece, one cancer surgeon talks about his own experience and argues that shutting down your emotional responses is neither feasible nor desirable. This article was first published in The Oncologist vol. 18 no.2, and is republished with permission. © 2013
- [Investment biobanking – increased returns from tissue samples](https://archive.cancerworld.net/impact-factor/investment-biobanking-–-increased-returns-from-tissue-samples/) - Researchers now expect that samples obtained from biobanks are accompanied with well-annotated clinical data. Opened in 2010, the Breast Cancer Campaign Tissue Bank takes this criterion a step further: researchers obtaining tissues are required to return the data they generate from every sample back to the Tissue Bank. This article was first published in Nature
- [London (UK), 24/3/2017 - 4th ESO Prostate Cancer Observatory: innovation and care in the next 12 months](https://archive.cancerworld.net/past-events/london-uk-24032017-4th-eso-prostate-cancer-observatory-innovation-and-care-in-the-next-12-months/) - The European School of Oncology is pleased to announce the 4th edition of "ESO Prostate Cancer Observatory: innovation and care in the next 12 months", which will be held during the EAU17 Congress on March 24 in London, chaired by Prof. H. van Poppel and Prof. R. Valdagni. AIMS AND OBJECTIVES ESO Observatories are high
- [Nauen OT Groß Behnitz (Berlin area, Germany) 25-30/3/2017 - 16th ESO-ESMO Masterclass in Clinical Oncology](https://archive.cancerworld.net/past-events/nauen-ot-gros-behnitz-berlin-area-germany-25-30032017-16th-eso-esmo-masterclass-in-clinical-oncology/) - This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, colorectal, lung, genito-urinary,
- [Njimegen (The Netherlands), 3-6/3/2017 – Masterclass in Endoscopy in Gastrointestinal Oncology](https://archive.cancerworld.net/past-events/njimegen-the-netherlands-3-632017-masterclass-in-endoscopy-in-gastrointestinal-oncology/) - The aim of this Masterclass is to provide an update of the role of endoscopy in the diagnosis and treatment of gastrointestinal neoplasia. The Masterclass is specifically addressed to junior specialists and each topic will be analysed in a systematic and propaedeutic way, from basic to the most complex and difficult procedures. The Masterclass will
- [Cambridge (United Kingdom) 21-23/6/2017 - Masterclass in Oncology Basics for Beginners](https://archive.cancerworld.net/past-events/cambridge-united-kingdom-21-23062017-masterclass-in-oncology-basics-for-beginners/) - Although some of the principles underlying oncology practice are similar to those in other branches of medicine, subspecialisation has reduced the exposure of medical students and junior residents to oncological concepts and practice. New oncology trainees face a number of specific challenges. These include navigation of an extensive curriculum with no clear starting point, a
- [My World - Fedro Alessandro Peccatori](https://archive.cancerworld.net/spotlight-on/my-world-fedro-alessandro-peccatori/) - Fedro Alessandro Peccatori is director of the Fertility and Reproduction Unit at the European Institute of Oncology in Milan. He specialises in breast and gynaecological cancers and tumours of young adults, and has particular responsibility for the care of women who have cancer while pregnant, and patients with fertility problems after a cancer diagnosis. Why
- [The right place for the right patient... at the right cost](https://archive.cancerworld.net/editorial/the-right-place-for-the-right-patient-at-the-right-cost/) - Urology surgeon Nicola Nicolai proposes key criteria for sustainable services that provide each patient with access to the level of specialist services that they need. Debates about the benefits and drawbacks of centralising the planning and delivery of cancer services in a few large referral centres, such as featured in the March–April issue of Cancer
- [Semir Beslija: the sky's the limit in Sarajevo](https://archive.cancerworld.net/cover-story/semir-beslija-the-skys-the-limit-in-sarajevo/) - Semir Beslija's tenacious efforts have built the Sarajevo Oncology Institute from ‘zero' at the end of the war, to the regional centre of excellence and trusted trials centre it is today. The taxi driver who is weaving through the Sarajevo rush-hour traffic speaks good English. He wants to know why an Englishman like me wants
- [Exploiting a nano-sized breach in cancer's defences](https://archive.cancerworld.net/cutting-edge/exploiting-a-nano-sized-breach-in-cancers-defences/) - It's long been the stuff of science fiction, but could the prospect of nanotechnology systems that deliver ‘atomic bombs' direct to cancer cells soon become reality? It’s a compelling vision: tiny particles, primed with a highly effective cancer killing drug, able to move round the body and seek out and destroy tumour cells, only releasing
- [Stigma: breaking the vicious cycle](https://archive.cancerworld.net/patient-voice/stigma-breaking-the-vicious-cycle/) - Stigma breeds silence, which fuels the fear and ignorance that feeds the stigma. Breaking this vicious circle not only makes life easier for people with cancer, but can also change public attitudes towards prevention and early detection. I learned that a person with cancer is a person and must be helped.” This statement is one
- [Personalised cancer care: where do we stand today?](https://archive.cancerworld.net/e-grandround/personalised-cancer-care-where-do-we-stand-today/) - Since the concept of personalised cancer therapies first emerged, the picture has become so much more complex and challenging. “If it were not for the great variability between individuals, medicine might as well be a science, not an art.” Sir William Osler (1892) The whole concept of personalised medicine is not really new. We’ve been
- [The biology of breast cancer in young women is unique - a debate](https://archive.cancerworld.net/focus/the-biology-of-breast-cancer-in-young-women-is-unique-a-debate/) - This Focus article presents a debate between two experts to try to understand more about why younger women with breast cancer tend to have a poorer prognosis than their older counterparts. Breast cancer in young women frequently presents with an aggressive phenotype, leading to a poorer prognosis than in older women. The critical issue centres
- [Post-traumatic stress disorder - prevalent and persistent](https://archive.cancerworld.net/impact-factor/post-traumatic-stress-disorder-prevalent-and-persistent/) - Post-traumatic stress disorder (PTSD) is prevalent in patients with breast cancer, and African American, Asian and younger women are disproportionally affected. PTSD is associated with adverse effects on psychological and physical health and might be an indicator of other risk factors. It is important to screen and treat for PTSD, and more research is needed.
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-14/) - Selected reports edited by Janet Fricker ABVD less effective and more toxic in older patients =>Journal of Clinical Oncology In patients aged 60 years or older with Hodgkin lymphoma (HL), four cycles of ABVD is associated with substantial toxicity, resulting in grade 3−4 toxicities in more than two-thirds of them, a German study has found.
- [My World - Mariagrazia De Lisa](https://archive.cancerworld.net/spotlight-on/my-world-mariagrazia-de-lisa/) - Mariagrazia De Lisa is a second-year resident at the medical oncology department of the university hospital Ospedali Riuniti delle Marche, in Ancona, Italy. She came top out of 63 other students from 25 countries in the learning assessment test at the end of this year's ESO Masterclass in Clinical Oncology. Why I chose to work
- [Supporting patients in distress](https://archive.cancerworld.net/editorial/supporting-patients-in-distress/) - The emotional and psychological impact of being diagnosed and treated for cancer can be at least as severe as the toll the disease and treatment takes on a patient's physical health. Distress – the range of unpleasant emotions associated with a cancer experience – is common in patients and their loved ones. With appropriate support
- [Jim Watson: DNA revealed the causes, it may never reveal a cure](https://archive.cancerworld.net/cover-story/jim-watson-dna-revealed-the-causes-it-may-never-reveal-a-cure/) - Nobel laureate Jim Watson is calling on the cancer community to take a long hard look at what has been achieved by blocking the molecular signals that drive individual cancers Sixty years after Jim Watson and Francis Crick famously resolved the double helix structure of DNA, which opened the door to understanding the nature of
- [A calculated choice](https://archive.cancerworld.net/cutting-edge/a-calculated-choice/) - Computers are better than doctors at processing the large amounts of information involved in personalising treatments. But which decision-making tools can be relied on, and how can they best be used to help inform shared clinical decision making? The computer will see you now.’ This was a recent headline on a British newspaper story about
- [Easing the cancer journey](https://archive.cancerworld.net/patient-voice/easing-the-cancer-journey/) - Having to travel long distances or stay away from home while being treated for cancer takes its toll in anxiety, stress and isolation. Could more be done to ensure policies that centralise services don’t make some patients’ lives unbearable? Since his diagnosis in 2009, Dearn McClintock has been undergoing tests and treatment for prostate cancer
- [Radiotherapy capacity across Europe: What it should be, and what it is](https://archive.cancerworld.net/spotlight-on/radiotherapy-capacity-across-europe-what-it-should-be-and-what-it-is/) - Winning the argument for expanding and upgrading radiotherapy facilities is not easy in the present economic climate. How many radiotherapy mach-ines are there in each country in Europe? It might seem an easy question to answer given that it is hard to overlook a large radiotherapy suite complete with several linear accelerators (linacs), and ancillary
- [New paradigms to explain metastasis](https://archive.cancerworld.net/e-grandround/new-paradigms-to-explain-metastasis/) - Understanding what drives cancer cells to break loose, travel around the body and seed new tumours – and how to inhibit this process – will be key to developing effective new therapies Metastasis – the spread of cancer cells to distant organs – is one of the conditions that I primarily take care of as
- [Refusing treatment](https://archive.cancerworld.net/focus/refusing-treatment/) - People take treatment decisions on the basis of their personal perspectives as much as the medical pros and cons. Doctors need to be able to deal with this. This article was first published in The Oncologist vol. 18 no.5, and is republished with permission. © 2013 AlphaMed Press. doi:10.1634/theoncologist.2012-0436 In the late 1990s, I was
- [Secobarbital in Seattle - why lose sleep?](https://archive.cancerworld.net/impact-factor/secobarbital-in-seattle-why-lose-sleep/) - The Seattle Cancer Care Alliance has added physician-assisted suicide to its host of services for patients within the final six months of life. According to a recent report published in the New England Journal of Medicine, the programme has been well received by patients and clinicians alike. So, why lose sleep? This article was first
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-13/) - Selected reports edited by Janet Fricker Study evaluates specificity and sensitivity of lung cancer screening =>New England Journal of Medicine The latest data to be published from the US National Lung Screening Trial (NLST) documents exact differences between screening with low-dose computed tomography (LDCT) and chest X-ray (CXR), providing the first thorough evaluation of risks
- [My World - Clodagh McHugh](https://archive.cancerworld.net/senza-categoria/my-world-clodagh-mchugh/) - Clodagh McHugh works as an oncology nurse specialist with patients at every stage of their disease and with all types of cancer. Based at a leading teaching hospital in Dublin, she lectures on oncology nursing and is involved in drawing up safety guidelines relating to oral chemotherapy. She scored the top mark in the learning
- [We need to get serious about management](https://archive.cancerworld.net/editorial/we-need-to-get-serious-about-management/) - Clinicians are being increasingly called on to assume hospital management roles. This Editorial looks at an initiative designed to address this need and asks whether professional societies need to introduce management skills into their CME programmes. Management practices within hospitals play an important role in determining the quality of care. A strong relationship has been
- [David Cameron: What do we really know about the quality of care we provide?](https://archive.cancerworld.net/cover-story/david-cameron-what-do-we-really-know-about-the-quality-of-care-we-provide/) - We won’t improve cancer care until we know more about how well we are doing and how alternative approaches compare. It sounds obvious, but it’s not happening, says “the real” David Cameron Something in the cancer world doesn’t add up. The influential medical oncologist who voices the sentiment is a mathematician by background, so he
- [A coordinated approach to multidisciplinary guidelines](https://archive.cancerworld.net/systems-services/a-coordinated-approach-to-multidisciplinary-guidelines/) - Oncologists put their faith in evidence-based guidelines. But when the treatment is multidisciplinary, who decides on the evidence and how? ECCO’s new Guidelines Forum has come up with a plan. Clinicians in most medical specialities do not lack guidelines for their day-to-day treatment of patients, and oncologists certainly have many to choose from at both
- [Navigating uncharted waters: a guide to shared decision making](https://archive.cancerworld.net/patient-voice/navigating-uncharted-waters-a-guide-to-shared-decision-making/) - The principle of involving patients in decisions about their own care is no longer very controversial. The question is how you put that into practice when every option carries a level of uncertainty, patients may be feeling overwhelmed and none of the options may match their hopes or expectations. Nothing about us without us’ has
- [Going public on DCIS](https://archive.cancerworld.net/spotlight-on/going-public-on-dcis/) - Ending the overtreatment of women with DCIS will require enough women to have the courage and insight to demand something better. Tiffany O’Callaghan won a Best Cancer Reporter Award for opening up the debate with her article in the New Scientist, which is republished here. The lump in her right breast was smaller than a
- [Managing the sexual consequences of cancer and its treatment](https://archive.cancerworld.net/e-grandround/managing-the-sexual-consequences-of-cancer-and-its-treatment/) - The impact cancer and cancer treatment can have on a person’s sex life can cause physical, emotional and relationship difficulties. This overview describes the many problems that can be triggered, and a step-wise approach to addressing them, with a special focus on step one: asking patients about their sexual concerns. Sexual difficulties can affect everyone
- [Head and neck cancers are coming out of the closet](https://archive.cancerworld.net/spotlight-on/head-and-neck-cancers-are-coming-out-of-the-closet/) - If detected early, 80/90% of head and neck cancers can be cured. Yet lack of awareness means that two out of three cases are picked up late. The Make Sense campaign takes a message of hope to the streets and subway stations and to the media and politicians. Advocacy and awareness campaigns have transformed public
- [Practising in partnership with Dr Google](https://archive.cancerworld.net/focus/practising-in-partnership-with-dr-google/) - Online communities can help patients learn about and weigh up the options open to them. Where enough patients are involved, they are also helping to shape those options, opening up new opportunities for accelerating research and improving care. This article was first published in The Oncologist vol. 18 no.7, and is republished with permission. ©
- [Biorepositories for cancer research in developing countries](https://archive.cancerworld.net/impact-factor/biorepositories-for-cancer-research-in-developing-countries/) - Well-documented biorepositories are essential for cancer research. Currently, major biobanks are located in the developed world, which represents the minority global population; however, countries with low-resource settings contribute more than 50% of the global cancer burden. Therefore, there is an urgent need to establish next generation biorepositories in developing countries. This article was first published
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-12/) - Selected reports edited by Janet Fricker Cancer survivors less likely to be treated for infertility => Lancet Oncology Although women who survive childhood cancer face increased risks of infertility, nearly two-thirds who had tried unsuccessfully for at least one year to become pregnant eventually conceived, the latest findings from the Childhood Cancer Survivors Study (CCSS)
- [My World - Adel Araf](https://archive.cancerworld.net/spotlight-on/my-world-adel-araf/) - Adel Araf is a clinical oncologist who trained in Ain Shams University, Cairo, and is now working as a specialist medical oncologist in Dubai Hospital, in the UAE. He leads a group of young oncologists from the region who are working to drive up standards of cancer care throughout the Middle East and North Africa.
- ['Why me?' Helping patients find answers](https://archive.cancerworld.net/editorial/why-me-helping-patients-find-answers/) - People with cancer have time to think. Not every patient will think about spiritual matters, but most of us probably do, either alone, or when talking with close family or friends. People with cancer have time to think. Not every patient will think about spiritual matters, but most of us probably do, either alone, or
- [Roger Stupp: What's so ethical about strangling research?](https://archive.cancerworld.net/cover-story/roger-stupp-whats-so-ethical-about-strangling-research/) - Patients are losing out because the rules governing research are designed to restrain rather than facilitate. It’s got to change, says Roger Stupp, who is frustrated that 10 years after helping set a new standard of care for glioblastoma, patients are still waiting for something better. Until ten years ago, the average life expectancy for
- [Approval rating: how do the EMA and FDA compare?](https://archive.cancerworld.net/cutting-edge/approval-rating-how-do-the-ema-and-fda-compare/) - When new cancer therapies regularly become available more than half a year earlier in the US than in Europe, or get regulatory approval on one side of the Atlantic but not on the other, patients and clinicians want to know why. Few issues in healthcare are as emotive as access to new cancer drugs, as
- [Five steps to putting innovation at the heart of cancer care](https://archive.cancerworld.net/systems-services/five-steps-to-putting-innovation-at-the-heart-of-cancer-care/) - With health budgets flat-lining and demand for healthcare rising, the only way Europe can improve patient outcomes is by finding new ways to do things better. But who will champion innovation in cancer care and how? The European School of Oncology convened a Task Force to come up with some solutions. If reimbursement authorities in
- [Imaging in oncology - over a century of advances](https://archive.cancerworld.net/e-grandround/imaging-in-oncology-over-a-century-of-advances/) - Imaging techniques used in staging and evaluation of response to treatment have improved dramatically over the past 120 years. The issue going forward will be learning to combine anatomical and functional imaging modalities to get a picture that is as close to the truth as possible. This e-grandround charts the evolution of pioneering imaging techniques.
- [Complementary or alternative medicine in cancer care - myths and realities](https://archive.cancerworld.net/focus/complementary-or-alternative-medicine-in-cancer-care-myths-and-realities/) - Two practitioners of integrative oncology make the case for using non-traditional therapies alongside mainstream care – and for abandoning the term “complementary and alternative medicine” as unhelpful and misleading – in this comprehensive article, which first appeared in Nature Reviews Clinical Oncology. Imagine this scene: the oncologist concludes an outline of an adjuvant treatment plan
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-11/) - Selected reports edited by Janet Fricker Clinical trials lead to cost savings => British Journal of Cancer On average, non-commercial oncology clinical trials are associated with small excess treatment costs compared to the standard of care, while commercial trials are associated with high cost savings, concludes a UK study conducted in a single centre. Recruitment
- [My World - Bettina Ryll](https://archive.cancerworld.net/spotlight-on/my-world-bettina-ryll/) - Bettina Ryll is a patient advocate and founding member of the Independent Melanoma Community Advisory Board. A qualified doctor, with a PhD in molecular biology, she gained a deeper insight into the reality of cancer, and fighting cancer, when her husband Peter was diagnosed with advanced melanoma. She now uses that insight to help others
- [Spending cuts could jeopardise survival gains](https://archive.cancerworld.net/editorial/spending-cuts-could-jeopardise-survival-gains/) - EUROCARE-5 delivered the good news that survival rates have been increasing across Europe. In this editorial we ask: how much of this improvement is the result of the widespread increase in per capita health spending seen over the period 1999 to 2007 covered by EUROCARE-5? The largest study of cancer survival in Europe – EUROCARE
- [Jean-Charles Soria: Beyond the science](https://archive.cancerworld.net/cover-story/jean-charles-soria-beyond-the-science/) - Phase I trials now play an essential role in treating patients with metastatic cancer, offering vital “extra moves” in the battle to outplay the disease, says Jean-Charles Soria. He warns, however, that not every patient wants to play every move, at any cost. Getting that bit right is where the real challenge lies In 2002,
- [Mothers coping with cancer](https://archive.cancerworld.net/spotlight-on/mothers-coping-with-cancer/) - Better understanding of the impact that treating pregnant women for cancer has on their unborn child means women in this position have more options open to them, as Ainhoa Iriberri explains in this article, which was first published in SALUDRevista – a leading Spanish health magazine – and won her a Best Cancer Reporter runner-up
- [Are tumour boards defunct?](https://archive.cancerworld.net/spotlight-on/are-tumour-boards-defunct/) - The complexity of cancer, the risks and benefits associated with alternative treatment options, the care needs of patients, all point to the need for input from specialists in many disciplines. But are regular face-to-face multidisciplinary team meetings the best way to achieve this? The advantages of a multidiscipli¬nary approach to managing cancer patients are no
- [Thombosis and cancer](https://archive.cancerworld.net/e-grandround/thombosis-and-cancer/) - Thrombosis is the second most common preventable cause of death in patients with cancer, so oncologists need to know how to identify who is at risk, and strategies for prevention and treatment. This overview presents the evidence and raises alerts about the use of oral anticoagulants in the cancer setting. The bidirectional relationship between cancer
- [Living with cancer: advocates define their priorities for advanced disease](https://archive.cancerworld.net/patient-voice/living-with-cancer-advocates-define-their-priorities-for-advanced-disease/) - The ABC conference on advanced breast cancer gives centre stage to a group of patients who feel they’ve been marginalised and their needs ignored for too long. People who have been treated for early-stage breast cancer have many issues to handle, not least the fear of a recurrence. However, the advocacy and support movement for
- [Let us convince you! Enticing medical students into oncology](https://archive.cancerworld.net/spotlight-on/let-us-convince-you-enticing-medical-students-into-oncology/) - Every summer a group of top oncologists gather in the ancient city of Ioannina to give a select group of motivated medical students a taste of what it’s like to work in cancer. The number of people who develop cancers in greater Europe is expected to grow to 3.4 million a year by 2020, a
- [Passport to the future: Improving life for survivors of childhood cancer](https://archive.cancerworld.net/spotlight-on/passport-to-the-future-improving-life-for-survivors-of-childhood-cancer/) - By the time they reach 40, survivors of childhood cancers are likely to have at least one chronic health problem resulting from their treatment. The search is now on for ways to help people manage their risk and get appropriate care. Childhood cancer may be rare, but survivors are not. One of the big success
- [Addressing cancer disparities in Europe](https://archive.cancerworld.net/focus/addressing-cancer-disparities-in-europe/) - As we learn more about what lies behind the differences in cancer outcomes across Europe, the question becomes: how do we end them? This article was first published in The Oncologist vol.18 no.12, and is republished with permission. © 2013 AlphaMed Press. doi:10.1634/theoncologist.2013-0438 Are We Winning the War on Cancer?” was the rather provocative title
- [CT screening for lung cancer – do we have an answer?](https://archive.cancerworld.net/impact-factor/ct-screening-for-lung-cancer-–-do-we-have-an-answer/) - Concerns still exist regarding the best use of low-dose CT screening for lung cancer and how to select high-risk individuals who will benefit most from participation in screening programmes. Two studies now indicate factors that may reduce the false-positive rate of lung cancer screening with low-dose CT. This article was first published in Nature Reviews
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-10/) - Selected reports edited by Janet Fricker Study defines optimum exercise level in breast cancer =>JNCI Undertaking higher volumes of aerobic exercise or combining aerobic exercise with resistance exercise improves physical functioning and symptoms for breast cancer patients more than standard volumes of exercise, the Canadian CARE trial has found. For patients undergoing chemotherapy, aerobic and
- [Cancer control is (still) a vote winner](https://archive.cancerworld.net/editorial/cancer-control-is-still-a-vote-winner/) - The Comprehensive Cancer Control Joint Action (CANCON) will pick up where the recently ended European Partnership for Action Against Cancer (EPAAC) left off. It will cover many of the same areas, but with a greater focus on integrating cancer services at a regional level and on the role of primary and community care – areas
- [Enriqueta Felip: breaking boundaries in lung cancer](https://archive.cancerworld.net/cover-story/enriqueta-felip-breaking-boundaries-in-lung-cancer/) - Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta Felip’s career. Her focus today is on increasing collaboration across Europe, which she sees as key if patients are to benefit quickly from the new opportunities offered by personalised therapies. It’s a clear and
- [Protecting patients' nervous systems: Are we getting the care-cure balance right?](https://archive.cancerworld.net/cutting-edge/protecting-patients-nervous-systems-are-we-getting-the-care-cure-balance-right/) - The debilitating impact neurotoxic drugs can have on patients’ long-term quality of life has been systematically underestimated. Can oncologists do more to pick up potential symptoms before they become irreversible? Cancer patients about to start chemotherapy are often faced with a long list of possible side-effects, depending on the type of cancer and the drug
- [The patient touts](https://archive.cancerworld.net/spotlight-on/the-patient-touts/) - Christiane Hawranek and Marco Maurer, freelance print and radio journalists, won a Best Cancer Reporter Award for their exposé of the agencies that exploit foreign patients seeking treatment for cancer and other serious conditions. They published this piece in Die Zeit, and the story was also broadcast on radio by Bayerischer Rundfunk. Ruslana Fadiwa is
- [Living with cancer or dying of cancer?](https://archive.cancerworld.net/systems-services/living-with-cancer-or-dying-of-cancer/) - People do better throughout their cancer journey when their physical, psychological and spiritual care needs are attended to. But how do we overcome entrenched mind sets that still resist integrating palliative and oncologic care? Philip Larkin, associate professor in clinical nursing at University College, Dublin, began working as a palliative care specialist 25 years ago
- [What did we learn from the European Partnership for Action Against Cancer?](https://archive.cancerworld.net/spotlight-on/what-did-we-learn-from-the-european-partnership-for-action-against-cancer/) - The recently concluded Partnership programme marked the first time that EU member states have taken a joint approach to improving cancer plans and the organisation of services. Was it a worthwhile exercise? And where do we go from here? Can countries improve the way they organise and deliver cancer care by working together at a
- [Top trials group turns its attention to survivors](https://archive.cancerworld.net/patient-voice/top-trials-group-turns-its-attention-to-survivors/) - EORTC boosts efforts to address the long-term problems faced by people who have been treated for cancer. The number of people who are living long lives after cancer treatment has been rising year on year, leading to a quadrupling of this population between 1975 and 2005, with an estimated 35 million survivors now living in
- [How Europe can develop better, cheaper cancer drugs](https://archive.cancerworld.net/e-grandround/how-europe-can-develop-better-cheaper-cancer-drugs/) - Modern tools of biological investigation give us opportunities to develop drugs much more efficiently. The president of Europe’s most important trials organisation explains how these opportunities can – and must – be exploited to start delivering drugs that are more effective and more affordable. The road to developing a new medicine – translating a new
- [Smart therapeutic strategies in immuno-oncology](https://archive.cancerworld.net/impact-factor/smart-therapeutic-strategies-in-immuno-oncology/) - For cancer therapies to succeed, induction of an anticancer immune response is required. Immuno-oncology approaches are shaping the treatment landscape for patients with advanced-stage melanoma and other solid tumours. These new approaches may enhance immune system activity to improve outcomes, including the potential to achieve long-term survival benefits in many patients This article was first
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-9/) - Selected reports edited by Janet Fricker Optimal time for initiation of adjuvant chemotherapy according to subtype => Journal of Clinical Oncology Time delays in initiation of adjuvant chemotherapy have an adverse effect on outcomes for breast cancer patients with stage II and III disease, triple-negative tumours and HER2-positive tumours treated with trastuzumab, a single-institution retrospective
- [Stories that give witness, stories that save lives: the special role of health reporters in Africa](https://archive.cancerworld.net/spotlight-on/stories-that-give-witness-stories-that-save-lives-the-special-role-of-health-reporters-in-africa/) - How can journalists help raise the profile of cancer and get it on the political agenda in countries where infectious diseases get most attention, reliable data are scarce, doctors are reluctant to talk and editors prefer cheery topics? Two award-winning reporters speak of the challenges they face In April, Cancer Research UK reported that half
- [Change must come from within](https://archive.cancerworld.net/editorial/change-must-come-from-within/) - Is progress against cancer is being stifled because young researchers are obliged to spend their best years competing for grants within a system biased against innovation? Half a century ago, a man named Denis Burkitt gave us an extraordinary model for global collaboration in cancer research. A one-eyed surgeon, working out of a bare-bones hospital
- [Marcel Verheij: Revolutionising radiotherapy](https://archive.cancerworld.net/cover-story/marcel-verheij-revolutionising-radiotherapy/) - Could intelligent combinations of drugs and radiation take precision radiotherapy to new levels? Marcel Verheij believes so, but may struggle to prove it without a fairer share of funding In the mid-80s, radiotherapy looked doomed. Chemotherapy was in the ascendant, targeted therapies were starting to appear, and in the face of new innovation radiotherapy seemed
- [Keeping one step ahead: Could trials do more for patients with incurable cancer?](https://archive.cancerworld.net/cutting-edge/keeping-one-step-ahead-could-trials-do-more-for-patients-with-incurable-cancer/) - Joining a clinical trial can be a lifeline for patients with few options open to them. But are outdated attitudes and practices preventing them from benefiting as much as they could? The transformation in the nature of cancer trials over the past 20 years has been well documented. Gone are the days when phase I
- [Survivors demand a fair deal from financial services](https://archive.cancerworld.net/patient-voice/survivors-demand-a-fair-deal-from-financial-services/) - Companies should no longer be allowed to deny mortgage or insurance services to cancer survivors without explanation or a transparent risk assessment, say patient advocates. A few hopeful signs show their message may be getting across. It was in November 2010 that Nicky, a young government worker in Belgium, was diagnosed with lymphoma. It was
- [Putting precision pathology on the policy agenda](https://archive.cancerworld.net/systems-services/putting-precision-pathology-on-the-policy-agenda/) - Will pathology services need a serious overhaul if they are to deliver the accuracy required for precision medicine? Two European initiatives are trying to build the case for change in this least visible of cancer disciplines. The shift towards personalised medicine has placed a new premium on detailed and accurate pathology reports to inform treatment
- [All the benefits of expert nursing care](https://archive.cancerworld.net/spotlight-on/all-the-benefits-of-expert-nursing-care/) - When key figures in European cancer nursing gathered at the Royal Marsden to mark 30 years of EONS, they found they had a lot to celebrate – and a lot more work to do. All people affected by cancer across Europe will benefit from the care of well-educated, well-informed and highly competent cancer nurses, who
- [Nutritional support for cancer patients](https://archive.cancerworld.net/e-grandround/nutritional-support-for-cancer-patients/) - Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition. Malnutrition, which is easily identified during clinical examination by weight loss and hypophagia, is an independent negative prognostic factor for cancer patients.
- [To treat or not to treat: who should decide?](https://archive.cancerworld.net/focus/to-treat-or-not-to-treat-who-should-decide/) - Shared decision making is ethically sound and the evidence shows it leads to better outcomes. But if a patient is determined that they want no part in the decision, is it paternalistic to insist? This article was first published in The Oncologist vol.19 no.4, and is republished with permission. ©2014 Alpha Med Press doi:10.1634/theoncologist.2013-0258 Mr
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-8/) - Selected reports edited by Janet Fricker Health risks continue into middle age for childhood cancer survivors => Journal of Clinical Oncology Elevated risks for morbidity and mortality among survivors of childhood cancers increase beyond the fourth decade of life. An analysis of the retrospective Childhood Cancer Survivor Study (CCSS) shows survivors of childhood cancers aged
- [Tackling rare cancers through more unified research and care all around Europe](https://archive.cancerworld.net/news/tackling-rare-cancers-through-more-unified-research-and-care-all-around-europe/) - Rare cancers were among the topics discussed last month at the 3rd conference on European Reference Networks held in Vilnius, in Lithuania, where Dr Paolo Casali, from the Milan's Istituto Nazionale dei Tumori illustrated the goals of the Joint Action on Rare Cancers (JARC), that was launched to integrate and maximize efforts of the European Union (EU) Commission, EU Member
- [Cancer prevention, bad luck and bad wording](https://archive.cancerworld.net/news/cancer-prevention-bad-luck-and-bad-wording/) - Cancer, genetics, “bad luck” and prevention through lifestyle: two years after their first study that tried to quantify the random mutations that accumulate during stem cell divisions in healthy cells and drive cancer in different tissues, cancer geneticist Bert Vogelstein and mathematician Cristian Tomasetti, from the Johns Hopkins University in Baltimore, Maryland, published a new
- [If you want better drugs consult a PRO](https://archive.cancerworld.net/editorial/if-you-want-better-drugs-consult-a-pro/) - Our systems for evaluating new therapies are only as good as the accuracy of the judgements we make about how far patients benefit and how far they feel the burden of side-effects and other drawbacks. In this Editorial we welcome moves on both sides of the Atlantic to include patients’ own assessments into evaluation procedures,
- [Shelley Dolan: walking alongside patients](https://archive.cancerworld.net/cover-story/shelley-dolan-walking-alongside-patients/) - Nurses are not the only ones who care and can nurture, support and explain things to patients who are scared and vulnerable, says pioneering cancer nurse Shelley Dolan. But they are the only health professionals to have this as their key role, and she is calling for Europe to do everything possible to empower them.
- [Deconstructing evolution: can number crunchers find the answer to resistance?](https://archive.cancerworld.net/cutting-edge/deconstructing-evolution-can-number-crunchers-find-the-answer-to-resistance/) - Is there a logic, a pattern, a system behind the way cancer cells adapt to develop resistance to agents designed to kill them? Cancer research is calling on systems biologists to see if they can make sense of it all. Imagine you are building a house from bricks. You can see how one brick works
- [Cancer and inequality: bringing the message home](https://archive.cancerworld.net/spotlight-on/cancer-and-inequality-bringing-the-message-home/) - Why do fewer people die of cancer in my neighbourhood than on the other side of town? Steve Buist of the Hamilton Spectator asked this question of his home city in southern Ontario, and used a variety of local data and sources to find answers. The story he told, using interactive maps and personal stories,
- [A seat at the table: patient advocates prepare for life on the inside](https://archive.cancerworld.net/patient-voice/a-seat-at-the-table-patient-advocates-prepare-for-life-on-the-inside/) - Little by little, patient advocates are winning their battle to be involved in decisions that affect them. They are now focusing on how to use their new-found voice to deliver real change for the people they represent. The days when patient groups were all about tea and sympathy are long gone. Over the past 20
- [Learning the art of leadership](https://archive.cancerworld.net/spotlight-on/learning-the-art-of-leadership/) - A course teaching leadership skills to cancer clinicians is proving a hit among the growing number of oncologists now finding themselves being asked to take on management roles. According to a 2012 report from Leeds University Business School – ‘Clinicians in Management: Does it Make a Difference?’ – increasing the number of doctors on NHS
- [Accreditation of breast centres: why and how](https://archive.cancerworld.net/e-grandround/accreditation-of-breast-centres-why-and-how/) - The European Commission is developing a Europe-wide accreditation scheme for breast centres to push up standards of diagnosis and care. Here experts from both sides of the Atlantic take a look at existing schemes, the criteria they use and the challenges in applying them across diverse populations. Cary Kaufman: In the US we were prompted
- [The letter to which I couldn't reply](https://archive.cancerworld.net/senza-categoria/the-letter-to-which-i-couldnt-reply/) - With all the investigations, imaging and testing involved in personalising treatments, it can be hard to remember to listen to what the patient is saying. One doctor keeps a letter with him as a permanent reminder. This article was first published in The Oncologist vol.19 no.5, and is republished with permission. ©2014 Alpha Med Press
- [Dropping bars or rising hoops – phase III outcomes of NSCLC](https://archive.cancerworld.net/impact-factor/dropping-bars-or-rising-hoops-–-phase-iii-outcomes-of-nsclc/) - Over the past three decades, the interpretation of clinical trial outcomes in studies of advanced-stage non-small-cell lung cancer has changed. The robustness of findings from these trials has been called into question. We believe this change is a reflection of the improved understanding of molecular-based therapeutics and continued advances in this field. This article was
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-7/) - Selected reports edited by Janet Fricker New treatment option for premenopausal women with hormone-sensitive breast cancer =>New England Journal of Medicine In premenopausal women with hormone-receptor-positive early breast cancer the aromatase inhibitor exemestane plus ovarian suppression is more effective at preventing recurrence than tamoxifen plus ovarian suppression, a combined analysis of the TEXT and SOFT
- [Action for access](https://archive.cancerworld.net/editorial/action-for-access/) - More and more people across Europe are finding it hard to access high-quality cancer care in the wake of years of public spending cuts. This Editorial looks at some initiatives to address growing inequalities and argues that everyone involved in planning and providing treatment and care has a key role and responsibility . The EU
- [Christopher Wild: Let's be practical](https://archive.cancerworld.net/cover-story/christopher-wild-lets-be-practical/) - Understanding how cancer wreaks its havoc on the human body is important for the head of the International Agency for Research on Cancer, but his main concern is how to stop it. In the 30 years he has worked in research, Christopher Wild has been asked many times whether there will ever be a cure
- [Biology in the bunker](https://archive.cancerworld.net/cutting-edge/biology-in-the-bunker/) - Advances in imaging and molecular biology are opening up a wealth of new avenues for research and treatment in radiotherapy. But could progress be held back by a lack of public awareness of the potential for innovation? About half of people diagnosed with cancer in developed countries are likely to receive radiotherapy as part of
- [Inside India's cancer epidemic](https://archive.cancerworld.net/spotlight-on/inside-indias-cancer-epidemic/) - Epidemiologists have long been warning of the rapid rise in cancer rates hitting low- and middle-income countries. But it takes a journalist to get across how those statistics are playing out in people’s lives. Jason Gale, who covers Asian Healthcare for Bloomberg Markets, received a Best Cancer Reporter Award for his piece on the cost
- [Age discrimination at a time of health rationing: unthinkable or common sense?](https://archive.cancerworld.net/spotlight-on/age-discrimination-at-a-time-of-health-rationing-unthinkable-or-common-sense/) - Karol Sikora, a medical oncologist who has directed cancer services at a major London hospital, triggered an angry reaction earlier this year when he suggested that younger patients should have priority when it comes to accessing very expensive, potentially life extending, cancer therapies. But did he have a point? we asked Ulrich Wedding, a specialist
- [Mindfulness: a way to live life in the present tense](https://archive.cancerworld.net/patient-voice/mindfulness-a-way-to-live-life-in-the-present-tense/) - I have learned to shift from seeing myself as invulnerable to quite vulnerable – and to know that as not something to push away. There are good things about vulnerability. I have never felt so loved, supported, treasured and have come to know some people in a way I think I never would otherwise.” These
- [Treatment of skin rash and pruritus induced by biological therapies](https://archive.cancerworld.net/spotlight-on/treatment-of-skin-rash-and-pruritus-induced-by-biological-therapies/) - Skin rash and itchy skin are known to be common side-effects in patients treated with EGFR and tyrosine kinase inhibitors, and can be distressing, particularly when severe. A growing understanding of why this happens is leading to new ways of managing the problem This e-oncoreview was sponsored by Helsinn Pruritus, more commonly known as itchy
- [The heroic role of the caregiver in oncology](https://archive.cancerworld.net/focus/the-heroic-role-of-the-caregiver-in-oncology/) - Doctors in Tel Aviv teamed up with a photojournalist to learn more about the role of the ‘unsung heroes’ who place their patient–companion at the heart of their world. This article was first published in The Oncologist vol.18 no.10, and is republished in abridged form with permission. ©2014 Alpha Med Press doi:10.1634/theoncologist.2013-0163 Our Tel Aviv
- [Redefining the primary objective of phase I oncology trials](https://archive.cancerworld.net/impact-factor/redefining-the-primary-objective-of-phase-i-oncology-trials/) - Cytotoxic agents are conventionally dosed on the basis of the maximum tolerated dose defined in phase I trials. A study assessing adverse events in over 2,000 patients treated with molecularly targeted agents suggests a need to redefine criteria for dosing of molecularly targeted agents, which should be based on randomised, dose-ranging phase II trials. This
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-6/) - Selected reports edited by Janet Fricker Decisional aids increase patient knowledge and reduce regret =>British Journal of Cancer Use of decision aids can potentially increase knowledge and reduce decisional regret around clinical trial participation, a recent study has found. But the joint Australian and UK study, representing the first randomised controlled trial of a decision
- [Europe's cancer drugs shortage is hurting patients](https://archive.cancerworld.net/editorial/europes-cancer-drugs-shortage-is-hurting-patients/) - Hospital pharmacies across Europe are experiencing frequent delays in accessing a wide range of commonly used cancer drugs. This editorial examines the extent of the problem and calls for action at an EU level to protect patients from its harmful consequences. Hospital pharmacies across Europe are reporting difficulties getting hold of a range of commonly
- [George Coukos: a temple from translational research](https://archive.cancerworld.net/cover-story/george-coukos-a-temple-from-translational-research/) - Switzerland wants a cancer centre that will promote “opportunity, integration and innovation”, focused tightly on delivering major benefits to patients. George Coukos is the man charged with making it happen. by Simon Crompton Within 15 years, says George Coukos, treatment advances in immunotherapy will mean that cancer cure rates could rise from 50% to 75%.
- [Right patient, right drug, wrong dose?](https://archive.cancerworld.net/cutting-edge/right-patient-right-drug-wrong-dose/) - Dose too strongly and the patient gets more harm than benefit, too weakly and the drug can’t do its job. Could oncology learn from other fields about using pharmacokinetics in the clinic to hit it right in each patient? Personalised medicine is about tailoring treatment and care to the individual patient and their specific disease.
- [The price of survival](https://archive.cancerworld.net/spotlight-on/the-price-of-survival/) - Broadcaster Katrin Zöfel showed the value of good journalism with her half-hour broadcast for Deutschlandfunk, German national radio, which told the stories of people living with long-term effects of being treated for cancer. More than 2 million people who live in Germany today were treated for cancer ten or more years ago, according to estimates
- [A life worth living: we could do much more to help patients with depression](https://archive.cancerworld.net/systems-services/a-life-worth-living-we-could-do-much-more-to-help-patients-with-depression/) - A new model for caring for depression in cancer patients shows how much can be achieved even on a tight budget. That being diagnosed with cancer carries an increased risk of depression is perhaps not unexpected. What comes as a surprise to many people, however, is how effectively even major depression in cancer patients can
- [Overdiagnosis under the microscope](https://archive.cancerworld.net/spotlight-on/overdiagnosis-under-the-microscope/) - A new conference looks at the social as well as individual implications of how we use diagnostic tests that cannot accurately pick out real from apparent threats. Improving the way we spot, report and explore genuine danger signs is a priority in cancer. But what happens if the tools that we use are poor at
- [Lymphoedema following treatment for breast cancer: a new approach to an old problem](https://archive.cancerworld.net/e-grandround/lymphoedema-following-treatment-for-breast-cancer-a-new-approach-to-an-old-problem/) - Screening breast cancer patients for lymphoedema makes it possible to identify problems early and take action to halt its progression. Oncologists have an important role to play, particularly given the rise in lymphoedema rates that may be expected due to greater use of regional radiotherapy in early breast cancer. In the past, lymphoedema was relatively
- [Caring for one of our own](https://archive.cancerworld.net/focus/caring-for-one-of-our-own/) - When you’re caring for a patient and friend, who was recently your colleague, working out boundaries and negotiating the particular privileges and pressures of caring for them can be hard. The problem was explored in a Schwartz Center Round* at the Massachusetts General Hospital. This article was first published in The Oncologist vol. 19, no.
- [EU data protection regulation harming cancer research](https://archive.cancerworld.net/impact-factor/eu-data-protection-regulation-harming-cancer-research/) - The cancer community is deeply concerned about the unintended consequences of the current wording of the European Union (EU) draft Regulation on Data Protection, which may challenge the survival of retrospective clinical research, biobanking, and population-based cancer registries in the EU. This directive could negatively affect Europe’s competitiveness in cancer research. This article was first
- [Newsround](https://archive.cancerworld.net/senza-categoria/newsround-5/) - Statins improve survival in colorectal cancer => Journal of Clinical Oncology Using statins after a diagnosis of colorectal cancer was found to be associated with improved survival, finds a large population-based cohort study. The study, funded by the Northern Ireland Public Health Agency, also showed a dose-response association, with more marked reductions for cancer patients
- [Breast units are effective, and must become the standard: the EBC Manifesto](https://archive.cancerworld.net/news/breast-units-are-effective-and-must-become-the-standard-the-ebc-manifesto/) - Breast units staffed with specialist multidisciplinary teams deliver superior care and quality of life to women and men with breast cancer: this is the premise of the Manifesto on Breast Cancer Centres/Units that was discussed in 2016 at the 10th European Breast Cancer Conference in Amsterdam, and was recently published on the European Journal of
- [A new model for active surveillance of low-risk prostate cancer](https://archive.cancerworld.net/news/a-new-model-for-active-surveillance-of-low-risk-prostate-cancer/) - A new model of active surveillance (AS) for patients with low-risk prostate cancer proved to be effective in helping clinicians to appropriately select and follow patients preventing the risk of overtreatment, according to the results of a three-year study published online in the journal Urology. “Active surveillance is a strategy that is recommended by physician
- [Mental health might be negatively affected by a recent cancer diagnosis](https://archive.cancerworld.net/news/mental-health-might-also-suffer-from-a-cancer-diagnosis/) - Cancer diagnosis seems associated with an increased risk of some mental health disorders, and increased use of psychiatric medications, according to a Swedish cohort study published on JAMA Oncology. The study by Donghao Lu and coauthors of the Karolinska Institutet in Stockholm included 304118 patients with cancer and over 3 million cancer-free individuals who were randomly
- [Journalists can apply for Amsterdam conference until Wed Nov 16th](https://archive.cancerworld.net/news/journalists-can-apply-for-amsterdam-conference-until-wed-nov-16th/) - The deadline for applying for a journalist grant to the ECCO congress has been extended. The new deadline is Wednesday 16th November Reporting on Cancer ESO @ #ECCOCongress Fellowship 27-30 January 2017 Amsterdam The European School of Oncology (ESO) is collaborating with the European CanCer Organisation (ECCO) to offer Grants to up to 12 European health journalists to attend the European Cancer Congress
- [How to improve cancer care in Europe? Two reports propose solutions](https://archive.cancerworld.net/news/how-to-improve-cancer-care-in-europe-two-reports-propose-solutions/) - Two comprehensive reports addressing cancer care in Europe have been published recently: «Past and current approaches to cancer care may not be sufficient for tomorrow. We face limited resources and a demand for cancer that will only increase in quantity and complexity in years to come. As a result, we need to find new ways
- ["Help a Dane": a brilliant online campaign against melanoma](https://archive.cancerworld.net/news/help-a-dane-a-brilliant-online-campaign-against-melanoma/) - https://www.youtube.com/watch?v=bvT4SVG8fMc Images of carbonized pizza, paella, croissant and meatballs with tzaziki are smartly used by a Danish campaign on sun safety advice for Danes tourists who love to spend their holidays in Southern Europe, where their delicate skins are in danger. The brilliant online campaign launched by the Danish Cancer Society in collaboration with the
- [Romanians protest against corruption that plagues hospitals](https://archive.cancerworld.net/news/romanians-protest-against-corruption-that-plagues-hospitals/) - The protest that brought many Romanians in the streets, ignited by a law proposal on corruption, soon touched other sensitive topics, including the dramatic state of public hospitals. A highly contested law proposed by the government – led by the socialist party that recently won the election – was seen as a helping hand for
- [Cost of drugs and the role of patients: lessons learned at ECCO 2017](https://archive.cancerworld.net/news/cost-of-drugs-and-the-role-of-patients-lessons-learned-at-ecco-2017/) - The cost of drugs and the critical importance of the patient voice in designing clinical trials were two of the key issues picked out by journalists who attended the European Cancer Congress (ECCO 2017) recently held in Amsterdam. The European School of Oncology supported 12 journalists to attend the congress and to meet together with
- [Is first-in-human clinical research always ethical?](https://archive.cancerworld.net/news/is-first-in-human-clinical-research-always-ethical/) - «We must abandon the fiction that current oversight systems are adequate to protect volunteers in first-in-human trials or to steward scientific efforts»: this is the strong conclusion of a paper published in Nature by two bioethicists of the McGill University, in Montreal, on first-in-human studies, often approved despite the lack of evidence of a significant
- [US healthcare and research communities protest Trump’s ban on seven Muslim countries](https://archive.cancerworld.net/news/us-healthcare-and-research-communities-protest-trumps-ban-on-seven-muslim-countries/) - Healthcare professionals in the United States are worried by the impact that the executive order by President Donald Trump barring access in the country to nationals of seven predominantly Muslim countries is having on hospitals and research centres, after many reports of clinicians and researchers prevented from re-entering in the United States despite having a perfectly
- [A viral campaign recruits lemons against breast cancer](https://archive.cancerworld.net/news/a-viral-campaign-recruits-lemons-against-breast-cancer/) - A brilliant visual campaign called «Know your Lemons» (hashtag #knowyourlemons), launched by a British charity to increase awareness about breast cancer prevention, become viral on social media, with over 7 million views in a few days just on Facebook alone. The visual campaign was designed many years ago by a young British designer, Corrine Beaumont, who had lost both her grandmothers to
- [Kudos to the recipients of the Cancer World Journalism Awards 2016](https://archive.cancerworld.net/news/kudos-to-the-recipients-of-the-cancer-world-journalism-awards-2016/) - Journalists from China, Germany, India and Kenya have been recognised for their outstanding articles on cancer in the 2016 Cancer World Journalism Awards. The awards, organised by the European School of Oncology’s Cancer World magazine, attracted 145 entries from every corner of the globe. There were winners in four categories, who each receive € 1.500.
- [Not all social relationships are beneficial to breast cancer patients](https://archive.cancerworld.net/news/not-all-social-relationships-are-beneficial-to-breast-cancer-patients/) - In women hit by breast cancer, the size and type of social relationships influence the rates of recurrence and mortality, according to a research published on Cancer, a peer-reviewed journal of the American Cancer Society. In general terms, the analysis led by Candyce Kroenke and colleagues of the Kaiser Permanente Division of Research in Oakland,

## Pages

- [Magazine](https://archive.cancerworld.net/) - Cancer World is a magazine about cancer care: in the online archive you will find articles and pdfs of the magazine from 2004 to 2019.

## Downloads

- [Cancer World 70](https://archive.cancerworld.net/download/cancer-world-70/)

## Categories

- [Senza categoria](https://archive.cancerworld.net/./senza-categoria/)
- [Editorial](https://archive.cancerworld.net/./editorial/)
- [Cover Story](https://archive.cancerworld.net/./cover-story/)
- [Cutting Edge](https://archive.cancerworld.net/./cutting-edge/)
- [Profile](https://archive.cancerworld.net/./profile/)
- [Spotlight on](https://archive.cancerworld.net/./spotlight-on/)
- [Patient Voice](https://archive.cancerworld.net/./patient-voice/)
- [Our World](https://archive.cancerworld.net/./our-world/)
- [Impact Factor](https://archive.cancerworld.net/./impact-factor/)
- [News](https://archive.cancerworld.net/./news/)
- [Eso news](https://archive.cancerworld.net/./agenda/)
- [Grandround](https://archive.cancerworld.net/./e-grandround/)
- [Featured](https://archive.cancerworld.net/./featured/)
- [Highlight](https://archive.cancerworld.net/./highlight/)
- [Focus](https://archive.cancerworld.net/./focus/)
- [Systems & Services](https://archive.cancerworld.net/./systems-services/)
- [Readers' Corner](https://archive.cancerworld.net/./readers-corner/)
- [paid announcements](https://archive.cancerworld.net/./paid-announcements/) - paid announcements
- [Drug Watch](https://archive.cancerworld.net/./drug-watch/)
- [hot seat](https://archive.cancerworld.net/./hot-seat/)
- [Past events](https://archive.cancerworld.net/./past-events/)
- [voices](https://archive.cancerworld.net/./voices/)
- [obituary](https://archive.cancerworld.net/./obituary/)
- [comment](https://archive.cancerworld.net/./comment/)
- [World Oncology Forum videos](https://archive.cancerworld.net/./wof-video/)
- [CancerWorld Plus](https://archive.cancerworld.net/./cancerworld-plus/)
- [in the media](https://archive.cancerworld.net/./in-the-media/)
- [Media Partnership](https://archive.cancerworld.net/./media-partnership/)

## Tags

- [MRI](https://archive.cancerworld.net/tag/mri/)
- [prostate cancer](https://archive.cancerworld.net/tag/prostate-cancer/)
- [active surveillance](https://archive.cancerworld.net/tag/active-surveillance/)
- [diagnosis](https://archive.cancerworld.net/tag/diagnosis/)
- [staging](https://archive.cancerworld.net/tag/staging/)
- [treatment planning](https://archive.cancerworld.net/tag/treatment-planning/)
- [monitoring](https://archive.cancerworld.net/tag/monitoring/)
- [focal therapy](https://archive.cancerworld.net/tag/focal-therapy/)
- [radical prostatectomy](https://archive.cancerworld.net/tag/radical-prostatectomy/)
- [prevention](https://archive.cancerworld.net/tag/prevention/)
- [cancer strategy](https://archive.cancerworld.net/tag/cancer-strategy/)
- [World Oncology Forum](https://archive.cancerworld.net/tag/world-oncology-forum/)
- [prevent the preventable](https://archive.cancerworld.net/tag/prevent-the-preventable/)
- [microbiota](https://archive.cancerworld.net/tag/microbiota/)
- [nutrition](https://archive.cancerworld.net/tag/nutrition/)
- [preventive therapies](https://archive.cancerworld.net/tag/preventive-therapies/)
- [carcinogenesis](https://archive.cancerworld.net/tag/carcinogenesis/)
- [immune response](https://archive.cancerworld.net/tag/immune-response/)
- [hormonal cancers](https://archive.cancerworld.net/tag/hormonal-cancers/)
- [obesity](https://archive.cancerworld.net/tag/obesity/)
- [diet](https://archive.cancerworld.net/tag/diet/)
- [inflammatory response](https://archive.cancerworld.net/tag/inflammatory-response/)
- [inflammation](https://archive.cancerworld.net/tag/inflammation/)
- [war against cancer](https://archive.cancerworld.net/tag/war-against-cancer/)
- [Cancer World magazine](https://archive.cancerworld.net/tag/cancer-world-magazine/)
- [European School of Oncology](https://archive.cancerworld.net/tag/european-school-of-oncology/)
- [cognitive effects](https://archive.cancerworld.net/tag/cognitive-effects/)
- [endocrine therapy](https://archive.cancerworld.net/tag/endocrine-therapy/)
- [breast cancer](https://archive.cancerworld.net/tag/breast-cancer/)
- [tamoxifen](https://archive.cancerworld.net/tag/tamoxifen/)
- [aromatase](https://archive.cancerworld.net/tag/aromatase/)
- [targeted cancer therapies](https://archive.cancerworld.net/tag/targeted-cancer-therapies/)
- [side-effects](https://archive.cancerworld.net/tag/side-effects/)
- [side effect management](https://archive.cancerworld.net/tag/side-effect-management/)
- [clinical trials](https://archive.cancerworld.net/tag/clinical-trials/)
- [risk assessment](https://archive.cancerworld.net/tag/risk-assessment/)
- [progress](https://archive.cancerworld.net/tag/progress/)
- [toxicity](https://archive.cancerworld.net/tag/toxicity/)
- [new therapies](https://archive.cancerworld.net/tag/new-therapies/)
- [doseage](https://archive.cancerworld.net/tag/doseage/)
- [reporting](https://archive.cancerworld.net/tag/reporting/)
- [EMA](https://archive.cancerworld.net/tag/ema/)
- [drug regulation.](https://archive.cancerworld.net/tag/drug-regulation/)
- [Fedro Alessandro Peccatori](https://archive.cancerworld.net/tag/fedro-alessandro-peccatori/)
- [Advanced Breast Cancer Conference](https://archive.cancerworld.net/tag/advanced-breast-cancer-conference/)
- [metastatic breast cancer](https://archive.cancerworld.net/tag/metastatic-breast-cancer/)
- [European Cancer Code](https://archive.cancerworld.net/tag/european-cancer-code/)
- [behaviour change](https://archive.cancerworld.net/tag/behaviour-change/)
- [Bogotà](https://archive.cancerworld.net/tag/bogota/)
- [Colombia](https://archive.cancerworld.net/tag/colombia/)
- [ESO](https://archive.cancerworld.net/tag/eso/)
- [ESMO](https://archive.cancerworld.net/tag/esmo/)
- [Masterclass](https://archive.cancerworld.net/tag/masterclass/)
- [clinical oncology](https://archive.cancerworld.net/tag/clinical-oncology/)
- [Familial Cancer](https://archive.cancerworld.net/tag/familial-cancer/)
- [NRCO](https://archive.cancerworld.net/tag/nrco/)
- [CNIO](https://archive.cancerworld.net/tag/cnio/)
- [breast](https://archive.cancerworld.net/tag/breast/)
- [ovarian](https://archive.cancerworld.net/tag/ovarian/)
- [colon](https://archive.cancerworld.net/tag/colon/)
- [prostate](https://archive.cancerworld.net/tag/prostate/)
- [ovary](https://archive.cancerworld.net/tag/ovary/)
- [cancer](https://archive.cancerworld.net/tag/cancer/)
- [next generation sequencing](https://archive.cancerworld.net/tag/next-generation-sequencing/)
- [genetics](https://archive.cancerworld.net/tag/genetics/)
- [Pharmacology of anti-cancer drugs](https://archive.cancerworld.net/tag/pharmacology-of-anti-cancer-drugs/)
- [Haematological malignancies](https://archive.cancerworld.net/tag/haematological-malignancies/)
- [Palliative and supportive care](https://archive.cancerworld.net/tag/palliative-and-supportive-care/)
- [Genito-urinary cancers](https://archive.cancerworld.net/tag/genito-urinary-cancers/)
- [Lung cancer and mesothelioma](https://archive.cancerworld.net/tag/lung-cancer-and-mesothelioma/)
- [Gastro-intestinal tumours](https://archive.cancerworld.net/tag/gastro-intestinal-tumours/)
- [watchful waiting](https://archive.cancerworld.net/tag/watchful-waiting/)
- [urology](https://archive.cancerworld.net/tag/urology/)
- [overtreatment](https://archive.cancerworld.net/tag/overtreatment/)
- [quality of life](https://archive.cancerworld.net/tag/quality-of-life/)
- [immune-modulating therapies](https://archive.cancerworld.net/tag/immune-modulating-therapies/)
- [pharmaco-epi studies](https://archive.cancerworld.net/tag/pharmaco-epi-studies/)
- [melanoma](https://archive.cancerworld.net/tag/melanoma/)
- [UV tanning](https://archive.cancerworld.net/tag/uv-tanning/)
- [Prostate cancer units network](https://archive.cancerworld.net/tag/prostate-cancer-units-network/)
- [depression](https://archive.cancerworld.net/tag/depression/)
- [anxiety](https://archive.cancerworld.net/tag/anxiety/)
- [cancer diagnosis](https://archive.cancerworld.net/tag/cancer-diagnosis/)
- [mental health](https://archive.cancerworld.net/tag/mental-health/)
- [substance abuse](https://archive.cancerworld.net/tag/substance-abuse/)
- [drugs](https://archive.cancerworld.net/tag/drugs/)
- [win](https://archive.cancerworld.net/tag/win/)
- [2016](https://archive.cancerworld.net/tag/2016/)
- [Paris](https://archive.cancerworld.net/tag/paris/)
- [Innovative Approaches to Improve Cancer Patient Outcomes](https://archive.cancerworld.net/tag/innovative-approaches-to-improve-cancer-patient-outcomes/)
- [outcomes](https://archive.cancerworld.net/tag/outcomes/)
- [innovation](https://archive.cancerworld.net/tag/innovation/)
- [therapy](https://archive.cancerworld.net/tag/therapy/)
- [Supportive Care in Cancer Patients](https://archive.cancerworld.net/tag/supportive-care-in-cancer-patients/)
- [Balkan](https://archive.cancerworld.net/tag/balkan/)
- [Eastern Europe](https://archive.cancerworld.net/tag/eastern-europe/)
- [Belgrade](https://archive.cancerworld.net/tag/belgrade/)
- [oncology](https://archive.cancerworld.net/tag/oncology/)
- [meeting](https://archive.cancerworld.net/tag/meeting/)
- [Franco Cavalli](https://archive.cancerworld.net/tag/franco-cavalli/)
- [Louis Denis](https://archive.cancerworld.net/tag/louis-denis/)
- [Michael Peckham](https://archive.cancerworld.net/tag/michael-peckham/)
- [Bob Pinedo](https://archive.cancerworld.net/tag/bob-pinedo/)
- [Umberto Veronesi](https://archive.cancerworld.net/tag/umberto-veronesi/)
- [Europa Uomo](https://archive.cancerworld.net/tag/europa-uomo/)
- [immunotherapy](https://archive.cancerworld.net/tag/immunotherapy/)
- [advanced disease](https://archive.cancerworld.net/tag/advanced-disease/)
- [metastatic disease](https://archive.cancerworld.net/tag/metastatic-disease/)
- [ethics](https://archive.cancerworld.net/tag/ethics/)
- [surrogate end points](https://archive.cancerworld.net/tag/surrogate-end-points/)
- [survival](https://archive.cancerworld.net/tag/survival/)
- [end of life](https://archive.cancerworld.net/tag/end-of-life/)
- [death](https://archive.cancerworld.net/tag/death/)
- [doctors](https://archive.cancerworld.net/tag/doctors/)
- [intensive care](https://archive.cancerworld.net/tag/intensive-care/)
- [cpr](https://archive.cancerworld.net/tag/cpr/)
- [life support](https://archive.cancerworld.net/tag/life-support/)
- [resuscitation](https://archive.cancerworld.net/tag/resuscitation/)
- [terminal illness](https://archive.cancerworld.net/tag/terminal-illness/)
- [risk](https://archive.cancerworld.net/tag/risk/)
- [lifestyle](https://archive.cancerworld.net/tag/lifestyle/)
- [Shaping the Future of Cancer Prevention](https://archive.cancerworld.net/tag/shaping-the-future-of-cancer-prevention/)
- [Challenging Dogmas](https://archive.cancerworld.net/tag/challenging-dogmas/)
- [risk factors](https://archive.cancerworld.net/tag/risk-factors/)
- [undertreatment](https://archive.cancerworld.net/tag/undertreatment/)
- [personalised medicine](https://archive.cancerworld.net/tag/personalised-medicine/)
- [risk-benefit](https://archive.cancerworld.net/tag/risk-benefit/)
- [targeted therapies](https://archive.cancerworld.net/tag/targeted-therapies/)
- [genomics](https://archive.cancerworld.net/tag/genomics/)
- [proteomics](https://archive.cancerworld.net/tag/proteomics/)
- [metabolomics](https://archive.cancerworld.net/tag/metabolomics/)
- [transcriptomics](https://archive.cancerworld.net/tag/transcriptomics/)
- [imaging](https://archive.cancerworld.net/tag/imaging/)
- [PET](https://archive.cancerworld.net/tag/pet/)
- [Hodgkin’s lymphoma](https://archive.cancerworld.net/tag/hodgkins-lymphoma/)
- [Kate Granger](https://archive.cancerworld.net/tag/kate-granger/)
- [human touch](https://archive.cancerworld.net/tag/human-touch/)
- [#hellomynameis](https://archive.cancerworld.net/tag/hellomynameis/)
- [sharing information](https://archive.cancerworld.net/tag/sharing-information/)
- [twitter](https://archive.cancerworld.net/tag/twitter/)
- [health campaign](https://archive.cancerworld.net/tag/health-campaign/)
- [time pressure](https://archive.cancerworld.net/tag/time-pressure/)
- [A Graceful Death](https://archive.cancerworld.net/tag/a-graceful-death/)
- [Antonia Rolls](https://archive.cancerworld.net/tag/antonia-rolls/)
- [Eurocare](https://archive.cancerworld.net/tag/eurocare/)
- [gap](https://archive.cancerworld.net/tag/gap/)
- [Europe](https://archive.cancerworld.net/tag/europe/)
- [statistics](https://archive.cancerworld.net/tag/statistics/)
- [benchmarking](https://archive.cancerworld.net/tag/benchmarking/)
- [comparison](https://archive.cancerworld.net/tag/comparison/)
- [comparative studies](https://archive.cancerworld.net/tag/comparative-studies/)
- [conflict](https://archive.cancerworld.net/tag/conflict/)
- [war](https://archive.cancerworld.net/tag/war/)
- [refugees](https://archive.cancerworld.net/tag/refugees/)
- [Middle East](https://archive.cancerworld.net/tag/middle-east/)
- [Syria](https://archive.cancerworld.net/tag/syria/)
- [Africa](https://archive.cancerworld.net/tag/africa/)
- [Iraq](https://archive.cancerworld.net/tag/iraq/)
- [Lybia](https://archive.cancerworld.net/tag/lybia/)
- [Gaza](https://archive.cancerworld.net/tag/gaza/)
- [Mexico](https://archive.cancerworld.net/tag/mexico/)
- [Jordan](https://archive.cancerworld.net/tag/jordan/)
- [UNHCR](https://archive.cancerworld.net/tag/unhcr/)
- [Tunisia](https://archive.cancerworld.net/tag/tunisia/)
- [non-communicable diseases](https://archive.cancerworld.net/tag/non-communicable-diseases/)
- [training](https://archive.cancerworld.net/tag/training/)
- [teamwork](https://archive.cancerworld.net/tag/teamwork/)
- [nurses](https://archive.cancerworld.net/tag/nurses/)
- [communication](https://archive.cancerworld.net/tag/communication/)
- [interprofessional education](https://archive.cancerworld.net/tag/interprofessional-education/)
- [WHO](https://archive.cancerworld.net/tag/who/)
- [radiotherapy](https://archive.cancerworld.net/tag/radiotherapy/)
- [skin reactions](https://archive.cancerworld.net/tag/skin-reactions/)
- [fractionation](https://archive.cancerworld.net/tag/fractionation/)
- [skin care](https://archive.cancerworld.net/tag/skin-care/)
- [biobank](https://archive.cancerworld.net/tag/biobank/)
- [resistance](https://archive.cancerworld.net/tag/resistance/)
- [database](https://archive.cancerworld.net/tag/database/)
- [tissue](https://archive.cancerworld.net/tag/tissue/)
- [blood](https://archive.cancerworld.net/tag/blood/)
- [rights](https://archive.cancerworld.net/tag/rights/)
- [property](https://archive.cancerworld.net/tag/property/)
- [combinatorial therapies](https://archive.cancerworld.net/tag/combinatorial-therapies/)
- [drug repurposing](https://archive.cancerworld.net/tag/drug-repurposing/)
- [new indications](https://archive.cancerworld.net/tag/new-indications/)
- [New Ideas in Cancer](https://archive.cancerworld.net/tag/new-ideas-in-cancer/)
- [Mumbai](https://archive.cancerworld.net/tag/mumbai/)
- [Tata](https://archive.cancerworld.net/tag/tata/)
- [doctors with cancer](https://archive.cancerworld.net/tag/doctors-with-cancer/)
- [metaxa](https://archive.cancerworld.net/tag/metaxa/)
- [listening to time](https://archive.cancerworld.net/tag/listening-to-time/)
- [Immuno-oncology](https://archive.cancerworld.net/tag/immuno-oncology/)
- [Amsterdam](https://archive.cancerworld.net/tag/amsterdam/)
- [Madrid](https://archive.cancerworld.net/tag/madrid/)
- [Zurich](https://archive.cancerworld.net/tag/zurich/)
- [Rare cancers](https://archive.cancerworld.net/tag/rare-cancers/)
- [Adult](https://archive.cancerworld.net/tag/adult/)
- [Solid Cancers](https://archive.cancerworld.net/tag/solid-cancers/)
- [Milan](https://archive.cancerworld.net/tag/milan/)
- [RCE](https://archive.cancerworld.net/tag/rce/)
- [futile treatment](https://archive.cancerworld.net/tag/futile-treatment/)
- [medical ethics](https://archive.cancerworld.net/tag/medical-ethics/)
- [survey](https://archive.cancerworld.net/tag/survey/)
- [journalists](https://archive.cancerworld.net/tag/journalists/)
- [grant](https://archive.cancerworld.net/tag/grant/)
- [fellowship](https://archive.cancerworld.net/tag/fellowship/)
- [reporting on cancer](https://archive.cancerworld.net/tag/reporting-on-cancer/)
- [ECCO](https://archive.cancerworld.net/tag/ecco/)
- [2017](https://archive.cancerworld.net/tag/2017/)
- [media](https://archive.cancerworld.net/tag/media/)
- [covering cancer](https://archive.cancerworld.net/tag/covering-cancer/)
- [Cancer World Journalism Award](https://archive.cancerworld.net/tag/cancer-world-journalism-award/)
- [award](https://archive.cancerworld.net/tag/award/)
- [health journalism](https://archive.cancerworld.net/tag/health-journalism/)
- [prize](https://archive.cancerworld.net/tag/prize/)
- [professional development](https://archive.cancerworld.net/tag/professional-development/)
- [value](https://archive.cancerworld.net/tag/value/)
- [cost](https://archive.cancerworld.net/tag/cost/)
- [affordable care](https://archive.cancerworld.net/tag/affordable-care/)
- [AHCJ](https://archive.cancerworld.net/tag/ahcj/)
- [NCCN](https://archive.cancerworld.net/tag/nccn/)
- [Evidence blocks](https://archive.cancerworld.net/tag/evidence-blocks/)
- [surgery](https://archive.cancerworld.net/tag/surgery/)
- [Ukraine](https://archive.cancerworld.net/tag/ukraine/)
- [Germany](https://archive.cancerworld.net/tag/germany/)
- [repurposing](https://archive.cancerworld.net/tag/repurposing/)
- [sarcoma](https://archive.cancerworld.net/tag/sarcoma/)
- [gastrointestinal stromal tumours](https://archive.cancerworld.net/tag/gastrointestinal-stromal-tumours/)
- [Paolo Casali](https://archive.cancerworld.net/tag/paolo-casali/)
- [Fortunato Ciardiello](https://archive.cancerworld.net/tag/fortunato-ciardiello/)
- [2020 vision](https://archive.cancerworld.net/tag/2020-vision/)
- [glioblastoma](https://archive.cancerworld.net/tag/glioblastoma/)
- [Health systems strengthening](https://archive.cancerworld.net/tag/health-systems-strengthening/)
- [global health](https://archive.cancerworld.net/tag/global-health/)
- [Kidney Cancer Canada](https://archive.cancerworld.net/tag/kidney-cancer-canada/)
- [Melanoma Patient Network Europe](https://archive.cancerworld.net/tag/melanoma-patient-network-europe/)
- [Bettina Ryll](https://archive.cancerworld.net/tag/bettina-ryll/)
- [Deb Maskens](https://archive.cancerworld.net/tag/deb-maskens/)
- [International Kidney Cancer Coalition](https://archive.cancerworld.net/tag/international-kidney-cancer-coalition/)
- [Francesco Pignatti](https://archive.cancerworld.net/tag/francesco-pignatti/)
- [CML Advocates Network](https://archive.cancerworld.net/tag/cml-advocates-network/)
- [Europa Donna](https://archive.cancerworld.net/tag/europa-donna/)
- [European Breast Cancer Coalition](https://archive.cancerworld.net/tag/european-breast-cancer-coalition/)
- [European Cancer Patient Coalition](https://archive.cancerworld.net/tag/european-cancer-patient-coalition/)
- [Susan Knox](https://archive.cancerworld.net/tag/susan-knox/)
- [Clinical Trials Regulation](https://archive.cancerworld.net/tag/clinical-trials-regulation/)
- [Örjan Brinkman](https://archive.cancerworld.net/tag/orjan-brinkman/)
- [European Consumer Organisation](https://archive.cancerworld.net/tag/european-consumer-organisation/)
- [Elmar Doppelfeld](https://archive.cancerworld.net/tag/elmar-doppelfeld/)
- [European Network of Research Ethics Committees](https://archive.cancerworld.net/tag/european-network-of-research-ethics-committees/)
- [ethics assesment](https://archive.cancerworld.net/tag/ethics-assesment/)
- [trials](https://archive.cancerworld.net/tag/trials/)
- [centralised ethical approval](https://archive.cancerworld.net/tag/centralised-ethical-approval/)
- [evaluation](https://archive.cancerworld.net/tag/evaluation/)
- [speed of approval](https://archive.cancerworld.net/tag/speed-of-approval/)
- [Iain Galloway](https://archive.cancerworld.net/tag/iain-galloway/)
- [Kathy Oliver](https://archive.cancerworld.net/tag/kathy-oliver/)
- [Anna Barker](https://archive.cancerworld.net/tag/anna-barker/)
- [Lex Eggermont](https://archive.cancerworld.net/tag/lex-eggermont/)
- [Fatima Cardoso](https://archive.cancerworld.net/tag/fatima-cardoso/)
- [Richard Bergström](https://archive.cancerworld.net/tag/richard-bergstrom/)
- [European Federation of Pharmaceutical Industries and Associations](https://archive.cancerworld.net/tag/european-federation-of-pharmaceutical-industries-and-associations/)
- [Martine Piccart](https://archive.cancerworld.net/tag/martine-piccart/)
- [new drugs](https://archive.cancerworld.net/tag/new-drugs/)
- [childhood](https://archive.cancerworld.net/tag/childhood/)
- [bioethics](https://archive.cancerworld.net/tag/bioethics/)
- [biotech](https://archive.cancerworld.net/tag/biotech/)
- [Philippe Autier](https://archive.cancerworld.net/tag/philippe-autier/)
- [melanome](https://archive.cancerworld.net/tag/melanome/)
- [mortality](https://archive.cancerworld.net/tag/mortality/)
- [curve](https://archive.cancerworld.net/tag/curve/)
- [Greece](https://archive.cancerworld.net/tag/greece/)
- [Crete](https://archive.cancerworld.net/tag/crete/)
- [peak](https://archive.cancerworld.net/tag/peak/)
- [breast cancer in young women](https://archive.cancerworld.net/tag/breast-cancer-in-young-women/)
- [multi-disciplinary management](https://archive.cancerworld.net/tag/multi-disciplinary-management/)
- [consensus](https://archive.cancerworld.net/tag/consensus/)
- [guidelines](https://archive.cancerworld.net/tag/guidelines/)
- [patients](https://archive.cancerworld.net/tag/patients/)
- [Vienna](https://archive.cancerworld.net/tag/vienna/)
- [18FDG PET-CT](https://archive.cancerworld.net/tag/18fdg-pet-ct/)
- [Lymphoma](https://archive.cancerworld.net/tag/lymphoma/)
- [Geriatric Oncology](https://archive.cancerworld.net/tag/geriatric-oncology/)
- [aging population](https://archive.cancerworld.net/tag/aging-population/)
- [age](https://archive.cancerworld.net/tag/age/)
- [frailty](https://archive.cancerworld.net/tag/frailty/)
- [comorbidities](https://archive.cancerworld.net/tag/comorbidities/)
- [inclusion criteria](https://archive.cancerworld.net/tag/inclusion-criteria/)
- [ageism](https://archive.cancerworld.net/tag/ageism/)
- [markers](https://archive.cancerworld.net/tag/markers/)
- [patient perspective](https://archive.cancerworld.net/tag/patient-perspective/)
- [molecular markers](https://archive.cancerworld.net/tag/molecular-markers/)
- [chemotherapy](https://archive.cancerworld.net/tag/chemotherapy/)
- [bankruptcy](https://archive.cancerworld.net/tag/bankruptcy/)
- [advanced prostate cancer](https://archive.cancerworld.net/tag/advanced-prostate-cancer/)
- [Silke Gillessen](https://archive.cancerworld.net/tag/silke-gillessen/)
- [John Ioannidis](https://archive.cancerworld.net/tag/john-ioannidis/)
- [clinical research](https://archive.cancerworld.net/tag/clinical-research/)
- [reproducibility](https://archive.cancerworld.net/tag/reproducibility/)
- [crisis](https://archive.cancerworld.net/tag/crisis/)
- [medical literature](https://archive.cancerworld.net/tag/medical-literature/)
- [reliability](https://archive.cancerworld.net/tag/reliability/)
- [early hepatobiliary cancer](https://archive.cancerworld.net/tag/early-hepatobiliary-cancer/)
- [early pancreatic cancer](https://archive.cancerworld.net/tag/early-pancreatic-cancer/)
- [pancreas](https://archive.cancerworld.net/tag/pancreas/)
- [management](https://archive.cancerworld.net/tag/management/)
- [EORTC](https://archive.cancerworld.net/tag/eortc/)
- [Jonas Feilchenfeldt](https://archive.cancerworld.net/tag/jonas-feilchenfeldt/)
- [Gian Carlo Mattiucci](https://archive.cancerworld.net/tag/gian-carlo-mattiucci/)
- [GI cancers](https://archive.cancerworld.net/tag/gi-cancers/)
- [Irene Esposito](https://archive.cancerworld.net/tag/irene-esposito/)
- [Beat Gloor](https://archive.cancerworld.net/tag/beat-gloor/)
- [Karin Haustermans](https://archive.cancerworld.net/tag/karin-haustermans/)
- [Jean-Charles Nault](https://archive.cancerworld.net/tag/jean-charles-nault/)
- [John Bridgewater](https://archive.cancerworld.net/tag/john-bridgewater/)
- [Stefan Staettner](https://archive.cancerworld.net/tag/stefan-staettner/)
- [turning point](https://archive.cancerworld.net/tag/turning-point/)
- [bisphosphonates](https://archive.cancerworld.net/tag/bisphosphonates/)
- [postmenopausal](https://archive.cancerworld.net/tag/postmenopausal/)
- [menopause](https://archive.cancerworld.net/tag/menopause/)
- [Robert Coleman](https://archive.cancerworld.net/tag/robert-coleman/)
- [death cafe](https://archive.cancerworld.net/tag/death-cafe/)
- [dying](https://archive.cancerworld.net/tag/dying/)
- [Richard Smith](https://archive.cancerworld.net/tag/richard-smith/)
- [blog](https://archive.cancerworld.net/tag/blog/)
- [BMJ](https://archive.cancerworld.net/tag/bmj/)
- [Charlotte Vrinten](https://archive.cancerworld.net/tag/charlotte-vrinten/)
- [Jane Wardle](https://archive.cancerworld.net/tag/jane-wardle/)
- [ovarian cancer](https://archive.cancerworld.net/tag/ovarian-cancer/)
- [advanced-stage](https://archive.cancerworld.net/tag/advanced-stage/)
- [Steven Narod](https://archive.cancerworld.net/tag/steven-narod/)
- [UICC](https://archive.cancerworld.net/tag/uicc/)
- [NCD Alliance](https://archive.cancerworld.net/tag/ncd-alliance/)
- [global development](https://archive.cancerworld.net/tag/global-development/)
- [agenda](https://archive.cancerworld.net/tag/agenda/)
- [policy](https://archive.cancerworld.net/tag/policy/)
- [Epigenetics](https://archive.cancerworld.net/tag/epigenetics/)
- [Pharmacogenomics](https://archive.cancerworld.net/tag/pharmacogenomics/)
- [pharmacogenetics](https://archive.cancerworld.net/tag/pharmacogenetics/)
- [Immunology](https://archive.cancerworld.net/tag/immunology/)
- [Lung cancer](https://archive.cancerworld.net/tag/lung-cancer/)
- [Colorectal cancer](https://archive.cancerworld.net/tag/colorectal-cancer/)
- [molecular diagnostics](https://archive.cancerworld.net/tag/molecular-diagnostics/)
- [Rare skin cancers and non-cutaneous melanoma](https://archive.cancerworld.net/tag/rare-skin-cancers-and-non-cutaneous-melanoma/)
- [Rare thoracic tumors](https://archive.cancerworld.net/tag/rare-thoracic-tumors/)
- [Rare female genital cancers](https://archive.cancerworld.net/tag/rare-female-genital-cancers/)
- [Neuroendocrine tumors](https://archive.cancerworld.net/tag/neuroendocrine-tumors/)
- [Endocrine gland tumors](https://archive.cancerworld.net/tag/endocrine-gland-tumors/)
- [Sarcomas](https://archive.cancerworld.net/tag/sarcomas/)
- [Digestive rare cancers](https://archive.cancerworld.net/tag/digestive-rare-cancers/)
- [Rare urological and male genital tumors](https://archive.cancerworld.net/tag/rare-urological-and-male-genital-tumors/)
- [Central nervous system neoplasms](https://archive.cancerworld.net/tag/central-nervous-system-neoplasms/)
- [Head and neck cancers](https://archive.cancerworld.net/tag/head-and-neck-cancers/)
- [Tomosynthesis](https://archive.cancerworld.net/tag/tomosynthesis/)
- [screening](https://archive.cancerworld.net/tag/screening/)
- [Risk based screening](https://archive.cancerworld.net/tag/risk-based-screening/)
- [obituary](https://archive.cancerworld.net/tag/obituary/)
- [SEE](https://archive.cancerworld.net/tag/see/)
- [national research foundation](https://archive.cancerworld.net/tag/national-research-foundation/)
- [research](https://archive.cancerworld.net/tag/research/)
- [comprehensive cancer research center](https://archive.cancerworld.net/tag/comprehensive-cancer-research-center/)
- [Athens](https://archive.cancerworld.net/tag/athens/)
- [Vasilis Gregoriou](https://archive.cancerworld.net/tag/vasilis-gregoriou/)
- [burden](https://archive.cancerworld.net/tag/burden/)
- [global burden of disease](https://archive.cancerworld.net/tag/global-burden-of-disease/)
- [2005](https://archive.cancerworld.net/tag/2005/)
- [2015](https://archive.cancerworld.net/tag/2015/)
- [Jama Oncology](https://archive.cancerworld.net/tag/jama-oncology/)
- [social relationships](https://archive.cancerworld.net/tag/social-relationships/)
- [social networks](https://archive.cancerworld.net/tag/social-networks/)
- [recurrence](https://archive.cancerworld.net/tag/recurrence/)
- [marker](https://archive.cancerworld.net/tag/marker/)
- [prognosis](https://archive.cancerworld.net/tag/prognosis/)
- [Philip Poortmans](https://archive.cancerworld.net/tag/philip-poortmans/)
- [President](https://archive.cancerworld.net/tag/president/)
- [president-elect](https://archive.cancerworld.net/tag/president-elect/)
- [gene testing](https://archive.cancerworld.net/tag/gene-testing/)
- [narcotics](https://archive.cancerworld.net/tag/narcotics/)
- [China](https://archive.cancerworld.net/tag/china/)
- [India](https://archive.cancerworld.net/tag/india/)
- [Kenya](https://archive.cancerworld.net/tag/kenya/)
- [alternative medicine](https://archive.cancerworld.net/tag/alternative-medicine/)
- [charlatan](https://archive.cancerworld.net/tag/charlatan/)
- [naturopathy](https://archive.cancerworld.net/tag/naturopathy/)
- [healers](https://archive.cancerworld.net/tag/healers/)
- [safety](https://archive.cancerworld.net/tag/safety/)
- [danger](https://archive.cancerworld.net/tag/danger/)
- [regulation](https://archive.cancerworld.net/tag/regulation/)
- [unnecessary deaths](https://archive.cancerworld.net/tag/unnecessary-deaths/)
- [fatal](https://archive.cancerworld.net/tag/fatal/)
- [lethal](https://archive.cancerworld.net/tag/lethal/)
- [TKI therapy](https://archive.cancerworld.net/tag/tki-therapy/)
- [tyrosine kinase inhibitors](https://archive.cancerworld.net/tag/tyrosine-kinase-inhibitors/)
- [EGFR](https://archive.cancerworld.net/tag/egfr/)
- [VEGFR](https://archive.cancerworld.net/tag/vegfr/)
- [Her2](https://archive.cancerworld.net/tag/her2/)
- [BCR-ABL](https://archive.cancerworld.net/tag/bcr-abl/)
- [ALK](https://archive.cancerworld.net/tag/alk/)
- [toxic effects](https://archive.cancerworld.net/tag/toxic-effects/)
- [class effect](https://archive.cancerworld.net/tag/class-effect/)
- [advanced breast cancer](https://archive.cancerworld.net/tag/advanced-breast-cancer/)
- [ABC guidelines](https://archive.cancerworld.net/tag/abc-guidelines/)
- [advanced practice](https://archive.cancerworld.net/tag/advanced-practice/)
- [needs](https://archive.cancerworld.net/tag/needs/)
- [psychological](https://archive.cancerworld.net/tag/psychological/)
- [emotional](https://archive.cancerworld.net/tag/emotional/)
- [sexual](https://archive.cancerworld.net/tag/sexual/)
- [financial](https://archive.cancerworld.net/tag/financial/)
- [fatigue](https://archive.cancerworld.net/tag/fatigue/)
- [pain](https://archive.cancerworld.net/tag/pain/)
- [support](https://archive.cancerworld.net/tag/support/)
- [services](https://archive.cancerworld.net/tag/services/)
- [multiprofessional](https://archive.cancerworld.net/tag/multiprofessional/)
- [cancer suspicion](https://archive.cancerworld.net/tag/cancer-suspicion/)
- [education](https://archive.cancerworld.net/tag/education/)
- [health literacy](https://archive.cancerworld.net/tag/health-literacy/)
- [PSA](https://archive.cancerworld.net/tag/psa/)
- [salvage androgen deprivation therapy](https://archive.cancerworld.net/tag/salvage-androgen-deprivation-therapy/)
- [assisted reproductive technology](https://archive.cancerworld.net/tag/assisted-reproductive-technology/)
- [biomarkers](https://archive.cancerworld.net/tag/biomarkers/)
- [pancreatic cancer](https://archive.cancerworld.net/tag/pancreatic-cancer/)
- [breast density](https://archive.cancerworld.net/tag/breast-density/)
- [colonoscopy](https://archive.cancerworld.net/tag/colonoscopy/)
- [Best Cancer Reporter Award](https://archive.cancerworld.net/tag/best-cancer-reporter-award/)
- [journalism](https://archive.cancerworld.net/tag/journalism/)
- [Matthew Hill](https://archive.cancerworld.net/tag/matthew-hill/)
- [biosimilars](https://archive.cancerworld.net/tag/biosimilars/)
- [monoclonal antibodies](https://archive.cancerworld.net/tag/monoclonal-antibodies/)
- [biological drugs](https://archive.cancerworld.net/tag/biological-drugs/)
- [efficacy](https://archive.cancerworld.net/tag/efficacy/)
- [extrapolation](https://archive.cancerworld.net/tag/extrapolation/)
- [substitution](https://archive.cancerworld.net/tag/substitution/)
- [savings](https://archive.cancerworld.net/tag/savings/)
- [Kathy Redmond](https://archive.cancerworld.net/tag/kathy-redmond/)
- [Cancer World](https://archive.cancerworld.net/tag/cancer-world/)
- [Alberto Costa](https://archive.cancerworld.net/tag/alberto-costa/)
- [editor](https://archive.cancerworld.net/tag/editor/)
- [debate](https://archive.cancerworld.net/tag/debate/)
- [founding editor](https://archive.cancerworld.net/tag/founding-editor/)
- [discussion](https://archive.cancerworld.net/tag/discussion/)
- [cancer care](https://archive.cancerworld.net/tag/cancer-care/)
- [community](https://archive.cancerworld.net/tag/community/)
- [professionals](https://archive.cancerworld.net/tag/professionals/)
- [organisation](https://archive.cancerworld.net/tag/organisation/)
- [governance](https://archive.cancerworld.net/tag/governance/)
- [views](https://archive.cancerworld.net/tag/views/)
- [opinions](https://archive.cancerworld.net/tag/opinions/)
- [keywords](https://archive.cancerworld.net/tag/keywords/)
- [founding](https://archive.cancerworld.net/tag/founding/)
- [future](https://archive.cancerworld.net/tag/future/)
- [Statins](https://archive.cancerworld.net/tag/statins/)
- [Hodgkin�s disease](https://archive.cancerworld.net/tag/hodgkin�s-disease/)
- [fertility](https://archive.cancerworld.net/tag/fertility/)
- [elderly](https://archive.cancerworld.net/tag/elderly/)
- [anatomy](https://archive.cancerworld.net/tag/anatomy/)
- [humanity](https://archive.cancerworld.net/tag/humanity/)
- [desensitise](https://archive.cancerworld.net/tag/desensitise/)
- [learn](https://archive.cancerworld.net/tag/learn/)
- [respect](https://archive.cancerworld.net/tag/respect/)
- [teenage cancer patients](https://archive.cancerworld.net/tag/teenage-cancer-patients/)
- [young adults](https://archive.cancerworld.net/tag/young-adults/)
- [survivors](https://archive.cancerworld.net/tag/survivors/)
- [dependence](https://archive.cancerworld.net/tag/dependence/)
- [independance](https://archive.cancerworld.net/tag/independance/)
- [social integration](https://archive.cancerworld.net/tag/social-integration/)
- [fulfillment](https://archive.cancerworld.net/tag/fulfillment/)
- [disease-free survival](https://archive.cancerworld.net/tag/disease-free-survival/)
- [progression-free survival](https://archive.cancerworld.net/tag/progression-free-survival/)
- [overall survival](https://archive.cancerworld.net/tag/overall-survival/)
- [endpoints](https://archive.cancerworld.net/tag/endpoints/)
- [surrogate endpoints](https://archive.cancerworld.net/tag/surrogate-endpoints/)
- [correlation](https://archive.cancerworld.net/tag/correlation/)
- [prediction](https://archive.cancerworld.net/tag/prediction/)
- [gold standard](https://archive.cancerworld.net/tag/gold-standard/)
- [EU](https://archive.cancerworld.net/tag/eu/)
- [European Union](https://archive.cancerworld.net/tag/european-union/)
- [Health Commissioner](https://archive.cancerworld.net/tag/health-commissioner/)
- [Vytenis Andriukitis](https://archive.cancerworld.net/tag/vytenis-andriukitis/)
- [spending cuts](https://archive.cancerworld.net/tag/spending-cuts/)
- [public spending](https://archive.cancerworld.net/tag/public-spending/)
- [investment](https://archive.cancerworld.net/tag/investment/)
- [exercise](https://archive.cancerworld.net/tag/exercise/)
- [evidence](https://archive.cancerworld.net/tag/evidence/)
- [energy balance](https://archive.cancerworld.net/tag/energy-balance/)
- [observational](https://archive.cancerworld.net/tag/observational/)
- [weight](https://archive.cancerworld.net/tag/weight/)
- [Clifton Leaf](https://archive.cancerworld.net/tag/clifton-leaf/)
- [death rates](https://archive.cancerworld.net/tag/death-rates/)
- [demographics](https://archive.cancerworld.net/tag/demographics/)
- [tumours](https://archive.cancerworld.net/tag/tumours/)
- [biopsy](https://archive.cancerworld.net/tag/biopsy/)
- [diagnostics](https://archive.cancerworld.net/tag/diagnostics/)
- [mutations](https://archive.cancerworld.net/tag/mutations/)
- [heterogeneity](https://archive.cancerworld.net/tag/heterogeneity/)
- [circulating tumour DNA](https://archive.cancerworld.net/tag/circulating-tumour-dna/)
- [circulating tumour cells](https://archive.cancerworld.net/tag/circulating-tumour-cells/)
- [blood samples](https://archive.cancerworld.net/tag/blood-samples/)
- [SPECTA](https://archive.cancerworld.net/tag/specta/)
- [practice changing](https://archive.cancerworld.net/tag/practice-changing/)
- [exploratory](https://archive.cancerworld.net/tag/exploratory/)
- [collaboration](https://archive.cancerworld.net/tag/collaboration/)
- [personalized](https://archive.cancerworld.net/tag/personalized/)
- [academia](https://archive.cancerworld.net/tag/academia/)
- [industry](https://archive.cancerworld.net/tag/industry/)
- [data](https://archive.cancerworld.net/tag/data/)
- [sharing](https://archive.cancerworld.net/tag/sharing/)
- [open](https://archive.cancerworld.net/tag/open/)
- [multidisciplinary](https://archive.cancerworld.net/tag/multidisciplinary/)
- [follow-up](https://archive.cancerworld.net/tag/follow-up/)
- [international](https://archive.cancerworld.net/tag/international/)
- [long-term](https://archive.cancerworld.net/tag/long-term/)
- [multidisciplinarity](https://archive.cancerworld.net/tag/multidisciplinarity/)
- [congress](https://archive.cancerworld.net/tag/congress/)
- [shared decision making](https://archive.cancerworld.net/tag/shared-decision-making/)
- [uncertainty](https://archive.cancerworld.net/tag/uncertainty/)
- [novel treatments](https://archive.cancerworld.net/tag/novel-treatments/)
- [standard of care](https://archive.cancerworld.net/tag/standard-of-care/)
- [options](https://archive.cancerworld.net/tag/options/)
- [multiple myeloma](https://archive.cancerworld.net/tag/multiple-myeloma/)
- [leaks](https://archive.cancerworld.net/tag/leaks/)
- [extravasation](https://archive.cancerworld.net/tag/extravasation/)
- [rescue](https://archive.cancerworld.net/tag/rescue/)
- [central line](https://archive.cancerworld.net/tag/central-line/)
- [devices](https://archive.cancerworld.net/tag/devices/)
- [peripheral cannula](https://archive.cancerworld.net/tag/peripheral-cannula/)
- [translational research](https://archive.cancerworld.net/tag/translational-research/)
- [cancer centres](https://archive.cancerworld.net/tag/cancer-centres/)
- [research institute](https://archive.cancerworld.net/tag/research-institute/)
- [hospital](https://archive.cancerworld.net/tag/hospital/)
- [medical tourism](https://archive.cancerworld.net/tag/medical-tourism/)
- [health tourism](https://archive.cancerworld.net/tag/health-tourism/)
- [medical travel](https://archive.cancerworld.net/tag/medical-travel/)
- [cross-border healthcare directive](https://archive.cancerworld.net/tag/cross-border-healthcare-directive/)
- [treatment](https://archive.cancerworld.net/tag/treatment/)
- [exploitation](https://archive.cancerworld.net/tag/exploitation/)
- [market](https://archive.cancerworld.net/tag/market/)
- [quality](https://archive.cancerworld.net/tag/quality/)
- [capacity](https://archive.cancerworld.net/tag/capacity/)
- [latitude](https://archive.cancerworld.net/tag/latitude/)
- [vitamin D](https://archive.cancerworld.net/tag/vitamin-d/)
- [calcitriol](https://archive.cancerworld.net/tag/calcitriol/)
- [paricalcitol](https://archive.cancerworld.net/tag/paricalcitol/)
- [sun](https://archive.cancerworld.net/tag/sun/)
- [pregnancy](https://archive.cancerworld.net/tag/pregnancy/)
- [foetus](https://archive.cancerworld.net/tag/foetus/)
- [placenta](https://archive.cancerworld.net/tag/placenta/)
- [development](https://archive.cancerworld.net/tag/development/)
- [health](https://archive.cancerworld.net/tag/health/)
- [Neoadjuvant](https://archive.cancerworld.net/tag/neoadjuvant/)
- [surrogate](https://archive.cancerworld.net/tag/surrogate/)
- [tumour response](https://archive.cancerworld.net/tag/tumour-response/)
- [treatment strategies](https://archive.cancerworld.net/tag/treatment-strategies/)
- [multicentre](https://archive.cancerworld.net/tag/multicentre/)
- [multi gene assays](https://archive.cancerworld.net/tag/multi-gene-assays/)
- [standards](https://archive.cancerworld.net/tag/standards/)
- [research strategies](https://archive.cancerworld.net/tag/research-strategies/)
- [failure](https://archive.cancerworld.net/tag/failure/)
- [oesophageal cancer](https://archive.cancerworld.net/tag/oesophageal-cancer/)
- [geriatric](https://archive.cancerworld.net/tag/geriatric/)
- [physical activity and cancer](https://archive.cancerworld.net/tag/physical-activity-and-cancer/)
- [BRCA mutations](https://archive.cancerworld.net/tag/brca-mutations/)
- [bad luck](https://archive.cancerworld.net/tag/bad-luck/)
- [Tomasetti](https://archive.cancerworld.net/tag/tomasetti/)
- [cell division](https://archive.cancerworld.net/tag/cell-division/)
- [Vogelstein](https://archive.cancerworld.net/tag/vogelstein/)
- [mass media](https://archive.cancerworld.net/tag/mass-media/)
- [news](https://archive.cancerworld.net/tag/news/)
- [terminal](https://archive.cancerworld.net/tag/terminal/)
- [good life](https://archive.cancerworld.net/tag/good-life/)
- [eubiosia](https://archive.cancerworld.net/tag/eubiosia/)
- [pain free](https://archive.cancerworld.net/tag/pain-free/)
- [international collaboration](https://archive.cancerworld.net/tag/international-collaboration/)
- [Cold war](https://archive.cancerworld.net/tag/cold-war/)
- [dying at home](https://archive.cancerworld.net/tag/dying-at-home/)
- [family](https://archive.cancerworld.net/tag/family/)
- [teenage cancer units](https://archive.cancerworld.net/tag/teenage-cancer-units/)
- [specialist services](https://archive.cancerworld.net/tag/specialist-services/)
- [age-appropriate](https://archive.cancerworld.net/tag/age-appropriate/)
- [priorities](https://archive.cancerworld.net/tag/priorities/)
- [questions](https://archive.cancerworld.net/tag/questions/)
- [patient advocates](https://archive.cancerworld.net/tag/patient-advocates/)
- [proposals](https://archive.cancerworld.net/tag/proposals/)
- [expert patients](https://archive.cancerworld.net/tag/expert-patients/)
- [equal](https://archive.cancerworld.net/tag/equal/)
- [role](https://archive.cancerworld.net/tag/role/)
- [James Lind Alliance](https://archive.cancerworld.net/tag/james-lind-alliance/)
- [Cochrane](https://archive.cancerworld.net/tag/cochrane/)
- [EUPATI](https://archive.cancerworld.net/tag/eupati/)
- [NCRI](https://archive.cancerworld.net/tag/ncri/)
- [knowledge](https://archive.cancerworld.net/tag/knowledge/)
- [skills](https://archive.cancerworld.net/tag/skills/)
- [expertise](https://archive.cancerworld.net/tag/expertise/)
- [metabolism](https://archive.cancerworld.net/tag/metabolism/)
- [Warburg](https://archive.cancerworld.net/tag/warburg/)
- [diabetes](https://archive.cancerworld.net/tag/diabetes/)
- [metformin](https://archive.cancerworld.net/tag/metformin/)
- [turf wars](https://archive.cancerworld.net/tag/turf-wars/)
- [multidisciplinary team](https://archive.cancerworld.net/tag/multidisciplinary-team/)
- [prostate centres](https://archive.cancerworld.net/tag/prostate-centres/)
- [EAU](https://archive.cancerworld.net/tag/eau/)
- [PSA testing](https://archive.cancerworld.net/tag/psa-testing/)
- [healthcare workforce](https://archive.cancerworld.net/tag/healthcare-workforce/)
- [shortage](https://archive.cancerworld.net/tag/shortage/)
- [personnel](https://archive.cancerworld.net/tag/personnel/)
- [roles](https://archive.cancerworld.net/tag/roles/)
- [Spironolactone](https://archive.cancerworld.net/tag/spironolactone/)
- [anthracycline](https://archive.cancerworld.net/tag/anthracycline/)
- [cardiotoxicity](https://archive.cancerworld.net/tag/cardiotoxicity/)
- [chemotherapy modification](https://archive.cancerworld.net/tag/chemotherapy-modification/)
- [information provision](https://archive.cancerworld.net/tag/information-provision/)
- [CRC mortality](https://archive.cancerworld.net/tag/crc-mortality/)
- [care](https://archive.cancerworld.net/tag/care/)
- [empathy](https://archive.cancerworld.net/tag/empathy/)
- [patient-centred](https://archive.cancerworld.net/tag/patient-centred/)
- [holistic](https://archive.cancerworld.net/tag/holistic/)
- [humanistic](https://archive.cancerworld.net/tag/humanistic/)
- [intratumoural drug metabolism](https://archive.cancerworld.net/tag/intratumoural-drug-metabolism/)
- [intervention](https://archive.cancerworld.net/tag/intervention/)
- [therapeutic strategies](https://archive.cancerworld.net/tag/therapeutic-strategies/)
- [CYP](https://archive.cancerworld.net/tag/cyp/)
- [inhibition](https://archive.cancerworld.net/tag/inhibition/)
- [World Economic Forum](https://archive.cancerworld.net/tag/world-economic-forum/)
- [Davos](https://archive.cancerworld.net/tag/davos/)
- [global fund](https://archive.cancerworld.net/tag/global-fund/)
- [cure](https://archive.cancerworld.net/tag/cure/)
- [access](https://archive.cancerworld.net/tag/access/)
- [antibody-drug conjugates](https://archive.cancerworld.net/tag/antibody-drug-conjugates/)
- [ADCs](https://archive.cancerworld.net/tag/adcs/)
- [novel therapies](https://archive.cancerworld.net/tag/novel-therapies/)
- [technology](https://archive.cancerworld.net/tag/technology/)
- [generic drugs](https://archive.cancerworld.net/tag/generic-drugs/)
- [transparency](https://archive.cancerworld.net/tag/transparency/)
- [prescribing](https://archive.cancerworld.net/tag/prescribing/)
- [switching](https://archive.cancerworld.net/tag/switching/)
- [trust](https://archive.cancerworld.net/tag/trust/)
- [equivalence](https://archive.cancerworld.net/tag/equivalence/)
- [patient reports](https://archive.cancerworld.net/tag/patient-reports/)
- [information](https://archive.cancerworld.net/tag/information/)
- [perceptions](https://archive.cancerworld.net/tag/perceptions/)
- [adherence](https://archive.cancerworld.net/tag/adherence/)
- [PRO-CTCAE](https://archive.cancerworld.net/tag/pro-ctcae/)
- [terminology](https://archive.cancerworld.net/tag/terminology/)
- [nursing](https://archive.cancerworld.net/tag/nursing/)
- [approval process](https://archive.cancerworld.net/tag/approval-process/)
- [conditional](https://archive.cancerworld.net/tag/conditional/)
- [adaptive](https://archive.cancerworld.net/tag/adaptive/)
- [licensing](https://archive.cancerworld.net/tag/licensing/)
- [HTA](https://archive.cancerworld.net/tag/hta/)
- [TNM](https://archive.cancerworld.net/tag/tnm/)
- [randomised clinical trials](https://archive.cancerworld.net/tag/randomised-clinical-trials/)
- [EURECCA](https://archive.cancerworld.net/tag/eurecca/)
- [PET-CT](https://archive.cancerworld.net/tag/pet-ct/)
- [follicular lymphoma](https://archive.cancerworld.net/tag/follicular-lymphoma/)
- [low-dose](https://archive.cancerworld.net/tag/low-dose/)
- [lung cancer screening](https://archive.cancerworld.net/tag/lung-cancer-screening/)
- [Daniel Helbling](https://archive.cancerworld.net/tag/daniel-helbling/)
- [DVT](https://archive.cancerworld.net/tag/dvt/)
- [anticoagulant treatment](https://archive.cancerworld.net/tag/anticoagulant-treatment/)
- [data protection](https://archive.cancerworld.net/tag/data-protection/)
- [cancer research](https://archive.cancerworld.net/tag/cancer-research/)
- [cancer professional](https://archive.cancerworld.net/tag/cancer-professional/)
- [health professional](https://archive.cancerworld.net/tag/health-professional/)
- [friend](https://archive.cancerworld.net/tag/friend/)
- [responsibility](https://archive.cancerworld.net/tag/responsibility/)
- [lymphoedema](https://archive.cancerworld.net/tag/lymphoedema/)
- [scanning](https://archive.cancerworld.net/tag/scanning/)
- [early intervention](https://archive.cancerworld.net/tag/early-intervention/)
- [Axillary node dissection](https://archive.cancerworld.net/tag/axillary-node-dissection/)
- [sentinel node mapping](https://archive.cancerworld.net/tag/sentinel-node-mapping/)
- [regional radiation](https://archive.cancerworld.net/tag/regional-radiation/)
- [long-term effects](https://archive.cancerworld.net/tag/long-term-effects/)
- [overdiagnosis](https://archive.cancerworld.net/tag/overdiagnosis/)
- [signs](https://archive.cancerworld.net/tag/signs/)
- [benign](https://archive.cancerworld.net/tag/benign/)
- [malignant](https://archive.cancerworld.net/tag/malignant/)
- [severe depression](https://archive.cancerworld.net/tag/severe-depression/)
- [clinical trial](https://archive.cancerworld.net/tag/clinical-trial/)
- [cost-effectiveness](https://archive.cancerworld.net/tag/cost-effectiveness/)
- [effective](https://archive.cancerworld.net/tag/effective/)
- [affordable](https://archive.cancerworld.net/tag/affordable/)
- [integrated](https://archive.cancerworld.net/tag/integrated/)
- [unmet need](https://archive.cancerworld.net/tag/unmet-need/)
- [radio](https://archive.cancerworld.net/tag/radio/)
- [therapeutic monitoring](https://archive.cancerworld.net/tag/therapeutic-monitoring/)
- [Therapeutic drug monitoring](https://archive.cancerworld.net/tag/therapeutic-drug-monitoring/)
- [underdose](https://archive.cancerworld.net/tag/underdose/)
- [overdose](https://archive.cancerworld.net/tag/overdose/)
- [pharmacokinetics](https://archive.cancerworld.net/tag/pharmacokinetics/)
- [funding](https://archive.cancerworld.net/tag/funding/)
- [pharmacy](https://archive.cancerworld.net/tag/pharmacy/)
- [delays](https://archive.cancerworld.net/tag/delays/)
- [interruptions](https://archive.cancerworld.net/tag/interruptions/)
- [decision aids](https://archive.cancerworld.net/tag/decision-aids/)
- [lung adenocarcinoma](https://archive.cancerworld.net/tag/lung-adenocarcinoma/)
- [MR-guided ultrasound](https://archive.cancerworld.net/tag/mr-guided-ultrasound/)
- [patient support](https://archive.cancerworld.net/tag/patient-support/)
- [phase I trials](https://archive.cancerworld.net/tag/phase-i-trials/)
- [Cytotoxic agents](https://archive.cancerworld.net/tag/cytotoxic-agents/)
- [molecularly targeted agents](https://archive.cancerworld.net/tag/molecularly-targeted-agents/)
- [caregiver](https://archive.cancerworld.net/tag/caregiver/)
- [photojournalism](https://archive.cancerworld.net/tag/photojournalism/)
- [photodocumentary](https://archive.cancerworld.net/tag/photodocumentary/)
- [rash](https://archive.cancerworld.net/tag/rash/)
- [pruritus](https://archive.cancerworld.net/tag/pruritus/)
- [itch](https://archive.cancerworld.net/tag/itch/)
- [EGFR inhibitors](https://archive.cancerworld.net/tag/egfr-inhibitors/)
- [incidence](https://archive.cancerworld.net/tag/incidence/)
- [pathophysiology](https://archive.cancerworld.net/tag/pathophysiology/)
- [discrimination](https://archive.cancerworld.net/tag/discrimination/)
- [chronological](https://archive.cancerworld.net/tag/chronological/)
- [sustainable](https://archive.cancerworld.net/tag/sustainable/)
- [expensive](https://archive.cancerworld.net/tag/expensive/)
- [therapies](https://archive.cancerworld.net/tag/therapies/)
- [equality](https://archive.cancerworld.net/tag/equality/)
- [developing countries](https://archive.cancerworld.net/tag/developing-countries/)
- [LMICs](https://archive.cancerworld.net/tag/lmics/)
- [emerging countries](https://archive.cancerworld.net/tag/emerging-countries/)
- [quality care](https://archive.cancerworld.net/tag/quality-care/)
- [biology](https://archive.cancerworld.net/tag/biology/)
- [essential care](https://archive.cancerworld.net/tag/essential-care/)
- [epidemiology](https://archive.cancerworld.net/tag/epidemiology/)
- [early detection](https://archive.cancerworld.net/tag/early-detection/)
- [translational](https://archive.cancerworld.net/tag/translational/)
- [hypoxia](https://archive.cancerworld.net/tag/hypoxia/)
- [radioresistance](https://archive.cancerworld.net/tag/radioresistance/)
- [chemoradiation](https://archive.cancerworld.net/tag/chemoradiation/)
- [heavy ion therapy](https://archive.cancerworld.net/tag/heavy-ion-therapy/)
- [proton therapy](https://archive.cancerworld.net/tag/proton-therapy/)
- [IGRT](https://archive.cancerworld.net/tag/igrt/)
- [IMRT](https://archive.cancerworld.net/tag/imrt/)
- [stereotactic](https://archive.cancerworld.net/tag/stereotactic/)
- [oligometastases](https://archive.cancerworld.net/tag/oligometastases/)
- [IARC](https://archive.cancerworld.net/tag/iarc/)
- [implementation](https://archive.cancerworld.net/tag/implementation/)
- [tobacco](https://archive.cancerworld.net/tag/tobacco/)
- [pollution](https://archive.cancerworld.net/tag/pollution/)
- [alcohol](https://archive.cancerworld.net/tag/alcohol/)
- [infection](https://archive.cancerworld.net/tag/infection/)
- [vaccination](https://archive.cancerworld.net/tag/vaccination/)
- [inequality](https://archive.cancerworld.net/tag/inequality/)
- [cuts](https://archive.cancerworld.net/tag/cuts/)
- [high-quality cancer care](https://archive.cancerworld.net/tag/high-quality-cancer-care/)
- [choosing wisely](https://archive.cancerworld.net/tag/choosing-wisely/)
- [responsability](https://archive.cancerworld.net/tag/responsability/)
- [hormone sensitive cancers](https://archive.cancerworld.net/tag/hormone-sensitive-cancers/)
- [robotic-assisted lobectomy](https://archive.cancerworld.net/tag/robotic-assisted-lobectomy/)
- [melatonin](https://archive.cancerworld.net/tag/melatonin/)
- [Adjuvant online](https://archive.cancerworld.net/tag/adjuvant-online/)
- [NSCLC](https://archive.cancerworld.net/tag/nsclc/)
- [trauma](https://archive.cancerworld.net/tag/trauma/)
- [advocacy](https://archive.cancerworld.net/tag/advocacy/)
- [doctor-patient relationship](https://archive.cancerworld.net/tag/doctor-patient-relationship/)
- [advanced cancer](https://archive.cancerworld.net/tag/advanced-cancer/)
- [breast units](https://archive.cancerworld.net/tag/breast-units/)
- [breast centre](https://archive.cancerworld.net/tag/breast-centre/)
- [accreditation](https://archive.cancerworld.net/tag/accreditation/)
- [criteria](https://archive.cancerworld.net/tag/criteria/)
- [voluntary](https://archive.cancerworld.net/tag/voluntary/)
- [compulsory](https://archive.cancerworld.net/tag/compulsory/)
- [NAPBC](https://archive.cancerworld.net/tag/napbc/)
- [USA](https://archive.cancerworld.net/tag/usa/)
- [EUSOMA](https://archive.cancerworld.net/tag/eusoma/)
- [HPV](https://archive.cancerworld.net/tag/hpv/)
- [HPV faster](https://archive.cancerworld.net/tag/hpv-faster/)
- [clinician](https://archive.cancerworld.net/tag/clinician/)
- [clinical managers](https://archive.cancerworld.net/tag/clinical-managers/)
- [leadership](https://archive.cancerworld.net/tag/leadership/)
- [POLE](https://archive.cancerworld.net/tag/pole/)
- [reimbursement](https://archive.cancerworld.net/tag/reimbursement/)
- [drug approval](https://archive.cancerworld.net/tag/drug-approval/)
- [patient voice](https://archive.cancerworld.net/tag/patient-voice/)
- [trial design](https://archive.cancerworld.net/tag/trial-design/)
- [Patient groups](https://archive.cancerworld.net/tag/patient-groups/)
- [patient experts](https://archive.cancerworld.net/tag/patient-experts/)
- [data mapping](https://archive.cancerworld.net/tag/data-mapping/)
- [interactive](https://archive.cancerworld.net/tag/interactive/)
- [graphics](https://archive.cancerworld.net/tag/graphics/)
- [risk mortality](https://archive.cancerworld.net/tag/risk-mortality/)
- [income](https://archive.cancerworld.net/tag/income/)
- [ethnicity](https://archive.cancerworld.net/tag/ethnicity/)
- [social determinants](https://archive.cancerworld.net/tag/social-determinants/)
- [mathematical biology](https://archive.cancerworld.net/tag/mathematical-biology/)
- [systems biology](https://archive.cancerworld.net/tag/systems-biology/)
- [modelling](https://archive.cancerworld.net/tag/modelling/)
- [game therapy](https://archive.cancerworld.net/tag/game-therapy/)
- [phase i triallist](https://archive.cancerworld.net/tag/phase-i-triallist/)
- [evolution](https://archive.cancerworld.net/tag/evolution/)
- [cancer nursing](https://archive.cancerworld.net/tag/cancer-nursing/)
- [specialist nursing](https://archive.cancerworld.net/tag/specialist-nursing/)
- [patient-centred care](https://archive.cancerworld.net/tag/patient-centred-care/)
- [EONS](https://archive.cancerworld.net/tag/eons/)
- [patient reported outcomes](https://archive.cancerworld.net/tag/patient-reported-outcomes/)
- [benefits](https://archive.cancerworld.net/tag/benefits/)
- [assessment](https://archive.cancerworld.net/tag/assessment/)
- [Aleksandra Filipovic](https://archive.cancerworld.net/tag/aleksandra-filipovic/)
- [staff shortages](https://archive.cancerworld.net/tag/staff-shortages/)
- [clinical workforce](https://archive.cancerworld.net/tag/clinical-workforce/)
- [radiation](https://archive.cancerworld.net/tag/radiation/)
- [paternalism](https://archive.cancerworld.net/tag/paternalism/)
- [scientific literature](https://archive.cancerworld.net/tag/scientific-literature/)
- [critical appraisal](https://archive.cancerworld.net/tag/critical-appraisal/)
- [EBM](https://archive.cancerworld.net/tag/ebm/)
- [evidence-based medicine](https://archive.cancerworld.net/tag/evidence-based-medicine/)
- [systematic reviews](https://archive.cancerworld.net/tag/systematic-reviews/)
- [publications](https://archive.cancerworld.net/tag/publications/)
- [clinical studies](https://archive.cancerworld.net/tag/clinical-studies/)
- [Cochrane Collaboration](https://archive.cancerworld.net/tag/cochrane-collaboration/)
- [metanalysis](https://archive.cancerworld.net/tag/metanalysis/)
- [malnutrition](https://archive.cancerworld.net/tag/malnutrition/)
- [experience](https://archive.cancerworld.net/tag/experience/)
- [specialist](https://archive.cancerworld.net/tag/specialist/)
- [professional](https://archive.cancerworld.net/tag/professional/)
- [multidisciplinary teams](https://archive.cancerworld.net/tag/multidisciplinary-teams/)
- [pathology](https://archive.cancerworld.net/tag/pathology/)
- [quality control](https://archive.cancerworld.net/tag/quality-control/)
- [classification](https://archive.cancerworld.net/tag/classification/)
- [insurance](https://archive.cancerworld.net/tag/insurance/)
- [mortgage](https://archive.cancerworld.net/tag/mortgage/)
- [financial services](https://archive.cancerworld.net/tag/financial-services/)
- [palliative care](https://archive.cancerworld.net/tag/palliative-care/)
- [science cafes](https://archive.cancerworld.net/tag/science-cafes/)
- [awareness](https://archive.cancerworld.net/tag/awareness/)
- [public health](https://archive.cancerworld.net/tag/public-health/)
- [phase 1 trials](https://archive.cancerworld.net/tag/phase-1-trials/)
- [precision](https://archive.cancerworld.net/tag/precision/)
- [combination therapies](https://archive.cancerworld.net/tag/combination-therapies/)
- [culture](https://archive.cancerworld.net/tag/culture/)
- [establishment](https://archive.cancerworld.net/tag/establishment/)
- [data sharing](https://archive.cancerworld.net/tag/data-sharing/)
- [grants](https://archive.cancerworld.net/tag/grants/)
- [George Pentheroudakis](https://archive.cancerworld.net/tag/george-pentheroudakis/)
- [financial crisis](https://archive.cancerworld.net/tag/financial-crisis/)
- [scarcity](https://archive.cancerworld.net/tag/scarcity/)
- [tool](https://archive.cancerworld.net/tag/tool/)
- [decision-making](https://archive.cancerworld.net/tag/decision-making/)
- [clinical benefit](https://archive.cancerworld.net/tag/clinical-benefit/)
- [population screening](https://archive.cancerworld.net/tag/population-screening/)
- [early diagnosis](https://archive.cancerworld.net/tag/early-diagnosis/)
- [legacy](https://archive.cancerworld.net/tag/legacy/)
- [contributions](https://archive.cancerworld.net/tag/contributions/)
- [conserving surgery](https://archive.cancerworld.net/tag/conserving-surgery/)
- [quadrantectomy](https://archive.cancerworld.net/tag/quadrantectomy/)
- [sentinel node](https://archive.cancerworld.net/tag/sentinel-node/)
- [minimun effective](https://archive.cancerworld.net/tag/minimun-effective/)
- [maximum tolerable](https://archive.cancerworld.net/tag/maximum-tolerable/)
- [sentinel node biopsy](https://archive.cancerworld.net/tag/sentinel-node-biopsy/)
- [head and neck cancer](https://archive.cancerworld.net/tag/head-and-neck-cancer/)
- [burnout](https://archive.cancerworld.net/tag/burnout/)
- [adjuvant chemotherapy](https://archive.cancerworld.net/tag/adjuvant-chemotherapy/)
- [molecular screening](https://archive.cancerworld.net/tag/molecular-screening/)
- [drug development](https://archive.cancerworld.net/tag/drug-development/)
- [early phase](https://archive.cancerworld.net/tag/early-phase/)
- [registries](https://archive.cancerworld.net/tag/registries/)
- [EPAAC](https://archive.cancerworld.net/tag/epaac/)
- [European Partnership for Action Against Cancer](https://archive.cancerworld.net/tag/european-partnership-for-action-against-cancer/)
- [cancer services](https://archive.cancerworld.net/tag/cancer-services/)
- [cancer plans](https://archive.cancerworld.net/tag/cancer-plans/)
- [best practise](https://archive.cancerworld.net/tag/best-practise/)
- [cancer networks](https://archive.cancerworld.net/tag/cancer-networks/)
- [Joint Action](https://archive.cancerworld.net/tag/joint-action/)
- [early](https://archive.cancerworld.net/tag/early/)
- [end of life care](https://archive.cancerworld.net/tag/end-of-life-care/)
- [Supportive care](https://archive.cancerworld.net/tag/supportive-care/)
- [integrated care](https://archive.cancerworld.net/tag/integrated-care/)
- [living](https://archive.cancerworld.net/tag/living/)
- [cross-border healthcare](https://archive.cancerworld.net/tag/cross-border-healthcare/)
- [neurotoxicity](https://archive.cancerworld.net/tag/neurotoxicity/)
- [adverse event reporting](https://archive.cancerworld.net/tag/adverse-event-reporting/)
- [CTCAE](https://archive.cancerworld.net/tag/ctcae/)
- [numbness](https://archive.cancerworld.net/tag/numbness/)
- [CANCON](https://archive.cancerworld.net/tag/cancon/)
- [pelvic exenteration](https://archive.cancerworld.net/tag/pelvic-exenteration/)
- [uterine cancer](https://archive.cancerworld.net/tag/uterine-cancer/)
- [CT lung screening](https://archive.cancerworld.net/tag/ct-lung-screening/)
- [age discrimination](https://archive.cancerworld.net/tag/age-discrimination/)
- [childhood cancer](https://archive.cancerworld.net/tag/childhood-cancer/)
- [adolescent cancer](https://archive.cancerworld.net/tag/adolescent-cancer/)
- [passport](https://archive.cancerworld.net/tag/passport/)
- [late-effects](https://archive.cancerworld.net/tag/late-effects/)
- [chronic](https://archive.cancerworld.net/tag/chronic/)
- [primary care](https://archive.cancerworld.net/tag/primary-care/)
- [clinical data](https://archive.cancerworld.net/tag/clinical-data/)
- [PanCare](https://archive.cancerworld.net/tag/pancare/)
- [paediatric](https://archive.cancerworld.net/tag/paediatric/)
- [oncology education](https://archive.cancerworld.net/tag/oncology-education/)
- [medical students](https://archive.cancerworld.net/tag/medical-students/)
- [Ioannina](https://archive.cancerworld.net/tag/ioannina/)
- [career](https://archive.cancerworld.net/tag/career/)
- [speciality](https://archive.cancerworld.net/tag/speciality/)
- [care pathways](https://archive.cancerworld.net/tag/care-pathways/)
- [venous thromboembolism](https://archive.cancerworld.net/tag/venous-thromboembolism/)
- [thrombosis](https://archive.cancerworld.net/tag/thrombosis/)
- [cancer-associated thrombosis](https://archive.cancerworld.net/tag/cancer-associated-thrombosis/)
- [prophylaxis](https://archive.cancerworld.net/tag/prophylaxis/)
- [recurrent](https://archive.cancerworld.net/tag/recurrent/)
- [tumour boards](https://archive.cancerworld.net/tag/tumour-boards/)
- [MDTs](https://archive.cancerworld.net/tag/mdts/)
- [social media](https://archive.cancerworld.net/tag/social-media/)
- [facebook](https://archive.cancerworld.net/tag/facebook/)
- [real time](https://archive.cancerworld.net/tag/real-time/)
- [interaction](https://archive.cancerworld.net/tag/interaction/)
- [inclusion](https://archive.cancerworld.net/tag/inclusion/)
- [delay](https://archive.cancerworld.net/tag/delay/)
- [care plan](https://archive.cancerworld.net/tag/care-plan/)
- [symtoms](https://archive.cancerworld.net/tag/symtoms/)
- [science](https://archive.cancerworld.net/tag/science/)
- [eurocare 5](https://archive.cancerworld.net/tag/eurocare-5/)
- [health spending](https://archive.cancerworld.net/tag/health-spending/)
- [survival rates](https://archive.cancerworld.net/tag/survival-rates/)
- [efficiency](https://archive.cancerworld.net/tag/efficiency/)
- [resources](https://archive.cancerworld.net/tag/resources/)
- [START](https://archive.cancerworld.net/tag/start/)
- [sentinel lymph nodes](https://archive.cancerworld.net/tag/sentinel-lymph-nodes/)
- [early breast cancer](https://archive.cancerworld.net/tag/early-breast-cancer/)
- [adjuvant gemcitabine](https://archive.cancerworld.net/tag/adjuvant-gemcitabine/)
- [anthracyline treatment](https://archive.cancerworld.net/tag/anthracyline-treatment/)
- [metastatic cancer](https://archive.cancerworld.net/tag/metastatic-cancer/)
- [complementary medicine](https://archive.cancerworld.net/tag/complementary-medicine/)
- [alternative therapies](https://archive.cancerworld.net/tag/alternative-therapies/)
- [integrative medicine](https://archive.cancerworld.net/tag/integrative-medicine/)
- [CAM](https://archive.cancerworld.net/tag/cam/)
- [precision medicine](https://archive.cancerworld.net/tag/precision-medicine/)
- [response to treatment](https://archive.cancerworld.net/tag/response-to-treatment/)
- [CT](https://archive.cancerworld.net/tag/ct/)
- [FDG radiolabelling](https://archive.cancerworld.net/tag/fdg-radiolabelling/)
- [health technology assessment](https://archive.cancerworld.net/tag/health-technology-assessment/)
- [roll out](https://archive.cancerworld.net/tag/roll-out/)
- [uptake](https://archive.cancerworld.net/tag/uptake/)
- [dissemination](https://archive.cancerworld.net/tag/dissemination/)
- [change](https://archive.cancerworld.net/tag/change/)
- [low-tech](https://archive.cancerworld.net/tag/low-tech/)
- [marketing approval](https://archive.cancerworld.net/tag/marketing-approval/)
- [regulators](https://archive.cancerworld.net/tag/regulators/)
- [FDA](https://archive.cancerworld.net/tag/fda/)
- [approval timeline](https://archive.cancerworld.net/tag/approval-timeline/)
- [rules](https://archive.cancerworld.net/tag/rules/)
- [legislation](https://archive.cancerworld.net/tag/legislation/)
- [institutional review boards](https://archive.cancerworld.net/tag/institutional-review-boards/)
- [Spiritual support](https://archive.cancerworld.net/tag/spiritual-support/)
- [existential](https://archive.cancerworld.net/tag/existential/)
- [counselling](https://archive.cancerworld.net/tag/counselling/)
- [infertility](https://archive.cancerworld.net/tag/infertility/)
- [Neuropathy](https://archive.cancerworld.net/tag/neuropathy/)
- [neoadjuvant treatment](https://archive.cancerworld.net/tag/neoadjuvant-treatment/)
- [trastuzumab](https://archive.cancerworld.net/tag/trastuzumab/)
- [Biorepositories](https://archive.cancerworld.net/tag/biorepositories/)
- [google](https://archive.cancerworld.net/tag/google/)
- [Make Sense campaign](https://archive.cancerworld.net/tag/make-sense-campaign/)
- [patient advocacy](https://archive.cancerworld.net/tag/patient-advocacy/)
- [stigma](https://archive.cancerworld.net/tag/stigma/)
- [ignorance](https://archive.cancerworld.net/tag/ignorance/)
- [sex life](https://archive.cancerworld.net/tag/sex-life/)
- [sexuality](https://archive.cancerworld.net/tag/sexuality/)
- [sexual problems](https://archive.cancerworld.net/tag/sexual-problems/)
- [sexual function](https://archive.cancerworld.net/tag/sexual-function/)
- [myth](https://archive.cancerworld.net/tag/myth/)
- [DCIS](https://archive.cancerworld.net/tag/dcis/)
- [trial](https://archive.cancerworld.net/tag/trial/)
- [preferences](https://archive.cancerworld.net/tag/preferences/)
- [goals](https://archive.cancerworld.net/tag/goals/)
- [coordination](https://archive.cancerworld.net/tag/coordination/)
- [multidisciplinary guidelines](https://archive.cancerworld.net/tag/multidisciplinary-guidelines/)
- [quality criteria](https://archive.cancerworld.net/tag/quality-criteria/)
- [cost�benefit](https://archive.cancerworld.net/tag/cost�benefit/)
- [hospital management](https://archive.cancerworld.net/tag/hospital-management/)
- [clinician managers](https://archive.cancerworld.net/tag/clinician-managers/)
- [CME](https://archive.cancerworld.net/tag/cme/)
- [management training](https://archive.cancerworld.net/tag/management-training/)
- [home deaths](https://archive.cancerworld.net/tag/home-deaths/)
- [Clostridium difficile](https://archive.cancerworld.net/tag/clostridium-difficile/)
- [anthracyclines](https://archive.cancerworld.net/tag/anthracyclines/)
- [cancer and pregnancy](https://archive.cancerworld.net/tag/cancer-and-pregnancy/)
- [Cancer of unknown primary](https://archive.cancerworld.net/tag/cancer-of-unknown-primary/)
- [tumour profiling](https://archive.cancerworld.net/tag/tumour-profiling/)
- [Secobarbital](https://archive.cancerworld.net/tag/secobarbital/)
- [Assisted suicide](https://archive.cancerworld.net/tag/assisted-suicide/)
- [metastasis](https://archive.cancerworld.net/tag/metastasis/)
- [self-seeding](https://archive.cancerworld.net/tag/self-seeding/)
- [paradigms](https://archive.cancerworld.net/tag/paradigms/)
- [seed-soil](https://archive.cancerworld.net/tag/seed-soil/)
- [inhibitor](https://archive.cancerworld.net/tag/inhibitor/)
- [Gompertzian growth](https://archive.cancerworld.net/tag/gompertzian-growth/)
- [upgrade](https://archive.cancerworld.net/tag/upgrade/)
- [DIRAC](https://archive.cancerworld.net/tag/dirac/)
- [economic modelling](https://archive.cancerworld.net/tag/economic-modelling/)
- [HERO](https://archive.cancerworld.net/tag/hero/)
- [centralisation](https://archive.cancerworld.net/tag/centralisation/)
- [distance](https://archive.cancerworld.net/tag/distance/)
- [travel](https://archive.cancerworld.net/tag/travel/)
- [accommodation](https://archive.cancerworld.net/tag/accommodation/)
- [isolation](https://archive.cancerworld.net/tag/isolation/)
- [personalised cancer therapies](https://archive.cancerworld.net/tag/personalised-cancer-therapies/)
- [computer-aided decision making](https://archive.cancerworld.net/tag/computer-aided-decision-making/)
- [validation](https://archive.cancerworld.net/tag/validation/)
- [decision tools](https://archive.cancerworld.net/tag/decision-tools/)
- [Jim Watson](https://archive.cancerworld.net/tag/jim-watson/)
- [DNA](https://archive.cancerworld.net/tag/dna/)
- [reactive oxygen species](https://archive.cancerworld.net/tag/reactive-oxygen-species/)
- [stress](https://archive.cancerworld.net/tag/stress/)
- [anti-oxidants](https://archive.cancerworld.net/tag/anti-oxidants/)